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 vi ABSTRACT 
The 23 pairs of chromosomes comprising the human genome are 
intricately folded within the nucleus of each cell in a manner that promotes 
efficient gene regulation and cell function. Consequently, active gene rich regions 
are compartmentally segregated from inactive gene poor regions of the genome. 
To better understand the mechanisms driving compartmentalization we 
investigated what would occur if this system was disrupted. By digesting the 
genome to varying sizes and analyzing the fragmented 3D structure over time, 
our work revealed essential laws governing nuclear compartmentalization.  
At a finer resolution within compartments, chromatin forms loop structures 
capable of regulating gene expression. Genome wide association studies have 
identified numerous single nucleotide polymorphisms (SNPs) associated with the 
neuropsychiatric disease schizophrenia. When these SNPs are not located within 
a gene it is difficult to gain insight into disease pathology; however, in some 
cases chromatin loops may link these noncoding schizophrenia risk variants to 
their pathological gene targets. By generating 3D genome maps, we identified 
and analyzed loops of glial cells, neural progenitor cells, and neurons thereby 
expanding the set of genes conferring schizophrenia risk. 
The binding of T-cell receptors (TCRs) to foreign peptides on the surface 
of diseased cells triggers an immune response against the foreign invader. 
Utilizing available structural information of the TCR antigen interface, we 
developed computational methods for successful prediction of TCR-antigen 
 
 vii binding. As this binding is a prerequisite for immune response, such 
improvements in binding prediction could lead to important advancements in the 
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Because the history of evolution is that life escapes all barriers. Life breaks 
free. Life expands to new territories. Painfully, perhaps even dangerously. 
But life finds a way. 





 1 CHAPTER I: INTRODUCTION 
Computational Biology 
 The origins of computational biology can be traced back to the early 
1960s. Amino acid sequence arrangements of proteins were being determined 
for the first time. However, method limitations required larger protein sequences 
to be assembled by their smaller peptide sequence fragments. For large proteins 
composed of hundreds or thousands of amino acids, sequence assembly proved 
to be a combinatorial nightmare. To address this challenge Margaret Dayhoff and 
colleagues developed COMPROTEIN: a computer program to aid primary protein 
structure determination (Dayhoff and Ledley, 1962; Gauthier et al., 2019). 
COMPROTEIN was one of the first programs described as bioinformatics 
software and was coded entirely on punch-cards.  
 As the sequences of more proteins were determined and technology 
advanced, computational biology expanded from its use in determining protein 
primary structure to predicting tertiary structure, the three-dimensional (3D) 
shape of a protein. Since its establishment in 1994, the Critical Assessment of 
protein Structure Prediction (CASP) initiative has held a prediction experiment 
every two years where dozens of groups across the globe implement 
computational methods with the goal of predicting target protein 3D structure 
from sequence (Moult et al., 1995).  
 
 2  Beyond protein studies, computational biology has become a fundamental 
component to the analysis of nucleic acids. The increase in computational 
biology pioneers and methods was driven largely by the publication of the human 
genome at the start of the 21st century and the advancements to next generation 
sequencing technologies which followed (Craig Venter et al., 2001; Lander et al., 
2001). As sequencing costs decreased and data increased a need emerged for 
the computational biologist, capable of drawing connections in such vast and 
complex data.  
 Today, computational biology describes a field fundamental to the study of 
proteomics, transcriptomics, genomics, and epigenomics. From the processing of 
billions of paired-end DNA sequences to machine learning strategies for 
prediction of protein binding affinity, this thesis describes in detail the 
development of computational methods, models, and algorithms, to explain 
biological phenomena.     
Genome structure 
 In the field of biology and beyond, the ability to visually represent what is 
hidden from the naked eye has been key to understanding how our world works.  
The discovery that DNA forms a 3D double helix structure led to many 
critical scientific breakthroughs over the last sixty-seven years (James Watson 
and Crick, 1953). The knowledge that a single strand of the double helix can act 
as a template to code for a partner strand allowed us to answer the question of 
how DNA is replicated from cell to cell, and how inherited traits can be passed 
 
 3 down from generation to generation (J Watson and Crick, 1953; Meselson and 
Stahl, 1958). The central dogma of molecular biology, that information is 
transferred from DNA and RNA to proteins but information cannot be transferred 
from a protein to DNA, was also predicated upon solving the 3D structure of DNA 
(F. H. Crick, 1958). Although the atomic structure of DNA has been known for 
some time, the larger picture illustrating how exactly the double helix is folded 
inside the cell nucleus still remains a puzzle.  
Only within the last decade, with the aid of deep sequencing technologies, 
have we been able to begin unraveling the full 3D architecture of DNA in the 
context of how markedly long molecules of double helix DNA spatially fit inside 
the cell nucleus. The sheer size of a genome can make this question difficult to 
answer. The human genome is roughly three billion base pairs of DNA in length. 
Fitting all of that DNA inside a nucleus roughly 10 m in diameter is analogous to 
fitting 30 miles of string inside a basketball. The nucleus is packed with DNA; 
however, we now know that this packing is not an arbitrary random entanglement 
of the DNA polymer. From human to mouse to fly and even in single cell 
organisms, the 3D architecture of DNA inside the nucleus is highly organized in a 
manner to promote cell function (Lieberman-Aiden et al., 2009; Duan et al., 2010; 
Sexton et al., 2012; Zhang et al., 2012).  
Although some general features of this 3D architecture are conserved 
across varying cell types and even across different species (Dixon et al., 2012), 
changes in the 3D architecture of DNA have been associated with gene 
 
 4 regulation, cell type specificity, and cell fate (Dixon et al., 2015; Tang et al., 2015; 
Schmitt et al., 2016). It follows that the mechanisms controlling the 3D 
architecture must be properly regulated and impairment of this architecture can 
lead to improper cell function and subsequent disease (Lupiáñez et al., 2015). 
A DNA molecule does not solely fold itself into its proper 3D conformation, 
but is aided by a myriad of DNA-binding proteins to form chromatin. In 
eukaryotes, the basic structural unit of chromatin is generated by the wrapping of 
146 base pairs of DNA around eight histone proteins forming the nucleosome 
(Kornberg, 1974; Morse and Simpson, 1988). This wrapping of DNA into 
nucleosome structures not only helps to compact DNA molecules to fit inside the 
nucleus, but furthermore can act as method of gene regulation. Nucleosomes 
can inhibit transcription initiation and inversely, loss of nucleosomes can lead to 
transcriptional activation (Lorch, LaPointe and Kornberg, 1987; Han and 
Grunstein, 1988). Zooming out from the nucleosome level and examining full 
chromosomes, condensin complex proteins condense DNA to a further degree 
when preparing the cell for mitotic division (Hirano and Mitchison, 1994). The 3D 
architecture of chromatin inside the nucleus is never static, but instead a dynamic 
system that must replicate chromosomes followed by radical condensation and 
spatial chromosome segregation every cell cycle.  
Visualization of mitotic cells through microscopy show chromosomes as 
condensed sausage like structures (Rieder and Khodjakov, 2003); however, the 
spatial occupancy of chromosomes during interphase is more difficult to resolve. 
 
 5 Early microbeam radiation experiments, fluorescence microscopy results, and 
more recent deep sequencing data have all supported the now unequivocal 
conclusion that individual chromosomes again occupy separate territories during 
interphase of the cell cycle (Cremer et al., 1982; Bolzer et al., 2005; Lieberman-
Aiden et al., 2009).  
While the existence of chromosome territories is clear, how certain 
features of the chromosome relate to the chromosome’s spatial localization is still 
under debate. For instance, there is evidence for both random and non-random 
proximity of homologous chromosomes in somatic cells dependent upon cell type 
and species (Henikoff, 1997; Bolzer et al., 2005). In humans, chromosome size 
has been associated with nuclear positioning with smaller chromosomes 
primarily located in the interior and larger chromosomes residing around the 
nuclear periphery (Sun, Shen and Yokota, 2000). However, this positioning may 
not be a result of chromosome size, but instead due to the clustering of gene rich 
active regions of chromosomes versus inactive gene poor regions. In agreement 
with this notion, the similar sized human chromosomes, 18 and 19, were shown 
to occupy different nuclear neighborhoods in lymphoblastoid cells. Specifically, 
gene rich Chromosome 19 was positioned near the nuclear center while the gene 
poor Chromosome 18 was closer to the periphery (Boyle, 2001).  
Keeping active and inactive regions of the genome spatially segregated 
makes logical sense. Just as a city may cluster its financial district into a space 
 
 6 separated from parks and housing to promote commerce, the cell may separate 
gene rich from gene poor regions to promote transcriptional activity (Figure 1.1). 
 
Figure 0.1F igure 1.1 |  Il lustration  of compartmentalization  
Figure 1.1 | Illustration of compartmentalization.                                            
Nucleus (black) housing chromosomes with spatially separated active regions 
(red) and inactive regions (blue) of the genome. 
 
Experimental evidence from the last couple of decades has made this 
hypothesis of nuclear compartmentalization undoubtable (Fraser and Bickmore, 
2007; Lieberman-Aiden et al., 2009). However, information regarding the stability 
of these compartments and the mechanisms governing compartmentalization is 
still lacking. In the next section, I review the tools and experiments used to 
identify compartments and the current hypotheses proposed regarding 
compartment formation and its properties.  
 
 7 Compartments 
Fluorescence in situ hybridization (FISH) and microscopy techniques 
provided some of the first evidence for the spatial segregation of active and 
inactive chromatin domains into compartments. In FISH, hybridization of a 
fluorescent probe to a genomic region of interest facilitates visual localization of 
the genomic region within the nucleus. FISH studies in Drosophila showed that 
the eye color gene brown can relocate near inactive regions after an insertion of 
inactive chromatin in the brown gene itself. Silencing of wildtype brown due to its 
proximity to inactive chromatin provided further evidence supporting a functional 
role for compartmentalization (Dernburg et al., 1996). Similar FISH experiments 
in mouse indicate that active genes migrate toward specific nuclear regions 
promoting transcription, which may act as ‘transcription factories’ (Osborne et al., 
2004; Shopland et al., 2006). However, this model has been challenged by more 
recent studies which provide evidence for highly dynamic and transient 
transcription clusters (Cisse et al., 2013; Furlong and Levine, 2018). While FISH 
studies laid the groundwork for visualizing interphase compartmentalization 
patterns in eukaryotic cells, they were typically restricted to investigating a single 
locus or only a handful of loci. Later chromosome conformation capture 
experiments extended these clues from individual loci to validating a genome 
wide phenomenon.  
 
 8 Chromosome conformation capture (3C) experiments and their derivatives 
allow for the detection of proximal DNA loci within a population of cells (Dekker et 
al., 2002). In brief, these experiments apply the following three steps:  
(1) Cells or isolated nuclei are crosslinked with formaldehyde, linking 
protein to protein and DNA to protein interactions throughout the nucleus. (2) 
DNA is digested with a restriction enzyme creating free ends of the cut DNA. (3) 
Free ends of cross-linked DNA fragments are ligated together.  
The resulting DNA ligation products indicate a spatial proximity between 
the DNA loci on either end of the ligation junction. These loci can then be 
detected using specific primers in PCR reactions, microarrays, or through deep 
sequencing (Dekker et al., 2002; Simonis et al., 2006; Lieberman-Aiden et al., 
2009). 
Chromosome conformation capture-on-chip (4C) extended the 3C method 
to interrogate the interaction profile of a single locus with the rest of the genome. 
This was accomplished by hybridizing PCR products from circular ligations on a 
microarray containing probes for loci scattered throughout the genome (Simonis 
et al., 2006). 4C provided evidence that the active -globin genes in fetal liver 
interact with other actively transcribed regions, and conversely the inactive -
globin genes in fetal brain interact with other transcriptionally silent regions 
(Simonis et al., 2006). The advent of the 3C/4C methods along with advances in 
microarray technology allowed for validation of the compartmentalization features 
 
 9 seen in FISH by probing the interactions of one locus versus the rest of the 
genome. A few years later, a further derivative of the 3C technology, known as 
Hi-C, would harness deep sequencing technology to simultaneously interrogate 
all interactions between all genomic loci.  
By adding a biotin incorporation step before ligation and subsequent pull 
down of ligation junctions followed by deep sequencing, the Hi-C method led to 
the production of the first chromatin contact map of the human genome at one 
megabase (Mb) resolution (Lieberman-Aiden et al., 2009). Chromosomal 
territories reported for interphase cells by previous microscopy studies were well 
represented in the genome wide contact maps, as loci within each chromosome 
(intra-chromosomal) were found to interact with much greater frequency than loci 
on different chromosomes (inter-chromosomal). Perhaps the most interesting 
observations came from chromatin contacts maps generated for intra-
chromosomal interactions. For example, examining the contact map of 
Chromosome 14, a striking checkerboard pattern emerged from the Hi-C data. 
Overlapping the checkerboard pattern with gene density, histone modification, 
and open chromatin tracks, it was evident the checkerboard pattern reflected the 
spatial preferences of compartmentalization. Dark squares of the checkerboard 
represented either preferential interactions between active genomic regions or 
the preferential interactions between inactive regions, while light squares 
represented the depletion of interactions between inactive and active regions. A 
principle component analysis on the Hi-C contact matrix was used to demarcate 
 
 10 boundaries between the spatially segregated active and inactive genomic 
regions, defining them as A and B compartments, respectively.  (Lieberman-
Aiden et al., 2009).  
Over the next decade, Hi-C contact maps have demonstrated that 
compartmentalization occurs across a wide array of human cell types (Schmitt et 
al., 2016), in other mammals (Zhang et al., 2012; Bonev et al., 2017), in chicken 
(Gibcus et al., 2018), in fly (Rowley et al., 2017), and even in some plants (Dong 
et al., 2017). Clearly, A/B compartmentalization of interphase nuclei is a 
conserved organizational principle (Jost, Bertulat and Cardoso, 2012) for many 
eukaryotes. Next, I will review the genetic and epigenetic properties of A/B 
compartment regions and introduce the current theoretical mechanisms 
proposed for compartment formation. 
While direct evidence for genome wide segregation of active and inactive 
chromatin during interphase was not available until recently, many results from 
previous chromatin studies fall in line with this concept of compartmentalization 
and aid in distinguishing A compartments from their B counterparts. As early as 
1929, Emil Heitz coined the terms heterochromatin and euchromatin to describe 
chromatin that appeared darker and lighter, respectively, on mitotic 
chromosomes stained with DNA dyes (Jost, Bertulat and Cardoso, 2012). 
Sedimentation experiments provided further evidence for two structurally distinct 
types of chromatin: condensed/closed heterochromatin and decondensed/open 
euchromatin (Gilbert et al., 2004). These two structural states of chromatin are 
 
 11 also in line with gene positioning along chromosomes with euchromatin enriched 
in genes and heterochromatin comprised primarily of gene deserts. Accordingly, 
A compartments are predominately composed of euchromatic regions and B 
compartments are predominately heterochromatin. It is important to note that the 
A/B compartment designations used here are defined strictly by the spatial 
segregation illustrated in Hi-C contact maps and although A compartments 
typically contain active genes there are exceptions to the rule (Vieux-Rochas et 
al., 2015; Bonev et al., 2017).  
While genetic sequence alone may not be enough to accurately predict 
compartments regions, correlations can be made between sequence composition 
and A/B compartment designation. B compartments contain many transposable 
elements and are enriched in adenine (A) and thymine (T) nucleotides, while A 
compartments are generally more gene dense and enriched in guanine (G) and 
cytosine (C) (Slotkin and Martienssen, 2007; Lieberman-Aiden et al., 2009; 
Imakaev et al., 2012). Beyond sequence characteristics, epigenetic marks have 
shown high correlations with A/B compartments and provide further clues into 
compartment formation and function  (Lieberman-Aiden et al., 2009; Allis and 
Jenuwein, 2016; Allshire and Madhani, 2018). 
Chemical modifications to the lysines of nucleosome histone tails can 
regulate gene expression by changing the local chromatin environment 
(Bannister and Kouzarides, 2011). Typically, acetylation of histone tails is 
associated with active transcription and an open chromatin environment, while 
 
 12 methylation is associated with either transcriptional activation or repression 
dependent upon the methylation site. For example, the methylated histone 
marks, H3K4me3 and H3K36me3, are located near active regions (Bannister et 
al., 2005; Barski et al., 2007), while the marks, H3K27me3 and H3K9me3, are 
found in repressed regions (Becker, Nicetto and Zaret, 2016; Wiles and Selker, 
2017). In some of the first 1 and 0.5 Mb scale contact maps, compartments were 
shown to correlate with active and repressive histone marks (Lieberman-Aiden et 
al., 2009; Kalhor et al., 2012). As technology increased and sequencing costs 
decreased, higher resolution Hi-C maps emerged further refining the 
compartmentalization phenomenon and its relation to the epigenetic chromatin 
landscape (Rao et al., 2014; Rowley et al., 2017).  
Upon examining kilobase resolution contact maps comprised of billions of 
Hi-C contacts in human lymphoblastoid cells, spatial preferences appeared within 
and across the original A/B compartments (Rao et al., 2014).  The positions of 
these subcompartments (A1, A2, B1, B2, and B3) were found to correlate with 
specific histone modifications and proximity to different sub-nuclear structures 
revealing a higher order level of 3D chromatin organization. 
 A1 and A2 subcompartments were found to be enriched in the original A 
compartment and are both correlated with active histone markers such as 
H3K27ac, H3K9ac, and H3K36me3 (Rao et al., 2014). However, in contrast to 
A2, the A1 subcompartment was found to specifically co-localize with nuclear 
speckles, which are hubs for pre-mRNA splicing factors (Chen et al., 2018). The 
 
 13 co-localization of A1 chromatin with nuclear speckles would in effect bring 
actively transcribed regions to the machinery which processes transcribed 
products for nuclear export (Misteli, Cáceres and Spector, 1997), or conversely 
speckles may form at active genes to promote efficient processing. 
B1, B2, and B3 subcompartments all correlate with inactive 
heterochromatic regions of the genome. B2 and B3 subcompartments are both 
depleted of active histone marks and enriched for lamin A/C, a protein localized 
at the nuclear periphery (Rao et al., 2014). In contrast to B3, the B2 
subcompartment was found to additionally and specifically co-localize with the 
nucleolus, where ribosome biogenesis occurs (Boisvert et al., 2007). Unique from 
all other subcompartments, the B1 subcompartment is specifically enriched in the 
repressive histone mark H3K27me3 (Rao et al., 2014). Polycomb group proteins 
trimethylate H3K27 to silence genes, a mechanism that is essential for proper 
vertebrate and invertebrate development (Aranda, Mas and Croce, 2015). 
Genomic loci bound by polycomb are shown to cluster inside the nucleus into 
visible polycomb bodies (Saurin et al., 1998), validating preferential B1 
interactions and suggesting a functional role for their subcompartmentalization.  
Low (Mb) resolution interaction maps illustrated the spatial segregation of 
the genome into two compartments highly correlated with active and inactive 
regions. Later, higher (kb) resolution maps revealed chromatin state dictates a 
finer level of compartmentalization by the co-localization of regions with similar 
epigenetic marks or co-localization of regions interacting with specific sub-
 
 14 nuclear structures. While spatial compartmentalization of the genome is evident, 
the mechanisms driving this compartmentalization remain ambiguous.  
Evidence suggests transcription may be a driver for compartmentalization. 
Specifically, experiments inhibiting transcription have led to a reduction in 
compartmentalization (Rowley et al., 2017). However, it is still debatable whether 
such reductions are a consequence of inhibiting transcription processes such as 
initiation and elongation or a consequence of loss in RNA polymerase II (Pol II) 
binding to DNA (Rowley and Corces, 2018).  
Applying theories from polymer physics has led to some notable insights 
into compartment formation. Modeling chromosomes as polymers, a chain of 
elementary units called monomers, simplifies the complex conformational 
structure of chromatin. Specifically, the conformation a polymer can adopt relies 
on three characteristics: (1) flexibility of the chain, (2) interactions between 
monomers on the chain and (3) interactions with the polymer’s surroundings 
(Rubinstein and Colby, 2003). A chromosome with alternating blocks of A and B 
compartments where each block may vary in size, can be modeled as a block 
copolymer. In a block copolymer, each block is comprised of consecutive A or 
consecutive B monomers. Simulations using block copolymers are capable of 
reproducing the checkerboard pattern displayed in Hi-C interaction maps 
(Haddad, Jost and Vaillant, 2017; Falk et al., 2019). Importantly, such studies 
can provide estimations of attractive forces between A/B monomer types which 
aid in solving the puzzle of compartment formation. In contradiction to results that 
 
 15 support transcription driving compartment formation, a recent study utilizing block 
copolymer modeling to investigate compartmentalization in mouse described 
euchromatic A-A interactions as weak and more or less dispensable for 
compartmentalization. This study rather suggests that strong heterochromatic B-
B interactions are responsible for genome compartmentalization via a phase 
separation mechanism (Falk et al., 2019).  
Similar to the phase separation of oil and water, recent studies have 
suggested that compartmentalization may be due to phase separation of 
compartment regions with the surrounding nucleoplasm (Hnisz et al., 2017; 
Larson et al., 2017; Strom et al., 2017). Liquid-liquid phase separation may occur 
through the oligomerization of soluble multivalent proteins (Erdel and Rippe, 
2018). Self-associating oligomerization of these proteins can lead to a liquid-like 
droplet forming a phase separate from its surroundings. When these self-
associating proteins bind to chromatin they may induce compartmentalization by 
incorporating one compartment into the liquid-like droplet phase while excluding 
the unbound chromatin of the opposite compartment. For example, the 
multivalent protein HP1α binds the H3K9me3 mark enriched in heterochromatin. 
In vitro binding of HP1α with DNA can form liquid-like droplets (Larson et al., 
2017). Furthermore, DNA curtain experiments reveal HP1α proteins are capable 
of compacting DNA (Larson et al., 2017). Accordingly, B compartmentalization 
may be due in part to the liquid-liquid phase separation of heterochromatic 
regions bound by HP1α. 
 
 16 Similar to blocking transcription, perturbing other elements intrinsic to a 
functional cell nucleus has led to changes in compartmentalization. For instance, 
chromatin is known to form loops spanning more than a megabase in genomic 
distance (Rao et al., 2014). Degrading proteins vital to loop formation leads to an 
elimination of loops and a subsequent enhancement of compartmentalization 
(Rao et al., 2017). These results suggest chromatin loops can act 
antagonistically to the compartmentalization phenomenon bringing A and B loci 
in closer proximity than attractive and repulsive forces between them would 
ordinarily allow.  
In terms of understanding how compartments are formed and maintained, 
there is still much work to be done. Chapter II of this thesis focuses on answering 
the unknowns of compartmentalization and leads to the discovery of new 
principles and characteristics pertaining to compartmentalization of interphase 
nuclei. In the next section, I further introduce another 3D structure, the chromatin 
loop, and expand on its role in gene regulation, specifically in mediating 
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Figure 1.2 | Illustration of chromatin loop mediated promoter-enhancer 
interaction.                                                                                                                              
Chromatin loop formation allows a distal enhancer region (yellow) to regulate its 
target gene (red) by placing the enhancer region in close physical proximity to its 
target gene promoter.     
 
Promoter-Enhancer Interactions 
In eukaryotes, gene activation is defined by its transcription conducted by 
the Pol II multiprotein enzyme. As a prerequisite to gene activation, Pol II must 
first bind a promoter region proximal to the transcription start site (TSS) of a 
gene. Binding of Pol II and other transcription factors (TFs) to promoter regions 
leads to the initiation of transcription. Hence, occupancy of Pol II and TFs at 
promoters regulates gene activity (Andersson and Sandelin, 2020). In a similar 
fashion, enhancer regions distal from a gene in terms of linear sequence can 
activate a gene through recruitment of regulatory TFs. Enhancer function was 
identified as early as 1981 by transfection assays which showed a 72 bp repeat 
of viral DNA could increase activity of the β-globin gene across a distance of over 
3 kb (Banerji, Rusconi and Schaffner, 1981). Later studies provided evidence 
 
 18 enhancers can act on gene targets as far as a megabase away (Carter et al., 
2002; Lettice et al., 2003). To reconcile how enhancers could regulate such 
distant targets, the 3D structure of chromatin at these regions was investigated.  
3C studies at the β-globin locus revealed chromatin is capable of forming 
a loop structure linking a distal enhancer to its target promoter and activating β-
globin gene expression (Tolhuis et al., 2002; Deng et al., 2012). Formation of a 
chromatin loop could reconcile how distal enhancers can regulate their target 
genes. However, the relationship between chromatin loop structures and 
transcriptional activity is a topic still under much deliberation. 
Identifying loop machinery and characterizing their modes of action in 
interphase nuclei has provided some insight into the role of chromatin loops in 
gene regulation. Two key components, CCCTC binding factor (CTCF) and the 
cohesin complex, have proven to be critical for the formation of many chromatin 
loop structures. CTCF is a highly conserved transcription factor capable of 
forming homodimers and known to recognize a sequence specific DNA binding 
motif (Nichols and Corces, 2015). The cohesin complex is a ring shaped protein 
complex known to regulate the separation of sister chromatids during cell division 
(Makrantoni and Marston, 2018). Together, CTCF and cohesin may mediate 
chromatin loop formation via a loop extrusion mechanism (Fudenberg et al., 
2016). In this model, binding of cohesin to chromatin leads to translocation of 
cohesin along the chromatin fiber causing extrusion of a small chromatin loop 
away from or out of the cohesin ring. Extrusion continues until cohesin is stalled 
 
 19 by CTCF anchors bound to chromatin at opposite loop ends. Hence, in this 
model cohesin would bring the CTCF anchors of a loop close together in 3D 
space and loop size would be dependent on the 1D genomic distance between 
CTCF anchor sites. In support of the loop extrusion model, recent in vitro 
microscopy experiments show human cohesin complexes can form loops at up to 
2.1 kb per second likely in a pseudo-topological or non-topological manner 
(Davidson et al., 2019; Kim et al., 2019).  
Although CTCF/cohesin mediated loops may appear as a promising 
mechanistic candidate for the linking of promoters with enhancers, the 
relationship between CTCF/cohesin mediated loops and promoter-enhancer 
interactions is not as clear cut. Upon identification of loop structures in a high 
resolution Hi-C map of the human cell line GM12878, a majority of loop anchors 
are bound by CTCF (~86%) and cohesin (~86%) (Rao et al., 2014). However, far 
fewer of these loops (~30%) actually linked together known promoters and 
enhancers. It follows, the functional role of CTCF/cohesin loops likely extends 
beyond the direct facilitation of promoter-enhancer interactions.  
ChIA-PET experiments provide 3D chromatin interaction information 
between DNA loci bound by a protein of interest (Fullwood et al., 2009). ChIA-
PET experiments targeting CTCF have shown CTCF loop anchors are enriched 
for active epigenomic markers, Pol II occupancy, and TSSs of genes (Tang et al., 
2015). Furthermore, constitutively expressed genes were found to be enriched at 
CTCF/cohesin loop anchors, while tissue specific genes primarily resided within 
 
 20 the body of loops suggesting a functional role for loops in mediating cell type 
specificity (Tang et al., 2015). The binding motif of CTCF is non-palindromic and 
thus directional. The vast majority of CTCF loops identified in the human cell line 
GM12878 contained anchors with CTCF binding motifs in a convergent 
orientation (Rao et al., 2014). Surprisingly, the directionality of transcription for 
genes with a TSS located in a CTCF loop anchor is in harmony with the CTCF 
motif orientation, again suggesting a regulatory role for CTCF/cohesin loops 
(Tang et al., 2015).  
Beyond associations between CTCF/cohesin loops and gene positioning 
or activity, mutagenesis studies have shown changes in gene expression can 
occur upon induced loop disruptions. Regulation of the Shh gene in mouse by 
the ZRS enhancer (located ~850 kb away from the Shh promoter) is vital to 
proper limb development. Disrupting CTCF/cohesin loop formation by inversion 
of a region encompassing the ZRS enhancer leads to downregulation of Shh in 
limb buds and malformation of limb structures (Symmons et al., 2016). 
Interestingly, limb formation is partially rescued upon placing the inverted ZRS 
region in closer genomic distance to Shh (Symmons et al., 2016). Similarly, 
inversion and deletion experiments disrupting CTCF loops at the EPHA4 locus in 
mice causes ectopic interactions and expression patterns resulting in pathogenic 
phenotypes (Lupiáñez et al., 2015).  Hence, CTCF/cohesin loops may function to 
provide insulated neighborhoods within which dynamic movement of chromatin 
can link promoters and enhancers with a higher probability of interaction 
 
 21 occurring based on linear genomic distance. In further support of this model, 
inversion of CTCF binding-sites away from the convergent orientation seen in 
loop formations can result in an altered 3D architecture at loop loci, loss of 
contacts between promoters and enhancers, and changes in gene expression 
(Guo et al., 2015).  
To further dissect the functionality of CTCF/cohesin mediated loops, 
recent studies have utilized the auxin-inducible degron system to degrade CTCF 
or a specific subunit of the cohesin complex (Nora et al., 2017; Rao et al., 2017). 
Depletion of CTCF or a subunit of the cohesin complex led to a loss of loop 
structures present in 3C based conformation maps (Nora et al., 2017; Rao et al., 
2017). 
Degradation of CTCF was shown to result in the differential expression of 
nearly 5,000 genes in mouse which was roughly evenly split between 
upregulated and downregulated genes (Nora et al., 2017). Downregulated genes 
due to CTCF degradation were enriched in CTCF near promoters which 
suggested a role for CTCF/cohesin loop formations in promoting the activity of 
these genes. However, few of these genes overlap with loop structures that 
would connect their promoter to an active enhancer region. Hence, CTCF 
degradation is likely not directly disrupting promoter-enhancer loops formations. 
Instead of CTCF functioning to actively link promoter with enhancer, its role in 
gene regulation may be more often inhibitory. Indeed, when analyzing 
upregulated genes after CTCF degradation, a higher majority of upregulated 
 
 22 genes were genomically closer to active enhancers than down-or non-regulated 
genes (Nora et al., 2017). Such a result would support CTCF/cohesin loops as 
forming insulated neighborhoods preventing ectopic interactions between 
promoters and enhancers which reside in different loop domains.  
Contrary to a model where CTCF/cohesin loops function to prevent 
ectopic promoter-enhancer interactions, degradation of a cohesin subunit 
resulted in a limited number of gene activations. Only roughly 1% of the 
unexpressed genes prior to cohesin subunit depletion were activated after 
subunit depletion (Rao et al., 2017). Upon examining expressed genes before 
cohesin subunit depletion, the large majority of these genes presented similar 
expression levels after cohesin subunit depletion and subsequent loss in loop 
formations (Rao et al., 2017). Hence, while a small subset of genes may be 
affected by a loss in CTCF/cohesin mediated loops, results from degradation 
studies imply CTCF/cohesin looping structures may play a limited role in gene 
regulation.  
Beyond CTCF and cohesin, promoter-enhancer interactions may be 
mediated by other factors. The transcription factor Yin Yang 1 (YY1) is known to 
bind both enhancer and promoter elements and can form dimers. Deletion of 
YY1 binding sites or depletion of YY1 has been shown to disrupt chromatin loop 
formations and alter gene expression (Weintraub et al., 2017). Another factor 
with evidence for facilitating promoter-enhancer interactions is the transcriptional 
coactivator mediator. Mediator forms a complex with cohesin capable of 
 
 23 connecting distal genomic loci. 3C studies show occupancy of mediator and 
cohesin at promoter and enhancer elements predicts chromatin loop formation 
linking enhancers to the promoters of Nanog, Oct4, Phc1, and Lefty1 in mouse 
(Kagey et al., 2010). Aside from protein complexes, there is also evidence non-
coding RNAs may play a role in stabilizing promoter-enhancer interactions (Lai et 
al., 2013; Hsieh et al., 2014). Many questions still remain regarding how these 
factors coincide with CTCF/cohesin loops and their effect on transcription.  
Identification of promoter-enhancer interactions is fundamental to the 
mapping of regulatory pathways and critical to the dissection of abnormal 
regulation in diseased states. High resolution Hi-C interaction maps are a 
powerful resource for the detection of promoter-enhancer looping interactions 
(Rao et al., 2014). A chromatin loop in a Hi-C map appears as a ‘dot’ of 
significant interaction intensity above its background neighborhood. These dots 
represent the high probability of interactions between anchors of loop loci, 
commonly CTCF sites brought together in close proximity by the cohesin 
complex in the loop extrusion model (Fudenberg et al., 2016). From a 
computational standpoint, genome wide identification of these loci presents a 
significant challenge. Dots representing chromatin loops appear at a resolution of 
~10 kb in a Hi-C interaction map. At this resolution, investigating every 3D 
interaction in a map of the human genome would require the investigation of over 
a hundred billion pairs of loci.  
 
 24 Several computational methods have been developed for the identification 
of looping interactions in Hi-C interaction maps. These methods typically come in 
two flavors: (1) significant enrichment of looping interaction above global 
background (all interactions at equivalent genomic distance), or significant 
enrichment of looping interaction above a local background (interactions 
occurring in an ~50 kb radius surrounding looping interaction). In both methods, 
significant enrichment is determined using binomial or Poisson statistics and 
resultant p-values are corrected for multiple testing (Ay, Bailey and Noble, 2014; 
Rao et al., 2014; Mifsud et al., 2017). While these methods have been successful 
in identification of loops and promoter-enhancer contacts, the reproducibility of 
significant interactions between replicates was shown to be low for all methods 
(Forcato et al., 2017). Furthermore, the number of looping interactions identified 
was shown to be dependent upon sequencing depth, which could convolute 
results made from samples of differing coverage (Forcato et al., 2017). It is also 
important to note that identified significant interactions represent only 3D looping 
interactions which may or may not link a promoter and enhancer. As Hi-C 
interaction maps represent a population average, some dynamic promoter-
enhancer interactions may also fail to be identified as significant via such loop 
calling methods. It follows, while 3D conformations assays provide evidence for 
promoter-enhancer interactions, they may be most suitable when investigating 
candidate promoter and enhancer elements identified previously by other 
genomic assays.  
 
 25 As less than 2% of the human genome is comprised of protein coding 
sequences, annotating non-coding enhancer elements and their target promoters 
could lead to important discoveries in disease pathologies, particularly when 
disease causing genetic variations lie outside of coding genes (Alexander et al., 
2010). It follows, the annotation of enhancer elements is a primary goal for many 
scientific groups including the Encyclopedia of DNA elements (ENCODE) 
consortium, a community consisting of dozens of research groups specializing in 
various fields of genomics (Dunham et al., 2012). Numerous computational 
methods have utilized assays that identify open chromatin regions (e.g. DNase-
seq) or specific histone marks associated with enhancer activity (e.g. H3K27ac or 
H3K4me1 ChIP-seq) to identify enhancer elements (Ernst et al., 2011; Hoffman 
et al., 2012; Thurman et al., 2012; Rajagopal et al., 2013; Kundaje et al., 2015). 
In some cases, enhancers do not always activate their nearest gene in terms of 
linear sequence space complicating the mapping of enhancers to their gene 
targets (Lettice et al., 2003). This difficulty in linking promoters with enhancers 
has been resolved via chromosome conformation assays similar to methods 
described earlier (Li et al., 2012; Mifsud et al., 2015) or by correlating genomic 
and epigenomic signals at enhancers and promoters across a range of varying 
biosamples (Ernst et al., 2011; Thurman et al., 2012). Such efforts have led to 
lists of candidate regulatory enhancer elements in a variety of different tissue 
types. However, while genetic or epigenetic marks along with 3D proximity 
information may be predictive of enhancer activity such assays do not provide a 
 
 26 ground truth for enhancer identification. To validate an enhancer one must show 
its presence definitively leads to the expression of its target gene.   
The canonical method for validating enhancer activity is to clone an 
enhancer sequence upstream of a minimal promoter of a reporter gene (e.g. 
LacZ) and analyze reporter gene expression. Using such methods in vivo, the 
VISTA enhancer browser contains results from the interrogation of hundreds of 
enhancer sequences (Visel et al., 2007). Here, the enhancer reporter construct is 
microinjected into a fertilized mouse egg followed by implantation into a female 
mouse. LacZ staining of the harvested mouse embryo reveals tissue specific 
enhancer activity (Visel et al., 2007). A drawback to such transgenic mouse 
assays, is that transfection of the enhancer reporter construct leads to random 
integration in the mouse genome. Hence, while results from reporter assays 
validate enhancer function they do not take into account the enhancer’s native 
chromatin context.  
The CRISPR/Cas9 genome editing system can be utilized to delete 
genomic sequences inside the nucleus of the cell (Cong et al., 2013; Yao et al., 
2014; Won et al., 2016). This is accomplished by the design of single-guide 
RNAs (sgRNAs) complementary to regions flanking the DNA sequence selected 
for deletion. The binding of sgRNA to a catalytically active Cas9 protein guides 
Cas9 to a site flanking the selected DNA sequence for subsequent Cas9 
mediated cleavage. To validate enhancer function, this method can be adapted 
to deletion of a candidate enhancer element. Quantitative measuring of gene 
 
 27 expression for the candidate enhancer target before and after CRISPR/Cas9 
mediated deletion of the enhancer sequence provides validation of enhancer 
function within the enhancer’s original chromatin environment (Yao et al., 2014; 
Won et al., 2016).   
Even when applying current methods and technologies, identification and 
validation of promoter-enhancer interactions remains a significant challenge. 
Chapter III of this thesis utilizes Hi-C experiments to assay the 3D genome 
architecture in human glial cells, neural progenitor cells and neurons. The 
resultant Hi-C interaction maps are used to predict cell-type specific promoter-
enhancer interactions occurring at or near schizophrenia risk variants. Upon 
identification of risk variants in close spatial proximity to potential gene targets, 
CRISPR/Cas9 strategies are applied to test the regulatory functions of risk 
variant loci.  
Schizophrenia, Neurons, and 3D organization 
 Symptoms of schizophrenia include hallucinations, delusions, 
disorganized speech, and social withdrawal, along with a broad set of cognitive 
dysfunctions (Kahn et al., 2015). Schizophrenia is not considered a rare disorder. 
Studies of disease prevalence estimate about seven individuals per one 
thousand will develop schizophrenia during their lifetime (McGrath et al., 2008). 
The disorder has also been shown to have an effect on average life span. Based 
on the standardized mortality ratio, individuals diagnosed with schizophrenia 
 
 28 have a two to threefold increased risk of dying with suicide as a main contributing 
factor (McGrath et al., 2008).    
 Current treatments of schizophrenia rely on the action of antipsychotic 
drugs such as chlorpromazine or clozapine which block receptors in the 
dopamine pathway (Kane and Correll, 2010; Miyamoto et al., 2012). While such 
antipsychotic drugs help to manage patient symptoms, in many cases, patients 
symptoms are either resistant to treatment or successful symptom treatment is 
accompanied by adverse side effects (Lally and MacCabe, 2015). It follows, 
specialized treatments taking into account patient specific characteristics may 
result in healthier patient outcomes. However, the lack of knowledge in regard to 
the etiology of schizophrenia presents a major challenge to the advent of 
improved or specialized therapeutics to treat the disorder.  
 While the etiology of schizophrenia is largely unknown, evidence suggests 
that along with environmental factors the disorder carries a heritable genetic 
component. In a study of over 30,000 twin pairs born in Denmark with 448 twin 
pairs affected by schizophrenia, heritability of the disorder was estimated to be 
79% in accordance with previous studies (Sullivan, Kendler and Neale, 2003; 
Hilker et al., 2018). Both rare and common allele variants have been implicated 
in the pathology of schizophrenia (McClellan, Susser and King, 2007; Purcell et 
al., 2009). To further explore this landscape of genetic variants, large scale 
genome-wide association studies (GWAS) have been employed to search for 
SNPs associated with schizophrenia. A recent GWAS encompassing genotypes 
 
 29 from 36,989 schizophrenia cases and 113,075 controls reported 108 risk loci 
harboring risk variants significantly associated with the disorder (Ripke et al., 
2014). Expanding upon this study, Pardiñas and colleagues performed GWAS 
analysis on an additional 11,260 cases and 24,542 controls, which resulted in the 
identification of 50 additional novel risk loci (Pardiñas et al., 2018). When risk loci 
were overlapped with epigenetic marks for active enhancers, risk SNPs were 
found to be enriched in enhancers active in brain (Ripke et al., 2014).  
 The enrichment of schizophrenia risk SNPs at active enhancers in brain 
suggests disruption of regulatory mechanisms may underlie disorder pathology. 
Such a model would assign a possibility of risk to noncoding variants which, 
unlike coding variants, are incapable of directly altering the amino acid 
composition of a protein product. Supporting this model, schizophrenia risk 
variants were shown to be enriched for alleles that affect gene expression and lie 
within promoter or enhancers (Roussos et al., 2014). Expression quantitative trait 
loci (eQTLs) are defined as loci containing variants which alter gene expression 
(Nica and Dermitzakis, 2013). A schizophrenia associated eQTL within the intron 
of its target gene was found to be in closer spatial proximity to its target gene 
TSS compared with other sequences closer in genomic space (Roussos et al., 
2014). Furthermore, this eQTL variant locus resided in an enhancer region 
suggesting potential promoter-enhancer looping mechanisms may be at play.  
 It is plausible that eQTL variants located in enhancer regions could alter 
their gene target’s expression by disrupting binding of transcription factors to 
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or by disrupting promoter-enhancer loop formation, none of which are necessarily 
mutually exclusive events. In further support of risk variants modulating gene 
expression, complex trait associated SNPs are significantly more likely to be 
eQTLs than minor-allele-frequency matched SNPs (Nicolae et al., 2010).  
Additionally, when overlapping GWAS identified schizophrenia risk loci with an 
independent eQTL dataset generated from RNA sequencing of dorsolateral 
prefrontal cortex from both schizophrenia and control cases, results indicated 
~20% of schizophrenia risk loci have variants that could contribute to altered 
gene expression (Fromer et al., 2016).  
 Genetic regulatory pathways contributing to schizophrenia pathology may 
have cell type specific characteristics. Neurons and glial cells make up two broad 
classes of cells in the nervous system. Neurons are electrically excitable capable 
of relaying information through electrical impulses, while glial cells provide 
mechanical and metabolic support for neurons among other functions (Squire et 
al., 2008). Recent studies have shown a preferential link between schizophrenia 
risk architecture and the neuron cell type (Genovese et al., 2016; Skene et al., 
2018). Correlations between cell type specificity and enrichment for 
schizophrenia SNP heritability across genes, associated neurons with 
schizophrenia risk architecture over embryonic, progenitor or glial cells (Skene et 
al., 2018). Similarly, an analysis of ultra-rare variants, reported individuals with 
schizophrenia were enriched for ultra-rare variants in genes that were neuronally 
 
 31 expressed (Genovese et al., 2016). It follows that an analysis of cell type specific 
gene regulation systems may lead to pivotal observations concerning 
schizophrenia etiology.  
 Human induced pluripotent stem cell (hiPSC) technology has advanced 
the study of human disease mechanisms in vitro. Over a decade ago it was 
discovered adult mice fibroblasts can be reprogrammed into pluripotent stem 
cells by the introduction of four transcription factors: Oct3/4, Sox2, c-Myc, and 
Klf4 (Takahashi and Yamanaka, 2006). Building upon this, Brennand and 
colleagues reprogrammed fibroblasts from schizophrenia patients into hiPSCs 
followed by subsequent differentiation into both neural progenitor cells (NPCs) 
and neurons (Brennand et al., 2011). RNA analysis of control and schizophrenia 
hiPSC neurons showed differential expression in several genes characterizing 
potential regulatory mechanisms of the disorder (Brennand et al., 2011). Further 
advancements in hiPSC technology has led to the differentiation of hiPSC 
derived NPCs by overexpression of the neuronal transcription factor, NGN2, 
producing near pure populations of postmitotic neurons capable of forming 
mature pre and post-synaptic formations (Ho et al., 2016). Alternatively, hiPSC 
derived NPCs may also be differentiated into astrocytes of the glial lineage 
capable of responding to inflammatory stimulants and displaying phagocytic 
capacity (TCW et al., 2017). Such methods provide new systems for testing the 
effects of differentiation and cell type specificity on regulatory gene networks and 
3D genome organization.  
 
 32  Gene expression changes influence determination of cell type and cell fate 
(Dunham et al., 2012; Wang et al., 2018). However, much is still unknown 
regarding the mechanisms of cell type specific regulation and the related role of 
3D genome architecture. Many 3D genome conformations are conserved across 
a variety of cell types, tissues, and even syntenic regions between species 
(Dixon et al., 2012; Schmitt et al., 2016). While 3D genome architecture is highly 
conserved, cell type specific changes in 3D architecture such as compartment 
switching and altered looping contacts have been reported (Rao et al., 2014; 
Schmitt et al., 2016; Won et al., 2016). Such changes have also been described 
throughout the course of development. A/B compartment switching was observed 
upon differentiation of human embryonic stem cells (ESCs) into four other ESC-
cell-derived lineages (Dixon et al., 2015). Differentiation of mouse ESCs to neural 
stem cells resulted in a widespread gain of chromatin loop formations (Pękowska 
et al., 2018). High resolution Hi-C maps of mouse ESCs, derived NPCs and 
further derived cortical neurons revealed dynamic chromatin looping formations 
occur near genes encoding neural transcription factors in a cell type specific 
manner which correlated with gene expression (Bonev et al., 2017). Further 
experiments associating cell type specific regulatory programs with changing 3D 
architecture will help unravel the mechanisms driving cell fate and likely elucidate 
discoveries related to diseases driven by malfunctions in specific cell types.  
 Won and colleagues, characterized 3D genome architectures in human 
brain development in the context of associating the 3D genome with 
 
 33 schizophrenia risk variants (Won et al., 2016). This study generated Hi-C maps 
of bulk tissue from the germinal zone (primarily neural progenitor cells) and 
cortical plate (primarily adult neurons). In Chapter III, we expand upon this study 
by applying hiPSC technology to produce high resolution Hi-C maps of hiPSC 
derived NPCs, glial cells and neurons. Such contact maps allowed for analyses 
revealing cell type specific chromatin conformation changes which we further 
studied in the context of schizophrenia risk.  
 In the next section, I move away from the 3D genome and introduce 
background relevant to Chapters IV and V, which describe computational 
methods for prediction of T cell receptor antigens via 3D structural information. 
TCR-pMHC Interactions 
In humans and other vertebrates, T cells and B cells cooperate in the 
adaptive immune system to protect the body from invading pathogens. 
Immunological protection is facilitated via recognition, elimination and memory of 
such pathogens (Owen et al., 2013). While B cells produce antibodies which can 
directly bind pathogen antigens and signal for their destruction, most T cells 
recognize antigens displayed by specific proteins termed major histocompatibility 
complex (MHC) molecules, on the surface of antigen presenting cells 
(Zinkernagel and Doherty, 1974). Upon recognition of pathogenic antigens 
displayed on infected cells, T cells may initiate the direct killing of such infected 
cells or trigger other immune cells to attack the identified pathogen.  
 
 34  Before a T cell is equipped to successfully and specifically target infected 
cells, each T cell must be tested for competence during development. T cell 
precursors originating in the bone marrow travel to the thymus via the 
bloodstream to undergo critical developmental processes including: T cell 
receptor formation, positive selection and negative selection (Koch and Radtke, 
2011).   
 T cells use T-cell receptors (TCRs) to recognize antigens displayed by 
MHC molecules on infected cells. The TCR is made up of two chains linked by 
disulfide bonds on the cell surface. These chain pairs are typically α and β, or γ 
and δ, which are encoded by the four genetic loci TRA, TRB, TRG, TRD, 
respectively. αβ T cells represent the dominant participants in adaptive immune 
functions and will be the focus of work presented in this thesis. In order to 
recognize a diverse and broad range of hazardous antigens, αβ T cells in the 
blood encompass a large repertoire of variable αβ TCRs, estimated to be on the 
order of 107 unique αβ TCRs per human (Arstila et al., 1999). This large 
assortment of variable TCRs is accomplished by V(D)J recombination events 
during thymic development.  
 Within each TRA and TRB locus, multiple genes exist to encode single 
domains of the TCR chain. For example, in humans, the TRB locus contains over 
60 genes encoding the variable domain of the TCR β chain (Lefranc, 2011). 
V(D)J recombination of these genes leads to the translation of a functional chain 
encoded by a random subset of these genes (Hozumi and Tonegawa, 1976). 
 
 35 Nucleotide deletions and insertions during the recombination process, and 
combinatorial αβ pairing, leads to further diversification of the TCR repertoire. 
Hence, before successful exit from the thymus, each T cell will express a distinct 
TCR, such that a population of mature T cells will be adequate for recognition of 
variable pathogenic antigens.  
 Once a T cell has formed a TCR, functional testing of the TCR takes place 
during positive selection. Here, further maturation of the T cell is dependent upon 
the affinity between the TCR and MHC molecules of an antigen presenting cell 
displaying self (non-foreign) antigens. If binding between TCR and self-antigen-
MHC is not strong enough, the developing T cell will not be positively selected 
and instead undergo apoptosis (Boehmer and Kisielow, 1990; Starr, Jameson 
and Hogquist, 2003). Therefore, positive selection functions to ensure the 
population of mature T cells are capable of recognizing antigen-MHC targets. 
However, strong recognition of self-derived antigens is hazardous, as this could 
lead to an immune response and attack against healthy cells and tissues. To 
ensure the mature T cell engages the correct targets, negative selection deletes 
T cells with too strong an affinity for self-antigen-MHC complexes (Boehmer and 
Kisielow, 1990; Starr, Jameson and Hogquist, 2003). Finally, if a T cell survives 
both positive and negative selections in the thymus, it is then recruited to 
secondary lymphoid organs such as the lymph node to patrol for harmful 
invaders.  
 
 36  The first step toward an immune response occurs via recognition of 
antigen-MHC by a patrolling TCR. These MHC molecules are highly polymorphic 
with over 25,000 recorded human MHC alleles (Robinson et al., 2020). The high 
degree of polymorphism has been attributed to evolutionary causes, whereby 
infectious diseases may drive MHC polymorphism (Radwan et al., 2020). Antigen 
presenting MHC molecules are categorized into distinct classes. Class I MHC 
molecules are comprised of a single α chain noncovalently bound to a β2-
microglobulin protein. These molecules are expressed on the surface of the 
majority of nucleated cells in the body, and they display peptide fragments from 
endogenous antigens degraded in the cytosol. In contrast, class II MHC 
molecules are comprised of an α chain and a noncovalently associated β chain, 
are expressed in a limited set of cell types, and they display peptide fragments 
from exogenous antigens endocytosed into the cell (Owen et al., 2013). 
 During thymic development T cells also commit to a specific cell lineage 
by expression of either cluster of differentiation 4 (CD4) or cluster of 
differentiation 8 (CD8) coreceptor molecules. These coreceptors maintain 
specific binding preferences, such that CD4+ T cells interact with MHC class II 
molecules and CD8+ T cells interact with MHC molecules of class I (Germain, 
2002). Upon recognition of antigen, these T cell lineages have varying effector 
functions. CD4+ T cells (helper T cells) help to activate an immune response by 
stimulating responses in other cells; for example, helper T cells can stimulate B 
cells to produce antibodies to opsonize pathogenic targets (Crotty, 2015). 
 
 37 Alternatively, CD8+ T cells (cytotoxic T cells) are capable of directly killing 
infected cells; for example, cytotoxic T cells may release serine proteases into 
the target cell triggering caspase activation and cell death (Barry and Bleackley, 
2002). Hence, the MHC class preference of T cell coreceptors also functions to 
guide T cell specific effector functions toward their appropriate target cell type. 
Given the larger setting of how T cells mount an immune response, the 
remainder of this introduction will focus on a specific step in the immune 
response, namely the interaction between TCR and peptide-MHC (pMHC) 
(Figure 1.3).  
 
Figure 0.3F igure 1.3 |  Cryst al structure of TCR-pMHC complex 
Figure 1.3 | Crystal structure of TCR-pMHC complex.                                                                                                                              
Crystal structure of the human A6 TCR (α chain:green, β chain: orange) 
recognizing the Tax peptide (magenta) and MHC allele HLA-A*02:01 (cyan). β2-
microglobulin is shown in yellow (Garboczi et al., 1996).  
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 In 1987, Bjorkman and colleagues successfully determined the first MHC 
structure, the human HLA-A2 molecule. The crystal structure revealed 
membrane distal domains formed a β-sheet platform topped by α-helices with a 
long groove between the helices, likely representing the location for bound 
peptide antigen (Strominger et al., 1987). Determination of the class I MHC 
structure led to many hypotheses concerning the docking orientation of an 
interacting TCR. It was not until nearly a decade later that human and mouse 
TCR-pMHC complex structures would be solved, and these provided answers to 
previous hypotheses (Garboczi et al., 1996; Garcia et al., 1996). In both reports, 
the TCR was found to dock in a conserved diagonal orientation over the pMHC 
molecule surface (Figure 1.3).  
 The variable domain of each TCR α and β chain contains three 
complementarity-determining region (CDR) loops. CDR1 and CDR2 loops are 
encoded by the variable gene segment, while the CDR3 loops are encoded by 
the junction of variable and joining (or variable, diversity, and joining) gene 
segments, leading to a greater diversity in CDR3 (Hughes et al., 2003). The 
solved TCR-pMHC structures showed that the CDR3 loops were primarily 
positioned to contact the peptide antigen, whereas the less diverse CDR1 and 
CDR2 loops were positioned closer to the MHC helices. Placing the more diverse 
TCR region over the peptide makes logical sense, as this could help improve 
discrimination against the vast space of foreign peptide antigens. Future studies 
 
 39 have shown a consensus of diagonal docking topologies for TCR interactions 
between class I and class II pMHC complexes, although atypical docking 
topologies do exist (Rossjohn et al., 2015).   
 Due to negative selection, TCRs bind pMHC molecules with weak 
affinities and short half-lives in comparison with antibody-antigen affinities. 
Dissociation constants, KDs, from TCR-pMHC binding assays are in the 
micromolar range (KD = 0.1 µM – 500 µM) and half-lives are on the order of 
seconds (Cole et al., 2007, 2013; Bridgeman et al., 2012).  
 Structural features of the TCR-pMHC interface have been associated with 
affinity changes. The α-helices which cradle the peptide in MHC class I 
molecules are closed at their ends in contrast to an open conformation in MHC 
class II structures (Brown et al., 1993). This structural feature conforms to MHC 
class I molecules displaying peptides with lengths typically ranging from eight to 
ten amino acids, while class II molecules can display peptides with lengths 
beyond fourteen amino acids, protruding from open ends of the MHC binding 
groove (Bjorkman, 2015). The different antigen surfaces of pMHC classes are 
associated with a change in binding affinity by interacting TCRs. Specifically, 
TCR-pMHC affinities for class I pMHC molecules are stronger, on average, 
compared with class II pMHC molecules. Changes in affinity were ascribed to 
significantly greater on-rates for TCRs binding with class I pMHC compared with 
class II pMHC, while similar off-rates were reported (Cole et al., 2007). 
 
 40   Aside from structural distinctions due to MHC class, weaker affinities for 
pMHC have also been noted for autoreactive TCRs binding self peptides 
compared with canonical TCRs engaging foreign peptides (Bridgeman et al., 
2012). This observation may be in concordance with thymic selection, whereby 
the weak binding of such autoreactive TCRs works to prevent harmful 
autoimmune responses.  
 Structural conformations of the TCR also play a role in determining 
binding affinity. Increased contacts made between the TCR CDR3 loops and 
peptide result in higher affinity TCR-pMHC interactions (Cole et al., 2013). 
Furthermore, structure based design methods have led to the development of 
TCR mutants capable of binding pMHC up to 400 times more strongly than 
wildtype TCR (Haidar et al., 2009; Zoete et al., 2013; Malecek et al., 2014; Pierce 
et al., 2014). Collectively, such studies support the hypothesis that 3D 
interactions at the TCR-pMHC interface can be used to inform studies aimed at 
altering TCR-pMHC binding affinity.  
Binding affinity for TCR-pMHC complexes can be determined using 
surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) 
experiments. In SPR experiments, binding affinity is quantified by optically 
measuring how fast light travels through a sensor surface (i.e. measuring the 
refractive index of the sensor surface). Here, the sensor surface makes up the 
floor of a flow cell, through which an aqueous solution can pass under continuous 
flow. To detect binding, a ligand (e.g. pMHC) is immobilized onto the sensor 
 
 41 surface, while an analyte (e.g. TCR) is flowed over the ligand bound surface. As 
the analyte binds to the ligand, an accumulation of binding complexes on the 
surface leads to a change in the refractive index of the surface. Analyzing these 
changes in refractive index over time and at different concentrations of analyte 
leads to determination of analyte-ligand binding affinity, KD (Merwe, 2000). 
Similarly, ITC experiments can be used to derive KD values for TCR-pMHC 
interactions by directly measuring changes in enthalpy. However, ITC is rarely 
used for analyzing TCR-pMHC binding due to the much larger amounts of protein 
required for the study in comparison to SPR (Miller et al., 2007). Indeed, the vast 
majority of affinity values used for training and testing in Chapter IV were 
obtained from SPR experiments.  
 Several methods exist for the computational prediction of TCR-pMHC 
interactions. These methods can be categorized as either sequence based or 
structure based depending on the information used for prediction. Sequence 
based methods rely on machine learning algorithms that input sequence features 
of TCRs, peptides, and MHC molecules during model training. Such methods 
have been utilized to predict immunogenicity of a peptide or to predict reactivity 
of a TCR sequence (Tung et al., 2011; Gielis et al., 2019). Structural based 
methods rely on energy force fields and scoring functions, sometimes in 
combination with machine learning, to predict TCR-pMHC interactions. Such 
methods have similarly been utilized to predict immunogenicity of a peptide, but 
 
 42 also to predict TCR-pMHC binding affinity (Pierce and Weng, 2013; Lanzarotti, 
Marcatili and Nielsen, 2018; Schneidman-Duhovny et al., 2018).  
 Although TCR-pMHC binding is a prerequisite for an immune response, 
binding affinity does not directly confer immunogenicity (Stone and Kranz, 2013). 
Extracellular TCR-pMHC binding causes a cascade of intracellular signaling 
events which eventually leads to activated transcription factors initiating immune 
response programs (Owen et al., 2013). Experimental assays measuring T cell 
proliferation, cytotoxicity, or cytokine secretion are vital toward unraveling the 
larger picture of antigen immunogenicity.  
 In Chapters IV and V, I focus on the TCR-pMHC interaction in the context 
of antigen prediction via structural properties. Chapter IV introduces the 
development of a publicly available database, Altered TCR Ligand Affinities and 
Structures (ATLAS), linking 3D TCR-pMHC complexes with their experimentally 
measured binding affinities. Regression analyses performed with data from 
ATLAS were used to predict hundreds of TCR-pMHC binding energies. In 
Chapter V, we repurpose deep sequencing data to expand previous antigen 




 43 CHAPTER II: COMPARTMENT-DEPENDENT CHROMATIN 
INTERACTION DYNAMICS REVEALED BY LIQUID CHROMATIN 
HI-C 
Preface 
 This chapter is adapted from a manuscript currently under review at 
Nature Genetics authored by Houda Belaghzal, myself, Andrew D. Stephens, 
Denis L. Lafontaine, Sergey Venev, Zhiping Weng, John F. Marko, and Job 
Dekker titled: Compartment-dependent chromatin interaction dynamics revealed 
by liquid chromatin Hi-C. 
 The project was conceived by Job Dekker. 3C, 5C, Hi-C and liquid 
chromatin Hi-C and chromatin fractionation experiments were performed by 
Houda Belaghzal. Restriction digestion efficiency (DpnII-seq) experiments were 
performed by Denis L. Lafontaine. Micromechanical studies and their analysis 
was performed by Andrew D. Stephens. Data analysis was performed by myself 
and Houda Belaghzal. Specifically, I computationally processed liquid chromatin 
Hi-C sequencing datasets, developed the liquid-chromatin-Hi-C computational 
analysis toolkit to calculate LOS and t1/2 stability metrics, developed the DpnII-
seq computational pipeline, processed and analyzed fragment size assessment 
sequencing data, and performed the sub-nuclear structure analysis. Tools for 
liquid chromatin Hi-C analysis were contributed by Sergey Venev. Polymer 
scaling ideas relevant to data interpretation were provided by John F. Marko. The 
 
 44 paper was written and figures produced by Houda Belaghzal, myself, and Job 
Dekker with contributions from all coauthors.  
Abstract 
 Nuclear compartmentalization of active and inactive chromatin is thought 
to occur through microphase separation mediated by interactions between loci of 
similar type. The nature and dynamics of these interactions are not known. We 
developed liquid chromatin Hi-C to map the stability of associations between loci. 
Before fixation and Hi-C, chromosomes are fragmented, removing the strong 
polymeric constraint to enable detection of intrinsic locus-locus interaction 
stabilities. Compartmentalization is stable when fragments are over 10-25 kb. 
Fragmenting chromatin into pieces smaller than 6 kb leads to gradual loss of 
genome organization. Lamin-associated domains are most stable, while 
interactions for speckle and polycomb-associated loci are more dynamic. 
Cohesin-mediated loops dissolve after fragmentation. Liquid chromatin Hi-C 
provides a genome-wide view of chromosome interaction dynamics. 
Introduction 
 Genomic and imaging approaches are producing high-resolution 
descriptions of the conformation of chromosomes in cell populations, in single 
cells, across the cell cycle, and during development (Lieberman-Aiden et al., 
2009; Bickmore and Van Steensel, 2013; Nagano et al., 2017; Naumova et al., 
2013; Nagano et al., 2013; Rao et al., 2014; Bonev and Cavalli, 2016; Wang et 
al., 2016; Dekker and Mirny, 2016; Ramani et al., 2017; Dekker et al., 2017; Hug 
 
 45 et al., 2017; Nir et al., 2018; Chen et al., 2018; Gibcus et al., 2018; Kaaij et al., 
2018). At the mega-base (Mb) scale chromosomes are compartmentalized and 
different types of chromosomal domains can be discerned. Hi-C interaction maps 
display a “plaid” pattern, which reflects the segregation of the genome in two 
major spatial compartments referred to as A and B compartments that 
correspond to open, active chromatin and closed, silent chromatin, respectively 
(Simonis et al., 2006; Lieberman-Aiden et al., 2009). High-resolution (kb) Hi-C 
maps allowed splitting compartments in 5 subtypes (A1, A2, B1, B2, and B3) that 
differ in interaction patterns and chromatin state (Rao et al., 2014). At the scale 
of tens to hundreds of kb, topologically associating domains (TADs) were 
identified as domains separated by boundaries that are in many cases bound by 
CTCF. Higher resolution Hi-C (Rao et al., 2014), ChIA-PET (Tang et al., 2015), 
and 4C data (de Wit et al., 2015; Guo et al., 2015; Vietri Rudan et al., 2015) 
showed that convergent CTCF sites at boundaries can engage in looping 
interactions. 
Major questions revolve around the molecular and biophysical processes 
by which different aspects of chromosome conformation form. TADs and loops 
between CTCF sites form via loop extrusion cohesin (Riggs, 1990; Nasmyth, 
2001; Alipour and Marko, 2012; Sanborn et al., 2015; Fudenberg et al., 2016, 
2018; Rao et al., 2017). Less is known about the processes that determine 
compartmentalization. Compartmentalization has been proposed to be the result 
of polymer phase separation driven by attractions between chromatin domains of 
 
 46 the same or similar status (Lieberman-Aiden et al., 2009; Jost et al., 2014; Di 
Pierro et al., 2016; Michieletto, Orlandini and Marenduzzo, 2016; Erdel and 
Rippe, 2018; MacPherson, Beltran and Spakowitz, 2018; Nuebler et al., 2018; 
Shi et al., 2018; Falk et al., 2019). Polymer models simulating such attractions 
can reproduce the plaid pattern characteristic of Hi-C interaction maps (Jost et 
al., 2014; Di Pierro et al., 2016; Nuebler et al., 2018; Falk et al., 2019).  
Hi-C interaction maps are steady-state datasets and do not reveal the 
biophysical nature of the interactions that drive compartment formation or the 
dynamic mobility of loci within them. Live cell imaging studies have shown that 
loci are constrained in their motion and that there is variation in the dynamics and 
mobility of loci, e.g. euchromatic vs. heterochromatic loci and loci tethered to the 
nuclear periphery vs. loci located in the nuclear interior (Marshall et al., 1997; 
Hediger et al., 2002; Thakar, Gordon and Csink, 2006; Bronshtein et al., 2009, 
2015; Therizolsa et al., 2010; Shinkai et al., 2016; Nagashima et al., 2019). 
Imaging-based studies have been instrumental in uncovering aspects of 
chromatin interactions and dynamics, but are limited in scale, i.e. only one or a 
few specific loci can be studied at one time. In addition, when whole genome 
dynamics are analyzed microscopically (e.g. (Zidovska, Weitz and Mitchison, 
2013)), positions of specific sequences have not yet been determined. Therefore, 
new approaches are required to identify and quantify the molecular processes 
and biophysical forces involved in chromatin interactions and nuclear 
compartmentalization. Here we describe liquid chromatin Hi-C, a Hi-C variant 
 
 47 that quantifies the stability of chromosome conformation and chromatin 
interactions genome-wide.   
Results  
Measuring stability of chromatin interactions and nuclear 
compartmentalization  
 The formation of spatially segregated heterochromatic and euchromatic 
domains can be viewed as microphase separation of a polymer composed of 
different types of monomers (loci). A “block copolymer” is a polymer that contains 
a series of alternating blocks (e.g., A-type and B-type, or blocks of euchromatin 
and heterochromatin), each composed of multiple monomers (A monomers and 
B monomers; Figure 2.1, A). When As attract As and Bs attract Bs, such polymer 
can fold into spatially segregated domains of As and Bs (Figure 2.1, A, (de 
Gennes, 1979; Leibler, 1980; Matsen and Schick, 1994)). Applied to chromatin in 
vivo, microphase separation may underlie the formation of segregated 
compartments. The biophysical forces and interaction dynamics that determine 
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Figure 2.1 | Approach for measuring chromatin interaction stability.           
(A) Block copolymer composed of a series of alternating A and B blocks, each 
composed of a number of monomers (left). The polymer can fold into spatially 
segregated domains of As and Bs (middle). Flory-Huggins polymer theory 
predicts that spatial segregation will occur when the product of the length of the 
blocks N (the number of monomers that make up blocks) and their effective 
preferential homotypic interaction strength χ (difference in the strength of 
homotypic interactions as compared to heterotypic (A-B) interactions) is larger 
than a critical value C. (B) Workflow to determine the stability of chromatin 
interactions genome-wide. DNA: black, varying chromatin features or proteins 
maintaining DNA conformation: grey ovals.). 
 
Whether microphase separation of a block copolymer occurs depends on 
the interaction strengths between monomers as well as the lengths of the blocks 
of monomers of each type (Figure 2.1, A). Flory-Huggins polymer theory predicts 
that spatial segregation will occur when the product of the length of the blocks (N, 
the number of monomers that make up blocks) and their effective preferential 
 
 49 homotypic interaction strength (χ, a parameter that represents the difference in 
the strength of homotypic interactions as compared to heterotypic (A-B) 
interactions) is larger than a critical value C,(de Gennes, 1979; Leibler, 1980; 
Matsen and Schick, 1994). Large blocks of a polymer can spatially segregate 
even when attractive interactions among monomers are weak, while short blocks 
will only phase separate when interactions are sufficiently strong. The 
dependence of microdomain formation on the product of block size and 
interaction strength suggests an experimental approach to quantify the strengths 
and dynamics of interactions between individual loci that drive chromosome 
compartmentalization (Figure 2.1 A, B). One can start with a compartmentalized 
state of the genome and fragment the chromosomes by in situ restriction 
digestion, and then identify conditions where chromatin fragments become so 
short that the chromatin interaction strength between the segments is not 
sufficient to maintain a phase- or microphase-separated (due to restriction of 
separation by the polymeric constraint) state. As a result, chromosomal domains 
and compartments will disassemble over time and the chromosomal fragments of 
different type (e.g., As and Bs) will become mixed, i.e. chromatin becomes liquid-
like. The kinetics of this dissolution and mixing process can then be assessed 
genome-wide by Hi-C at different times after chromatin fragmentation. Domains 
formed by strong, stable, and abundant interactions will dissociate more slowly 
than domains formed by weak, unstable, or infrequent interactions (Figure 2.1, A, 
B). Here we describe such a strategy that we call liquid chromatin Hi-C. 
 
 50 Chromosome conformation in isolated nuclei 
 To facilitate enzymatic fragmentation of chromosomes, we isolated nuclei 
from K562 cells. We performed four analyses to demonstrate that chromosome 
conformation in isolated K562 nuclei was the same as that in intact cells. First, 
DAPI staining and imaging showed that nuclei were intact with Lamin A as a ring 
at the nuclear periphery (Figure 2.2, A). Second, using 3C (Dekker et al., 2002) 
we readily detected known looping interactions in the beta-globin locus (Dostie et 
al., 2006; Chien et al., 2011) (Figure 2.3). Third, 5C analysis (Dostie et al., 2006) 
of a 1 Mb region surrounding the beta-globin locus showed that known CTCF-
mediated interactions were preserved (Figure 2.3, (Tolhuis et al., 2002; Dostie et 
al., 2006; Splinter et al., 2006; Kang et al., 2017). Fourth, genome-wide Hi-C 
analysis (Lieberman-Aiden et al., 2009; Belaghzal, Dekker and Gibcus, 2017) 
confirmed that chromosome territories, compartments (determined by principle 
component analysis, with compartments captured by the first principle 
component (PC1 (Lieberman-Aiden et al., 2009; Belaghzal, Dekker and Gibcus, 
2017)), TADs, and CTCF-CTCF loops were intact in isolated nuclei and 
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Figure 2.2 | Extensive fragmentation of chromatin leads to liquefied 
chromatin.                                                                                                                                 
(A) Nuclear and chromatin morphology before and after chromatin fragmentation.  
Top row: control nuclei in restriction buffer, middle row nuclei digested for 4 hours 
with HindIII. Bottom row: nuclei digested for 4 hours with DpnII. Nuclei were 
stained with DAPI (left column), with antibodies against Lamin A (middle column). 
The right column shows the overlay of the DAPI and Lamin A stained images. 
HindIII digestion did not lead to major alteration in nuclear morphology and 
chromatin appearance, while DpnII digestion led to the appearance of DAPI 
stained droplets (arrow) exiting the nuclei. (B)Top: DNA purified from undigested 
nuclei, and nuclei pre-digested with DpnII and HindIII was run on a Fragment 
Analyzer. Bottom: cumulative DNA length distributions calculated from the 
 
 52 Fragment Analyzer data. (C) Micromanipulation of single nuclei. Isolated nuclei 
were attached to two micropipettes at opposite ends. Nuclei were extended by 
moving the right micropipette (Extension micropipette) and the force required 
was calculated from the deflection of the calibrated “force” (left) pipette. Blue and 
orange lines indicate the position of the force pipette before and after extension 
for control nuclei. After digestion of nuclei with DpnII (bottom) extension required 
less force as indicated by the much smaller deflection of the force pipette as 
compared to control nuclei. (D) Force-extension plots (left) for control nuclei 
before and 60 minutes after incubation in restriction buffer (pre- and post-
control), for nuclei before and after digestion with DpnII, and for nuclei before and 
after HindIII digestion. Right panel: relative change in nuclear spring constants, 
calculated from the slopes of the force-extension plots shown on the left. Bars 
indicate standard error of the mean (n = 5 DpnII pre-digested nuclei, and n = 4 




Figure 0.3F igure 2.3 |  Chromosome conformation in isolated  nuclei 
 
Figure 2.3 | Chromosome conformation in isolated nuclei.                            
(A) Hi-C 2.0 intra-chromosomal interaction maps for K562 cells display 
 
 54 chromosomal compartments and TADs. Top: cells. Bottom: purified nuclei. (B) 
5C interaction map of 1 Mb region surrounding the beta-globin locus in K562 
cells. Top: cells. Bottom: purified nuclei. CTCF-mediated interactions are 
preserved in purified nuclei.  Red circles: positions of CTCF sites, purple square 
Beta-globin locus control region (LCR). (C) 3C-PCR for a 44120 kb region 
surrounding the beta-globin LCR on chromosome 11, detects at high resolution 
the known looping interactions between the LCR and the expressed gamma-
globin genes (HBE1, HBG2) in K562 cells. Looping interactions are not detected 
in GM12878 cells that do not express these genes. Top: cells. Bottom: purified 
nuclei. (D) Compartmentalization saddle plots: average intra-chromosomal 
interaction frequencies between 100 kb bins, normalized by genomic distance. 
Bins are sorted by their PC1 value derived from Hi-C data obtained with K562 
cells. In these plots preferential B-B interactions are in the upper left corner, and 
preferential A-A interactions are in the lower right corner. Numbers in the corners 
represent the strength of AA interactions as compared to AB interactions and BB 
interactions over BA interactions. Left: cells. Right: purified nuclei. (E) Spearman 
correlation of PC1 in cells vs PC1 in nuclei for chromosome 2 at 100kb resolution 
(ρ = 0.99). 
 
Extensive chromatin fragmentation leads to the formation of liquid 
chromatin 
 We incubated purified nuclei for four hours with restriction enzymes that 
digest chromatin with different frequencies. Digestion with HindIII resulted in 
fragments that ranged in size from ~10-25 kb (Figure 2.2, B). A minority of 
molecules was over 25 kb (<15%), indicating that most of the genome was 
fragmented to a similar extent. Digestion with DpnII resulted in fragments that 
ranged in size between ~1 and ~6 kb, with less than 6% of fragments >6 kb 
(Figure 2.2, B). Microscopic inspection of nuclear morphology by DAPI and 
Lamin A immunofluorescence staining showed that fragmentation of chromatin 
with HindIII had only minor effects on nuclear morphology (Figure 2.2, A). In 
contrast, fragmentation of chromatin with DpnII led to large-scale alteration of 
 
 55 nuclear morphology as detected by DAPI staining, and large buds of apparently 
liquid chromatin (not surrounded by Lamin A) protruding from the nuclear 
periphery (Figure 2.2, A, arrow). After spinning down nuclei we detected no DNA 
in the supernatant, indicating that the liquified chromatin remains largely within 
the nuclear envelope.  
We next tested whether different chromatin fragmentation levels had an 
effect on nuclear stiffness, which reflects the integrity of chromatin interactions 
inside the nucleus. Nuclei were isolated from K562 cells, attached to two 
micropipettes at opposite ends, and the whole nucleus was extended by moving 
an extension micropipette (Methods). The deflection of a force micropipette 
provides a measure of the force (Figure 2.2, C). This data provides a force vs. 
extension plot (Figure 2.2, D, plots on the left), in which the slope of the line fitted 
to the data is the nuclear spring constant in nN/µm (Figure 2.2, D, bar plots on 
the right). Extension between 0 – 30% strain measures the chromatin-dominated 
regime of nuclear force response (Banigan, Stephens and Marko, 2017; 
Stephens et al., 2017, 2018). Isolated single nuclei were measured for their 
native spring constant before treatment. We find the stiffness can vary somewhat 
between individual nuclei. We then measured the stiffness of the same nuclei 
again 60 minutes post-treatment. Nuclei treated with control conditions (only 
restriction buffer added to the media) showed a slight stiffening of the nucleus 
(Figure 2.2, D). Treatment of nuclei with HindIII did not significantly decrease the 
stiffness as compared to their stiffness pre-treatment. In contrast, DpnII-treated 
 
 56 nuclei displayed a significant decrease (~75%) in stiffness, consistent with 
previous experiments (Stephens et al., 2017). We conclude that chromosome 
and nuclear organization can tolerate fragmentation to 10-25 kb segments. In 
contrast, fragmenting the genome to smaller than 6 kb segments results in 
extensive loss of chromatin-mediated stiffness.  
Compartmental segregation requires chromatin fragments larger than 6 kb 
 To determine how chromosome folding and compartmentalization is 
altered as a function of chromatin fragmentation level, we applied Hi-C before 
(conventional Hi-C) and after chromatin liquefication (liquid chromatin Hi-C). 
Nuclei were digested with either HindIII or DpnII for 4 hours followed by 
formaldehyde fixation and Hi-C analysis (Figure 2.4, A). Liquid chromatin Hi-C 
interaction maps obtained from nuclei that were pre-digested with HindIII were 
remarkably similar to those obtained with nuclei that were not pre-digested 
(Figure 2.5, A). The relationship between interaction frequency and genomic 
distance was largely unaffected (Figure 2.5, B). The ratio of intra- vs. inter-
chromosomal interactions was also highly similar to that in untreated nuclei 
(Figure 2.5, B). Compartments (Figure 2.5, D) were readily detectable and 
captured by the first principle component (PC1). Compartment positions were 




Figure 0.4F igure 2.4 |  Chromosome conformation d issolut ion upon  chromatin fragment ation  
Figure 2.4 | Chromosome conformation dissolution upon chromatin 
fragmentation.                                                                                                                       
(A) Workflow for Liquid chromatin Hi-C. (B) Illustration of loss of structure metric 
using a pre-digested sample and a control. (C) Hi-C interaction maps and 
 
 58 compartmentalization saddle plots for a second replicate of control nuclei 
(incubated for 4 hours in restriction buffer) and nuclei pre-digested with HindIII for 
4 hours. (D) Left: Spearman correlation of DpnII restriction digestion efficiency 
(DpnII-seq) and PC1 for chromosome 2 at 40 kb resolution. Right: Partial 
correlation of LOS (LOS residuals) with PC1 after controlling for restriction 
efficiency (DpnII-seq), for chromosome 2 at 40kb resolution. Spearman 
correlation is indicated. (E) compartmentalization saddle plots for the 
corresponding conditions. Numbers indicate strength of A-A and B-B interactions 








 60 Figure 2.5 | Hi-C analysis reveals chromosome disassembly upon 
chromatin liquefication.                                                                                      
(A) Hi-C interaction maps of chromosome 2 binned at 500 kb. Left: interaction 
map for control nuclei in restriction buffer for 4 hours. Middle: nuclei pre-digested 
for 4 hours with HindIII prior to Hi-C. Right: nuclei digested for 4 hours with DpnII 
prior to Hi-C (see Figure 2.4, A). (B) Left: genome-wide interaction frequency as 
function of genomic distance for control nuclei (dark blue), nuclei pre-digested 
with HindIII (red), and nuclei pre-digested with DpnII (cyan). Right: percentage of 
inter-chromosomal (trans) interaction frequencies. (C) Compartmentalization 
saddle plots: average intra-chromosomal interaction frequencies between 40 kb 
bins, normalized by expected interaction frequency based on genomic distance. 
Bins are sorted by their PC1 value derived from Hi-C data obtained with control 
nuclei. In these plots preferential B-B interactions are in the upper left corner, and 
preferential A-A interactions are in the lower right corner. Numbers in corners 
represent the strength of AA interactions as compared to AB interaction and BB 
interactions over BA interactions (Figure 2.10,B). (D) Top plot: Eigenvector 1 
values (PC1, 40 kb resolution) across a section of chromosome 2, representing A 
(red) and B (blue) compartments. Second plot: Loss of pair-wise interactions 
“LOS” (Methods and Figure 2.4, B) along chromosome 2 at 40 kb resolution for 
nuclei pre-digested with HindIII. Third plot: LOS for nuclei pre-digested with 
DpnII. Fourth plot: DpnII-seq signal along chromosome 2 at 40 kb resolution. 
Bottom plot: LOS-residuals for nuclei pre-digested with DpnII after correction for 
DpnII signal. (E) Correlation between LOS for nuclei pre-digested with HindIII 
(left) or DpnII (right) and PC1 (for chromosome 2, Spearman correlation values 
are indicated). (F) Left: correlation between LOS for nuclei pre-digested with 
DpnII and DpnII-seq signal (for chromosome 2). Grey line indicates moving 
average used for residual calculation. Right: correlation between LOS for nuclei 
pre-digested with DpnII and PC1 for loci cut to the same extent by DpnII (1000-
1100 DpnII-seq reads/ 40 kb bin; for chromosome 2). Spearman correlation 
values are indicated. (G) Left: partial correlation between residuals of LOS for 
nuclei pre-digested with DpnII and residuals of PC1 after correcting for 
correlations between LOS and DpnII-seq and PC1 and DpnII-seq signal. Right: 
partial correlation between residuals of LOS for nuclei pre-digested with DpnII 
and residuals of DpnII-seq signal after correcting for correlations between LOS 
and PC1 and DpnII-seq signal and PC1. Spearman correlation values are 
indicated. 
 
Chromosome compartment strength can be visualized and quantified by 
plotting interaction frequencies between pairs of 40 kb loci arranged by their 
values along the first eigenvector (PC1) to obtain compartmentalization saddle 
 
 61 plots (Figure 2.5, C). In nuclei pre-digested with HindIII, the strength of 
preferential A-A and B-B interactions (the ratio of the frequency of A-A and B-B 
interactions divided by the frequency of A-B interactions) was very similar to 
untreated nuclei (Figure 2.5, C; see Figure 2.4, C for a replicate). 
Much more extensive changes were observed when nuclei were pre-
digested for 4 hours with the frequent cutting enzyme DpnII (Figure 2.5, A) 
followed by formaldehyde fixation and Hi-C analysis. We observed a 
considerable redistribution of interactions with loss of short range (<10 Mb) intra-
chromosomal interactions, and a gain of longer range (>10 Mb) interactions and 
inter-chromosomal interactions (Figure 2.5, B). The gain in inter-chromosomal 
interactions appeared to be the result of random mixing of As and Bs from 
different chromosomes as the preference for interchromosomal A-A and B-B 
interactions decreased (Figure 2.4, E). Moreover, compartment strength in cis 
was greatly reduced with a greater relative reduction evident in the A 
compartment (Figure 2.5, C). These observations show that fragmentation in <6 
kb fragments leads to loss of spatial segregation of A and B compartments with 
more extensive loss of the A compartment.  
Quantification of chromosome conformation dissolution 
 Loss of chromosome conformation and dissolution of chromosomal 
compartments will result in random mixing of previously spatially separated loci 
both in cis and in trans. In Hi-C, this effect will be apparent by a redistribution of 
contacts from short-range interactions towards longer range and inter-
 
 62 chromosomal interactions. We developed a metric which represents the 
percentage change in short range intra-chromosomal interactions (up to 6 Mb), 
and concomitant increase in long-range and interchromosomal interactions after 
fragmentation relative to control nuclei, which we call “loss of structure” (LOS) 
(Figure 2.4, B).  
We first calculated LOS after 4 hours for chromatin fragmented with 
HindIII. We observe that in general short-range interactions are only somewhat 
reduced (less than 5%; Figure 2.5, B). When LOS is plotted along chromosomes 
(Figure 2.5, D), we observed that LOS was very weakly negatively correlated 
with PC1 (Figure 2.5, D and E left panel). 
We performed the same analysis for nuclei pre-digested with DpnII for 4 
hours. We find extensive loss of chromosome conformation, with LOS generally 
>80%. LOS varies along chromosomes and is strongly positively correlated with 
PC1 with loci in the A compartment displaying the largest loss (Figure 2.5, D and 
E). These results show that chromatin fragmentation to <6 kb fragments leads to 
extensive genome-wide dissolution of chromosome conformation, loss of spatial 
segregation of A and B compartments, with the A compartment affected the 
most. 
 
 63 After correcting for differential fragmentation LOS remains highly 
correlated with compartment status 
 One explanation for the greater effect of fragmentation on chromatin 
interactions in the A compartment could be that DpnII cuts more frequently in the 
A compartment producing smaller fragments. We performed two experiments to 
assess differential fragmentation. First, we determined the cutting frequency of 
DpnII in isolated nuclei across the genome by sequencing the ends of the DNA 
fragments (DpnII-seq; Figure 2.6, see Methods). Second, we directly determined 
the average fragment size along the genome by purifying DNA of different sizes 
after pre-digestion with DpnII, sequencing the ends and using the data to 
calculate for each 40 kb bin the average fragment size (see Methods). The 
average fragment size for most 40 kb bins ranged from 2.7 to 3.7 kb and was on 
average slightly smaller for A compartments compared to B compartments (3.1 
kb and 3.2 respectively). Cutting frequency and average fragment size are both 
correlated with PC1 and with LOS (Figure 2.5, D and F left panel, Figure 2.4, D, 
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Figure 2.6 | Experimental protocol and computational workflow for DpnII-
seq.                                                                                                                       
(A) Schematic of DpnII-seq experimental protocol for recovering DNA fragments 
digested by the restriction enzyme DpnII. (B) Directed graph of DpnII-seq 
computational pipeline (C) Histogram of distance to nearest DpnII recognition site 
for each recovered DpnII digested fragment. (D) Raw DpnII-seq signal displaying 
multiple copy number states (2N, 3N, 4N) within chromosome 3 (data binned at 
40 kb). (E) Copy number corrected DpnII-seq signal displaying single copy 
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Figure 2.7 | Average fragment size per bin and correlation with chromatin 
stability.                                                                                                                       
(A) DNA purified from nuclei pre-digested with DpnII for 4 hours were separated 
into slices of three sizes and run on a Fragment Analyzer. (B) Fragment Analyzer 
distributions of DNA fragment sizes for the three separated slices (RFU: relative 
fluorescence unit, LM: lower marker, fragment sizes at distribution peaks are 
given in blue). (C) Top plot: Eigenvector 1 values (PC1, 40 kb resolution) across 
a section of chromosome 2, representing A (red) and B (blue) compartments. 
Bottom three plots: Normalized coverage of fragments from given slice size 
across a section of chromosome 2. (D) Percentages of fragments mapped to 
 
 67 each subcompartment for given slice size. (E) Top plot: LOS along chromosome 
2 at 40 kb resolution for nuclei pre-digested with DpnII. Middle plot: Average 
fragment size estimated for every 40kb bin after pre-digestion with DpnII 
(Methods). Bottom plot: LOS-residuals for nuclei pre-digested with DpnII after 
correction for average fragment size. (F) Boxplot of average fragment size for A 
compartment and B compartment bins. Significance determined by two-sample 
two tailed t-test (p < 2.2e-16). (G) Left plot: correlation between LOS for nuclei 
pre-digested with DpnII and average fragment size. Grey line indicates moving 
average used for residual calculation. Right plot: partial correlation between 
residuals of LOS for nuclei pre-digested with DpnII and residuals of PC1 after 
correcting for correlations between LOS and average fragment size and PC1 and 
average fragment size (for chromosome 2, Spearman correlation values are 
indicated). (H) Left plot: Correlation between DpnII-seq signal and average 
fragment size. Right plot: correlation between residuals of LOS after correcting 
for average fragment size and residuals of LOS after correcting for DpnII-seq 
signal (for chromosome 2, Spearman correlation values are indicated). (I) Partial 
correlation between residuals of t1/2 and residuals of PC1 after correcting for 
correlations between t1/2 and average fragment size and PC1 and average 
fragment size. 
 
Next, we corrected LOS for the differential efficiency of DpnII digestion by 
calculating the partial correlation between LOS and PC1 after correcting for the 
correlations of PC1 and LOS with DpnII digestion frequency (see Methods for 
details). We find that the residuals of PC1 and LOS, are still correlated 
(Spearman ρ = 0.38 for chromosome 2; Figure 2.5, G). Similarly, when we 
corrected LOS for differences in average fragment size we find that the residuals 
of LOS remain highly correlated with residuals of PC1 (Spearman ρ = 0.83 for 
chromosome 2, Figure 2.7). To illustrate the correlation between LOS and PC1 
independent of fragmentation level directly we selected a set of loci along 
chromosome 2 that are all cut to the same extent (1000-1100 reads in the DpnII-
seq dataset). When we plot LOS vs. PC1 for this set we find a strong correlation 
(Figure 2.5, F right panel, Spearman ρ = 0.46). Finally, we repeated the entire 
 
 68 liquid chromatin Hi-C procedure using a different restriction enzyme, FatI, which 
has a different pattern of digestion across the genome as compared to DpnII but 
produces fragments that are similarly small (Figure 2.8). We calculated LOS and 
corrected for differential FatI digestion along the genome using FatI-seq, exactly 
as above for DpnII. We again observe a high correlation between residuals of 
LOS and PC1 (Spearman ρ = 0.64 for chromosome 2, Figure 2.8). We conclude 
that LOS is correlated with compartment status, and that this result is robust for 
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Figure 2.8 | Liquid chromatin Hi-C results are reproducible using the 
restriction enzyme FatI.                                                                                                  
(A) Restriction sites for the selected restriction enzymes. Black triangles denote 
cut sites. (B) Top plot: Eigenvector 1 values (PC1, 40 kb resolution) across a 
section of chromosome 2, representing A (red) and B (blue) compartments. 
Bottom three plots: Coverage of restriction sites (40kb resolution). Spearman 
 
 70 correlation between restriction site coverage and PC1 is given for each restriction 
site track. (C) Third replicate of DpnII predigest liquid chromatin Hi-C. Hi-C 
interaction maps of chromosome 2 binned at 500 kb. Bottom left: control nuclei in 
restriction buffer for 4 hours. Top right: nuclei digested for 4 hours with DpnII 
prior to Hi-C. Left track: Eigenvector 1 values (PC1, 40 kb resolution) across a 
section of chromosome 2, representing A (red) and B (blue) compartments. (D) 
Top plot: LOS along chromosome 2 at 40 kb resolution for nuclei pre-digested 
with DpnII. Middle plot: DpnII-seq signal. Bottom plot: LOS-residuals for nuclei 
pre-digested with DpnII after correction for DpnII-seq signal. (E) FatI predigest 
liquid chromatin Hi-C. Hi-C interaction maps of chromosome 2 binned at 500 kb. 
Bottom left: control nuclei in restriction buffer for 4 hours. Top right: nuclei 
digested for 4 hours with FatI prior to Hi-C. Left track: Eigenvector 1 values (PC1, 
40 kb resolution) across a section of chromosome 2, representing A (red) and B 
(blue) compartments. (F) Top plot: LOS along chromosome 2 at 40 kb resolution 
for nuclei pre-digested with FatI. Middle plot: FatI-seq signal. Bottom plot: LOS-
residuals for nuclei pre-digested with FatI after correction for FatI-seq signal. (G) 
Left plot: Correlation between LOS for nuclei pre-digested with DpnII and PC1. 
Right plot: partial correlation between residuals of LOS for nuclei pre-digested 
with DpnII and residuals of PC1 after correcting for correlations between LOS 
and DpnII-seq and PC1 and DpnII-seq signal (for chromosome 2, Spearman 
correlation values are indicated). (H) Left plot: Correlation between LOS for 
nuclei pre-digested with FatI and PC1. Right plot: partial correlation between 
residuals of LOS for nuclei pre-digested with FatI and residuals of PC1 after 
correcting for correlations between LOS and FatI-seq and PC1 and FatI-seq 
signal (for chromosome 2, Spearman correlation values are indicated). (I) 
Correlation between LOS for nuclei pre-digested with FatI and LOS for nuclei 
pre-digested with DpnII (genome wide, Spearman correlation values are 
indicated). (J) Correlation between residuals of LOS for nuclei pre-digested with 
FatI and residuals of LOS for nuclei pre-digested with DpnII after correcting for 
correlations between FatI LOS and FatI-seq and DpnII LOS and DpnII-seq 
(genome wide, Spearman correlation values are indicated). 
 
Dissociation kinetics of chromatin interactions and compartments 
 The loss of conformation after DpnII pre-digestion allowed us to measure 
the dissociation kinetics of compartments and stability of chromatin interactions. 
We first determined the kinetics of chromatin fragmentation (Figure 2.9, A, Figure 
2.10, A). We digested nuclei with DpnII for 5 minutes up to 16 hours. After 5 
minutes the size range of fragments was between 3 and 15 kb (80% of 
 
 71 fragments; Figure 2.11, A). After one hour 80% of DNA fragments were smaller 
than 7 kb and after 16 hours 85% of fragments were smaller than 3.5 kb. We 
sequenced DNA ends to determine the distribution of DpnII cuts across the 
genome (Figure 2.11, B). At all timepoints the number of DpnII cuts per 40 kb bin 
was correlated with PC1 (Figure 2.11, B) and the pattern did not change over 




Figure 0.10Figure 2.9 | Variations in  Half-life and  LOS are not explained by Dpn II d igestion  kinetics 
Figure 2.9 | Variations in Half-life and LOS are not explained by DpnII 
digestion kinetics.                                                                                               
(A) DpnII-seq signals along chromosome 2 after indicated times of digestion. 
 
 73 Spearman correlations between DpnII-seq and t1/2 at each timepoint is indicated. 
(B) t1/2 residuals along chromosome 2 after correcting t1/2 values by the 
correlation between t1/2 and DpnII-seq signals shown on the left obtained after the 
indicated times of digestion. Spearman correlation between t1/2 residuals and 
PC1 residuals are indicated. (C) Top: Genome wide scatterplot of t1/2 versus 1 
hour DpnII-seq signal. Gray line: moving average. Bar plot above shows the 
number of loci displaying various levels of DpnII-mediated cuts. Bottom: residuals 
of t1/2 calculated by subtracting t1/2 from the corresponding average t1/2 (gray line 
in top plot) plotted vs. number of DpnII cuts. Red dots: loci in the A compartment; 
Blue dots: loci in the B compartment. The majority of loci have 500-1100 cuts. 
When comparing loci with similar number of DpnII cut we observe that loci in the 
A compartment have shorter t1/2 values as compared to loci in the B 
compartment. (D) Top: LOS along chromosome 2 at the indicated timepoints of 
digestion and calculated by comparison to Hi-C data obtained after 1 hour of 
digestion. Middle: calculation of t1/2 from LOS at different timepoints. Bottom: t1/2 
along chromosome 2. This t1/2 is calculated using the Hi-C data obtained after 1 
hour of pre-digestion as starting point. (E) Partial correlation between LOS and 
PC1 after correcting for their correlations with DpnII-seq. LOS (at 2 hours) is 
calculated as in panel C using the Hi-C data obtained after 1 hour of pre-
digestion as starting point (F) Partial correlation between t1/2 and PC1 after 
correcting for their correlations with DpnII seq. t1/2 is calculated as in panel D 
using the Hi-C data obtained after 1 hour of pre-digestion as starting point. 
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Figure 2.10 | Liquid chromatin-Hi-C protocol and quantification of loss of 
structure after chromatin pre-digestion.                                                          
(A) Workflow for Liquid chromatin Hi-C timecourse. CL = cross-linking step. (B) 
Compartment strength derived from compartment saddle plots (See Methods). 
Left: Diagram depicting compartment strength calculation for B-B interactions. 
 
 75 Plot to the right of diagram: B-B interaction strength as a function of bin number 
for all timepoints of the time course. Right: Diagram depicting compartment 
strength calculation for A-A interactions. Plot to the right of diagram: A-A 
interaction strength as a function of bin number for all time points of the time 
course. (C) Top: LOS signal across a 40 Mb region on chromosome 2 calculated 
for indicated timepoints in the digestion timecourse. Line colors as in Figure 2.11, 
E. Bottom: Exponential curve fit to LOS timepoints for a single 40kb bin. t1/2 
(dashed vertical blue line) representing time elapsed to reach half saturation of 
LOS signal. (D) Left: Density distributions of t1/2 for A and B compartments. Right: 
t1/2 saddle plots: average intra-chromosomal interaction frequencies between 40 
kb bins, normalized by genomic distance. Bins are sorted by their t1/2 value 
derived from digestion timecourse. Bins with high t1/2 preferentially interact 
(bottom right of heatmap) and bins with low t1/2 preferentially interact (top left of 
heatmap). (E) Scatterplot of t1/2 vs t1/2 for two timecourse replicates (R1 and R2) 
on chromosome 2. Regression line (red). Spearman correlation is indicated. (F) 
Scatterplot of PC1 vs t1/2 for chromosome 2. A compartment (red); B 
compartment (blue). (G) Left: Scatterplot of percent interactions occurring in cis 
within a 6 Mb distance out of total genome wide interactions for each 40 kb bin in 
control Hi-C map (Cis %) vs PC1. Middle: Cis% vs t1/2. Right: Scatterplot of 
partial correlation between PC1 and t1/2 controlled by Cis %. A compartment 
(red); B compartment (blue). Solid red lines are regression lines. Spearman 
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Figure 2.11 | Kinetics of chromatin fragmentation and chromatin 
dissolution. (A) DNA purified from undigested nuclei, and nuclei pre-digested 
with DpnII for different time points were run on a Fragment Analyzer. (B) Left: 
 
 77 DpnII-seq signals along chromosome 2 binned at 40 kb resolution after digestion 
for 5 minutes, 1 hour and 2 hours. Right: correlation between DpnII-seq signals 
and PC1 and between DpnII-seq signals at different time points. (C) Relative 
change in nuclear spring constant (nN/µm) after DpnII fragmentation at different 
time points. Spring constant is significantly decreased after 5 minutes and at 
background level by 1 hour (p = 0.002, two-tailed t-test). (D) Top row: Hi-C 
interaction maps of chromosome 2 binned at 500 kb. Control: nuclei in restriction 
buffer for 4 hours. Pre-digest DpnII: nuclei were pre-digested with DpnII for 5 
minutes up to 16 hours. (Figure 2.10, A). Bottom row: compartmentalization 
saddle plots for the corresponding conditions. Numbers indicate strength of A-A 
and B-B interactions. (E) Top: genome-wide interaction frequency as function of 
genomic distance for Hi-C data shown in panel (D). Bottom: percentage of inter-
chromosomal (trans) interactions genome-wide for control nuclei and for nuclei 
pre-digested with DpnII for up to 16 hours. (F) Top: PC1 along a section of 120 
Mb of chromosome 2. Second plot: LOS along chromosome 2 at 40 kb resolution 
for all time points (Figure 2.4, B). Third plot: half-life (t1/2) values derived from the 
exponential fit of the six time-points for every 40 kb bin (Figure 2.10, C). Bottom 
plot: residuals of t1/2 after correcting for correlations between t1/2 and DpnII-seq 
(DpnII-seq data for t = 1 hour). 
                                                       
 
Micromanipulation was again used to measure the nuclear spring constant 
corresponding to nuclear stiffness. Nuclei displayed a significant loss in stiffness 
within 5 minutes. Loss of stiffness leveled off at 30 minutes of digestion and 
showed a 60% decrease in nuclear rigidity, similar to previous experiments in 
other cell types ((Stephens et al., 2017), Figure 2.11, C). Combined these 
analyses show that the bulk of DNA fragmentation and chromatin liquefication 
occurs within the first hour.  
Next, we performed liquid chromatin Hi-C where nuclei were pre-digested 
with DpnII for 5 minutes up to 16 hours (Figure 2.10, A). Interestingly, after 5 
minutes of pre-digestion chromosome conformation and compartmentalization 
are intact, even though chromatin was fragmented to 3-15 kb segments before 
 
 78 fixation and nuclear stiffness was significantly reduced (Figure 2.11, C and D). 
The percentage of intra-chromosomal interactions especially for loci separated 
by <1 Mb was increased (Figure 2.11, E).  
At subsequent time points, when most chromatin fragments are <7 kb long 
we observe increased loss of intra-chromosomal interactions and concomitant 
increased inter-chromosomal interactions genome-wide (Figure 2.11, D and E). 
Compartmentalization, as quantified by the preference of A-A and B-B 
interactions over A-B interactions, is progressively lost (Figure 2.11, D lower row 
of heatmaps, Figure 2.10, B). A-A interactions disappear faster than B-B 
interactions. After 16 hours, only a low level of preferential B-B interaction 
remains.   
Quantification of the half-life of chromosome conformation across the 
genome 
 To quantify the kinetics of loss of chromosome conformation and 
compartmentalization, we calculated LOS genome-wide for each time point 
(Figure 2.11, F). At t = 5 minutes, LOS is generally negative indicating a gain in 
chromatin interactions: on average ~25% gain of intra-chromosomal interactions 
between loci separated by <6 Mb, consistent with the initial increase in overall 
intra-chromosomal interactions described above (Figure 2.11, E). LOS is 
inversely correlated with PC1, indicating that loci located within A compartments 
gain more intra-chromosomal interactions than loci located within B 
compartments (Spearman ρ = -0.53 for chromosome 2, Spearman ρ = -0.49 
 
 79 genome-wide). A “block copolymer” model predicts that partial DNA digestion 
can lead to a strengthening of compartmentalization by removing covalent 
linkages between A and B blocks, as long as the fragments are still large enough 
so that attractive forces between them are sufficient for phase segregation (see 
Methods). At subsequent time points, LOS is increasingly positive as intra-
chromosomal interactions are progressively lost and inter-chromosomal 
interactions are gained. LOS is the highest for loci located in the A compartment. 
At t = 16 hours, LOS is generally as high as 90%, intra-chromosomal interactions 
are low (<20% of total), and only preferential B-B interactions are still observed in 
the Hi-C interaction map (Figure 2.11, D). Similar results were obtained with an 
independent replicate time course experiment (see below).  
Next we determined for each 40 kb locus at which time LOS has reached 
50% of its maximal value at t = 16 hours. We refer to this time as the half-life, t1/2 
(minutes), of chromatin interactions at each locus (Figure 2.11, F).  To identify t1/2 
we plotted LOS as a function of time for each 40 kb locus and fit the data to an 
exponential curve so that t1/2 could be determined when LOS equals 50% of its 
maximum (Figure 2.10, C). Examining t1/2 along chromosomes, we observe a 
strong inverse correlation with PC1 (Spearman ρ = -0.87, Figure 2.10, F): 
interactions in the A compartment dissolve relatively fast (t1/2 = 40-80 minutes) 
while interactions in the B compartment dissolve slower (t1/2 = 60-120 minutes, 
Figure 2.10, D). We also calculated t1/2 genome-wide for the second independent 
time course experiment and find a strong correlation between t1/2 calculated from 
 
 80 the two datasets (Spearman ρ = 0.78 for chromosome 2, Spearman ρ = 0.76 
genome-wide, Figure 2.10, E). The value of t1/2 is proportional to a dissociation 
rate constant and thus independent of the initial level of intra-chromosomal 
interactions for a given locus. t1/2 remains highly correlated with PC1 after 
correcting for the initial level of intra-chromosomal (<6 Mb) interactions for each 
bin (Spearman ρ = -0.82, Figure 2.10, F and G).  
Similar to LOS, t1/2 is correlated with DpnII digestion frequency at all 
timepoints (Figure 2.9, A). We calculated the partial correlation between t1/2 and 
PC1 after correcting for correlations between PC1 and t1/2 with DpnII cutting 
frequency. We find that t1/2 and PC1 remain strongly correlated (Figure 2.11, F), 
regardless of which DpnII fragmentation dataset (genome wide Spearman ρ 
ranging from -0.41 to -0.60, t = 5 min up to t = 16 hours) was used for the 
calculation of the partial correlation (Figure 2.9, A and B). Although loci in the A 
compartment are often cut more frequently than loci in the B compartment, when 
comparing loci cut with similar frequency, loci in the A compartments had shorter 
half-lives (Figure 2.9, C). Similar results were obtained when t1/2 was corrected 
for average fragment size for each bin (Figure 2.7, I, Spearman ρ = -0.85 for 
chromosome 2, Spearman ρ = -0.76 genome-wide). 
We considered whether we could have overestimated the t1/2 for loci in the 
B compartment because fragmentation of these loci could be slower than for loci 
in the A compartment. We reasoned that because after 1 hour incubation with 
DpnII digestion is largely complete, calculation of LOS using the Hi-C data at t = 
 
 81 1 hour as starting condition would provide an estimate of dissolution kinetics 
starting at a timepoint when A and B compartments are both extensively 
fragmented. We find that LOS, and t1/2 calculated this way are still strongly 
correlated with PC1, and this correlation remains strong after correcting for 
fragmentation level (Figure 2.9 D to F).   
Dissociation kinetics of chromatin interactions at different sub-nuclear 
structures  
 The A1 sub-compartment is most enriched in active histone modifications 
and found near nuclear speckles (Chen et al., 2018). B2 and B3 are located near 
the nuclear lamina (B2 and B3) and the nucleolus (B2) (Rao et al., 2014; Chen et 
al., 2018; Quinodoz et al., 2018). B1 is enriched in the repressive H3K27me3 
mark, which is often associated with polycomb binding. To relate sub-
compartment status to chromatin dissociation rates, we compared the residuals 
of t1/2 (after correcting for fragmentation level using DpnII-seq) for loci located in 
the 5 sub-compartments defined for K562 cells ((Xiong and Ma, 2018), Figure 
2.12, A). We find that residual t1/2 varies greatly between sub-compartments: 
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Figure 2.12 | Dissociation kinetics of chromatin interactions at different 
sub-nuclear structures.                                                                                              
(A) Cumulative distributions of residuals of t1/2 (in minutes) for each of the five 
annotated sub-compartments. (B) Top: the genome was split into 10 bins, where 
each bin corresponds to sets of loci that share the same t1/2 residual interval. 
 
 83 Middle: For each t1/2 residual interval a heatmap of mean z-score signal of Repli-
Seq data in different phases of the cell cycle G1, S1-4, G2. Bottom: For each t1/2 
residual interval a heatmap of mean z-score signal enrichment was quantified for 
various markers of sub-nuclear structures (See Methods). (C) Boxplot of t1/2 
residuals for bins with expressed genes (mean FPKM > 1) and bins with low or 
no expression (mean FPKM <=1) stratified by sub-compartment. Significance 
determined by two-sample two tailed t-test *(p < 0.003). (D) Homotypic 
interaction saddle plots for loci ranked by their association with speckles (as 
detected by SON-TSA-seq, top 3) and by their association with the nuclear 
lamina. Preferential pair-wise interactions between loci associated with the 
lamina can still be observed after several hours, whereas preferential pair-wise 
interactions between loci associated with speckles are lost more quickly. 
 
It is noteworthy that interaction dissociation rates for loci in the polycomb 
related B1 sub-compartment are as high or higher (residuals of t1/2 as or more 
negative) than those for loci in the active and open A1 sub-compartment. 
Interactions between Lamin-associated loci in the B3 sub-compartments 
dissociate the slowest while interactions between loci in the B2 sub-compartment 
dissociate somewhat faster. These observations indicate that loci associated with 
different sub-nuclear structures display a range of interaction stabilities.  
We coarse-grained t1/2 residuals by splitting them into 10 intervals and 
then assigned these intervals genome-wide. We then explored the enrichment for 
varying chromatin features for each t1/2 residual interval (Figure 2.12, B). 
Chromatin interactions for early replicating domains had short half-lives, while 
interactions for loci in later replicating domains were more stable (Figure 2.12, B). 
Interestingly, loci with the shortest t1/2 residuals replicate in the middle of S-
phase.  
 
 84 We find that loci near the speckle-associated proteins pSC35 or SON are 
engaged in the most unstable interactions. Similarly, transcriptionally active loci, 
identified by ChIP-seq for a range of histone modifications and factors associated 
with open chromatin such as H3K4me3 and RNA PolII, were also involved in 
relatively unstable chromatin interactions.  
Interactions for loci bound by polycomb complexes (a subset of which are 
in the B1 sub-compartment) were as unstable as active speckle associated loci 
(Figure 2.12, B, Figure 2.13, B). Half-lives differed for loci bound by different 
polycomb subunits. Loci with the shortest t1/2 residual values are enriched for 
binding the CBX8 subunit. An example of a large polycomb-bound domain in 
K562 cells is the HoxD cluster. The cluster is ~100 kb and covered by polycomb 
subunits Suz12, RNF2, CBX8 and BMI1 and the histone modification H3K27me3 
(Figure 2.13, C). The half-life of chromatin interactions for loci in the HoxD cluster 
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Figure 2.13 | Associations between sub-nuclear structures and chromatin 
interaction stability.                                                                                           
(A) Spearman correlation matrix between signals for various chromatin state 
markers of various sub-nuclear structures, chromatin remodellers and histone 
modifications with row order determined by hierarchical clustering. (B) The 
genome was split into 16 bins, where each bin corresponds to sets of loci that 
share the same t1/2 interval. For each t1/2 interval the mean z-score signal 
enrichment for various markers of sub-nuclear structures, chromatin remodellers 
and histone modifications was calculated and shown as a heatmap. Row order 
determined by hierarchical clustering. (C) 3 Mb region surrounding HoxD locus. 
Top: Hi-C contact map for K562 control nuclei showing the position of the HoxD 
 
 86 locus. Tracks: ChIP-seq tracks for polycomb subunits (cyan) and the polycomb 
associated histone modification H3K27me3 (green). t1/2 (blue). Minus strand and 
plus-strand signal of total RNA-seq (red). Refseq Genes (blue/black). The 
polycomb-bound domain displays shorter half-life compared to expressed genes 
in flanking regions. 
 
Silent and closed chromatin loci around the nucleolus or at the nuclear 
lamina were engaged in the most stable interactions (Figure 2.12, B). Chromatin 
interactions for loci associated with HP1γ (CBX3) were relatively unstable while 
interactions for loci associated with HP1β (CBX1) or HP1α (CBX5) were more 
stable. This variation is in agreement with the chromosomal locations and 
dynamics of these three HP1 proteins. HP1γ is associated with active chromatin 
and mobile, while HP1α and HP1β are typically found in constitutive 
heterochromatin near (peri) centromeres and are much less mobile (Dialynas et 
al., 2007).  
For each sub-compartment, we split loci into expressed (FPKM>=1) or not 
expressed (FPKM<1) categories (Figure 2.12, C). We find that sub-compartment 
status is the major determinant of chromatin interaction stability, irrespective of 
transcriptional status. However, transcriptional status modulates t1/2 to some 
extent: in general, loci located in B2 and B3 sub-compartments are engaged in 
relatively stable chromatin interactions, but interactions that involve loci that are 
expressed have shorter half-lives. The expression status of loci located in the A1, 
A2 sub-compartments had only very minor effect on the t1/2.  
 
 87 The differential stability of pair-wise chromatin interactions at different sub-
nuclear structures can be quantified by plotting interaction frequencies between 
pairs of 40 kb loci arranged by their level of factor binding to obtain homotypic 
interaction saddle plots (Figure 2.12, D). In these plots, pair-wise interactions 
between loci enriched in factor binding are shown in the lower right corner, and 
pair-wise interactions between loci not bound by the factor are shown in the 
upper left corner. After chromatin fragmentation we observe loss of preferential 
interactions between speckle associated loci, while preferential interactions 
between non-speckle associated loci can be observed even after 16 hours. 
Conversely, preferential interactions between lamin-associated loci remain 
detectable even at late time points, while interactions between loci not at the 
lamina disappear relatively fast.   
Chromatin loops dissociate upon chromatin fragmentation  
 Enriched point-to-point looping interactions are detected as “dots” in Hi-C 
interaction maps. The majority of these represent cohesin-mediated interactions 
between pairs of convergent CTCF sites (Rao et al., 2014). We aggregated Hi-C 
data at pairs of sites that had previously been shown to engage in looping 
interactions in K562 cells (Rao et al., 2014). We readily detected these loops in 
intact purified nuclei (Figure 2.14, A). After fragmentation with HindIII for 4 hours, 
loops appeared to become slightly stronger. Fragmenting chromatin with DpnII 
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Figure 2.14 | Chromatin loop dissociation upon fragmentation.                   
(A) Aggregated distance-normalized Hi-C interactions around 6,057 loops 
detected in K562 cells by HiCCUPS (Rao et al., 2014) at 10 kb resolution, for 
control nuclei and nuclei digested with DpnII up to 4 hours, and for nuclei 
digested with HindIII for 4 hours. (B) Western blot analysis of CTCF, cohesin and 
Histone H3 abundance in soluble and chromatin-bound fractions obtained from 
control nuclei and from nuclei pre-digested with DpnII up to 4 hours and HindIII 
for 4 hours. (C) Quantification of the data shown in panel B. Percentage of 
released protein is the ratio of protein level in the soluble fraction divided by the 
sum of the levels in the soluble and chromatin-bound fractions. 
 
We assessed whether CTCF and cohesin binding to chromatin is affected 
by chromatin fragmentation. We fractionated proteins in chromatin-bound and 
soluble fractions ((Liang and Stillman, 1997), Methods). In intact nuclei, most of 
the CTCF and cohesin is associated with chromatin (Figure 2.14, B and C). 
Digesting chromatin with HindIII did not lead to dissociation of CTCF or cohesin. 
 
 89 However, fragmenting chromatin with DpnII led to dissociation of cohesin after 1 
hour, while CTCF binding was only weakly affected. We conclude that DNA 
fragmentation to <6 kb fragments, but not to 10-25 kb fragments, leads to loss of 
cohesin binding and loss of looping interactions. These results are consistent 
with earlier observations that showed that in yeast stable chromatin binding by 
cohesin requires intact DNA (Ciosk et al., 2000). These data can be interpreted 
in the context of the model where cohesin rings encircle DNA (pseudo-) 
topologically (Srinivasan et al., 2018). Possibly, when DNA is fragmented, the 
cohesin ring can slide off nearby free ends. 
Discussion 
 Using liquid chromatin Hi-C we obtained a view of the dynamics of 
chromatin interactions throughout the nucleus and the genome (Figure 2.15, A). 
Previously, live cell imaging experiments found differences in mobility dependent 
on sub-nuclear position and chromatin state and activity (Marshall et al., 1997; 
Hediger et al., 2002; Thakar, Gordon and Csink, 2006; Bronshtein et al., 2009, 
2015; Therizolsa et al., 2010; Shinkai et al., 2016; Nagashima et al., 2019). In 
such experiments the movement detected is strongly constrained by the fact that 
loci are part of very long chromosomes. A previous study, which inspired the 
current work, aimed to identify factors that determine intrinsic locus-locus 
interactions and locus mobility by removing the polymeric constraint due to 
linkage (Gartenberg et al., 2004). In that work a silent locus was excised from the 
chromosome (Gartenberg et al., 2004) and its mobility and preference for 
 
 90 association with other silent loci and the nuclear periphery was found to depend 
on specific silencing complexes. In our liquid chromatin Hi-C experiments, the 
polymeric constraint on movement is removed for all loci simultaneously, in effect 
performing a genome-wide variant of the experiments performed by Gartenberg 
et al.  
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Figure 2.15 | Illustration of chromatin interaction dynamics in the nucleus 
and model for cohesin loss after chromatin digestion.                                 
(A) Left: Schematic representation of varying chromatin interactions dynamics at 
different sub-nuclear domains. Shortest half-life reflects the least stable 
interactions (yellow), while longest half-life reflects the most stable interactions 
(dark orange). Nuclear subdomains differ greatly in their stability. Top right: 
Chromatin anchored at speckles is driven by the most dynamic interactions. 
Bottom right: Chromatin anchored at the nuclear lamina involves the most stable 
interactions. (B) Model for how cohesin rings stabilize CTCF-CTCF loops by 
encircling loop bases. Top: Cohesin ring encircles loop bases at convergent 
CTCF sites. Middle: Pre-digestion with DpnII cuts loop into chromatin fragments 
<6 kb, and the cohesin ring can slide off nearby ends. Bottom: CTCF remains 
bound to digested chromatin fragments but interactions between CTCF-bound 
sites are lost 
 
Chromosomal compartmentalization tolerates genome-wide fragmentation 
with HindIII in >10-25 kb fragments. Micro-mechanical measurements also show 
 
 91 that chromosomes remain mechanically fully connected. We conclude that stable 
chromosome conformation and phase segregation can occur when blocks of a 
particular chromatin state are at least 10 kb. Our results obtained with DpnII 
digestion where the genome is fragmented in <6 kb (average ~3.1 kb) fragments 
show that these fragments are too short to maintain phase-segregated domains. 
The stability of interactions between <6 kb fragments depends on their chromatin 
state and association with sub-nuclear structures: interactions at the nuclear 
lamina are relatively stable, those near nuclear speckles and polycomb 
complexes are highly unstable, while interactions for loci associated with different 
heterochromatin proteins and the nucleolus displayed a range of intermediate 
stabilities. The dynamics of associations between loci are therefore determined 
by chromatin-associated factors, and may also be determined directly by the 
biochemical properties of histone tail modifications. For instance, the Rosen lab 
found that chromatin fragments can form droplets in vitro and that the dynamics 
of chromatin fragments within these droplets are dependent upon both H1 
binding and histone acetylation (Gibson et al., 2019).  
Loci associated with the three different HP1 proteins display different 
dissociation kinetics. Interestingly, these differences correlate with different 
dynamics and sub-nuclear locations of the HP1 proteins in the nucleus. HP1γ 
(CBX3) binds relatively transiently to euchromatin, which may explain the 
dynamic nature of chromatin interactions between loci bound by this protein 
(Dialynas et al., 2007). On the other hand, interactions between loci enriched in 
 
 92 HP1α (CBX5) are more stable, which likely is the result of more stable HP1α 
binding to heterochromatin (Strom et al., 2017). Our finding that lamin-associated 
and HP1α-associated loci are engaged in the most stable interactions is 
consistent with recent modeling of inverted nuclei where heterochromatin is 
located in the center of the nucleus. Such inverted arrangement can only occur 
when heterochromatic interactions are much more stable or abundant than 
interactions between active chromatin loci (Falk et al., 2019).  
Liquid chromatin Hi-C showed differences in chromatin interaction stability 
between facultative heterochromatic domains marked by polycomb and 
constitutive heterochromatic domains marked by lamina association or binding of 
HP1α/HP1β proteins. While many chromatin contacts in constitutive 
heterochromatin were maintained even after 16 hours of digestion, the half-life 
for chromatin contacts at polycomb-bound regions was short, on a scale similar 
to active regions of the genome. The compacted states of polycomb and HP1α 
bound chromatin appear to form via a similar phase-separation mechanism 
mediated by multivalent interactions between specific CBX homologs. In vitro 
and in vivo, both CBX2 (polycomb subunit) and CBX5 (HP1α) are capable of 
forming condensates of polycomb bodies and constitutive heterochromatin, 
respectively (Larson et al., 2017; Plys et al., 2019; Tatavosian et al., 2019). Our 
data indicate that these different condensates and associated chromatin have 
very different properties: the stability of interactions between loci mediated by 
these factors is distinct, possibly related to differences in affinity between CBX 
 
 93 proteins and chromatin: the binding affinity of CBX5 (HP1α) for its preferential 
histone modification H3K9me3 is higher than the affinity of CBX2 for its 
preferential mark H3K27me3 (Kaustov et al., 2011). This differential could have 
consequences for the ability of cells to regulate genes embedded within these 
different types of heterochromatin.  
Our results allow a crude estimate of the Flory-Huggins χ parameter for 
A/B segregation of chromatin in the nucleus. Given that HindIII and DpnII cut 
chromatin into segments of approximately 17±7 kb and 3±1 kb respectively (with 
FatI also generating approximately 3 kb average sized fragments), a reasonable 
estimate of the minimum length of fragments necessary to drive A/B segregation 
is N* = 10±4 kb. Given that these fragments are small compared to the A/B 
compartmentalization scale of a few Mb, the fragments will be essentially A- or B-
type (euchromatin or heterochromatin) homopolymers. The similar ~1.2 Mb 
average size of the A and B compartments, as well as the remarkably similar ~3 
kb fragment sizes observed for DpnII digestion of A and B regions (Figure 2.7, F) 
indicate that the simple Flory-Huggins model can be applied to a concentrated 
solution of symmetrical (equal length and concentration) A and B homopolymers. 
For homopolymers, the Flory-Huggins model predicts a critical length needed for 
phase separation of N*=2/χ (de Gennes, 1979), indicating χ = 0.20 ± 0.07/kb (χ = 
0.036±0.013 /nucleosome). Given that χ is in kBT units (1 kBT = 0.6 kcal/mol at 
physiological temperatures), its small value indicates that the effective demixing 
interaction between nucleosomes is weak, consistent with a liquid-like phase-
 
 94 separation picture for A and B compartments, where regulation of chromatin 
organization and compartmentalization is possible by relatively small changes in 
nucleosome interactions (e.g., via histone modifications). While extremely crude 
(e.g., we have used the χ estimate for a dense polymer melt rather than for a 
concentrated solution) our data clearly indicate a weak value for χ, and that the 
interactions that are driving compartmentalization are a small fraction of a 
kcal/(mol⋅nucleosome). Our result is within a factor of 2 of a recent theoretical 
estimate (critical size for demixing of 20 kb, (MacPherson, Beltran and 
Spakowitz, 2018)). We note that we have been able to rather use a simple 
application of Flory-Huggins theory by virtue of the similar A/B fragment and 
compartment sizes. We emphasize that these properties do need to be examined 
before similar estimates can be done for other cell types or species.  
We also note that our estimated χ assumes that the fragments are able to 
equilibrate their positions in both the DpnII and HindIII cases. It is conceivable 
that entanglements, cross-bridging or other effects may strongly retard or 
preclude demixing in the HindIII case.  Such effects would be a confounding 
factor in estimation of χ, but the DpnII data do solidly constrain the critical size for 
demixing to be larger than 3 kb (i.e., χ < 0.66/kb).  Further experiments on the 
kinetics of fragment demixing would be very interesting in this regard, as they 
would shed further light on the physical processes underlying A/B compartment 
formation in vivo.  
 
 95 It is important to point out that during the liquid chromatin Hi-C procedure 
some chromatin factors and RNAs may dissociate from the purified nuclei, and 
this could affect the locus mixing behavior we observe. The current work 
analyzed the intrinsic chromatin interaction strengths and dissolution kinetics of 
chromosome conformation within otherwise inactive nuclei. Future work should 
focus on how these kinetic properties change in cells or nuclei, where active 
processes such as transcription, replication, chromatin compaction and 
condensation, and loop extrusion are also acting, and on determining the roles of 
RNAs, protein complexes, and histone modifications in modulating the attractive 











 96 Tables 
 
Table 1Table 2.1 | Public dat asets used  to associat e l iquid  chromatin H i-C measured stab ilit y with various chromatin  features 
Chromatin Feature Assay 
ENCODE Accession 
ID Output type PubMed ID 
H3K36me3 ChIP-seq ENCFF223BKS fold change over control  
H3K27ac ChIP-seq ENCFF006RIO fold change over control  
H3K4me1 ChIP-seq ENCFF463AQS fold change over control  
H3K4me2 ChIP-seq ENCFF778DNU fold change over control  
H3K4me3 ChIP-seq ENCFF330TJF fold change over control  
H4K20me1 ChIP-seq ENCFF242XLB fold change over control  
H2AFZ ChIP-seq ENCFF430FSQ fold change over control  
H3K9me1 ChIP-seq ENCFF526UWC fold change over control  
H3K9me3 ChIP-seq ENCFF700FQH fold change over control  
H3K9ac ChIP-seq ENCFF527JUP fold change over control  
H3K27me3 ChIP-seq ENCFF936BVT fold change over control  
H3K79me2 ChIP-seq ENCFF619JRY fold change over control  
HP1β ChIP-seq ENCFF985MBQ fold change over control  
HP1γ ChIP-seq ENCFF630YDI fold change over control  
HP1α ChIP-seq ENCFF014XHT fold change over control  
EHMT2 ChIP-seq ENCFF982RMW fold change over control  
CBX8 ChIP-seq ENCFF206WVX fold change over control  
RNF2 ChIP-seq ENCFF071CIY fold change over control  
BMI1 ChIP-seq ENCFF514QBY fold change over control  
SUZ12 ChIP-seq ENCFF363DWX fold change over control  
RBBP5 ChIP-seq ENCFF058KTS fold change over control  
CTBP1 ChIP-seq ENCFF112LWM fold change over control  
KAT2B ChIP-seq ENCFF164NLF fold change over control  
BRD4 ChIP-seq ENCFF260JHC fold change over control  
NCOR1 ChIP-seq ENCFF292YLV fold change over control  
KDM5B ChIP-seq ENCFF293III fold change over control  
HDAC2 ChIP-seq ENCFF915GWT fold change over control  
SAP30 ChIP-seq ENCFF816KCQ fold change over control  
WHSC1 ChIP-seq ENCFF864WOR fold change over control  
PHF8 ChIP-seq ENCFF427QTV fold change over control  
REST ChIP-seq ENCFF518QUW fold change over control  
KDM1A ChIP-seq ENCFF734YKJ fold change over control  
POLR2A ChIP-seq ENCFF749YKR fold change over control  
POLR2B ChIP-seq ENCFF452WGO fold change over control  
POLR2G ChIP-seq ENCFF015NSS fold change over control  
PML ChIP-seq ENCFF157IUB fold change over control  
Methylation WGBS ENCFF867JRG methylation state at CpG  
NADS.IMR90 aCGH  NAD state 28575119 
SON TSA-seq  log2(pull-down / input) 30154186 
pSC35 TSA-seq  log2(pull-down / input) 30154186 
LaminA/C TSA-seq  log2(pull-down / input) 30154186 
 
 97 LaminB TSA-seq  log2(pull-down / input) 30154186 
Pol2 TSA-seq  log2(pull-down / input) 30154186 
LADs DamID  log2(Dam-LaminB1/Dam)  30154186 
G1 Repli-seq ENCFF001GRX percentage normalized signal  
S1 Repli-seq ENCFF001GSF percentage normalized signal  
S2 Repli-seq ENCFF001GSJ percentage normalized signal  
S3 Repli-seq ENCFF001GSN percentage normalized signal  
S4 Repli-seq ENCFF001GSP percentage normalized signal  
G2 Repli-seq ENCFF001GSB percentage normalized signal  
 
 
Table 2.1 | Public datasets used to associate liquid chromatin Hi-C 
measured stability with various chromatin features                                              
Data used to associate t1/2 with various chromatin histone modifications, 
transcription factors, DNA-binding proteins, sub-nuclear structures, and 










 98 Materials and methods 
Digestion, cross-linking and copolymer architecture and 
hetero/euchromatin phase separation  
Chromatin in the G1 nucleus can be considered as a set of blocks of 
euchromatin and heterochromatin (the A and B compartments consisting of 
regions of predominantly euchromatin vs heterchromatin, respectively), which are 
constrained to be near each other by being part of the same linear 
chromosomes, i.e., effectively being long many-block copolymers. We suppose 
that the A and B heterochromatin/euchromatin monomers have a weak tendency 
to repel one another (or equivalently that A-A or B-B attract one another, for 
example via protein-mediated nucleosome-nucleosome interactions acting 
preferentially on euchromatin or heterochromatin, or even via physio-chemical 
effects such as relative hydrophobicity of more methylated nucleosomes). 
If we suppose the A and B blocks to be on average N monomers long 
(roughly nucleosomes for the sake of this discussion), then under melt-like 
conditions the standard Flory theory of polymer phase separation predicts that if 
we were to cut the polymers into pure A and B blocks at the block boundaries 
(i.e., at a spacing of N monomers commensurate with the block sizes), they 
would phase separate for a segment-segment interaction strength stronger than 
χ* = 2/N (de Gennes, 1979). Note that this level of interaction (given 
approximately in kBT units) is proportional to 1/N where N is crudely in 
nucleosome units; for 200 kilobase blocks, we have approximately N=1000, 
 
 99 indicating that small fractions of a kBT in effective A/B repulsion or A-A or B-B 
attraction is sufficient to drive strong euchromatin/heterochromatin phase 
separation (Marko and Siggia, 1997).  
Now if we were to instead cut less frequently than this, say at every 
second block boundary, so as to arrive at a system of AB linear diblock 
copolymers each of length 2N (N monomers of A followed by N monomers of B), 
the constraint that the A and B blocks be connected suppresses phase 
separation, increasing the critical interaction (all other factors held constant) to χ * 
= 5.3/N (Leibler, 1980). In this case bulk phase separation cannot occur, but 
instead local, or "microphase separation" occurs, with formation of micelle-like or 
layered phase-separated structures. Nevertheless, for χ >> χ *, strong 
segregation of the A and B monomers can still occur.  
If we were to not cut at all, but rather to suppose that the chromosomes 
are very long multiblock copolymers, with many blocks each of N monomers 
alternating between A and B ("ABABABAB... multiblock copolymers"), the critical 
interaction strength will rise with increasing number of blocks, approaching the 
limit χ * = 7.5/N for many blocks (Matsen and Schick, 1994). Therefore, starting 
from this limit, the tendency for chromosome domains to phase separate will be 
enhanced by cutting the chromosomes up into successively smaller pieces: as 
chromatin cutting increases from no cutting, we expect to see intensification of 
A/B compartment contrast in the Hi-C map.   
 
 100 Now, if we cut too frequently, when the cuts become spaced smaller than 
the block size (cut spacing M < N monomers), we will have the situation that the 
critical interaction strength will become χ * = 2/M > 2/N, i.e., the cuts are frequent 
enough to suppress phase separation by decreasing the amount of interaction 
enthalpy per polymer "molecule". Therefore we expect that overly frequent 
cutting will cause a reduction in A/B compartment Hi-C map contrast, i.e., for 
some intermediate level of cutting similar to the sizes of the A and B blocks, one 
will see a maximum level of A/B compartment contrast.  
There is also likely an effect of “crosslinking” ("chromatin cross-bridging"), 
which provides an additional level of constraint suppressing phase separation, 
above the linear-multiblock architecture of chromosomes. For example, taking 
linear diblock copolymers (N A monomers followed by N B monomers) and 
circularizating them raises the critical interaction for microphase separation from 
5.3/N to 8.9/N, nearly a factor of 2 (Marko, 1993).  
Similarly, if we start with A and B homopolymers each of length N, 
constraining them to have their ends at a flat surface, thus forcing them to mix at 
the surface, increases the critical interaction for phase separation from 2/N up to 
4.5/N (Marko and Witten, 1991), with microphase separation again occurring in 
the constrained case. Releasing chromatin crosslinking/cross-bridging 
constraints (which also will occur for chromatin cutting) will in general also reduce 
the interaction strength needed to drive phase separation, increasing A/B 
compartment contrast in Hi-C maps.  
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gradually increasing the cleavage of chromatin will gradually increase the 
intensity of A/B compartment contrast in Hi-C maps until the cuts are spaced by 
approximately one A or B block; further cutting will reduce the intensity of phase 
separation and A/B compartment contrast. Notably, the nature of the segregation 
can be expected to be "microphase segregation" rather than bulk phase 
separation, until the number of cuts is sufficient to liberate A or B "homopolymer" 
segments. 
K562 nuclei purification  
 Three sucrose cushions were made before starting nuclei purification. 30 
mL of 30% sucrose [10 mM PIPES pH 7.4, 10 mM KCl, 2 mM MgCl2, pH 
adjusted to 7.4 using 1 N KOH, 30% sucrose, 1 mM DTT (added prior to use), 
1:100 protease inhibitor (Thermo Fisher 78438) (added prior to use)] was 
transferred to a 50 mL tube, then 5 mL of 10% sucrose [10 mM PIPES pH 7.4, 10 
mM KCl, 2 mM MgCl2, 10% Sucrose, 1 mM DTT (added prior to use), 1:100 
protease inhibitor (added prior to use)] was slowly loaded in top of 30% sucrose, 
and the tubes were incubated at 4°C until needed. K562 cell pellets (100 million 
cells) were lysed using the following nuclear isolation procedure. After the cells 
were spun, the pellets were washed twice with 10 mL HBSS, then pelleted after 
each wash at 300 rpm for 10 min at 4°C. Cell pellets were dissolved in 15 mL 
nuclear isolation buffer [10 mM PIPES PH 7.4, 10 mM KCl, 2 mM MgCl2, 1 mM 
DTT (added prior to use), 1:100 protease inhibitor (added prior to use)], pH 
 
 102 adjusted to 7.4 using 1 M KOH]. Then, cells were lysed on ice in a 15 mL Dounce 
homogenizer with pestle A (KIMBLE Kontes 885002-0015) by moving the pestle 
slowly up and down 20 times, followed by incubation on ice for 20 min and 
another 20 strokes. Next, each 5 mL of lysed extract was loaded slowly on top of 
a sucrose cushion prepared earlier. Then the tubes were spun for 15 min at 800 
g at 4°C. The supernatant was removed carefully for a good recovery of the 
nuclei pellet in the bottom of the tube. Nuclei pellets were resuspended in 1 mL 
of HBSS, then spun for 5 min at 5,000 g at 4°C using a benchtop refrigerated 
centrifuge. Then, the nuclei pellet was resuspended in 3 mL HBSS, and 1 µL was 
taken to quantify the nuclei before the 3 mL was split over two microfuge tubes 
and spun for 5 min at 5,000 g at 4°C using a benchtop refrigerated centrifuge. 
Finally, the nuclei pellet was dissolved into an adequate total volume to obtain 1 
million nuclei per 0.1 mL of Nuclei storage buffer (NSB) [10 mM PIPES pH 7.4, 
10 mM KCl, 2 mM MgCl2, 50% glycerol, 8.5% sucrose, 1 mM DTT (added prior 
to use), 1:100 protease inhibitor (added prior to use)]. Each 0.5 mL of NSB 
containing 5 million nuclei was transferred to a microfuge tube and stored at -
80ºC.  
3C (Chromosome Conformation Capture)  
 3C was performed as described in “From cells to chromatin: Capturing 
snapshots of genome organization with 5C technology” (Ferraiuolo et al., 2012). 
Crosslinking: 1.25 mL of 37% formaldehyde was added to 40 mL of HBSS. 50 
million cells or nuclei were washed twice using 20 mL of HBSS and then pelleted 
 
 103 at 500 g for 10 min. The pellet was resuspended in 5 mL HBSS and then added 
to 41.25 mL of HBSS and formaldehyde (final formaldehyde concentration was 
1% ). The sample was incubated at RT for 10 min on a rocking platform. 
Afterward, to stop cross-linking 2.5 mL of 2.5 M glycine was added and samples 
were incubated at RT for 5 min on a rotating platform. To pellet the crosslinked 
cells or nuclei the sample was centrifuged at 800 g for 10 min at 4°C. After 
discarding the supernatant the pellet was washed twice using HBSS. Next, the 
pellet was either processed immediately as described below or was stored at -80 
ºC after flash freezing using liquid nitrogen.  
Cell lysis: (This step was included when cells are used, but was skipped for 3C 
with purified nuclei).Cells were lysed by adding 2 mL of cold lysis buffer [10 mM 
Tris-HCl (pH=8.0), 10 mM NaCl, 0.2% Igepal CA-630 (NP40)] and 20 µL of 100x 
Protease inhibitors. The sample was incubated on ice for 15 min to let the cells 
swell. The cells were lysed on ice using the homogenizer with pestle A (KIMBLE 
Kontes 885300-0002) by moving the pestle slowly up and down 30 times and 
incubating on ice for 1 min followed by another 30 strokes. The sample was 
transferred to two 1.5 mL microcentrifuge tubes, spun at 5,000 g at RT for 5 min 
using a benchtop centrifuge. 
Digestion: each pellet was washed using 1 mL cold 1X NEBuffer 2.1, then spun 
at 5,000 g for 5 min at RT using a benchtop centrifuge, afterward each pellet was 
resuspended in 250 µL of 1X NEB2.1 buffer, and the two pellets were pooled (~ 
500 µL). 50 µL aliquots of the suspension were transferred to 10 new 1.5 mL 
 
 104 microfuge tube and 292 µL of 1x NEBuffer 2.1 was added to each tube. Next, 38 
µL of 1% SDS was added per tube and mixed well, the samples were incubated 
at 65ºC for 10 min, then placed on ice. 44 µL of 10% Triton X-100 was added to 
each tube to quench SDS. Finally, 400 U of EcoRI (NEB R0101L) was added per 
tube and incubated at 37ºC overnight on a thermocycler (with 900 rpm for 30 sec 
every 4 min). 
Ligation: 86 µL of 10% SDS was added to the digested samples and the samples 
were then incubated at 65ºC for 30 min for EcoRI inactivation after which the 
tubes were placed on ice. Each sample was then transferred to a 15 mL conical 
tube and 7.69 mL of ligation mix was added [820 µL 10% Triton X-100, 820 µL 
10x ligation buffer (500 mM Tris-HCl pH7.5, 100 mM MgCl2, 100mM DTT), 82 µL 
10 mg/mL BSA, 82 µL 100 mM ATP and 5.886 µL ultrapure distilled water]. 
Finally, 10 U of T4 ligase (Invitrogen 15224090) was added per tube before 
incubation at 16ºC for 2 hr on a thermocycler (with 900 rpm for 30 sec every 4 
min). 
Reverse Crosslinking: 50 μL of 10 mg/mL proteinase K (Fisher BP1750I-400) 
was added per tube, the sample was incubated at 65°C for 4 hr followed by a 
second addition of 50 μL 10 mg/mL Proteinase K and overnight incubation at 
65°C on a thermocycler (with 900 rpm for 30 sec every 4 min). 
DNA purification: Tubes were cooled at room temperature, at this stage each 
tube contains ~ 8.21 mL final volume. The samples from every two tubes were 
 
 105 combined to a 50 mL conical tube (~16,42 mL) to have five tubes in total. DNA 
was extracted by adding an equal volume of 17 mL of saturated phenol pH8.0: 
chloroform (1:1) (Fisher BP1750I-400) and vortexing for 3 min. Then the mix was 
transferred to a 15 mL phase-lock tube (Quiagen 129073) followed by spinning 
tubes at 5,000 g for 10 min. The upper phase was taken to a 50 mL tube to start 
the second extraction. We added an equal volume of 17 mL saturated phenol pH 
8.0: chloroform (1:1), vortexing for 1 min. Then the upper phase was transferred 
to a 15 mL phase-lock tube, and tubes were centrifuged at 5,000 g for 10 min. 
We pooled all the upper phases from all 5 tubes ~ 85 mL into a single 300 mL 
high-speed centrifuge tube to precipitate the DNA. 8.5 mL (1/10 volume) of 3M 
sodium acetate pH 5.2 was added and brief vortexing was performed, then 212 
mL (2.5 volumes) of ice-cold 100% ethanol was added, and the tube was 
inverted slowly several times and incubated at -80° C for 1 hr. Afterward, the 
DNA was pelleted at 16,000 g for 30 min at 4°C. The supernatant was discarded 
and the pellet was dissolved in 500 µL 1X TLE and transferred to a 0.5 mL 
AMICON Ultra Centrifuge filter (UFC5030BK EMD Millipore). The column was 
centrifuged for 5 min at 14,000 g and the flow-through was discarded. The 
column was washed 4 times using 450 µL of 1X TLE for desalting DNA. After the 
final wash, the library remaining in the column (~50 µL) was eluted in 30 µL of 
1XTLE, the column was flipped upside down into a new tube to collect DNA by 
centrifugation for 3 min at 4,000 g. RNA was degraded by adding 1 µL of 10 
mg/mL RNAase A and incubation for 30 min at 37°C. 
 
 106 Quality control assessment: to test the quality of the 3C library we used PCR to 
amplify a specific ligation product formed by two nearby restriction fragments, 
using the following primers: 
GPF33: GACCTCTGCACTAGGAATGGAAGGTTAGCC 
GPF23: GACTAATTCCTGACACTACTTGAGGGATAC 
The amplicon was digested with EcoRI to assess the efficiency of 3C ligation.  
BAC library for 3C-PCR   
BAC DNA was generated as described (Dostie et al., 2006). A control ligation 
library covering the Beta-globin locus (ENCODE region ENm009) was generated 
using BACs overlapping the region. Starting with a mixture of DNA of seven 
BACs (CTC-775N13, RP11-715G8, CTD-3048C22, CTD3055E11, CTD-2643I7, 
CTD-3234J1, and RP11-589G14) (Invitrogen), mixed in equimolar ratios, we 
used the same steps described in the 3C protocol above starting from the 
digestion step. BAC clones were digested with EcoRI, then randomly ligated, and 
the DNA was purified. The BAC ligation library reflects random ligation of EcoRI 
fragments throughout the beta-globin locus, so any difference in PCR signal for 
3C primer pairs along the beta-globin locus due to differences in primer efficiency 
can be corrected by normalizing the amount of PCR product obtained with the 3C 
library to the amount obtained with the BAC ligation library. 
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Experimental design 
Probes were designed as described (Dostie et al., 2006). 213 5C probes 
were designed for a ~1 Mb region (chr11:4730996 -5729937; hg18) around the 
Beta-globin locus at EcoRI restriction sites using publicly available 5C primer 
design tools (Lajoie et al., 2009). Probes were designed according to a single 
alternating scheme exactly as described before (Lajoie et al., 2009) and the 
genomic uniqueness of all primers was verified with the SSAHA algorithm. For 
each EcoRI fragment at the 1 Mb target region a primer was designed. 104 5’ 
forward (FOR) and 109  5’ reverse (REV) primers were designed.  
Generation of 5C libraries 
5C libraries were generated as described before (Ferraiuolo et al., 2012), with 
three modifications. First, we skipped the gel purification after the adaptor ligation 
and replaced this with a 1:1 Ampure step to remove unligated DNA and adaptors. 
Second, barcoded Illumina adaptors were used. Third, we performed the final 
PCR using TruSeq DNA LT kit Set A (REF 15041757). 
Annealing: The 5C probes were pooled and combined with the 3C template each 
reaction contained 800,000 genome copies of 3C template and 0.2 fmol per 5C 
probe [800,000 genome copies of 3C template, 2 µL of 10X NEB4 (NEB 
B7004S), 2.75 µL of Salmon Sperm DNA (250 ng; (Invitrogen™ 15632011), 0.25 
µL of 1 fmol/µL probes , up to 20 µL ultrapure distilled water]. We set up 8 
 
 108 annealing reactions for each library in a 96-well PCR plate. We then incubated 
the samples in a PCR machine and ran the following program [95°C for 9 min, 
Ramp 0.1°C/sec to 55 C, then keep at 55°C for 12 hr]. 
Ligation: We ligated 5C probe pairs, which represent a specific ligation junction in 
the 3C library, by adding 20 µL of ligation mix 2 µL of [10X Taq DNA ligase buffer 
(NEB B0208S), 0.25 µL Taq DNA ligase (NEB M0208S), 17.75 uL ultrapure 
distiller water] while the samples are kept in the PCR block at 55°C. We then 
incubated the reactions for 1 hr at 55°C followed by a 10 min incubation at 65°C; 
samples were then cooled to 4°C. Negative controls (no ligase, no template, no 
5C oligonucleotide) were included to ensure the absence of any contamination. 
PCR amplification:  Universal emulsion primers were used for amplification of the 
ligated product by using 5C forward and reverse emulsion primers 
[Forward_primer: CCTCTCTATGGGCAGTCGGTGAT. Reverse_primer : 
CTGCCCCGGGTTCCTCATTCTCT] for 25 PCR cycles [6 µL of ligation product, 
2.5 µL of 10XPCR (600 mM Tris-SO4, pH 8.9, 180 mM (NH4)2SO4), 1.8 mM 
MgCl2, 0.2 mM dNTP, 0.5 µL F-emulsion primer (80 µM), 0.5 µL R-emulsion 
primer (80 µM), 0.225 µL AmpliTaqÒ Gold DNA polymerase, ultrapure distilled 
water to bring volume up to 25 µL]. We then amplified DNA using this PCR 
program: [95° 9 min, 25 cycles (95°C 30 s, 65°C 30 s, 72° 30 s), 95°C 30 s, 65°C 
30 s, 72°C 8 min, 4°C]. 
 
 109 We pooled all the PCR reactions for the same library together and concentrated 
the DNA to 50 µL using 0.5 mL AMICON Ultra Centrifuge filter (UFC5030BK 
EMD Millipore). DNA was then loaded on a 2% agarose gel, along with a low 
molecular weight ladder, and the gel was run in a 4°C room at 200 volts for 90 
min. The 150 bp DNA that corresponded to the ligated 5C probes was isolated 
from the gel using the QIAquick Gel Extraction Kit Protocol (QIAGEN 28115). 
DNA was finally eluted in 32 µL of 1XTLE. 
A-tailing: A dATP was added to the 3’ ends of the 5C library by adding 18 µL of 
A-tailing mix [5 µL NEB buffer 2.1, 10 µl of 1 mM dATP, 3 µL Klenow exo (NEB 
M0212S)] to the 32 µL of DNA sample from the previous step. The reaction was 
then incubated in a PCR machine [at 37°C for 30 min, then at 65°C for 20 min, 
and finally cooled down to 4°C]. Next, the tube was placed on ice immediately. 
1:1 Ampure was used to remove unligated adaptors. The DNA was finally eluted 
in 40 µL 1X T4 DNA Ligase buffer (Invitrogen).   
Illumina adapter ligation and paired-end PCR: For this step, we used the TruSeq 
DNA LT kit Set A (REF 15041757). 10 µL of ligation mix [5 µL Illumina paired-
end adapters, 3 µL T4 DNA ligase Invitrogen, 2 µL 5x T4 DNA ligase buffer 
(Invitrogen 5X)] was added to the 40 µL sample from the previous step. The 
ligation sample was then incubated at RT for 2 hours on a tube rotator. 
Afterward, the sample was run on a 2% agarose gel in a cold room 4°C at 150 
volts for 120 min along with a low molecular weight ladder. The 270 bp band that 
corresponds to 5C products (150 bp) ligated to the two adaptors (64 bp) was 
 
 110 extracted from the gel and isolated using the QIAquick Gel Extraction Kit 
(QIAGEN 28115). DNA was finally eluted in 30 µL 1XTLE. 
Pre-digestion of nuclei (liquify chromatin) 
 Purified nuclei as described above (K562 nuclei purification) were placed 
on ice and 1 mL of HBSS was added to each 0.5 mL of 5 million frozen nuclei. 
After thawing, nuclei were centrifuged 5 min at 5,000 g. The nuclei pellet was 
washed twice with 1XNEB3.1 for nuclei that would be digested with DpnII or 
1XNEB2.1 for nuclei that would be digested with HindIII. The nuclei were pelleted 
for 5 min at 5,000 g after each wash.  
 
Isolated nuclei:  a sample of 5 million nuclei was resuspended in 1,250 µL of 1X 
NEB3.1 as control, and then processed immediately for Hi-C starting at the 
crosslinking step (see below Hi-C 2.0 protocol). 
Undigested nuclei:  Each sample of two million nuclei was resuspended in 500 
µL of 1X NEB3.1 on ice, as and control for the pre-digestion and then treated as 
described immediately below. 
DpnII pre-digestion: Each sample of two million nuclei was resuspended in 500 
µL of 1X NEB3.1 on ice. Next, 120 U of DpnII (NEB R0543S) was added to the 
sample in order to obtain 10 U DpnII/µg DNA and then treated as described 
immediately below. 
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of 1X NEB3.1 on ice. Next, 120 U of FatI (NEB R0650L) was added to the 
sample in order to obtain 10 U FatI/µg DNA and then treated as described 
immediately below. 
HindIII pre-digestion: Each sample of two million nuclei was resuspended in 500 
µL of 1X NEB2.1 on ice. Next, 600 U of HindIII (NEB R0104T) was added to the 
sample in order to obtain 50 U HindIII/µg of DNA and then treated as described 
immediately below. 
Next, control and pre-digestion samples were incubated at 37°C on a 
thermocycler (900 rpm for 30 sec every 4 min) for 5 min up to 16 h. Afterward, 
samples were placed on ice for 10 min.For DpnII-seq and assessment of 
fragmentation level , a final volume of 10 mM of EDTA was added to inactivate 
the endonuclease, followed immediately by the DpnII-seq protocol (details of 
protocols below. DpnII-Seq) or DNA purification for fragment analyzer analysis. 
For Hi-C, we proceeded immediately to the first step of the protocol (crosslinking 
as described below). For microscopy, nuclei samples were cross-linked with a 
4% final concentration of paraformaldehyde. 
Hi-C 2.0  
 Hi-C was performed as described (Belaghzal, Dekker and Gibcus, 2017) 
with some modifications in the crosslinking and lysis step as described below. Hi-
C was performed following the exact same protocol for mock treated and for pre-
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fragmented prior to fixation. There are several reasons to perform the full Hi-C 
procedure even for pre-digested nuclei. First, pre-digestion (e.g. with DpnII) leads 
to partial digestion. During the subsequent Hi-C procedure chromatin is digested 
with DpnII again, but this time the chromatin has been opened with SDS 
treatment. This allows more complete digestion. Second, by performing the full 
Hi-C procedure for pre-digested nuclei allows direct comparison of data obtained 
with mock treated nuclei, HindIII pre-digested nuclei, DpnII pre-digested nuclei 
and FatI  pre-digested nuclei. 
Crosslinking: isolated, undigested, and  pre-digested (with liquified chromatin) 
nuclei were not pelleted after the pre-digestion step above but were crosslinked 
immediately as follows: for each sample 1,250 µL volume of nuclei in the 
digestion buffer was transferred to a 21.875 mL mix [625 μL of 37% 
formaldehyde + 21.25 mL of HBSS]. For intact cells: 5 million K562 cells or nuclei 
were washed twice with 15 mL of HBSS and pelleted at 300 g for 10 min, then 
resuspended in 2.5 mL of HBSS. The sample was transferred to 20.625 mL 
crosslinking mix [625 μL of 37% formaldehyde + 20 mL of HBSS].  
All samples were incubated at RT for 10 min on a rocking platform. Next, to stop 
cross-linking 1.25 mL of 2.5 M glycine was added to each sample and the mix 
was incubated at RT for 5 min on a rocking platform. To pellet the crosslinked 
cells/nuclei, the sample was centrifuged at 1,000 g for 10 min at 4°C. The 
 
 113 supernatant was discarded and the pellet was washed twice with HBSS before 
going to the next step or storing samples at -80°C.  
Cells lysis: This step is not needed for isolated, undigested, and pre-digested 
(with liquified chromatin) nuclei. For Hi-C with intact cells: the 5 million 
crosslinked cells were lysed by adding 1 mL cold lysis buffer [10 mM Tris-HCl 
(pH=8.0), 10 mM NaCl, 0.2% Igepal CA-630 (NP40)] and 10 µL of 100X 
Protease inhibitors. The sample was incubated on ice for 15 min to let the cells 
swell. The cells were lysed on ice using a dounce homogenizer with pestle A 
(KIMBLE Kontes 885300-0002) by moving the pestle slowly up and down 30 
times and incubating on ice for 1 min followed by another 30 strokes. The sample 
was transferred to a new 1.5 mL microcentrifuge tube, and the sample was 
centrifuged at 5,000 g at RT for 5 min.  
Digestion:  from each sample (isolated undigested, and pre-digested (with 
liquified chromatin) nuclei and lysed cells) the pellet was resuspended in 500 μL 
of ice-cold 1X NEBuffer 3.1, and pelleted for 5 min at 4,000 g. The pellet was 
washed twice using 500 μL of ice-cold 1X NEBuffer 3.1. After the last wash, the 
pellet was resuspended in 350 µL 1X NEBuffer 3.1, and 8 µL was taken and kept 
at 4°C to assess the DNA integrity later. 38 μL of 1% SDS was added to 342 µL 
(380 µL total volume), and the mixture was resuspended and incubated for 10 
min at 65°C. The tube was placed on ice immediately afterward. Next 43 μL of 
10% Triton X-100 was added and the sample was mixed gently by pipetting. The 
 
 114 tubes were placed at room temperature and 12 µL of 10X NEBuffer 3.1 was 
added. Then 400 U of DpnII (R0543L) was added and mixed gently before an 
overnight incubation at 37°C on a thermocycler (with 900 rpm for 30 sec every 4 
min).  
Biotin Fill-in: After overnight digestion, the sample was incubated at 65˚C for 20 
min in order to inactivate the restriction enzyme. Then, 10 µL of the digested 
sample was taken and kept at 4°C to assess the digestion efficiency later. DNA 
ends were marked with biotin-14-dATP by adding 60 μL of biotin fill-in master mix 
[1XNEB 3.1, 0.25 mM dCTP, 0.25 mM dGTP, 0.25 mM dTTP, 0.25 mM biotin-
dATP (ThermoFisher#19524016), 50U Klenow polymerase Polymerase I (NEB 
M0210L)]. Next, the sample was incubated for 4 h at 23°C on a thermocycler 
(with 900 rpm for 30 sec every 4 min). Finally, the sample was placed on ice 
immediately for 15 min before proceeding to the next step. 
Ligation: After fill-in, the total sample volume was ~535 µL. Ligation was 
performed by adding 665 µL of ligation mix [240 μL of 5x ligation buffer (1.8X) 
(Invitrogen), 120 μL 10% Triton X-100, 12 μL of 10 mg/mL BSA, 50 μL T4 DNA 
ligase (Invitrogen 15224090), and 243 μL ultrapure distilled water (Invitrogen)], to 
make a total volume of 1,200 µL. The reaction was then incubated at 16°C for 4 
hours in a Thermomixer with interval shake. 
 
 115 Reverse Crosslinking: 50 μL of 10 mg/mL proteinase K (Fisher BP1750I-400) 
was added after ligation, the sample was incubated at 65°C for 4 hr followed by a 
second addition of 50 μL 10 mg/mL Proteinase K and overnight incubation 65°C 
DNA purification: Reactions were cooled to room temperature and the 1.3 mL 
total volume was transferred to a 15 mL tube. The DNA was extracted by adding 
an equal volume of 1.3 mL of saturated phenol pH 8.0: chloroform (1:1) (Fisher 
BP1750I-400) and vortexing for 1 min. Then the total volume of 2.6 mL was 
transferred to a 15 ml phase-lock tube (Quiagen #129065) and tubes were 
centrifuged at 5,000 g for 10 min. The upper phase was transferred to a 15 mL 
tube to start the second extraction. An equal volume of 1.3 mL saturated phenol 
pH8.0: chloroform (1:1) was added and the sample was vortexed for 1 min. Then 
the mix was transferred to 15 ml phase-lock tube (Quiagen #129065) followed by 
spinning tubes at 5,000 g for 10 min. The upper phase of ~1.3 mL was 
transferred to a 15 mL tube (high speed) to precipitate the DNA. 1/10 volume 
(130 μL) of 3 M sodium acetate pH 5.2 was added and the sample was briefly 
vortexed. Then, 2.5 volumes of ice-cold 100% ethanol 3.25 mL was added, the 
tube was inverted slowly several times and then incubated at -80° C for 1hr. 
Next, the DNA was pelleted at 16,000 g for 30 min at 4°C. The supernatant was 
discarded and the pellet was dissolved in 500 µL 1X TLE and transferred to a 0.5 
mL AMICON Ultra Centrifuge filter (UFC5030BK EMD Millipore). The column 
was spun for 5 min at 14,000 g and the flow-through was discarded. The column 
was washed 4 times using 450 µL of 1X TLE for desalting of DNA. After the final 
 
 116 wash the DNA remaining in the column (~50 µL) was eluted in  52 µL of 1XTLE. 
The column flipped upside down into a new tube to collect DNA and spun for 3 
min at 4,000 g, the volume was adjusted to 102 µL. RNA was degraded by 
adding 1 µL of 10 mg/mL RNAase A and incubation for 30 min at 37°C. To 
quantify the DNA concentration, 2 µL of the final DNA sample along with the first 
8 µL sample taken before digestion, the 10 µL sample taken after digestion, and 
various amounts of the 1 kb ladder (NEB#N3232s) were run on  1% Agarose gel. 
Removal of Biotin from unligated ends: To remove biotinylated nucleotides at 
DNA ends that did not ligate, the Hi-C sample was treated with T4 DNA 
polymerase. For each Hi-C sample, we assembled the following reaction: [up to 5 
µg of Hi-C library, 5 µL 10x NEBuffer 3.1, 0.025 mM dATP, 0.025 mM dGTP and 
15 U T4 DNA polymerase (NEB # M0203L). The samples were brought up to 50 
µL total volume adding ultrapure distilled water . Reactions were incubated at 
20°C for 4 hours, the enzyme was then inactivated by incubation of the reaction 
for 20 mins at 75°C and placed at 4°C. Next, the samples were pooled and the 
volume was brought up to 130 µL 1XTLE  in preparation for sonication. 
Sonication: the DNA was sheared to a size of 100-300 bp using a Covaris 
instrument [Duty cycle 10%, Intensity 5, Cycles per Burst 200, set Mode 
Frequency sweeping, continuous degassing, process time 60 sec, Number of 
cycles] for 3 cycles. The volume was brought up to 500 µL using TLE  for 
Ampure fractionation. 
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A63881) were added to a 1.5 mL tube labeled as 1.1X. Then the tube was placed 
on the Magnetic Particle Separator (MPS) for 5 min, and the supernatant was 
removed. Beads were resuspended in 150 µL AMpure mixture in order to make 
the 1.1X solution. 400 µL of AMpure mixture was added to 500 µL of sonicated 
DNA from the previous step and the tube was labeled 0.8X. The sample was 
vortexed and spun down briefly followed by incubation at RT for 10 min on a 
rotating platform. Then the tube was placed on the MPS for 5 min at RT. The 
supernatants were collected and added to the 1.1X tube, the tube was briefly 
vortexed and spun down followed by incubation at RT for 10 min on a rotating 
platform. Then the tube was placed on the MPS for 5 min at RT. The supernatant 
was discarded and the beads in 0.8X and 1.1X tubes were washed twice with 1 
mL 70% ethanol. Beads were reclaimed by the MPS for 5 min. Beads were then 
air-dried on the MPS until ethanol had evaporated completely. Next, 51 µL of 
1XTLE was added to the 0.8X and 1.1X tubes to resuspend the DNA from the 
beads. Tubes were incubated at RT on a rotating platform for 10 min. Then the 
tubes with AMpure beads from both 0.8X and 1.1X tubes were placed on the 
MPS for 5 min. Finally, the supernatants were transferred to 1.7 mL tubes 
labeled 0.8X and 1.1X. Our sample with DNA that ranges from 100-300 bp is in 
the 1.1X sample, the 0.8X sample was kept in case more DNA was needed. DNA 
from both samples 0.8X and 1.1X were quantified by running 1 µL on a 2% 
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(100 ng, 200 ng, 400 ng). 
End Repair: 50 µL of Hi-C sample was transferred to a PCR tube, then 20 µL of 
the end-repair mix [3.5X NEB ligation buffer (NEB B0202S), 17.5 mM dNTP mix, 
7.5 U T4 DNA polymerase (NEBM0203L), 25 U T4 polynucleotide kinase (NEB 
M0201S), 2.5 U Klenow polymerase Polymerase I (NEB M0210L)] was added. 
The 70 µL total volume reaction was then incubated at 37°C for 30 min, followed 
by incubation at 65°C for 20 min to inactivate Klenow polymerase, and then the 
sample was put at 4°C. The volume was brought up to 400 µL using 1X TLE for 
the next step. 
Biotin pull-down: All the following steps were performed with 1.5 mL loBind tubes 
(Eppendorf 22431021). 15 µL of MyOne streptavidin C1 beads mix (Thermo 
Fisher 65001) was transferred to a 1.5 mL tube. The beads were washed twice 
by adding 400 µL of TWB [5 mM Tris-HCl pH8.0, 0.5 mM EDTA, 1 M NaCl, 
0.05% Tween20] followed by incubation for 3 min at RT. The tube was then 
placed on an MPS for 1 min and the supernatant was removed. After the 
washes, the beads were resuspended in 400 µL of 2X Binding Buffer (BB) [10 
mM Tris-HCl pH8, 1 mM EDTA, 2 M NaCl] and mixed with the 400 µL DNA from 
the previous step in a new 1.5 mL tube. The mixture was incubated for 15 min at 
RT with rotation, the tube was then placed on the MPS for 1 min and the 
supernatant was removed. The DNA bound to the beads was washed by adding 
400 µL of 1X BB and transferred to a new tube. The beads were reclaimed 
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wash used 100 µL of 1X TLE, beads were reclaimed against MPS for 1 min, and 
the supernatant was discarded. Finally, the DNA bound to the beads was eluted 
in 32 µL of 1X TLE. 
A-tailing: A dATP was added to the 3’ ends by adding 18 µL of A-tailing mix [5 µL 
NEB buffer 3.1, 10 µL of 1 mM dATP, 3 U Klenow exo (NEB M0212S)] to the 32 
µL of DNA sample from the previous step. The reaction was incubated in a PCR 
machine [at 37°C for 30 min, then at 65°C for 20 min, followed by cool down to 
4°C]. Next, the tube was placed on ice immediately. The sample was transferred 
to a 1.5 mL loBind tube, the tube was placed on the MPS for 1 min and the 
supernatant was removed. The streptavidin beads bound to DNA were washed 
twice using 100 µL 1X T4 DNA Ligase Buffer (Invitrogen). Finally, streptavidin 
beads bound to DNA were resuspended in 40 µL 1X T4 DNA Ligase buffer 
(Invitrogen). 
Illumina adapter ligation and paired-end PCR: For this step, the TruSeq DNA LT 
kit Set A (REF#15041757) was used. 10 µL of ligation mix [5 µL Illumina paired-
end adapters, 3 µL T4 DNA ligase Invitrogen, 2 µL 5x T4 DNA ligase buffer 
(Invitrogen 5X)] was added to the 40 µL Hi-C sample from the previous step. The 
ligation sample was then incubated at RT for 2 hours on a rotator. The sample 
was transferred to a 1.5 mL loBind tube, the tube was placed on the MPS for 1 
min and the supernatant was removed. The streptavidin beads bound to DNA 
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the sample was resuspended in 20 µL 0f 1XTLE. 
Illumina Truseq Kit for PCR: We performed three trial PCR reactions as follows 
[2.5 µL DNA bound to beads, 2 µL of Primers mix (TruSeq DNA LT kit Set A 
15041757)), 10 µL Master Mix (TruSeq DNA LT kit Set A 15041757), 10.5 µL of 
ultrapure distilled water (Invitrogen)]. We split the 25 µL over three PCR tubes (5 
µL, 5 µL, 15 µL per tube). Each of the three samples was then amplified with 
different numbers of PCR cycles (6, 8, 10 respectively) to assess the Hi-C library 
quality: [30 sec at 98°C,  n cycles of (30 sec at 98°C, 30 sec at 65°C, 30 sec at 
72°C), 5 min at 72°C, hold at 10°C]. 10 µL was taken from the 15 µL sample 
(with 10 PCR cycles), the 10 µL sample was then digested with ClaI for 1 h by 
adding 10 µL of digestion mix [1.5 µL 10x NEB Cutsmart buffer, 1.5 µL ClaI  ( 
NEB R0197S ), 7 µL ultrapure distilled water]. The 5 µL of each PCR cycle 
sample along with the 20 µL digested sample, and titration of the low molecular 
ladder (100 ng, 200 ng, 400 ng) (NEB) were run on a 2% Agarose gel. After 
digestion with ClaI, a downward shift of the amplified DNA to smaller sizes is 
expected, which indicates DNA ends were correctly filled in and ligated (creating 
a ClaI site). The number of PCR cycles to generate the final Hi-C material for 
deep sequencing was chosen based the minimum number of PCR cycles in the 
PCR titration that was needed to obtain sufficient amounts of DNA for 
sequencing using the remaining 17.5 µL Hi-C sample. 
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 For each DpnII-Seq  library, 10 million nuclei were used right after the pre-
digestion procedure described above (Pre-digestion of nuclei). The pre-digested 
nuclei were then treated as follows: 
Proteinase K: 50 μL of 10 mg/mL proteinase K (ThermoFisher # 25530) was 
added to each 500 µL pre-digested nuclei sample (2 million nuclei) (See 
Methods: Pre-digestion) and the 5 tubes were incubated at 65°C for 3 hours. 
DNA purification: Tubes were cooled to room temperature and all 5 samples 
were pooled in a single 15 mL tube (2.75 mL total volume). The DNA was 
extracted by adding an equal volume of 2.75 mL of saturated phenol pH8.0: 
chloroform (1:1) (Fisher BP1750I-400), followed by vortexing for 1 min. The 
sample (5.5 mL) was transferred to a 15 mL phase-lock tube (Quiagen #129065) 
followed by centriguation at 5,000 g for 10 min. The upper phase was transferred 
to a 15 mL tube to start the second extraction. An equal volume of 2.75 mL 
saturated phenol pH8.0: chloroform (1:1) was added, followed by vortexing for 1 
min. Then the mix was transferred to a 15 mL phase-lock tube (Quiagen 
#129065) followed by centrifugation at 5,000 g for 10 min. The upper phase of ~ 
2.75 mL was transferred to a 15 mL tube (high speed), 1/10 volume (275 μL) 3M 
sodium acetate pH 5.2 was added followed by brief vortexing and then 2.5 
volumes of ice-cold 100% ethanol (6.875 mL) were added. The tube was inverted 
slowly several times, incubated at -80°C for 1 hr and then DNA was pelleted by 
 
 122 centrifugation at 16,000 g for 30 min at 4°C. The supernatant was discarded and 
the pellet was dissolved in 500 µL 1X NEB3.1 and transferred to a 0.5 mL 
AMICON Ultra Centrifuge filter (UFC5030BK EMD Millipore). The column was 
centrifuged for 5 min at 14,000 g and the flow-through was discarded. The 
column was washed 4 times using 450 µL of 1X NEB3.1 for desalting of DNA. 
After the final wash, the library remaining in the column (~50 µL) was eluted in 
450 µL of 1XNEB3.1; the column was flipped upside down into a new tube to 
collect DNA and centrifuged for 3 min at 4,000 g. ~500 µL of DNA was 
recovered. RNA was degraded by adding 1 µL of 10 mg/mL RNAase A and 
incubation for 30 min at 37°C.  The amount of DNA was estimated by running an 
aliquot on a 1% Agarose gel along with a 1kb ladder (NEB#N3232s). 
Biotin Fill-in: 1XNEB3.1 was added the reaction to a final volume of 680 µL, and 
then the 680 µL was split over 2 1.5 mL tubes. DNA ends were filled in and 
marked with biotin-14-dATP. To each tube 60 μL of biotin fill-in master mix  was 
added: [1xNEB2.1, 0.25 mM dCTP, 0.25 mM dGTP, 0.25 mM dTTP, 0.25 mM 
biotin-dATP (ThermoFisher#19524016), 50 U Klenow polymerase Polymerase I 
(NEB M0210L)]. Samples were incubated at 37°C in a Thermocycler for 75 mins. 
Next, the tubes were placed on ice immediately for 15 mins, and samples from 
the 2 tubes were combined to obtain a final volume ~800 µL. Amicon filters were 
used to reduce the volume of the final sample from 801 µL to 130 µL. 
Sonication: DNA was sonicated to a size of 100 – 300 bp using a Covaris 
instrument (Duty Cycle 10%, Intensity 5, Cycles per Burst 200, set Mode 
 
 123 Frequency sweeping, continuous degassing, process time 60 sec, Number of 
cycles) for 4 cycles. The 130 µL of sonicated DNA was transferred to a 1.5 mL 
tube and 1XTLE was added to a total volume of 500 µL. DNA fragment size was 
determined by running 2 µL of DNA along with low molecular ladder (NEB) on a 
2% agarose gel.  
Size fractionation using AMpure XP: 500 µL AMpure beads (Beckman Coulter 
A63881) were added to a 1.5 mL tube labeled as 1.1X. The tube was placed on 
the MPS for 5 min, and the supernatant was removed. Beads were resuspended 
in 150 µL AMpure mixture in order to make 1.1X. 400 µL of AMpure mixture was 
added to 500 µL of sonicated DNA from the previous step and the tube was 
labeled 0.8X. The sample was vortexed and centrifuged briefly using a tabletop 
small centrifuge followed by incubation at RT for 10 min on a rocking platform. 
Then the tube was placed on the MPS for 5 min at RT. The 0.8X supernatants 
were collected and added to the 1.1X tube, the tube was briefly vortexed and 
centrifuged followed by incubation at RT for 10 min on a rocking platform. The 
tube was placed on the MPS for 5 min at RT, and the supernatant discarded. 
Beads in the 0.8X and 1.1X tubes were washed twice with 1 mL 70% ethanol, 
reclaiming beads against the MPS for 5 min. Beads on the MPS were then dried 
until ethanol had evaporated completely. Next, 51 µL of 1XTLE was added to the 
0.8X  and 1.1X tubes to elute DNA from the beads. Tubes were incubated at RT 
on a rocking platform for 10 min. The 0.8X and 1.1X tubes were placed on the 
MPS for 5 min. Finally, the supernatants were transferred to 1.7 mL tubes 
 
 124 labeled 0.8X and 1.1X. The 1.1X sample contains DNA that ranges in size from 
100-300 bp. The DNA in the 0.8X sample was kept in case more DNA was 
required, in which case the DNA would be sonicated using 2 cycles followed by a 
similar round of size fractionation as described above. The amount of DNA from 
both samples 0.8X and 1.1X was quantified by running 1 µL on a 2% agarose gel 
along with a titration of low molecular weight DNA ladder (100 ng, 200 ng, 400 
ng). 
End Repair: 50 µL from the 1.1X sample was transferred to a PCR tube, and 20 
µL of end repair mix was added: [3.5X NEB ligation buffer (NEB B0202S), 0.875 
mM dNTP mix, 0.375 U/µL T4 DNA polymerase, 1.25 U/µL T4 polynucleotide 
kinase, 0.125 U/µL Klenow DNA polymerase]. The 70 µl total volume reaction 
was incubated for 30 min at 20°C in a PCR machine and then placed on ice. The 
DNA was purified by 1:2 Ampure, by adding 140 µL 2X Ampure solution to the 70 
µL DNA sample followed by incubation for 5 min at RT. The tube was placed on 
the MPS for 4 min to reclaim the beads and the supernatant was discarded. The 
beads were washed twice with 1 mL of 70% ethanol while on the MPS. After 
beads were dried DNA was eluted in 32 µL TLE (pH 8.0) and incubation for 10 
min at RT. The supernatant was transferred to a 1.5 mL tube. 
A-tailing: A dATP was added to the 3’ ends by adding 18 µL of A-tailing mix [5 µL 
NEB buffer 3.1, 10 µL of 1 mM dATP, 3 U Klenow exo (NEB M0212S)] to the 32 
µL of DNA sample from the previous step. The reaction was then incubated in a 
PCR machine at 37°C for 30 min followed by incubation 65°C for 20 min and 
 
 125 cooling down to 4°C. The tube was placed on ice. The volume was brought to 
100 µL by adding 1X NEB2.1. The DNA was then purified by adding 1:2 Ampure 
mix ( 200 µL of Ampure was added to the 100 µL final DNA volume). Finally, the 
DNA was eluted in 40 µL of 1X T4 DNA ligase buffer (Invitrogen 5X). 
Illumina adapter ligation and paired-end PCR: For this step we used the TruSeq 
DNA LT kit Set A (REF#15041757). 50 µL of ligation mix [25 µL Illumina paired-
end adapters, 15 µL T4 DNA ligase Invitrogen, 10 µL 5X T4 DNA ligase buffer 
(Invitrogen 5X)] was added to the 40 µL sample from the previous step. The 
ligation sample was then incubated at RT for 2 hours on a rotator. Next, the DNA 
was purified by adding 1:1 Ampure solution (180 µL of Ampure mix was added to 
the 90 µL sample), the supernatant was discarded and beads were washed twice 
with 1 mL of 70% ethanol. After the last wash step, the beads were resuspended 
in 400 µL of 1X TLE and incubated at RT on a rocking platform for 10 mins. The 
tube was placed on the MPS for 4 mins. Finally, the 400 µL supernatant was 
transferred to a new tube. 
Biotin pull-down: All the following steps are done using 1.5 mL loBind tube 
(Eppendorf 22431021). 15 µL of MyOne streptavidin C1 beads mix (Thermo 
Fisher 65001) was transferred to a 1.5 mL tube. The beads were washed twice 
with 400 µL of TWB [5 mM Tris-HCl pH8.0, 0.5 mM EDTA, 1 M NaCl, 0.05% 
Tween20] by incubation for 3 min at RT. After each wash, the tube was placed 
on the MPS for 1 min and the supernatant was removed. After the washes, the 
beads were resuspended in 400 µL of 2X Binding Buffer (BB) [10 mM Tris-HCl 
 
 126 pH8.0, 1 mM EDTA, 2 M NaCl] and mixed with the 400 µL DNA from the 
previous step in a new 1.5 mL. The mixture was incubated for 15 min at RT with 
rotation. The tube was then placed on the MPS for 1 min and the supernatant 
was removed. The DNA bound to the beads was washed first by adding 400 µL 
of 1X BB and transferring to a new tube. The beads were reclaimed against the 
MPS for 1 min, and the supernatant discarded. 100 µL of 1X TLE was added and 
the beads were reclaimed against the MPS for 1 min, then the supernatant was 
discarded. Finally, the DNA bound to the beads was eluted in 32.5 µL of 1X TLE. 
PCR optimization: The Illumina Truseq Kit (DNA LT kit Set A (REF#15041757)) 
was used for PCR amplification of DNA for DpnII-Seq. The trial PCR reaction 
was set up as follows: [2.5 µL DNA bound to beads, 2 µL of Primers mix (Truseq 
kit), 10 µL Master Mix (Truseq kit), 10.5 µL of ultrapure distilled water 
(Invitrogen)]. The 25 µL was split over four PCR tubes (5 µL/per tube). Each of 
the four samples was incubated for different PCR cycles (6, 8, 10, or 12 cycles): 
[30 sec at 98°C, n cycles of (30 sec at 98°C, 30 sec at 65°C, 30 sec at 72°C), 7 
min at 72°C, hold at 10°C]. The optimal PCR cycle number needed to get enough 
DNA for sequencing was determined by running the 4 PCR reactions on a 2% 
agarose gel along with low molecular ladder titration (100 ng, 200 ng, 400 ng). 
Three PCR reactions of 50 µL volume were then performed: [5 µL DNA bound to 
beads, 4 µL of Primers mix (Truseq kit), 20 µL Master Mix ( Truseq kit), 21 µL of 
ultrapure distilled water (Invitrogen)]. The 3 PCR reactions were pooled together 
to obtain 150 µL total volume. The samples were reclaimed against the MPS for 
 
 127 1 min, then the PCR products (supernatant) were taken to new 1.5 mL tubes. 1:1 
Ampure was performed for removal of primer dimers (150 µL of Ampure and 150 
µL DNA sample). Finally, beads were resuspended in 35 µL of TLE to elute the 
DNA. DNA that remained bound to beads was saved after a first wash using 
TBW followed by two washes with 1X TLE and then resuspended in 30 µL of 1X 
TLE. 
DpnII Pre-digestion size assessment 
4 million cells were pre-digested for 4 hours using DpnII procedure 
described above (Pre-digestion of nuclei). The pre-digested nuclei were then 
treated as follows: 
Proteinase K: 50 μL of 10 mg/mL proteinase K (ThermoFisher # 25530) was 
added to each 500 µL pre-digested nuclei sample (2 million nuclei) (See 
Methods: Pre-digestion) and the 2 tubes were incubated at 65°C for 3 hours. 
DNA purification: Tubes were cooled to room temperature and all 2 samples 
were pooled in a single 15 mL tube (1.1 mL total volume). The DNA was 
extracted by adding an equal volume of 1.1 of saturated phenol pH8.0: 
chloroform (1:1) (Fisher BP1750I-400), followed by vortexing for 1 min. The 
sample (2.2 mL) was transferred to a 15 mL phase-lock tube (Quiagen #129065) 
followed by centriguation at 5,000 g for 10 min. The upper phase was transferred 
to a 15 mL tube to start the second extraction. An equal volume of 1.1 mL 
saturated phenol pH8.0: chloroform (1:1) was added, followed by vortexing for 1 
 
 128 min. Then the mix was transferred to a 15 mL phase-lock tube (Quiagen 
#129065) followed by centrifugation at 5,000 g for 10 min. The upper phase of ~ 
1.1 mL was transferred to a 15 mL tube (high speed), 1/10 volume (110 μL) 3M 
sodium acetate pH 5.2 was added followed by brief vortexing and then 2.5 
volumes of ice-cold 100% ethanol (2.75 mL) were added. The tube was inverted 
slowly several times, incubated at -80°C for 1 hr and then DNA was pelleted by 
centrifugation at 16,000 g for 30 min at 4°C. The supernatant was discarded, and 
the pellet was dissolved in 500 µL 1X NEB3.1 and transferred to a 0.5 mL 
AMICON Ultra Centrifuge filter (UFC5030BK EMD Millipore). The column was 
centrifuged for 5 min at 14,000 g and the flow-through was discarded. The 
column was washed 4 times using 450 µL of 1X NEB3.1 for desalting of DNA. 
After the final wash, the DNA remaining in the column (~50 µL) was eluted in 70 
µL of 1XNEB3.1; the column was flipped upside down into a new tube to collect 
DNA and centrifuged for 3 min at 4,000 g. ~70 µL of DNA was recovered. RNA 
was degraded by adding 1 µL of 10 mg/mL RNAase A and incubation for 30 min 
at 37°C. The amount of DNA was estimated by running an aliquot on a 1% 
Agarose gel along with a 1kb ladder (NEB#N3232s). 
Blunting overhang: DNA ends were filled in by adding 60 μL of  fill-in master mix  
was added: [1xNEB2.1, 0.25 mM dCTP, 0.25 mM dGTP, 0.25 mM dTTP, 0.25 
mM dATP (ThermoFisher#19524016), 50 U Klenow polymerase Polymerase I 
(NEB M0210L)]. Samples were incubated at 37°C in a Thermocycler for 75 mins. 
Next, the tubes were placed on ice immediately for 15 mins. 
 
 129 Gel Extraction for size-selection: a 1% gel was prepared. 25µL of loading dye 
(blue dark) was added to the 130µL DNA sample from the previous step. 25µL of 
1kb DNA ladder was loaded in one well and all sample in the remaining wells. 
After elecrophoresis the DNA was isolated from the gel in three size intervals:  
less than 1kb, 1kb-3kb, and larger than 3kb.  
DNA purification from agarose gel: The DNA was extracted from the agarose gel 
using GFX™ PCR DNA and Gel Band Purification Kit ( GE28-9034-70 Millipore 
Sigma). After DNA extraction the sample was washed five times with TLE buffer 
using a 1.5 Amicon column followed by elution with 50 µl TLE. Aliquots of each 
DNA samples was analyzed on a fragment analyzer. 
Sonication: DNA from each size fraction was sonicated to a size of 100 – 300 bp 
using a Covaris instrument (Duty Cycle 10%, Intensity 5, Cycles per Burst 200, 
set Mode Frequency sweeping, continuous degassing, process time 60 sec, 
Number of cycles) for 4 cycles. The 130 µL of sonicated DNA was transferred to 
a 1.5 mL tube and 1XTLE was added to a total volume of 500 µL. DNA fragment 
size was determined by running 2 µL of DNA along with low molecular ladder 
(NEB) on a 2% agarose gel.  
Size fractionation using AMpure XP: 500 µL AMpure beads (Beckman Coulter 
A63881) were added to a 1.5 mL tube labeled as 1.1X. The tube was placed on 
the MPS for 5 min, and the supernatant was removed. Beads were resuspended 
in 150 µL AMpure mixture in order to make 1.1X. 400 µL of AMpure mixture was 
 
 130 added to 500 µL of sonicated DNA from the previous step and the tube was 
labeled 0.8X. The sample was vortexed and centrifuged briefly using a tabletop 
small centrifuge followed by incubation at RT for 10 min on a rocking platform. 
Then the tube was placed on the MPS for 5 min at RT. The 0.8X supernatants 
were collected and added to the 1.1X tube, the tube was briefly vortexed and 
centrifuged followed by incubation at RT for 10 min on a rocking platform. The 
tube was placed on the MPS for 5 min at RT, and the supernatant discarded. 
Beads in the 0.8X and 1.1X tubes were washed twice with 1 mL 70% ethanol, 
reclaiming beads against the MPS for 5 min. Beads on the MPS were then dried 
until ethanol had evaporated completely. Next, 51 µL of 1XTLE was added to the 
0.8X  and 1.1X tubes to elute DNA from the beads. Tubes were incubated at RT 
on a rocking platform for 10 min. The 0.8X and 1.1X tubes were placed on the 
MPS for 5 min. Finally, the supernatants were transferred to 1.7 mL tubes 
labeled 0.8X and 1.1X. The 1.1X sample contains DNA that ranges in size from 
100-300 bp. The DNA in the 0.8X sample was kept in case more DNA was 
required, in which case the DNA would be sonicated using 2 cycles followed by a 
similar round of size fractionation as described above. The amount of DNA from 
both samples 0.8X and 1.1X was quantified by running 1 µL on a 2% agarose gel 
along with a titration of low molecular weight DNA ladder (100 ng, 200 ng, 400 
ng). 
End Repair: 50 µL from the 1.1X sample was transferred to a PCR tube, and 20 
µL of end repair mix was added: [3.5X NEB ligation buffer (NEB B0202S), 0.875 
 
 131 mM dNTP mix, 0.375 U/µL T4 DNA polymerase, 1.25 U/µL T4 polynucleotide 
kinase, 0.125 U/µL Klenow DNA polymerase]. The 70 µl total volume reaction 
was incubated for 30 min at 20°C in a PCR machine and then placed on ice. The 
DNA was purified by 1:2 Ampure, by adding 140 µL 2X Ampure solution to the 70 
µL DNA sample followed by incubation for 5 min at RT. The tube was placed on 
the MPS for 4 min to reclaim the beads and the supernatant was discarded. The 
beads were washed twice with 1 mL of 70% ethanol while on the MPS. After 
beads were dried DNA was eluted in 32 µL TLE (pH 8.0) and incubation for 10 
min at RT. The supernatant was transferred to a 1.5 mL tube. 
A-tailing: A dATP was added to the 3’ ends by adding 18 µL of A-tailing mix [5 µL 
NEB buffer 3.1, 10 µL of 1 mM dATP, 3 U Klenow exo (NEB M0212S)] to the 32 
µL of DNA sample from the previous step. The reaction was then incubated in a 
PCR machine at 37°C for 30 min followed by incubation 65°C for 20 min and 
cooling down to 4°C. The tube was placed on ice. The volume was brought to 
100 µL by adding 1X NEB2.1. The DNA was then purified by adding 1:2 Ampure 
mix ( 200 µL of Ampure was added to the 100 µL final DNA volume). Finally, the 
DNA was eluted in 40 µL of 1X T4 DNA ligase buffer (Invitrogen 5X). 
Illumina adapter ligation and paired-end PCR: For this step we used the TruSeq 
DNA LT kit Set A (REF#15041757). 50 µL of ligation mix [25 µL Illumina paired-
end adapters, 15 µL T4 DNA ligase Invitrogen, 10 µL 5X T4 DNA ligase buffer 
(Invitrogen 5X)] was added to the 40 µL sample from the previous step. The 
ligation sample was then incubated at RT for 2 hours on a rotator. Next, the DNA 
 
 132 was purified by adding 1:1 Ampure solution (180 µL of Ampure mix was added to 
the 90 µL sample), the supernatant was discarded and beads were washed twice 
with 1 mL of 70% ethanol. After the last wash step, the beads were resuspended 
in 400 µL of 1X TLE and incubated at RT on a rocking platform for 10 mins. The 
tube was placed on the MPS for 4 mins. Finally, the 400 µL supernatant was 
transferred to a new tube. 
PCR optimization: The Illumina Truseq Kit (DNA LT kit Set A (REF#15041757)) 
was used for PCR amplification of DNA for DpnII-Seq. The trial PCR reaction 
was set up as follows: [2.5 µL DNA bound to beads, 2 µL of Primers mix (Truseq 
kit), 10 µL Master Mix (Truseq kit), 10.5 µL of ultrapure distilled water 
(Invitrogen)]. The 25 µL was split over four PCR tubes (5 µL/per tube). Each of 
the four samples was incubated for different PCR cycles (6, 8, 10, or 12 cycles): 
[30 sec at 98°C, n cycles of (30 sec at 98°C, 30 sec at 65°C, 30 sec at 72°C), 7 
min at 72°C, hold at 10°C]. The optimal PCR cycle number needed to get enough 
DNA for sequencing was determined by running the 4 PCR reactions on a 2% 
agarose gel along with low molecular ladder titration (100 ng, 200 ng, 400 ng). 
Three PCR reactions of 50 µL volume were then performed: [5 µL DNA bound to 
beads, 4 µL of Primers mix (Truseq kit), 20 µL Master Mix ( Truseq kit), 21 µL of 
ultrapure distilled water (Invitrogen)]. The 3 PCR reactions were pooled together 
to obtain 150 µL total volume. The samples were reclaimed against the MPS for 
1 min, then the PCR products (supernatant) were taken to new 1.5 mL tubes. 1:1 
Ampure was performed for removal of primer dimers (150 µL of Ampure and 150 
 
 133 µL DNA sample). Finally, beads were resuspended in 35 µL of TLE to elute the 
DNA. DNA that remained bound to beads was saved after a first wash using 
TBW followed by two washes with 1X TLE and then resuspended in 30 µL of 1X 
TLE. 
Lamin A Immunofluorescence and DAPI 
 For nuclei immunofluorescence, we prepared a coverslip by adding 1 mL 
of 0.1% Poly-L-lysine solution (Sigma SLBQ5716V) for 10 min, then coverslips 
were dried using Whatman papers. Each coverslip was transferred to a single 
well of an eight wells plate. The coverslips were washed twice using PBS. Next 
500 µL of 30% sucrose with 1 mM DTT was added on top of the coverslips to 
protect nuclei from an abrupt contact with coverslip during spinning. 1 million 
control nuclei or nuclei after chromatin digestion were crosslinked for 20 min 
using a 4% final concentration of Paraformaldehyde immediately after pre-
digestion. Next, nuclei were added slowly on top of he sucrose solutions on the 
coverslips and spun for 15 mins at 2,500 g at 4°C. Next, nuclei were assumed to 
be attached to the coverslips which were then transferred to a new 8 well plate. 
The coverslips were washed five times with 1% PBS. Next, non-specific binding 
of the primary antibody was blocked by adding 500 µL of the blocking buffer [3% 
BSA, 1X PBS, 0.1% Triton X-100 (Sigma 9002-93-1)] and incubating for 60 min 
at RT. Afterward,  lamin A antibody (ab 26300) was diluted 1:1000 in blocking 
buffer, and the coverslip was incubated face-down on top of a 250 µL of lamin A 
antibody droplet that was placed on parafilm for 120 min at RT. Then, the 
 
 134 coverslip was placed back in the well of a new plate face-up and washed five 
times with washing buffer (1X PBS, 0.1% Triton X-100). The secondary antibody 
Goat Anti-Rabbit (ab150077) was diluted 1:1000 in blocking buffer, and the 
coverslip was incubated face-down on top of a 250 µL droplet of the secondary 
antibody (Goat Abti-Rabbit (ab150077) that was placed on parafilm for 60 min at 
RT. Next, the coverslip was placed back in the well of a new plate face-up and 
washed five times with washing buffer (1X PBS, 0.1% Triton X-100) and twice 
with 1X PBS. The slide was mounted and sealed using 10 µL antifade mountant 
with DAPI (Invitrogen P36931).  
For image acquisition, we used a Nikon Eclipse Ti microscope. Imaging was 
performed using an Apo TIRF, N.A. 1.49, 60X oil immersion objective (Nikon), 
and a Zyla sCMOS camera (Andor). Z-series of 0.2 μm slices were acquired 
using Nikon Elements software (Version 4.4). 
Chromatin fractionation assay 
 Chromatin-bound proteins were isolated and separated from free proteins. 
A sample of 2 million control nuclei or pre-digested nuclei (obtained as described 
above “Pre-digestion of nuclei”) was centrifuged at 5,000 g for 5 min at 4°C. The 
supernatant was transferred to an Amicon column to reduce the volume from 500 
µL to 100 µL by centrifugation for 4 min at 14,000 g. This sample contains the 
free protein fraction. Next, 26 µL of glycerol and 1.3 µL of 100X protease inhibitor 
cocktail were added to the 100 µL free proteins sample. The pellet containing the 
nuclei was resuspended in 100 µL of nuclei purification buffer with Triton (10 mM 
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1mM DTT) and incubated for 10 min on ice. Then, in order to protect protein 
structure during sonication, 25 µL of glycerol was added to the 100 µL pellet 
sample to have 20% final glycerol concentration. The sample was sonicated 
using a Covaris instrument at 4°C as follows: (Duty Cycle 10%, Intensity 5, 
Cycles per Burst 200, set Mode Frequency sweeping, continuous degassing, 
process time 60 sec, 4 cycles). The pellet sample contains chromatin-bound 
proteins, was transferred to a 1.5 mL tube. All samples were stored at -20. These 
samples contain the protein bound CTCF and cohesin. Note: when these 
samples were centrifuged after the triton solubilization, we found that no SMC3 
or CTCF could be detected in the supernatant. These results indicate that non-
chromatin-bound proteins exit the nuclei and were recovered in the supernatant 
prior to triton solubilization step.  
For analysis of CTCF and SMC1 chromatin binding: 15 µL from each protein 
sample (supernatant or pellet) was mixed with 5 µL of 5X Lane Marker Reducing 
Sample Buffer (Thermo Fisher 39000), then the mix was boiled for 10 min. The 
samples were cooled down to RT before loading them on a 3-8% Tris-Acetate 
Protein Gels (Invitrogen EA0375PK2). Next, the gel was run in 1X Tris-Acetate 
SDS Running Buffer (Invitrogen LA0041) for 75 min at 150V. For Histone H3: 1 
µL of protein sample was mixed with 14 µL of PBS containing 1% Protease 
inhibitor, 5 µL of 5X Lane Marker Reducing Sample Buffer was added to the mix 
and boiled for 10 min. The samples were cooled down to RT before loading them 
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SDS running buffer (Invitrogen B0002) for 60 min at 150V. The proteins were 
transferred from the gel to nitrocellulose membrane using 1X western blot 
transfer buffer (Thermo science 35040). The transfer was 120 min for SMC1 and 
CTCF and 75 min for H3. The nitrocellulose membranes were washed using 1X 
TBST [50 mM Tris-Cl, pH 7.6; 150 mM NaCl, 0.1 mL of Tween 20], then Blocked 
for 120 min using 5% milk (1 g milk in 20 mL 1X TBST). The membrane when 
then incubated overnight at 4°C with primary antibody diluted in 5% milk [1:1000 
CTCF antibody cell signaling (activeMotif 61311), 1:2000 SMC1 (Bethyl  
Antibody, A300-055A), 1:4000 H3 Abcam (ab1791)] . Next, the membranes were 
washed 6 times for 10 min per wash using 1X TBST. The secondary antibody 
anti-rabbit IgG HRP from cell signaling was diluted using 5% milk for CTCF and 
SMC1 [1:1000 for CTCF, 1:2000 SMC1] and in 1% milk for H3 1:5000 dilution. 
Membranes were incubated for 120 min at RT. Finally, membranes were washed 
6 times for 10 min using 1X TBST. Finally, the membranes were developed using 
luminol-based enhanced chemiluminescence(Thermo science 34076). 
Micromanipulation force measurement and treatments of an isolated nuclei 
 Micromanipulation force measurements were conducted as described 
previously in Stephens et al. (Stephens et al., 2017). K562 cells were grown in 
microscope slide wells and treated with 1 µg/mL latrunculin A (Enzo Life 
Sciences) for ~45 min before single nucleus isolation. The nucleus was isolated 
by using small amounts of detergent (0.05% Triton X-100 in PBS) locally sprayed 
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a second micropipette to retrieve the nucleus from the cell, using slight aspiration 
and non-specific adherence to the inside of the micropipette. A third micropipette 
was then attached to the opposite end of the nucleus in a similar fashion. This 
last “force” micropipette was pre-calibrated for its deflection spring constant, 
which is on the order of 2 nN/µm. A custom computer program written in LabView 
was then run to move the “pull” micropipette and track the position of both the 
“pull” and “force” pipettes. The “pull” pipette was instructed to move 5 µm at 45 
nm/sec. The program then tracked the distance between the pipettes to provide a 
measure of nucleus extension ~3 µm. Tracking the distance that the “force” 
pipette moved/deflected multiplied by the pre-measured spring constant provides 
a calculation of force exerted. Calculations were done in Excel (Microsoft) to 
produce a force-extension plot from which the best-fit slope of the line would 
provide a spring constant of the nucleus (nN/µm). Isolated nuclei were measured 
twice initially to establish the native spring constant prior to treatment. After 50 uL 
of buffer only (control), 100 units DpnII (|GATC) with NEB buffer 3.1, or 100 units 
HindIII (A|AGCTT) with NEB buffer 2.1 was added to the 1.5 mL imaging well and 
mixed gently. Force measurements were performed 5 min, 30 min, and 60 min 
post-treatment. 
3C-PCR  
 The human β-globin locus is an ideal region to examine looping 
interactions between enhancers and genes because of the strong looping 
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line K562, which highly expresses the globin genes (Dostie et al., 2006). 3C 
libraries were generated from: (1) K562 cells that have an LCR-HBG interaction, 
(2) GM12878 cells in which the LCR-HBG looping interaction is absent, and (3) 
beta-globin BAC (ENm009) control to normalize for primer bias. To investigate 
the interaction between the LCR and HBG gene, 3C primers from (Dostie et al., 
2006) were used. 16 forward primers of 28-33 bp length were designed 40-60 bp 
upstream of each EcoRI site throughout a 110 kb region around the Beta Globin 
locus (chr11: 5221788- 5337325). The EcoRI fragment overlapping with the LCR 
(HS3,4,5) was used as an anchor to detect the interaction frequencies between 
the LCR and EcoRI fragments throughout the β-globin locus. For each primer 
pair, triplicate PCR reactions were set up, and the mean of the three was 
normalized to the BAC signal for the same primer pair before plotting normalized 
interaction frequency in the y-axis, the distance from EcoRI fragment overlapping 
with LCR to neighboring EcoRI fragments is plotted in the x-axis. Error bars are 
the standard error of the mean (SEM). 
5C data processing 
 The fastq files for 5C sequencing data were processed as described in 
https://github.com/dekkerlab/5C-CBFb-SMMHC-
Inhib/blob/master/data_processing_steps.md 
The Fastq files were mapped using novoalign to a reference genome built from 
the pool of all 277 probes. After mapping, we combined the read-pairs. The 
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previously described (Lajoie et al., 2009; Sanyal et al., 2012). First, interactions 
that belong to the same EcoRI fragment were removed. Second, outliers that are 
overrepresented as a result of overamplification were also removed. Outliers 
were defined as the interactions with a Z-score greater than 20 in all datasets. 
Third, probes that strongly over or underperform which leads to strongly enriched 
or depleted interactions in a whole row of interactions, were also removed. The 
four matrices were then scaled to the same number of total reads. Finally, data 
were binned at 20 Kb (median) with a sliding window with 2.5 Kb steps 
Hi-C data processing 
 Hi-C read mapping, filtering, binning and matrix normalization were 
performed using the cMapping pipeline available at 
https://github.com/dekkerlab/cMapping (Lajoie, Dekker and Kaplan, 2015). In 
brief, Hi-C reads were mapped to reference human genome assembly hg19 
using an iterative mapping strategy and Bowtie 2 (Langmead et al., 2009). 
Successfully mapped reads were then filtered to remove reads mapping to the 
same restriction fragment and to remove PCR duplicates. Interaction frequency 
versus distance plots displayed high variance for interactions below 1 kb for all 
samples. Hence, after mapping of valid pair, we removed all pairs with a genomic 
distance less than 1 kb. The remaining valid read pairs were then binned to 500 
kb, 40 kb, and 10 kb resolution matrices. Outlier bins of these matrices with low 
signal were assigned values of NA. Then as a bias correction step, matrices 
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approximately equivalent via an iterative correction procedure (ICE) (Imakaev et 
al., 2012). Lastly, for comparison between samples, matrices were scaled such 
that the total interactions for a genome-wide matrix equals one billion for each 
sample. These ICEd scaled matrices were used for subsequent analyses.   
A/B compartments 
 All reads from Hi-C in control K562 samples were pooled to identify A 
(active) and B (inactive) compartments in K562 cells. A/B compartments were 
identified at 40 kb resolution following the procedure described in (Lieberman-
Aiden et al., 2009) using matrix2compartment.pl in 
https://github.com/dekkerlab/cworld-dekker. Briefly, each cis interaction matrix 
was first transformed into a z-score matrix followed by transformation into a 
correlation matrix. PCA was performed on the correlation matrix and the first 
eigenvector (PC1) of the PCA analysis was used to identify compartments for 
each chromosome. A/B compartments were assigned based on gene density 
such that the A-compartment was more gene-dense than the B-compartment. 
Positive PC1 values indicate gene-rich A compartments and negative PC1 
values indicate gene-poor B compartments. For chromosome 9 the 
compartments were called for each chromosome arm separately as PC1 
captured preferences for interactions within the same arm as opposed to 
canonical compartment preferences.   
 
 141 LOS and half-life calculation 
 To measure the 3D structure changes resulting from DpnII, HindIII, or FatI 
pre-digestion we quantified the amount of cis interactions lost or gained in a 6 Mb 
window centered at every 40 kb bin genome wide. We note that we did not 
observe detectable amounts of DNA in the supernatant after chromatin 
fractionation indicating the large majority of liquefied DNA remains within the 
nuclei. Even if some DNA is lost, ICE balancing of Hi-C matrices ensures any 
biases in sequence coverage are removed. For each 40 kb bin, the percent of 
interactions occurring within its 6 Mb window (corresponding to interactions less 
than or equal to 3 Mb in distance either upstream or downstream from 40 kb bin) 
out of total interactions for the 40 kb bin (cis and trans) was calculated. These 6 
Mb cis percentages were calculated for control, DpnII pre-digested, HindIII-pre-
digested nuclei, and FatI pre-digested nuclei. The change in 3D structure relative 
to control using these cis percentages was given by the following loss of 
structure (LOS) metric: 
𝐿𝑂𝑆 =  
𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝐶𝑖𝑠% −  𝑃𝑟𝑒𝑑𝑖𝑔𝑒𝑠𝑡𝐶𝑖𝑠%
𝐶𝑜𝑛𝑡𝑟𝑜𝑙𝐶𝑖𝑠%
 
 Hence, LOS values in the range (0, 1) represent a loss in short range 
contacts after pre-digestion; LOS values < 0 represent an increase in short range 
contacts after pre-digest, and an LOS equal to zero would indicate no change in 
structure after pre-digestion. A window of 6 Mb was chosen as we sought here to 
quantify interactions disrupted by pre-digestion. Many longer range interactions 
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that start to mix. Difference noted in A and B stability was preserved when LOS 
was calculated using cis percentages for entire chromosomes as opposed to a 6 
Mb window, however the size of chromosomes did bias results by giving 40 kb 
bins in small chromosomes greater LOS. We note that any loci that may have 
been lost from the nuclei will not be included in the Hi-C dataset. LOS represents 
the relative redistribution of short-range interactions to longer-range and inter-
chromosomal interactions for the set of loci that remained contained within the 
nucleus after pre-digestion and we assume this re-distribution would not be 
affected by any lost loci. FatI-pre digested libraries were of lower sequencing 
coverage and hence had a lower signal to noise ratio compared with DpnII and 
HindIII-pre digested libraries. To reduce noise, we applied a loess based 
smoothing with an α smoothing parameter of 0.01 to the signal track of LOS for 
nuclei pre-digested using FatI. Correlations between FatI LOS and PC1 were 
evident both before and after smoothing. Correlations also remained evident 
before and after smoothing between FatI LOS residuals and PC1 residuals 
corrected for digestion efficiency by FatI-seq. 
To quantify the timing of disrupted interactions we generated a half-life track 
utilizing the Hi-C matrices from the DpnII timecourses. For each 40 kb bin we fit a 
curve to the LOS of each timepoint following an exponential decay of the form 
(Figure 2.10, C): 
𝐿𝑂𝑆 = 𝑎 − (𝑏 × 𝑒−𝑐 × 𝑚𝑖𝑛𝑢𝑡𝑒𝑠) 
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time required to reach half saturation, saturation being the 16 hour timepoint 
where maximal cis interactions have been lost. Half-life values were then 
computed for every 40 kb bin genome wide. To remove noisy and less reliable 
t1/2 data, we first removed all extreme outliers bins where the sum of squared 
residuals (SSR) for the exponential fit was greater than 0.1. Then all bins with an 
SSR greater than two standard deviations from the mean were deemed as 
outliers and also removed from analyses. 
As LOS and t1/2 are both dependent on digestion efficiency we also 
generated residual LOS and t1/2 tracks to account for bin to bin variation in 
digestion efficiency. We used a moving average approach to calculate residuals 
for LOS as a function of DpnII-seq signal and also t1/2 as a function of DpnII-seq 
signal since the relationships between these variables were non-linear (Figure 
2.5, F left, Figure 2.9, C). For both stability metrics LOS and t1/2, a sliding window 
of 200 DpnII-seq signal with a step size of one was used to calculate mean LOS 
or t1/2 signal for each DpnII-seq signal increment (Figure 2.5, F left, Figure 2.9, 
C). Window and step size were selected by manual inspection of moving 
averages and compromising between over and underfitting. These moving 
averages were used to calculate residuals such that a positive LOS residual 
indicates more structure loss than expected by given digestion efficiency and a 
negative LOS residual indicates less structure loss than expected. As t1/2 is 
inversely related to LOS, positive t1/2 residuals indicate less structure loss than 
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Moving averages were also used to generate residuals for DpnII-seq as a 
function of PC1 and LOS as a function of PC1 (Figure 2.5, G right). 
Similar to the digestion efficiency correction by DpnII-seq, we also used 
estimated average fragment size as an independent measure to correct LOS and 
t1/2 for biases in digestion efficiency (Figure 2.7). For both stability metrics LOS 
and t1/2, a sliding window of 200 bp with a step size of one was used to calculate 
mean LOS or t1/2 signal for each average fragment size bp increment (Figure 2.7, 
G). These moving averages were then used to calculate LOS residuals or t1/2 
residuals as in the DpnII-seq correction approach described previously. 
DpnII-seq data analysis 
 Sequenced reads were mapped to the hg19 genome using the Bowtie 
read aligner (Langmead et al., 2009) and reads mapping to multiple sites of the 
genome were removed. As expected, a high percentage of reads mapped 
precisely to their associated restriction cut site (Figure 2.6). To remove potential 
artificial biases, we filtered out paired-end reads from fragments whose start or 
end coordinate was more than three nucleotides from an appropriate restriction 
cut site. Filtered reads were then binned to 500 kb or 40 kb resolutions. The 
K562 cell line has a primarily triploid karyotype with regions of the genome in 
diploid and tetraploid states. Copy number state assignments for each 500 kb or 
40 kb bin were assigned using publicly available K562 copy number data from 
the Catalogue of Somatic Mutations In Cancer (COSMIC) database 
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COSMIC dataset were identified by PICNIC analysis of Affymetrix SNP6.0 array 
data (PMID:19837654). Read coverage files at 500 kb and 40 kb were corrected 
to a genome wide diploid state using the copy number state assignments and 
dividing coverage by appropriate correction value (diploid = 1, triploid =1.5, 
tetraploid = 2, etc.) per bin. (Figure 2.6, D and E). Final copy number corrected 
coverage files were used for all downstream analysis. DpnII-seq computational 
workflow is maintained at https://github.com/tborrman/DpnII-seq 
FatI-seq data analysis 
Computational workflow for FatI-seq analysis was identical to previously 
described DpnII-seq analysis, with the exception that FatI restriction sites were 
used in the filtering step as opposed to DpnII restriction sites. The DpnII-seq 
workflow maintained at https://github.com/tborrman/DpnII-seq has options for 
analyzing restriction enzyme-seq experiments using the following enzymes: 
DpnII, HindIII, and FatI. 
DpnII pre-digestion average fragment size analysis 
Pre-digestion by DpnII leads to variable DNA fragment sizes across the genome. 
To estimate the average fragment size for a genomic bin after a 4-hour DpnII 
pre-digestion, we first separated 4-hour DpnII pre-digestion DNA into three 
slices: less than 1kb, 1kb-3kb, and larger than 3kb (See previously described 
above: DpnII Pre-digestion size assessment, Figure 2.7 A and B). DNA 
fragments purified from these slices were sequenced and sequenced read pairs 
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al., 2009). Mapped reads were then binned to 40 kb resolution, normalized for 
sequencing depth, and corrected for copy number state as in the DpnII-seq 
workflow (See previously described above: DpnII-seq data analysis). This 
resulted in a coverage track for each of the three DpnII pre-digested slices: less 
than 1 kb, 1 kb – 3 kb, and larger than 3kb (Figure 2.7, C). 
To estimate average fragment size for a given genomic bin we used the following 
formula: 
𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝑓𝑟𝑎𝑔𝑚𝑒𝑛𝑡 𝑠𝑖𝑧𝑒 =  
𝑝1𝑞1𝑠1 + 𝑝2𝑞2𝑠2 +  𝑝3𝑞3𝑠3 
𝑝1𝑞1 +  𝑝2𝑞2 +  𝑝3𝑞3
 
such that px equals the percent of normalized slice x reads that mapped to bin, qx 
equals quantity of slice x fragments (ng/µL), and sx equals mean size of 
fragments from slice x (bp). The variable x represents one of the three slice 
intervals (1:  less than 1 kb, 2: 1 kb - 3 kb, and 3: larger than 3 kb). Hence, the 
average fragment size for a given bin estimates the quantity of fragments from 
each slice size mapping to the bin over the total quantity of fragments mapped to 
the bin. The values for px are extracted from our coverage tracks and vary bin to 
bin, while the values for qx and sx are extracted from the Fragment Analyzer 
analysis and are constants (s1 = 643 bp, s2 = 2332 bp, s3 = 5495 bp, q1 = 1.6562 
ng/µL, q2 = 2.544 ng/µL, q3 = 2.4632 ng/µL, Figure 2.7, B). The average fragment 
size track was then used as an independent metric for measuring 4-hour DpnII 
digestion efficiency as compared to the DpnII-seq signal track. 
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 Rao et al. (2014) divided the canonical A/B compartments into five primary 
subcompartments A1, A2, B1, B2, B3 based on each subcompartment’s 
preferential Hi-C interactions in GM12878 cells. Subcompartments were 
annotated using high resolution (~1 kb) Hi-C data and were shown to display 
unique genomic and epigenomic profiles. K562 subcompartments were 
annotated in (Xiong and Ma, 2019) via the method SNIPER using lower 
resolution Hi-C data. In short, SNIPER infers subcompartments via a neural 
network approach to accurately annotate subcompartments using Hi-C datasets 
with moderate coverage (~500 million mapped read pairs). Xiong et al.’s K562 
SNIPER subcompartments showed a substantial conservation with GM12878 
annotations from Rao et al. (Rao et al., 2014) and were also enriched in similar 
epigenetic features, hence we utilized these SNIPER annotations to compare 
subcompartment status with chromatin stability. K562 SNIPER subcompartments 
were annotated at 100 kb resolution. To compare with our 40kb resolution liquid 
chromatin Hi-C data, we binned the 100 kb subcompartment annotations to 40kb 
such that any 40 kb bin overlapping a boundary of two separate 
subcompartments was assigned a value of NA. Upon piling up K562 
subcompartment boundaries, we also found enrichment and depletion of various 
chromatin features consistent with those described in both Rao et al. (Rao et al., 
2014; Xiong and Ma, 2019). 
 
 148 Sub-nuclear structures 
 To assess the effect of sub-nuclear structures on chromatin stability we 
utilized the extensive genetic and epigenetic data publicly available for K562 cells 
(Table 2.1).  
 Fold change over control ChIP-seq tracks for histone modifications, 
chromatin remodellers, and other various proteins were downloaded from the 
ENCODE Portal. To compare ChIP-seq data with t1/2, or residuals of t1/2 after 
correction for DpnII-signal, we binned the ChIP-seq signal tracks into 40 kb such 
that each 40 kb bin represented the mean signal found across the bin. Bins with 
no overlapping signal were designated a value of NA.  
 To examine the association between methylation state and t1/2 or residuals 
of t1/2 after correction for DpnII-signal, we downloaded methylation state at CpG 
Whole-Genome Bisulfite Sequencing (WGBS) tracks from ENCODE. As the 
methylation data was mapped to hg38, we used the UCSC LiftOver program to 
convert coordinates to hg19. Then percentage methylation at CpG sites was 
binned to 40kb resolution using the mean.  
 As there is currently no nucleolus associated domains (NADs) data 
available for K562, we analyzed a binary NADs state track for the human 
embryonic fibroblast IMR90 cell line (Dillinger, Straub and Nemeth, 2017). 
Dillinger et al. annotated NADs via a two-state hidden Markov model of aCGH 
data from DNA of isolated nucleoli. Using these annotated NADs, coverage of 
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analyses.  
 Mapping of nuclear speckle, nuclear lamina and PolII associated loci for 
K562 cells was accomplished recently via the TSA-seq protocol (Chen et al., 
2018). Signal tracks of log2(pull-down/input) were downloaded from GEO and 
binned to 40 kb as previously described for ChIP-seq files. Microarray data for 
LaminB1 associated domains identified through the DamID protocol was also 
available from that study. We used the UCSC LiftOver program to convert 
coordinates from hg18 to hg19. We then binned the log2(Dam-LaminB1/Dam) 
signal to 40 kb bins as previously described for ChIP-seq files.  
 To analyze cell cycle relationship with chromatin stability we downloaded 
Repli-seq data for K562 cells from ENCODE. Actively replicating regions are 
quantified as a percentage normalized signal for FACS sorted cells in G1 phase, 
four stages of S phase (S1-S4) and G2 phase. Signal tracks for Repli-seq data 
were binned to 40 kb as previously described for ChIP-seq files.  
 Binning of data was performed using the bedtools/v2.26.0 software. To 
assess the quality of the publicly downloaded data we generated the spearman 
correlation matrix of all binned signal tracks (Figure 2.13, A). Hierarchical 
clustering of rows of the correlation matrix position heterochromatic marks 
(H3K9me3, HP1α, HP1β, NADs, and LADs) near one another as expected. The 
majority active marks form a larger cluster, with the markers for polycomb 
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heterochromatin clustered together segregating active from inactive marks. 
Gene Expression 
 To assess the effect of gene expression on chromatin stability we utilized 
processed gene expression quantifications of total RNA-seq for K562 cells 
available from ENCODE (Accession ID: ENCFF782PCD). Gene locations were 
mapped using the hg19 ensGene table from UCSC Table Browser. To compare 
expression values with 40 kb resolution t1/2 or residuals of t1/2 after correction for 
DpnII-signal tracks, fragments per kilobase million (FPKM) values for each gene 
were binned to 40 kb such that each 40 kb bin represented the mean FPKM for 
all genes overlapping that bin. Bins without any genes were assigned a value of 
NA. Binned FPKM >=1 was determined to be a reasonable cutoff for expression 
by inspection of the full distribution of FPKM values.  
Compartmentalization saddle plots 




To measure the strength of compartments, intra-chromosomal interaction 
frequencies were first normalized by the average interaction frequency at a given 
genomic distance (observed/expected Hi-C maps) at a resolution of 40 kb. Then 
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of a pair of bins that define a given interaction. Finally, sorted frequencies were 
aggregated into 50 by 50 groups according to their PC1 values and averaged to 
obtain a compartmentalization saddle plot. In a compartmentalization saddle plot, 
preferential B-B interactions are in the upper left corner, and preferential A-A 
interactions are in the lower right corner. 
Homotypic interaction saddle plots 
 Intra-chromosomal interactions frequencies between 40 kb bins were 
normalized by the average interaction frequency at a given genomic distance 
(observed/expected Hi-C maps). Then, the distance corrected interaction 
frequencies were sorted based on signal values (TSA-seq, DamID) of a pair of 
bins that define a given interaction, for a given factor (SON, Lamin). Finally, 
sorted frequencies were aggregated into 50 by 50 groups according to their 
signal values and averaged, to obtain homotypic interaction saddle plots. In 
these plots, pair-wise interactions between loci enriched in factor binding are 
shown in the lower right corner, and pair-wise interactions between loci not 
bound by the factor are shown in the upper left corner. 
Scaling plot 
 The script to generate scaling plots was adapted from cooltools 
(https://github.com/mirnylab/cooltools/tree/master/cooltools).  Genome-wide 
curves of normalized contact frequency P(s) is plotted as a function of genomic 
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total valid interactions 
Mean z-score heatmap 
 Each genome wide 40kb signal vector for a sub-nuclear structure was 
cleaned for outliers above three standard deviations of the vector’s mean. Each 
cleaned vector was z-score transformed and then partitioned based on the 
different t1/2 residual intervals for associated bins. The mean z-score for all bins 









 153 CHAPTER III: NEURON-SPECIFIC SIGNATURES IN THE 
CHROMOSOMAL CONNECTOME ASSOCIATED WITH 
SCHIZOPHRENIA RISK 
Preface 
 This chapter comprises work published in Science by Prashanth 
Rajarajan, myself, Will Liao, Nadine Schrode, Erin Flaherty, Charlize Casiño, 
Samuel Powell, Chittampalli Yashaswini, Elizabeth A. LaMarca, Bibi Kassim, 
Behnam Javidfar, Sergio Espeso-Gil, Aiqun Li, Hyejung Won, Daniel H. 
Geschwind, Seok-Man Ho, Matthew MacDonald, Gabriel E. Hoffman, Panos 
Roussos, Bin Zhang, Chang-Gyu Hahn, Zhiping Weng, Kristen J. Brennand, and 
Schahram Akbarian. The publication reference is “Neuron-specific signatures in 
the chromosomal connectome associated with schizophrenia risk” Science. Vol. 
362 Issue 6420 Dec. 2018 (Rajarajan et al., 2018) 
 Cell culture work including Hi-C, 3C, RNA-seq, ATAC-seq, Cas9, and 
dCas9 (epi)genome editing was performed by Prashanth Rajarajan, Charlize 
Casiño, Chittampalli Yashaswini, Bibi Kassim, Behnam Javidfar, Samuel Powell, 
Elizabeth A. LaMarca, Bin Zhang, Seok-Man Ho, and Aiqun Li. Biocomputing, 
informatics, and genomic analyses was performed by myself, Will Liao, Nadine 
Schrode, Sergio Espeso-Gil, Erin Flaherty, Gabriel E. Hoffman., and Zhiping 
Weng. Specifically, I computationally processed Hi-C sequencing datasets, 
performed loop calling, performed loop analysis, developed differential loop 
 
 154 calling method, performed gene ontology analyses, performed downstream RNA-
seq analyses, and performed coregulation analyses. Materials were contributed 
by Seok-Man Ho, Erin Flaherty, Hyejung Won, and Daniel H. Geschwind. 
Research was supervised by Zhiping Weng, Panos Roussos, Kristen J. 
Brennand and Schahram Akbarian. Experiments were conceived and designed 
by Prashanth Rajarajan, Kristen J. Brennand and Schahram Akbarian. The paper 
was written and figures were produced by Prashanth Rajarajan, myself, Will Liao, 
Kristen J. Brennand, and Schahram Akbarian with contributions from all 
coauthors. 
Abstract 
 To explore the developmental reorganization of the three-dimensional 
genome of the brain in the context of neuropsychiatric disease, we monitored 
chromosomal conformations in differentiating neural progenitor cells. Neuronal 
and glial differentiation was associated with widespread developmental 
remodeling of the chromosomal contact map and included interactions anchored 
in common variant sequences that confer heritable risk for schizophrenia. We 
describe cell type–specific chromosomal connectomes composed of 
schizophrenia risk variants and their distal targets, which altogether show 
enrichment for genes that regulate neuronal connectivity and chromatin 
remodeling, and evidence for coordinated transcriptional regulation and 
proteomic interaction of the participating genes. Developmentally regulated 
chromosomal conformation changes at schizophrenia-relevant sequences 
 
 155 disproportionally occurred in neurons, highlighting the existence of cell type–
specific disease risk vulnerabilities in spatial genome organization. 
Introduction 
 Spatial genome organization is highly regulated and critically important for 
normal brain development and function (Rajarajan et al., 2016). Many of the risk 
variants contributing to the heritability of complex genetic psychiatric disorders 
are located in noncoding sequences (Ripke et al., 2014) , presumably embedded 
in “three-dimensional genome” (3DG) structures important for transcriptional 
regulation, such as chromosomal loop formations that bypass linear genome on 
a kilobase (or megabase) scale and topologically associated domains (TADs) 
(Dixon et al., 2012; Nora et al., 2012) that assemble in nested fashion across 
hundreds of kilobases (Bharadwaj et al., 2013, 2014; Won et al., 2016; Jiang et 
al., 2017). By linking noncoding schizophrenia associated genetic variants with 
distal gene targets, 3DG mapping with Hi-C (Lieberman-Aiden et al., 2009; Rao 
et al., 2014) and other genome-scale approaches could inform how higher-order 
chromatin organization affects genetic risk for psychiatric disease. To date, only 
a very limited number of Hi-C datasets exist for the human brain: two generated 
from bulk tissue of developing forebrain structures (Won et al., 2016) and adult 
brain (Schmitt et al., 2016) and one from neural stem cells (Dixon et al., 2015). 
Although such datasets have advanced our understanding of the genetic risk 
architecture of psychiatric disease (Won et al., 2016; de la Torre-Ubieta et al., 
2018), 3DG mapping from postmortem tissue lacks cell type–specific resolution 
 
 156 and may not capture higher-order chromatin structures sensitive to the autolytic 
process (Mitchell et al., 2014). We monitored developmentally regulated changes 
in chromosomal conformations during the course of isogenic neuronal and glial 
differentiation, describing large-scale pruning of chromosomal contacts during 
the transition from neural progenitor cells (NPCs) to neurons. Furthermore, we 
uncovered an expanded 
3DG risk space for schizophrenia—with a functional network of disease-relevant 
regulators of neuronal connectivity, synaptic signaling, and chromatin 
remodeling—and demonstrate neural cell type–specific coordination at the level 
of the chromosomal connectome, transcriptome, and proteome. 
Results 
Neural progenitor differentiation is associated with dynamic 3DG 
remodeling 
 We applied in situ Hi-C (Rao et al., 2014) to map the 3DG of two male 
human induced pluripotent stem cell (hiPSC)–derived neural progenitor cells 
(NPCs) (Topol et al., 2016), together with isogenic populations of induced 
excitatory neurons (“neuron”) generated through viral overexpression of the 
transcription factor NGN2 (Ho et al., 2016) and differentiations of astrocyte-like 
glial cells (“glia”) (Figure 3.1, A and B, and Table 3.1) (TCW et al., 2017). 
Transcriptome RNA sequencing (RNA-seq) comparison with published datasets 
(Hoffman et al., 2017) confirmed that the NPCs, but not glia, from subjects S1 
and S2 clustered together with NPCs from independent donors, whereas S1 and 
 
 157 S2 NGN2 neurons closely aligned with directed differentiation forebrain neurons 
(Brennand et al., 2011) and prenatal brain datasets (Figure 3.2, A and B). As with 
our transcriptomic datasets, hierarchical clustering of our Hi-C datasets after 
initial processing (Figure 3.3, A) also showed clear separation by cell type 
(Figure 3.1 A and Figure 3.3, B). Genome-scale interaction matrices were 
enriched for intrachromosomal conformations (Figure 3.3, C), with the exception 
of the negative control (“No Ligase”) NPC library, in which we omitted the ligase 
step (Materials and methods) and observed an interaction map with no signal 
due to the loss of ligated chimeric fragments (Figure 3.3, D). Given the observed 
correlation between technical replicates of Hi-C assays from the same donor and 
cell type, and the correlation between cell type–specific Hi-C from the two donors 
(Rtechnical replicates, range = 0.970 to 0.979; Rsubject1-subject 2 by cell type, range = 0.962 to 




Figure 0.1F igure 3.1 |  Neural diff erentiation is associated with large- scale remodeling 
Figure 3.1 | Neural differentiation is associated with large-scale remodeling 
of the 3D genome. 
 (A) (Top) Derivation scheme of isogenic cell types from two male control cell 
lines. Pink oval, donor hiPSC; orange, NPC; green, neuron; purple, glia. (Bottom) 
Hierarchical clustering of intrachromosomal interactions (see Materials and 
methods) from six in situ Hi-C libraries. a and b are technical replicates of the 
same library; height corresponds to the distance between libraries (see Materials 
and methods) (Figure 3.3, B). (B) Immunofluorescent staining of characteristic 
cell markers for NPCs (Nestin and SOX2), neurons (TUJ1 and MAP2), and glia 
(Vimentin and S100β). (C) Venn diagram of loop calls specific to and shared by 
different subsets of cells, including previously published GM12878 
 
 159 lymphoblastoid Hi-C data. (D) Gene ontology (GO) enrichment (significant terms 
only) of genes overlapping anchors of loops shared by NPCs, neurons, and glia 
but absent in GM12878. (E) (Left) Cell-type pooled whole-genome heatmaps at 
500-kb resolution (Figure 3.3, C). (Right) “Arc map” showing intrachromosomal 
interactions at 40-kb resolution of the q-arm of chr17 for isogenic neurons, NPCs, 
and glia, as indicated, from subject 2. RNA-seq tracks for each cell type shown 
on top of arc maps. Green, neuron; orange, NPC; purple, glia. (F) FPKM gene 
expression of CUX2 across three cell types with heatmap zoomed in on CUX2 
loop (black arrow) (Figure 3.4). (G) Number of loops specific to each cell type 
(not shared with other cell types) with one anchor in an A compartment and 
another in a B compartment (pink), both in B compartments (red), or both in A 
compartments (blue). (H) (Left) Box and-whisker distribution plot of TAD size 
across four cell types. (Right) Mean TAD length for each of the four cell types. (I) 
Heatmaps at 40-kb resolution for a 3-Mb window at the CDH2 locus on chr18. 
(Bottom) Nested TAD landscape in glia with multiple subTADs (black arrows) 
called, which (top) is absent from neuronal Hi-C. RNA-seq tracks: green, neuron; 





Figure 0.2F igure 3.2 |  Cell- and tissue- specific gene expression  profiles 
 
3.2 | Cell- and tissue-specific gene expression profiles.  
(A) Multidimensional scaling with samples colored as indicated in cell- and 
tissue-specific manner. Note that neuronal cultures and NPC from subjects S1 
and S2 cluster together with fetal and perinatal brain tissue, intermingled in 
related cell types from other donors. (B) Pairwise distance matrix was computed 
 
 161 for all samples, and the median distance between all samples in each category 
were used to create a summary distance matrix in order to perform the final 
clustering. Note that samples from the present study (marked by ***) align with 







Figure 0.3F igure 3.3 |  Bioinformatic pipeline overview and  basic library characteristics 
Figure 3.3 | Bioinformatic pipeline overview and basic library 
characteristics.  
(A) Bioinformatic approaches involved in processing raw reads to arrive at Hi-C 
contact matrices, intrachromosomal loops and interactions, TADs, and 
compartments. Hi-C and other datasets used, both newly generated and 
previously published, are listed in green boxes. (B) Pearson correlation of log-
transformed interaction bin counts for the 10% most variable intrachromosomal 
interactions at 500kb resolution, showing separation of libraries by cell type and 
not by individual identity. (See hierarchical clustering in Figure 3.1 A.) (C) 
Genome-wide Hi-C interaction matrix for NPC, neuron, and glia from donor S2 at 
500kb resolution. (D) Genome-wide Hi-C heatmap of pooled NPC library (left) 
compared to No Ligase negative control library generated from NPC 1 (right), 
which shows a severely contact depleted map without the crucial ligation step. 
Black arrow points to chr5. Zoomed in TAD landscape at the clustered 
PROTOCADHERIN locus in pooled NPC library (left) and No Ligase NPC 1 
(right). (E) Pearson correlation at 500kb resolution of intra- and inter-
chromosomal interaction frequency between replicates, showing high level of 
correlation between different individuals (“1” v. “2”) and technical replicates (“a” v. 
“b”) within each cell type. 
 
 We first focused on intrachromosomal loop formations, which are 
conservatively defined as distinct contacts between two loci in the absence of 
similar interactions in the surrounding sequences (Rao et al., 2014). Our 
comparative analyses included published (Rao et al., 2014) in situ Hi-C data from 
the B lymphocyte–derived cell line GM12878 (Table 3.1). When analyzed with 
the HiCCUPS pipeline (5- and 10-kb loop resolutions combined, subsampled to 
372 million valid-intrachromosomal read pairs to reflect the library with the fewest 
reads after filtration) (Rao et al., 2014), 17,767 distinct loops were called: n = 
3118 (17.5%) were shared among all four cell types, whereas n = 5068 (28.5%) 
were specific to only one of the four cell types (Figure 3.1, C). Biologically 
relevant terms such as “central nervous system development,” “forebrain 
development,” and “neuron differentiation” were among the top gene ontology 
 
 164 (GO) enrichments from genes overlapping loops shared between NPCs, glia, and 
neurons (brain-specific) but not identified in lymphocytes (Figure 3.1, D and 
Table 3.2), indicating strong tissue-specific loop signatures that were also 
confirmed in individual cell types (Figure 3.4, A and Tables 3.3 to 3.6). 
 
Figure 0.4F igure 3.4 |  Cell t ype- specific features of the 3D genome 
Figure 3.4 | Cell type-specific features of the 3D genome. 
(A) GO enrichment of genes overlapping cell type-specific loops from non-
subsampled datasets, with genes overlapping loops specific to neural cell types 
involved in neurodevelopment while no such pattern is observed in GM12878. 
GO terms are color coded by functional categories (see legend). (B) Venn 
diagram of loops called from the non-subsampled datasets for each cell type. (C) 
 
 165 Count of loops called in each cell type in the subsampled (to 372M cis contacts) 
and non-subsampled datasets, showing drastically reduced number of loops 
called in neurons. (D) Heatmaps at 10kb resolution with a neuron-specific loop 
(arrows; left) at CUX2 gene locus called in neurons but not in NPCs (middle) or 
glia (right), respectively. (E) Frequency distribution of log(FDR) of 17,767 loops 
(5kb and 10kb resolutions combined) in neurons (left), NPCs (middle), and glia 
(right). Vertical red line denotes the log(FDR) for the 10kb-resolution loop 
overlapping CUX2 in each cell type. Note that CUX2 loop is significant in neurons 
and not in NPCs or glia. (F) Representative example of a loop called in NPCs 
and glia but not in neurons. This loop spans 370kb, overlapping the gene ANO3. 
(G) GO enrichment of genes overlapping anchors of loops that are lost in the 
transition from NPC to neuron (left) and NPC to glia (right). GO terms are color 
coded by functional categories (see legend). 
 
 Unexpectedly, there was a reduction (~40 to 50% decrease) in the total 
number of chromosomal loops in neurons relative to isogenic glia and NPCs 
(Figure 3.4, B and C). Reduced densities of chromosomal conformations were 
also evident in genome browser visualization of chromosomal arms, including 
chr17q (Figure 3.1, E). Although both glia and NPCs harbored ~13,000 loop 
formations, only 7206 were identified in neurons (Figure 3.1, C; Figure 3.4, B and 
C; and table S1), including 442 neuron-specific loop formations. One such 
neuron-specific loop was at CUX2, a transcription factor whose expression marks 
a subset of cortical projection neurons (Gil-Sanz et al., 2015) and that is highly 
expressed in our NGN2-induced neurons (Figure 3.1, F and Figure 3.4, D and E). 
Examples of loops lost in neurons include one spanning the Ca2+ channel and 
dystonia-risk gene, ANO3 (Figure 3.4, F) (Charlesworth et al., 2012). 
Furthermore, NPCs, neurons, and glia had similar proportions of loops anchored 
in solely active (A) compartments, solely inactive (B) compartments, or in both, 
indicating no preferential loss of either active or inactive loops in neurons (Figure 
 
 166 3.1, G). However, among the genes overlapping anchors of loops that underwent 
pruning during the course of the NPC-to-neuron transition, regulators of cell 
proliferation, morphogenesis, and neurogenesis ranked prominently in the top 25 
GO terms with significant enrichment (Benjamini-Hochberg corrected Prange = 
10−3 – 10−8) (Figure 3.4, G and Table 3.4, B), which is consistent with a departure 
from precursor stage toward postmitotic neuronal identity (Wang et al., 2017). 
Likewise, loops lost during NPC-to-glia transition were significantly enriched 
(Benjamini-Hochberg corrected Prange = 10-2 – 10-5) for neuron-specific functions, 
including “transmission across chemical synapse,” “g-aminobutyric acid (GABA) 
receptor activation,” and “postsynapse” (Figure 3.4, G and Table 3.4, C), which is 
consistent with non-neuronal lineage commitment.  
 We defined “loop genes” as genes that either have gene body or 
transcription start site (TSS) overlap with a loop anchor (5- or 10-kb bins forming 
the points of contact in a chromatin loop). Genes with loop-bound gene bodies 
(one-tailed Z test, Zrange = 42.1 to 59.2, P < 10−324 for all) or loop-bound TSS 
(one-tail Z-test, Zrange = 15.2 to 28.8, Prange = 2.32 × 10−52 to 4.40 × 10−182) both 
showed significantly greater expression [mean log10(FPKM + 1); FPKM, 
fragments per kilobase of exon per million fragments mapped] than that of 
background (all genes for all brain cell types) (Figure 3.5, A), suggesting that 
looping architecture was associated with increased gene expression. 
Furthermore, 3% of loops shared by NPCs, neurons, and glia (brain-specific 
loops) interconnected a brain expression quantitative trait locus (eQTL) single 
 
 167 nucleotide polymorphism (SNP) with its destined target gene(s), representing 
significant enrichment over background as determined with 1000 random 
distance- and functional annotation–matched loop samplings, (random sampling, 
one-sided empirical P = 0.012) (Materials and methods) (Figure 3.5, B).  
 
Figure 0.5F igure 3.5 |  Loop functional features and cell  t ype-specific patterns in  mu ltiple model systems 
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Figure 3.5 | Loop functional features and cell type-specific patterns in 
multiple model systems. 
(A) Box-and-whisker plot comparing gene expression (log10(FPKM+1)) across 
all genes (“All”), the subset of genes located within the loop anchor (“Gene 
body”), and the subset of genes whose TSSs specifically are overlapping the 
loop anchor (“TSS”). * P < 10-50, ** P < 10-150, *** P < 10-300. P < 10-324 for All v. 
Gene body across all 3 cell types (***); P = 4.40 x 10-182 All v. TSS in NPCs; P = 
2.32 x 10-52 All v. TSS in neurons; P = 8.23 x 10-173 All v. TSS in glia (non-
subsampled datasets). (B) Violin plot of the distribution of fraction of overlaps 
between 1000 background loop sets (generated in silico) and brain eQTL SNP-
target gene pairs. An eQTL loop was counted if one bin contained the eQTL SNP 
(i.e., eSNP) and the other bin contained the target gene (bottom). Red dashed 
line indicates the fraction of overlap observed between brain-specific loops and 
brain eSNP-gene pairs. (C) Count of 10kb resolution loops called by HiCCUPS in 
hiPSC-derived libraries only, including directed differentiation forebrain neurons 
from S1 (“FB Neuron”), all subsampled to 372M valid cis contacts. (D) Count of 
loops called in mouse ESC-derived libraries that were all subsampled to 472M 
valid cis contacts. (E) Count of loops after all human libraries, including 
previously published fetal brain Hi-C, were subsampled to 204M valid cis 
contacts. 
 
 We aimed to confirm that the observed net loss of loop formations during 
the NPC to neuron transition could be replicated across a variety of independent 
cell culture and in vivo approaches and was not specific to our methodological 
choice of NGN2-induction. We conducted an additional Hi-C experiment on cells 
differentiated from hiPSC-NPCs by means of a non-NGN2 protocol that used 
only differentiation medium and yielded a heterogeneous population of hiPSC 
forebrain-neurons in addition to a small subset of glia (Brennand et al., 2011). In 
addition, we reanalyzed Hi-C datasets generated from a mouse model of neural 
differentiation, consisting of mouse embryonic stem cell (mESCs), mESC derived 
NPCs (mNPC), and cortical neurons (mCN) differentiated from the mNPCs via 
inhibition of the Sonic Hedgehog (SHH) pathway (Bonev et al., 2017). To 
 
 169 examine whether such genome-wide chromosomal loop remodeling also 
occurred in the developing brain in vivo, we reanalyzed Hi-C data from human 
fetal cortical plate (CP), mostly composed of young neurons, and forebrain 
germinal zone (GZ), primarily harboring dividing neural precursor cells in addition 
to a smaller subset of newly generated neurons (Won et al., 2016). Across both 
the hiPSC-NPC-to-forebrain neuron and mESC-mNPC-mCN differentiation, in 
vitro neurons showed a 20% decrease in loops compared with their neural 
progenitors (Figure 3.5, C and D). Consistent with this, in vivo CP (neuron) 
compared with GZ (progenitor) showed a 13% decrease in loops genome-wide 
(Figure 3.5, E). The highly replicative cell types included here, mouse ESCs and 
human lymphoblastoid GM12878 cells, exhibited loop numbers very similar to 
their neuronal counterparts (Figure 3.5, D and E), suggesting that the changes in 
3DG architecture from NPC to neurons do not simply reflect a generalized effect 
explained by mitotic potential.  
 Along with having fewer total loops, neurons exhibited a greater proportion 
of longer-range (>100 kb) loops than did NPCs or glia (two-sample two-tailed 
Kolmogorov-Smirnov test, KSrange = 0.1269 to 0.2317, P < 2.2 × 10−16 for three 
comparisons: Neu versus NPC/Glia/GM) (Figure 3.6, A). Likewise, in each of the 
alternative in vitro and in vivo analyses considered above, neurons exhibited a 
greater proportion of longer range (>100 kb) loops than did NPCs or glia [two-
sample two-tailed Kolmogorov-Smirnov test, KS = 0.0427, P = 1.5 × 10−5 for 
hiPSC-NPC versus forebrain neuron; KS = 0.0936, P = 1.1 × 10−16 for mESC-
 
 170 NPC versus mCN; KS = 0.0663, P = 2.04 × 10−8 for fetal CP (neuron) compared 
with GZ (progenitor)] (Figure 3.6, B, C, D, and E). Therefore, multiple in vitro and 
in vivo approaches comparing, in human and mouse, neural precursors to young 
neurons consistently show a reduced number of loops in neuron-enriched 
cultures and tissues, primarily affecting shorter-range loops.  
 
Figure 0.6F igure 3.6 |  Loop/TAD size comparisons across multip le dat asets 
 
 
Figure 3.6 | Loop/TAD size comparisons across multiple datasets.  
(A) Cumulative loop size distribution where Fn(x) is the percent of loops whose 
size is less than or equal to the base pair distance (x). P-value is calculated using 
the Kolmogorov-Smirnov (KS) test. Neurons have a significantly larger proportion 
of loops that are longer in size than do other neural cells and non-neural 
GM12878 cells. (B) Cumulative loop size distribution of hiPSC-derived cell types 
subsampled to 372M cis contacts in the present study, including forebrain 
neurons. (C) Cumulative loop size distribution of mouse embryonic stem cells 
 
 171 (ESCs), ESC-derived neural progenitor cells (NPCs), and ESC-derived cortical 
neurons (CN). (D) Cumulative loop size distribution of germinal zone (GZ) and 
cortical plate (CP) (E) Table of p-values and corresponding KS test statistics for 
each comparison presented in B-D. (F) Box-and- whisker plot of the distribution 
of TAD sizes across cell types in non-subsampled datasets, showing larger TADs 
in neurons than in the other two neural cell types. (G) Violin plot of TAD size 
across hiPSC-derived neural cell types, including directed differentiation FB 
neurons, and non-neural GM12878 cell lines. P-value is calculated using the 
Wilcoxon-Mann-Whitney test. (H) 2D density plots with coverage-balanced, log2-
transformed ATAC signal for neurons on the x-axis and for NPCs on the y-axis. 
Open chromatin signatures of these two cell types were compared in 1kb bins 
genome-wide. P-values are reported from two-sided, paired t-tests. (I) 2D density 
plots with coverage-balanced, log2-transformed ATAC signal for neurons on the 
x-axis and for NPCs on the y-axis. Open chromatin signatures of these two cell 
types were compared in HiCCUPS loop anchors (5 and 10kb) that were shared 
by NPCs, neurons, and glia ("Brain"); specific to GM12878; or specific to only 
glia, NPCs, or neurons. P-values are reported from two-sided, paired t-tests. 
 
 Consistent with studies in peripheral tissues reporting conservation of the 
overall TAD landscape across developmental stages, tissues, and species (when 
considering syntenic loci) (Dixon et al., 2012, 2015), overall TAD landscapes 
(Rao et al., 2014) remained similar between neurons, glia, and NPCs. 
Nonetheless, TADs also showed a subtle (~10%) increase in average size in 
neurons compared with isogenic NPCs, independent of the differentiation 
protocol applied (Wilcoxon-Mann-Whitney test, P < 3.6 × 10-2) (Figure 3.1, H and 
Figure 3.6, F and G), as highlighted here at a 3.4-Mb TAD at the CDH2 cell 
adhesion gene locus (Figure 3.1, I). TAD remodeling may therefore reflect 
restructuring of nested subdomains within larger neuronal TADs (Tables 3.7 and 
3.8). To examine whether such developmental reorganization of the brain’s 
spatial genomes was associated with a generalized shift in chromatin structure, 
we applied the assay for transposase accessible chromatin with high-throughput 
 
 172 sequencing (ATAC-seq) to map open chromatin sequences before and after 
NGN2-neuronal induction (Table 3.1). Genome-wide distribution profiles for 
transposase-accessible chromatin were only minimally different between NPCs 
and neurons (Figure 3.6, H) and further revealed that both NPCs and neurons 
showed low to moderate chromatin accessibility [–2.5 < log2(ATAC signal) < 1] 
for ≥ 89% of the anchor sequences comprising cell type–specific and shared 
“brain” loops in our cell culture system (Figure 3.6, I). These findings, taken 
together, point to widespread 3DG changes during the NPC-to-neuron transition 
and NPC-to-glia transition in human and mouse brain that are unlikely 
attributable to global chromatin accessibility differences. This includes highly cell 
type–specific signatures in gene ontologies of differentiation-induced loop 
prunings, reflecting neuronal and glial (non-neuronal) lineage commitment 
(Figure 3.4, A and G, and Table 3.4, B and C), and a subtle widening of average 
loop and TAD length in young neurons (Figure 3.1, H and Figure 3.6, A to G). 
Chromosomal contacts associated with schizophrenia risk sequences 
 Because many schizophrenia risk variants lie in noncoding regions in 
proximity to several genes, we predicted that chromosomal contact mapping 
could resolve putative regulatory elements capable of conferring schizophrenia 
risk via their physical proximity (bypassing linear genome) to the target gene, as 
has been demonstrated in tissue in vivo (Won et al., 2016; de la Torre-Ubieta et 
al., 2018). We overlaid our cell type–specific interactions onto the 145 risk loci 
associated with schizophrenia risk (Ripke et al., 2014; Pardiñas et al., 2018). 
 
 173 Because only very few loops (defined as distinct pixels with greater contact 
frequency than neighboring pixels on a contact map) (Rao et al., 2014) were 
associated with schizophrenia risk loci (n = 212, 81, and 17 loops in NPC, glia, 
and neurons, respectively) (Table 3.9), we applied an established alternative 
approach to more comprehensively explore the 3DG in context of disease-
relevant sequences (Won et al., 2016). This approach defines interactions as 
those filtered contacts that stand out over the global background and applies 
binomial statistics to identify chromosomal contacts anchored at disease-relevant 
loci (Won et al., 2016). To begin, we examined the 40 loci with strongest 
statistical evidence for colocalization of an adult postmortem brain eQTL and 
schizophrenia genome-wide association study (GWAS) signal (Dobbyn et al., 
2018). Chromosomal contacts were called for 29 of the 46 eQTLs present in the 
40 loci, with 8 of 29 (28%) of the loci showing significant interactions (binomial 
test, –log q value range = 1.33 to 11.0) between the eQTL-SNPs (eSNPs) in the 
one contact anchor and the transcription start site of the associated gene(s) in 
the other anchor (Table 3.10). We conclude that ~30% of risk locus–associated 
eQTLs with strong evidence for colocalization with GWAS signal bypass the 
linear genome and are in physical proximity to the proximal promoter and 
transcription start site of the target gene, resonating with previous findings in fetal 
brain tissue that used a similar contact mapping strategy (Won et al., 2016).  
 Cell type–specific contact maps with 10-kb-wide bins, queried for the 
schizophrenia-associated loci, frequently revealed differential chromosomal 
 
 174 conformations in NPCs, glia, and neurons. For example, the risk locus upstream 
of the PROTOCADHERIN cell adhesion molecule gene clusters (chromosome 
5), which is critically relevant for neuronal connectivity in developing and adult 
brain (Figure 3.7, A) (Yagi, 2012; Chen and Maniatis, 2013), showed through 
both observed/expected interaction matrix (Durand, Robinson, et al., 2016) and 
global background-filtered contact mapping (Won et al., 2016) a bifurcated 
bundle of interactions in NPCs, with one bundle emanating to sequences 5′ and 
the other bundle to sequences 3′ from the risk locus. In neurons, the 3′ bundle 
was maintained, but the 5′ bundle was “pruned,” whereas glia showed the 
opposite pattern; these differences between the three cell types were highly 
significant (observed/expected Wilcoxon rank sum P < 10−9 to 10−15) (Figure 3.8, 
A to C). Dosage of the noncoding schizophrenia risk-SNP (rs111896713) at the 
PCDH locus significantly increased the expression of multiple 
PROTOCADHERIN genes (PCDHA2, PCDHA4, PCDHA7, PCDHA8, PCDHA9, 
PCDHA10, and PCDHA13) in adult frontal cortex of a large cohort of 579 
individuals, including cases with schizophrenia and controls (Figure 3.7, B and 
Table 3.11) (Fromer et al., 2016). The affected genes were interconnected to the 
disease relevant noncoding sequence in neurons and NPCs but not in glia 
(Figure 3.7, C). Therefore, cell-type-specific Hi-C identified chromosomal 
contacts anchored in schizophrenia-associated risk sequences that affected 
expression of the target gene(s). On the basis of earlier chromosome 
conformation capture assays at the site of candidate genes, the underlying 
 
 175 mechanisms may include alterations in transcription factor and other 
nucleoprotein binding at loop-bound cis-regulatory elements (Bharadwaj et al., 












 177 Figure 3.7 | Risk-associated chromosomal contact mapping.  
(A) RNA-seq FPKM expression for all clustered PCDH genes in NPCs (orange), 
neurons (green), and glia (purple). (B) The association of expression of PCDHA2 
(1; P = 1.874 x 10-9), PCDHA7 (2; P = 2.029 x 10-11), PCDHA8 (3; P = 5.517 x 10-
13), PCDHA10 (4; P = 2.4 x 10-14) with schizophrenia risk allele at the GWAS 
index SNP rs111896713, upstream of the clustered PCDH genes, using the 
CommonMind Consortium (CMC) postmortem prefrontal cortex RNA-seq dataset 
consisting of 258 schizophrenia subjects and 279 controls. (C) Binomial 
interaction landscape with 10kb anchor bin (gray vertical box) containing 
rs111896713 within the larger schizophrenia risk locus (solid red horizontal box), 
showing significant (above horizontal red dotted line) interactions with the four 
PROTOCADHERIN genes no. 1 to no. 4 significantly affected by risk 








Figure 0.8F igure 3.8 |  Cell t ype–specific chromosomal cont act maps at schizophren ia risk loci 
 
Figure 3.8 | Cell type–specific chromosomal contact maps at schizophrenia 
risk loci.  
(A) Juicebox observed/expected interaction heatmaps at 10-kb resolution for the 
risk associated clustered PCDH locus chr5:140023665−140222664 for NPC, glia, 
and neurons as indicated. (Far right) Grayscale heatmap depicts areas of highly 
cell-specific contact enrichments: upstream genes including ANKHD1 (dotted 
rectangle “A” and arrowhead) and downstream PCDH gene clusters (dotted 
rectangle “B” and arrows). Clustered PCDH gene expression patterns are 
available in Figure 3.7, A. (B) Violin plots of observed/expected interaction values 
in the regions A and B highlighted in (A). (C) Map of contacts identified by 
binomial statistics. Red box with dashed black line represents the schizophrenia 
risk locus, dotted boxes regions “A” and “B” in heatmaps. (D) Cell-type resolved 
contact map of 10-kb bins (bold, black vertical lines) within risk sequences on 
chr12 (left), chrX (middle), and chr5 (right); NPC (orange), neuron (green), glia 
(purple); –log q value, significance of contact between schizophrenia risk locus 
and each 10-kb bin; gene models (“Genes”) below with SNP-loop target gene 
highlighted in red. (E) Epigenomic editing (CRISPRa with nuclease-deficient 
dCas9 in NPCs) for three risk SNP-target gene pairs and their respective control 
sequences (top), measured with quantitative reverse transcription polymerase 
chain reaction (RT-PCR) (fold change from baseline) for VP64 (middle) and VPR 
(bottom) transcriptional activators. (F) Quantitative PCR gene expression 
changes upon directing catalytically active Cas9 to schizophrenia risk-associated 
credible SNPs (vertical red dashes with rsIDs) interacting via chromosomal 
contacts with promoters of ASCL1, EFNB1, and MATR3 in NPCs. Targeting 
strategy and contact distances depicted above; *P < 0.05, **P < 0.01, ***P < 
0.0001 (Figures 3.7 and 3.9). 
 
 Transcriptional profiles of hiPSC derived NPCs and neurons most closely 
resemble those of the human fetus in the first trimester (Brennand et al., 2015); 
moreover, a portion of the genetic risk architecture of schizophrenia matches to 
regulatory elements that are highly active during prenatal development (Gulsuner 
et al., 2013). We surveyed in our Hi-C datasets seven loci encompassing 36 
“credible” (potentially causal) schizophrenia-risk SNPs with known chromosomal 
interactions in fetal brain to genes important for neuron development and function 
(Won et al., 2016). We found that risk-associated chromosomal contacts were 
 
 180 conserved between our hiPSC NPCs and the published human fetal CP and 
germinal zone Hi-C datasets (Won et al., 2016) for five of the seven loci (71%) 
tested (CHRNA2, EFNB1, MATR3, PCDH, and SOX2, but not ASCL1 or DRD2) 
(Table 3.12). To test the regulatory function of these conserved risk sequence 
bound conformations, we performed single-guide RNA (sgRNA)-based 
epigenomic editing experiments on isogenic antibiotic-selected NPCs that stably 
express nuclease-deficient dCas9-VP64 (Maeder et al., 2013; Perez-Pinera et 
al., 2013) or dCas9-VPR (Chavez et al., 2016; Ho et al., 2017) transactivators 
(Table 3.13). Previous studies in peripheral cell lines succeeded in inducing gene 
expression changes by placing dCas9-repressor fusion proteins at the site of 
chromosomal contacts separated by up to 2 Mb of linear genome from the 
promoter target (Fulco et al., 2016). We tested ASCL1-, EFNB1-, MATR3-, and 
SOX2- bound chromosomal contacts separated by 200- to 700-kb interspersed 
sequences (Figure 3.8, D and E; Figure 3.9, A; and Table 3.14). Pools of five 
individual sgRNAs directed against a risk-associated noncoding sequence 
bypassing 225 and 355 kb of genome consistently resulted in significantly 
decreased expression of ASCL1 [one-way analysis of variance (ANOVA), 
FVP64(2, 15) = 22.20, P < 0.0001; Dunnett’s PVP64 = 0.023] and EFNB1 target 
genes [one-way ANOVA, FVP64(2, 6) = 14.47, P = 0.0051, Dunnett’s PVP64 = 
0.0356; FVPR(2, 6) = 1.46, P = 0.0111, Dunnett’s PVPR = 0.0088], in comparison 
with positive (promoter bound) and negative (linear genome) control sgRNAs. 
Epigenomic editing of risk sequence 500 to 600 kb distant from the SOX2 and 
 
 181 MATR3 loci did not alter target gene expression (Figure 3.8, D and E, and Figure 
3.9, A and B), which could reflect practical limitations in nonintegrative 
transfection based (as opposed to viral) methods, impact of epigenetic 
landscape, or suboptimal guide RNA positioning (Ho et al., 2017), further limited 
by the 10-kb contact map resolution. Because portions of the MATR3-bound risk 
sequences are embedded in repressive chromatin, we directed five sgRNAs for 
Cas9 nuclease mutagenesis toward a 138–base pair (bp) sequence within a 
MATR3 long-range contact that was enriched with trimethyl-histone H3K27me3, 
commonly associated with Polycomb repressive chromatin remodeling, in order 
to disrupt it (Figure 3.9, C to E). This strategy produced a significant increase in 
MATR3 expression upon ablation of the putative repressor sequence, whereas 
targeting MATR3 (linear genome) control sequence remained ineffective (Figure 
3.9, D and E). We conducted additional genomic mutagenesis assays, with 
sgRNAs directly overlapping credible SNPs participating in chromatin contacts 
with ASCL1, EFNB1, EP300, MATR3, PCDHA7, PCDHA8, and PCDHA10 (Table 
3.13). Cas9 nuclease deletion of interacting credible SNPs significantly increased 
gene expression of ASCL1, EFNB1, and EP300 (Prange = 0.0053 to 0.04, trange = 
2.449 to 4.265) (Figure 3.8, F and Figure 3.9, F). Similar targeting of four credible 
SNPs upstream of the clustered PCDH locus significantly decreased levels, by 
~50 to 60%, of PCDHA8 and PCDHA10 (Prange = 0.0122 to 0.0124, trange = 4.326 
to 4.343), two of the genes whose expression increased with dosage of the risk 
SNP rs111896713 in adult postmortem brain (Figure 3.7, B and Figure 3.9, G). 
 
 182 Taken together, our (epi)genomic editing assays (Figure 3.9, H) demonstrate that 
chromosomal contacts anchored in schizophrenia risk loci potentially affect target 
gene expression across hundreds of kilobases, which is consistent with 
predictions from chromosomal conformation maps from hiPSC-derived brain cells 
described here, and from developing (Won et al., 2016; de la Torre-Ubieta et al., 








Figure 3.9 | Epigenomic and genomic editing at schizophrenia risk-
associated chromosomal conformations. 
(A) Interaction landscape at the SOX2 locus on chr3, where highlighted (red) 
10kb bin in SOX2-OT has a strong interaction with SOX2, a key transcription 
factor important in maintaining pluripotency in neural precursors. (B) SOX2 
epigenomic editing strategy (top) with results from VP64 (middle) and VPR 
(bottom) platforms, demonstrating that promoter-targeted gRNAs show increased 
gene expression and schizophrenia (SZ) risk SNP-targeted gRNAs potentially 
 
 184 decrease expression. (C) Western blot for Cas9 protein levels in wild type (left) 
and NPCs transduced with lentiviral vector containing Cas9 (right). (D) CRISPR 
deletion strategy (top) for contact-associated schizophrenia risk region (top) and 
results (bottom), which shows increased MATR3 after noncoding deletion ~700kb 
from promoter. Note that no SNPs were targeted by sgRNAs in this experiment, 
and the closest risk-associated SNP was 400bp from the nearest sgRNA. 
Positions of sgRNA and of nearest risk SNP are shown in Panel E browser 
window. (E) ENCODE epigenomic landscape of H9/H1 NPCs at the targeted 
region in panel D, suggesting weak polycomb repressed region. (F) qPCR gene 
expression upon directing catalytically active Cas9 to schizophrenia risk-
associated credible SNPs (vertical red dashes with rsIDs) interacting with the 
promoters of EP300. Targeting strategy and interaction distance depicted above. 
(G) PCDH interaction landscape of 4 credible SNPs (vertical red dashes) with 
members of the PCDHα cluster, spanning roughly a 93kb distance (left). qPCR 
expression results for PCDHA7, PCDHA8, and PCDHA10 after Cas9 
mutagenesis of PCDH credible SNPs. (H) Summary table of CRISPR 
epigenomic and genomic editing experiments. 
 
Cell type–specific schizophrenia-related chromosomal connectomes are 
associated with gene co-regulation and protein-protein association 
networks 
 Having shown that the chromosomal contact maps anchored in 
sequences associated with schizophrenia heritability undergo cell type–specific 
regulation (Figure 3.8, A to C), are reproducible in neural cell culture and fetal 
brain (Table 3.12), frequently harbor risk-associated eQTLs (Table 3.10), and 
bypass extensive stretches of linear genome to affect target gene expression in 
genomic and epigenomic editing assays (Figure 3.8, D to F, and Figure 3.9), we 
investigated chromosomal contacts for all 145 GWAS-defined schizophrenia risk 
loci together (Pardiñas et al., 2018).We refer to the resulting “network” of risk loci 
and their 3D proximal genes as the “schizophrenia-related chromosomal 
connectome.”  
 
 185  Earlier studies in adult brain had shown that open-chromatin-associated 
histone modification and other “linear epigenome” mappings strongly link the 
genetic risk architecture of schizophrenia specifically with neuronal, as opposed 
to non-neuronal, chromatin (Girdhar et al., 2018), which would suggest that 
similar cell-specific signatures may emerge in the risk-associated 3DG. Neurons 
and NPCs, but not the isogenic glia, showed a high preponderance of 
chromosomal contacts with schizophrenia-associated risk loci (Figure 3.10, A). 
There were 1203 contacts involving schizophrenia risk sequences that were 
highly specific to neurons (median distance between risk and target bins = 510 
kb), 1100 highly specific for NPCs (median distance between risk and target bins 
= 520 kb), whereas only 425 highly specific for glia (median distance between 
risk and target bins = 580 kb) (Figure 3.10, A; Figure 3.11, A and B). There were 
also unexpectedly robust cell type- and gene-ontology-specific signatures, 
including genes associated with neuronal connectivity and synaptic signaling 
(Figure 3.10, B and Tables 3.15 and 3.16). Separate analysis of the Psychiatric 
Genomics Consortium “PGC2” 108 risk loci (Ripke et al., 2014) yielded similar 




Figure 0.10Figure 3.10 | Expanded GW AS risk connectome is associated  with  gene coregulation 
Figure 3.10 | Expanded GWAS risk connectome is associated with gene 
coregulation.  
(A) Counts of highly cell type–specific contacts associated with schizophrenia 
risk in each of the three hiPSC-derived cell types. (B) GO enrichment of genes 
located in schizophrenia risk contacts in NPCs (left), neurons (middle), and glia 
(right). (C) (Left) Schematic workflow of analyses performed with cell type 
specific contact genes, distinguished as “risk locus” and “risk locus–connect” 
genes. (Middle) Venn diagram of genes located in the 145 loci and those found in 
 
 187 cell type–specific contacts, with numbers in blue indicating “risk locus–connect” 
genes. (Right) Schematic workflow of analyses performed with combined set of 
“risk locus” and “risk locus–connect” genes. (D) RNA Pearson transcriptomic 
correlation heatmaps consisting of risk locus and risk locus–connect genes 
derived from the cell type–specific contacts of NPCs (left), neurons (middle), and 
glia (right). Organization scores (|r |avg) for each heatmap are reported with P 
values from sampling analysis. Schematics above heatmaps are representations 
of each cell type’s particular connectome (blue oval) and frequency distribution of 
organization scores from permutation analyses of randomly generated heatmaps 
(red, observed organization score of heatmap being tested). The gray bar 
corresponds to n genes that have at least 1 count per million in RNA-seq dataset 
out of the total number of genes and are used to construct the heatmap; red and 
blue bars indicate how many of the genes in the heatmap are in a risk locus (red) 
and are risk locus–connect (blue). Fuchsia, neuron connectivity/synaptic function 
genes; yellow, chromatin remodeling genes as determined from gene ontology 
analysis in (E). Additional information on coexpression clusters is provided in 
tables S22 and S23 (Figure 3.11 and 3.12). 
 
 




Figure 3.11 | Determining cell type-specific PGC interactions. 
(A) Frequency histograms of the distribution of –log(q) values of binomial 
interactions for each cell type. Colored lines = 95th percentile of the union set of 
 
 188 all –log(q) (1.47); grey dashed lines = 50th percentile of the union set of all –log(q) 
(0.33). (B) Work flow for determining cell type-specific PGC interactions. 
Interactions that had -log(q) values ≥ 95th percentile in one cell type (color 
highlight) and -log(q) values < 50th percentile in the remaining two cell types 







Figure 0.12Figure 3.12 | Expanded GW AS risk connectome is associated  with  significant  gene coregulation  and  prot ein-prot ein association net works 
 
Figure 3.12 | Expanded GWAS risk connectome is associated with 
significant gene coregulation and protein-protein association networks.  
(A) Counts of highly cell type-specific significant interactions in each of the 3 
hiPSC-derived cell types. (B) GO enrichment of genes located in significant 
schizophrenia risk- interactions in NPCs (left), neurons (middle), and glia (right). 
(C) Schematic workflow of analyses performed with cell type-specific interaction 
genes, distinguished as “risk locus” and “risk locus-connect” genes (left). Venn 
diagram (middle) of genes located in the 108 loci and those found in cell type-
specific interactions, with numbers in blue indicating “risk locus-connect” genes. 
(D) RNA Pearson correlation heatmaps consisting of risk locus and risk locus-
connect genes derived from the cell type-specific interactions of NPCs (left), 
neurons (middle), and glia (right). Organization scores (|r |avg) for each heatmap 
are reported with P-values from permutation analysis. Schematics above 
heatmaps are representations of each cell type’s unique connectome (blue oval) 
and frequency distribution of organization scores from permutation analyses of 
randomly generated heatmaps (red = observed organization score of heatmap 
being tested);grey bar corresponds to n genes that have at least 1 count per 
million in RNA-seq dataset out of the total number of genes and are used to 
construct the heatmap; red and blue bars indicate how many of the genes in the 
heatmap are in a risk locus (red) and are risk locus-connect (blue). (E) 
Representative example of a heatmap generated by randomly sampling an 
identical number of genes as in the heatmap being queried without (left) and with 
(right) distance constraints (see Materials and methods for inclusion criteria and 
further details). (F) Frequency distribution of permuted organization scores for 
NPCs (left), neurons (middle), and glia (right) for random permutation analyses 
without distance-constraint in the PGC2-anchored interactions. (G) Overview and 
representative examples (zoomed in) of protein-protein association networks in 
NPCs (left), neurons (middle), and glia (right). Numbers of edges connecting the 
proteins in each network and STRING-computed P-values are reported below. 
Grey bar indicates the subset of these genes whose proteins are involved in the 
network out of the total number of genes from cell type-specific interactions; red 
and blue bars indicate how many of the genes in the network are in a risk locus 
(red) and are risk locus-connect (blue). Risk locus (red circle outline) and risk 
locus-connect (blue circle outline) are marked in the representative examples. 
(H) Subset heatmaps of only those genes in the neuronal coexpression clusters 
1 and 2 (refer to Figure 3.10 D) from all 94 (hiPSC-derived NPC and neurons; N 
= 47 libraries from 14 schizophrenia cases and N = 47 libraries from 12 controls) 
samples (left), schizophrenia cases only (middle), and control only (right). 
 
Because spatial 3DG proximity of genes is an indicator for potential 
coregulation (Kustatscher, Grabowski and Rappsilber, 2017), we tested whether 
 
 191 the neural cell type–specific schizophrenia-related chromosomal connectome 
showed evidence of coordinated transcriptional regulation and proteomic 
interaction of the participating genes. To this end, we generated lists of genes 
anchored in the most highly cell type–specific schizophrenia risk associated 
contacts (Materials and methods) (Figure 3.10, C, Figure 3.11, B, and Table 
3.15). Thus, for the NPC-specific contacts, we counted 386 genes, including 146 
within the risk loci and another 240 genes positioned elsewhere in the linear 
genome but connected via an intrachromosomal contact to within-risk-locus 
sequences. Similarly, for the neuron-specific contacts, we identified 385 genes, 
including 158 within risk loci and 227 outside of risk loci (Figure 3.10, C). Last, for 
glia-specific contacts, we identified 201 genes, including 88 within and 113 
outside of risk loci. We labeled the intrachromosomal contact genes located 
outside of schizophrenia risk loci as “risk locus-connect,” which we define as a 
collection of genes identified only through Hi-C interaction data, expanding—
depending on cell type—by 50 to 150% the current network of known genes 
overlapping risk sequences that is informed only by GWAS (Figure 3.10, C).  
 To examine whether such types of disease associated, cell-type-specific 
chromosomal connectomes were linked to a coordinated program of gene 
expression, we analyzed a merged transcriptome dataset (comprised of 47 
hiPSC-NPC and 47 hiPSC-forebrain neuron RNA-seq libraries from 22 
schizophrenia and control donors not related to those of our Hi-C datasets) 
(Hoffman et al., 2017). We examined pair-wise correlations of the collective sets 
 
 192 of the 386 NPC, 385 neuron, and 201 glia genes representing “risk locus” and 
“risk locus-connect” genes (cell-type-specific “risk connectomes”). The risk 
connectome for each cell type showed extremely strong pair-wise correlations, 
with two of the largest clusters visualized on the neuron and NPC correlation 
matrices involving an admixture of 354 “risk locus” and “risk locus connect” 
genes each, and similarly 181 genes from the glia matrix (Figure 3.10, D and 
Table 3.17). The averaged gene-by-gene transcript correlation index for each 
matrix overall, defined here as “organization score” (|r |avg), for the NPCs, 
neurons, and glia were 0.22 to 0.25. Such levels of organized gene expression 
were robustly significant for NPC and neurons, after controlling for linear genomic 
distance (1000 random samplings, |r |avg, P < 0.001 for NPC and for neuron; P = 
0.041 for glia) (Figure 3.10, D, Figure 3.12, E, and Table 3.18). There were four 
large clusters in the correlation matrices of the neuronal and NPC risk 
connectome: neuronal connectivity and synaptic signaling proteins (neuron 
cluster 1 and NPC cluster 2) and epigenetic regulators (neuron cluster 2 and 
NPC cluster 1). For example, within neuron cluster 1 (Figure 3.10, D, middle), 62 
of 125 genes encoded neural cell adhesion and synaptic molecules, voltage-
gated ion channels, and other neuron specific genes (Figure 3.10, E and Tables 
3.19 and 3.20). We thus conclude that the chromosomal connectomes 
associated with schizophrenia risk are cell type specific, with the neuronal risk 
connectome particularly enriched for genes pertaining to neuronal connectivity, 
synaptic signaling, and chromatin remodeling (Figure 3.10, D and E). Analyses of 
 
 193 the subset of PGC2 risk loci (108 and 145) provided similar results (Figure 3.12, 
C to F). Additionally, organization scores for neuron cluster 1 and cluster 2 genes 
were similar between hiPSC-derived NPCs and forebrain neurons from 
schizophrenia cases (n = 47) and control (n=47), suggesting that many risk 
locus–connect and risk locus genes are coregulated across individuals (Figure 
3.12, H).  
 Numerous proteins encoded by risk locus and risk locus–connect genes 
were associated with synaptic signaling (Table 3.21). The cell type–specific risk 
locus–connect and risk locus genes show significant protein-protein interaction 
network effects for NPCs (P = 0.0004) and neurons (P = 0.009) but not glia 
(Figure 3.13, A, Figures 3.14 to 3.16, and Table 3.21) when examined by using 
the STRING database v10.5 (Szklarczyk et al., 2015, 2017). We observed many 
proteomic clusters, including large groups of epigenomic regulators associated 
with the SWI/SNF (SWItch/Sucrose Non-Fermentable) chromatin remodeling 
complex and histone lysine methyltransferases and demethylases (Figure 3.13, 
A and Figures 3.14 and 3.15), many of which were the genes identified in NPC 
cluster 1 and neuron cluster 2 of the transcriptome analysis (Figure 3.10, D and 
E). The transcriptomic correlation heatmaps for these protein networks 
(“STRING” genes), when compared with randomly generated subset heatmaps 
from the overall (“Full”) schizophrenia-related chromosomal connectome (Figure 
3.10, D), had higher organization scores in NPCs and neurons (NPC |r |avg = 
0.2963, P = 0.007; neuron |r |avg = 0.2877, P = 0.008, glia |r |avg = 0.2225, P = 
 
 194 0.595, STRING versus full permutation test) (Materials and methods) (Figure 
3.13, B, Figures 3.17 to 3.19, and table S21). Because the transcriptomic 
correlation heatmap for the schizophrenia-related chromosomal connectome was 
significantly decreased by the removal specifically of the NPC STRING protein 
network genes (P < 10−3) (Table 3.21), this subset of STRING-interacting 
proteins may drive the observed orchestrated coregulation. Within these 
transcriptome- and proteome-based regulatory networks were numerous 
occasions of coregulated (RNA) and interacting (protein) risk locus and risk 
locus–connect genes that share the same TAD, including CDC20, which 
regulates dendrite development (Puram et al., 2011; Watanabe, Khodosevich 
and Monyer, 2014) and is associated at the protein level with RNF220, an E3 




Figure 0.13Figure 3.13 | Expanded GW AS risk connectome is l inked  to prot ein-prot ein association net works 
 
Figure 3.13 | Expanded GWAS risk connectome is linked to protein-protein 
association networks.  
(A) Overview and representative examples (zoomed in) of protein-protein 
association networks in NPCs (left), neurons (middle), and glia (right). Numbers 
of edges connecting the proteins in each network and STRING-computed P 
values are reported below. Gray bar indicates the subset of these genes whose 
proteins are involved in the network out of the total number of genes from cell 
type–specific interactions; red and blue bars indicate how many of the genes in 
the network are in a risk locus (red) and are risk locus–connect (blue). 
 (B) Comparison of organization scores between the full RNA transcriptomic 
correlation heatmaps (brown) (Figure 3.10, D) and the “STRING” heatmaps (tan) 
(Figures 3.17 to 3.19), consisting of only those genes in protein networks for 
each cell type. Permutation test, **P<0.01. (C) Representative neuronal TAD 
landscape (chr1, ~2 Mb) depicting a schizophrenia risk–associated locus (red) 
with its risk locus–connect genes (blue), MED8, MPL, CDC20, and RNF220, 
which are members of the neuronal schizophrenia protein network (green circle). 
CDC20 and RNF220 interact at the protein level (green circle with gray border). 
 
 196 (D) (Left) Liquid chromotography–selected reaction monitoring (LC-SRM) mass 
spectrometry (MS) was performed on dorsolateral prefrontal cortex (DLPFC) 
tissue from 43 adult postmortem brains (23 schizophrenia, 20 control). (Middle) 
182 neuronal proteins were reliably quantified, and four of them were observed to 
have associations in the neuron protein network in (A). (Right) GABBR1, GRM3, 
GRIN2A, and GRIA1 proteins were found to have significantly more correlated 
expression than expected by random permutation analysis. Additional 
information on protein-protein interactions is provided in Figures 3.12 to 3.19. 
 
 
Figure 0.14Figure 3.14 | N PC sch izophrenia r isk-associat ed p rotein-p rotein  association net work 
 
Figure 3.14 | NPC schizophrenia risk-associated protein-protein association 
network.  
Protein-protein network (STRING) derived from genes located in NPC-specific 
schizophrenia risk interactions. Yellow circles roughly outline groups of genes 




Figure 0.15Figure 3.15 | N euron schizophrenia risk-associated  prot ein-prot ein association  net work 
 
Figure 3.15 | Neuron schizophrenia risk-associated protein-protein 
association network.  
(A) Protein-protein network (STRING) derived from genes located in neuron-
specific schizophrenia risk interactions. Yellow and fuchsia circles roughly outline 
groups of genes associated with chromatin remodeling and neuronal 
connectivity, respectively, as highlighted in Fig 3.10, D and E. (B) RNA 
correlation heatmap (PGC2) zoomed in to a cluster of coexpression that contains 
4 genes of interest (GABBR1, GRM3, GRIN2A, GRIA1) that were identified in the 
 
 198 protein network in panel A. Red = risk locus genes are in red; arrows indicate 4 
synaptic genes of interest; each color circle represents a different TAD whereby 
genes co-localized with one or more genes in same TAD or adjacent TADs share 
the same color. (C) Pearson correlation matrix of protein measures for the 4 


















Figure 0.16Figure 3.16 | Glia sch izophrenia risk- associated p rotein-protein association net work 
 
Figure 3.16 | Glia schizophrenia risk-associated protein-protein association 
network. 
Protein-protein network (STRING) derived from genes located in glia-specific 











 201 Figure 3.17 | NPC schizophrenia risk-associated STRING subset genes 
show greater transcriptional organization than full risk connectome gene 
list (PGC2).  
(A) Pearson correlation heatmap of genes participating in NPC-specific STRING 
protein-protein network. Risk locus gene (red), gene present in TAD with no other 
genes in the network (grey circle), gene co-localized with one or more genes in 
same TAD or adjacent TADs (colored circles; each color represents a different 
TAD; see Table S24). (B) Frequency distribution of permuted organization 
scores, randomly sampling from all genes in NPC risk connectome. Red line = 

























 203 Figure 3.18 | Neuron schizophrenia risk-associated STRING subset genes 
show greater transcriptional organization than full risk connectome gene 
list (PGC2).  
(A) Pearson correlation heatmap of genes participating in neuron-specific 
STRING protein-protein network. Risk locus gene (red), gene present in TAD 
with no other genes in the network (grey circle), gene co-localized with one or 
more genes in same TAD or adjacent TADs (colored circles; each color 
represents a different TAD; see Table S24). (B) Frequency distribution of 
permuted organization scores, randomly sampling from all genes in neuron risk 
connectome. Red line = organization score for risk-associated Pearson 

























 205 Figure 3.19 | Glia schizophrenia risk-associated STRING subset genes do 
not show greater transcriptional organization than full risk connectome 
gene list (PGC2).  
(A) Pearson correlation heatmap of genes participating in glia-specific STRING 
protein-protein network. (B) Frequency distribution of permuted organization 
scores, randomly sampling from all genes in glia risk connectome. Red line = 
organization score for risk-associated Pearson correlation in panel A. 
 
 To examine whether such coregulation could be representative of the 
prefrontal cortex proteome of the adult brain, we screened a newly generated 
mass spectrometry–based dataset of 182 neuronal proteins, the majority of 
which were synaptic, quantified from prefrontal cortex of n = 23 adult 
schizophrenia and n = 20 control subjects (Table 3.22) (Hahn et al., 2009). 
Among the 182 proteins, there were four from the risk-associated neuronal 
protein network (Figure 3.13, D): GABAB receptor subunit GABBR1 and 
ionotropic (GRIA1 and GRIN2A) and metabotropic glutamate receptor subunits 
(GRM3). Protein-protein correlation scores were significantly higher for these four 
risk-associated proteins than expected from random permutation analysis from 
the pool of 182 proteins (P < 0.002) across patients and controls. We conclude 
that the schizophrenia-related chromosomal connectome, tethering other 
portions of the genome to the sequences associated with schizophrenia 
heritability, provides a structural foundation for a functional connectome that 
reflects coordinated regulation of gene expression and interactions within the 
proteome.  
 
 206 Discussion  
 Neural progenitor differentiation into neurons and glia is associated with 
dynamic remodeling of chromosomal conformations, including loss of many 
NPC-specific chromosomal contacts, with differentiation-induced loop pruning 
primarily affecting a subset of genes important for neurogenesis (NPC-to-neuron 
loss) and neuronal function (NPC-to-glia loss). These findings broadly resonate 
with a recent report linking neural differentiation to multiple scales of 3DG folding, 
governed by multiple mechanisms, including CTCF-dependent loop alterations, 
repressive chromatin remodeling, and cell- and lineage-specific transcription 
factor networks (Bonev et al., 2017). Our results suggest that developmental 
3DG remodeling affects a substantial portion of sequences that confer liability for 
schizophrenia; furthermore, these genes in 3D physical proximity with 
schizophrenia-risk variants show a surprisingly strong correlation at the level of 
the transcriptome and proteome. How might the disease-relevant reorganization 
of the spatial genome (the “chromosomal connectome”) provide a structural 
foundation for coordinated regulation of expression? Recent Hi-C studies in 
mouse brain showed that chromosomal contacts preferentially occurred between 
loci targeted by the same transcription factors (Bonev et al., 2017), and likewise, 
multiple schizophrenia risk loci could converge on intra- and interchromosomal 
hubs sharing a similar regulatory architecture including specific enhancers as 
well as transcription and splicing factors (Lomvardas et al., 2006; Khanna, Hu 
and Belmont, 2014; Quinodoz et al., 2018). Intriguingly, the three major 
 
 207 functional categories associated with the genetic risk architecture of 
schizophrenia—neuronal connectivity, synaptic signaling, and chromatin 
remodeling (Gilman et al., 2012; O’dushlaine et al., 2015)—were heavily 
represented within the cell type–specific chromosomal connectomes of neurons 
and NPCs described here (Fig. 3.10, B and E) and in whole tissue in vivo (Won 
et al., 2016; de la Torre-Ubieta et al., 2018). Cell type–specific 3DG 
reorganization during the course of neural progenitor differentiation, as shown 
here, could therefore have profound implications for our understanding of the 
genetic underpinnings of psychiatric disease. For example, inclusion of the cell 
type–specific risk (sequence) associated chromosomal connectome may lead to 
refinements of cumulative schizophrenia risk allele burden estimates, including 
“polygenic risk score” (PRS) or “biologically informed multilocus profile scores” 
(BIMPS), which currently only explain a small portion of disease risk (Bogdan, 
Baranger and Agrawal, 2018). Cell type–specific intersection of 3DG and genetic 
risk maps are of clinical interest beyond psychiatric disorders; for example, risk 
variants that confer susceptibility to autoimmune disease were embedded in 
physically interacting chromosomal loci in lymphoblastoid cells (Grubert et al., 
2015). Our 3DG maps from neural progenitors and their isogenic neurons and 
glia are accessible through the PsychENCODE Knowledge Portal 
(https://synapse.org) and more than double the number of currently available Hi-
C datasets from human brain (Dixon et al., 2015; Schmitt et al., 2016; Won et al., 
2016), providing investigators with a resource to chart the expanded genome 
 
 208 space associated with cognitive and neuropsychiatric disease in context of cell 
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Loops Accession ID 




21% 2% 26% 372,787,143 372,787,143 Reevaluation 2661 5348 8009 1704 5502 7206   




21% 2% 26% 372,787,143 372,787,143 
Standard 






3% 26%         
  
    
  






3% 26%         
  
    
  
    
FB Neuron 
1 1,148,145,724 90% 38% 5% 24% 491,798,369 372,787,143 
Standard 
HiCCUPS         5741     
Glia 1 166,079,544 87% 20% 6% 27% 440,950,529 372,787,143 Reevaluation 7289 9153 16442 4531 8453 12984   
Glia 1 166,079,544 
87% 
20% 
6% 27% 440,950,529 372,787,143 
Standard 






4% 27%         
  
    
  






3% 27%         
  
    
  
    
NPC 1  239,221,938 87% 19% 4% 31% 616,826,359 372,787,143 Reevaluation 9070 10941 20011 4584 8429 13013   
NPC 1  239,221,938 
87% 
19% 
4% 31% 616,826,359 372,787,143 
Standard 






3% 28%         
  
    
  






2% 28%         
  
    
  






14% 41%         
  
    
  
    
GM12878 3,587,190,419 See Rao et al. (Ref. 15) 
1,989,154,220 









See Won et al. (2016) (Ref. 6) 545,496,617  204,476,188 
Standard 










" 540,079,810 204,476,188 
Standard 







ESC 1,035,319,145 See Bonev et al. (2017) (Ref. 17) 471,503,539 471,503,539 
Standard 




NPC 1,284,813,522 " 619,932,857 471,503,539 
Standard 





Neuron 1,298,855,792 " 615,843,081 471,503,539 
Standard 













NPC 2 134,380,774 99.02 74,493,904 36.33 
Neuron 
2 Rep 1 96,205,900 99.07 54,130,694 33.5 
Neuron 








 NPCs 695,893,249 
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Table 3.1 | Hi-C and ATAC-Seq sequencing summary and quality controls. 
Sequencing and quality control metrics for Hi-C libraries and loops called by cell 
type. Total reads, number of unfiltered reads; FR pairs, forward-reverse pairs;  
*Loops are only called from contacts pooled by cell type 
**Reevaluation= loops called from union set of initial loop calls (see Methods); 
Standard HiCCUPS= loop calls with no reevaluation 
*** Non-Sub = all cis contacts passing filters; Sub= cis contacts randomly 
sampled from all cell types         
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step down Neg log(P_corr) % Associated Nr. Genes 
Total 
genes in 




development 78.0E-9 21.0E-6 4.677780705 5.247225025 52 991 
[ARSB, BASP1, CDH11, CENPF, CEP120, CEP290, CLU, DNER, EN1, EPHA4, 
FUT10, GARS, GNG12, GRIK1, HOXA2, HOXB2, IGF2BP1, INHBA, IRS2, 
KDM4A, KIRREL3, LHX8, MACROD2, MAP2, MKKS, MYO1D, NAV2, NCOA3, 
NR2F2, NRG1, NRP2, PBX3, PDHX, PITX2, POU3F2, PTCH1, PTN, PTPRZ1, 
RCAN1, ROBO1, RTN4RL1, SALL1, SEMA3A, SLITRK5, SOX2, SOX4, 
SPOCK1, SUDS3, TOP2B, TRA2B, ZBTB16, ZEB1] 
GO:0035108 
limb 
morphogenesis 750.0E-9 200.0E-6 3.698970004 10.45751634 16 153 
[ALX1, B9D1, BMPR1B, CYP26B1, EN1, FMN1, HOXD12, MAP3K20, PITX2, 
PTCH1, SALL1, SALL4, SOX4, SP9, TGFB2, ZBTB16] 
GO:0072001 
renal system 
development 1.0E-6 270.0E-6 3.568636236 7.590759076 23 303 
[ADAMTS1, ADAMTS16, AGTR1, BASP1, CENPF, CEP290, COL4A4, DCN, 
EFNB2, EPHA4, FMN1, GARS, ITGA6, KIRREL3, NFIA, PTCH1, SALL1, 





differentiation 1.5E-6 410.0E-6 3.387216143 5.52407932 39 706 
[ADGRB3, ALCAM, ANK3, ART4, BMPR1B, BVES, CDH11, EPHA4, FBLN1, 
FEZ1, FLRT3, FMN1, GAP43, GFRA1, HEG1, HOXA2, IRS2, KLF7, LATS1, 
MAP1B, MAP2, NCOA3, NRG1, NRP2, PARD3, PIK3R1, PLXNB1, POU3F2, 




development 3.7E-6 970.0E-6 3.013228266 5.988023952 30 501 
[ALCAM, ANK3, ART4, BMPR1B, CDH11, EPHA4, FEZ1, FLRT3, GAP43, 
GFRA1, HOXA2, IRS2, KLF7, MAP1B, NCAM2, NRG1, NRP2, PARD3, 
PCDHA4, PIK3R1, PLXNB1, POU3F2, PTPRZ1, RGMA, ROBO1, RTN4RL1, 
SEMA3A, SLITRK5, TGFB2, TOP2B] 
GO:0001822 
kidney 
development 4.9E-6 1.2E-3 2.920818754 7.368421053 21 285 
[ADAMTS1, ADAMTS16, AGTR1, BASP1, CENPF, CEP290, COL4A4, DCN, 
EFNB2, EPHA4, FMN1, GARS, KIRREL3, PTCH1, SALL1, SMAD2, SOX4, 






differentiation 7.8E-6 2.0E-3 2.698970004 5.604203152 32 571 
[ADGRB3, ALCAM, ANK3, ART4, BMPR1B, CDH11, EPHA4, FEZ1, FLRT3, 
FMN1, GAP43, GFRA1, HOXA2, IRS2, KLF7, MAP1B, MAP2, NRG1, NRP2, 
PARD3, PIK3R1, PLXNB1, POU3F2, PTPRZ1, RGMA, ROBO1, SDC2, 
SEMA3A, SLITRK5, STRC, TGFB2, TOP2B] 
GO:0030326 
embryonic limb 
morphogenesis 15.0E-6 4.1E-3 2.387216143 9.848484848 13 132 
[ALX1, B9D1, CYP26B1, EN1, HOXD12, MAP3K20, PITX2, PTCH1, SALL1, 
SALL4, SP9, TGFB2, ZBTB16] 
GO:0007409 axonogenesis 17.0E-6 4.5E-3 2.346787486 5.844155844 27 462 
[ALCAM, ANK3, ART4, BMPR1B, CDH11, EPHA4, FEZ1, FLRT3, GAP43, 
GFRA1, HOXA2, IRS2, KLF7, MAP1B, NRG1, NRP2, PARD3, PIK3R1, 




morphogenesis 18.0E-6 4.7E-3 2.327902142 5.331179321 33 619 
[ADGRB3, ALCAM, ANK3, ART4, BMPR1B, CDH11, EPHA4, FEZ1, FLRT3, 
FMN1, GAP43, GFRA1, HOXA2, IRS2, KIRREL3, KLF7, MAP1B, MAP2, NRG1, 
NRP2, PARD3, PIK3R1, PLXNB1, POU3F2, PTPRZ1, RGMA, RIMS2, ROBO1, 
SDC2, SEMA3A, SLITRK5, TGFB2, TOP2B] 
GO:0008038 
neuron 
recognition 27.0E-6 6.9E-3 2.161150909 18.42105263 7 38 [EPHA4, GAP43, NCAM2, OPCML, PCDHA4, ROBO1, SEMA3A] 
GO:0030900 
forebrain 
development 39.0E-6 10.0E-3 2 5.940594059 24 404 
[CEP120, FUT10, GNG12, IGF2BP1, INHBA, KIRREL3, LHX8, MKKS, MYO1D, 
NCOA3, NR2F2, NRG1, NRP2, PITX2, POU3F2, PTN, ROBO1, RTN4RL1, 
SALL1, SEMA3A, SLITRK5, SOX2, TOP2B, TRA2B] 
GO:0031053 
primary miRNA 
processing 58.0E-6 14.0E-3 1.853871964 40 4 10 [GARS, HNRNPA2B1, NCBP1, SMAD2] 
GO:0007507 
heart 
development 80.0E-6 20.0E-3 1.698970004 5.263157895 29 551 
[ADAMTS1, BASP1, BVES, CALCRL, CASP7, DAND5, EFNB2, FLRT3, GARS, 
HDAC9, HEG1, KCNK2, KDM6A, MKKS, NEBL, NRG1, NRP2, PITX2, 




activity 94.0E-6 23.0E-3 1.638272164 6.211180124 20 322 
[CACNB2, CLU, FAM155A, GRIK1, GRIN2B, HCN4, ITPR2, KCND2, KCNE2, 
KCNH1, KCNK16, KCNK2, KCNMB1, KCNS1, NALCN, SCN1A, SCN9A, 
TRPM3, TRPM4, TRPM8] 
GO:0005272 
sodium channel 
activity 120.0E-6 32.0E-3 1.494850022 14.58333333 7 48 [CLU, GRIK1, HCN4, NALCN, SCN1A, SCN9A, TRPM4] 
GO:0005216 
ion channel 
activity 150.0E-6 37.0E-3 1.431798276 5.517241379 24 435 
[CACNB2, CLCN4, CLU, FAM155A, GABRP, GRIK1, GRIN2B, HCN4, ITPR2, 
KCND2, KCNE2, KCNH1, KCNK16, KCNK2, KCNMB1, KCNS1, NALCN, 




development 190.0E-6 48.0E-3 1.318758763 8.8 11 125 




Table 3.2 | Gene ontology (GO) of Brain-specific loops.                             
Gene ontology enrichment terms and details for genes in brain-specific loops.  
GOID, ClueGO term ID; Term PValue, uncorrected p-value; Term PValue 
Corrected with Bonferroni step down, p-value corrected for multiple comparisons; 
Neg log(P_corr), negative log-transformed corrected p-values; % Associated,  
percentage of genes in GO category found in input list of genes; Nr. Genes, 
number of genes from input list that match the GO category; Total genes in 
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Table 4Table 3.3 | N euron-specific loops GO 
GOID GOTerm 
Neg log 
(P) Ontology Source 
Term 
PValue 
Term PValue Corrected 

















GOA_23.02.2017_10h01 140.0E-6 4.0E-3 2.4 11.43 4 35 
[PCSK5, PDGFRA, 
SHH, SHOX2] 




GOA_23.02.2017_10h01 220.0E-6 5.8E-3 2.2 7.04 5 71 
[DMRTA2, GATA2, 
GBX1, SATB2, SHH] 
GO:2000179 
positive regulation of neural 













GOA_23.02.2017_10h01 580.0E-6 14.0E-3 1.9 40.00 2 5 [EGF, SHH] 
GO:0019054 





GOA_23.02.2017_10h01 920.0E-6 21.0E-3 1.7 12.00 3 25 [ATG7, KPNA7, VAPA] 
GO:0021902 
commitment of neuronal cell 












GOA_23.02.2017_10h01 1.2E-3 26.0E-3 1.6 6.67 4 60 
[PRMT8, SETD3, 
SMYD2, SMYD3] 
GO:0003030 DNA replication 
1.508638
306 KEGG_01.03.2017 31.0E-3 31.0E-3 1.5 5.56 2 36 [MCM6, POLA2] 
GO:0021940 
positive regulation of 





GOA_23.02.2017_10h01 2.0E-3 41.0E-3 1.4 22.22 2 9 [EGF, SHH] 
GO:0051895 





GOA_23.02.2017_10h01 10.0E-3 41.0E-3 1.4 10.00 2 20 [BCAS3, RCC2] 
GO:0060749 





GOA_23.02.2017_10h01 10.0E-3 41.0E-3 1.4 10.00 2 20 [EGF, ERBB4] 













GOA_23.02.2017_10h01 2.5E-3 48.0E-3 1.3 20.00 2 10 [DOCK2, SHH] 
 
Table 3.3 | Neuron-specific loops GO. 
Gene ontology enrichment terms and details for genes in neuron-specific loops 





























Table 5Table 3.4 | N PC-specific loops GO 
GOID GOTerm 
Neg 
log(P) Ontology Source 
Term 
PValue 
Term PValue Corrected with 





Total genes in 
Term 











GOA_23.02.2017_10h01 3.5E-21 5.4E-18 14.85 232.00 1562.00 




GOA_23.02.2017_10h01 6.0E-21 9.1E-18 15.10 221.00 1464.00 






21 590.0E-18 16.45 163.00 991.00 
GO:0048812 neuron projection morphogenesis 13 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 71.0E-18 100.0E-15 18.26 113.00 619.00 




GOA_23.02.2017_10h01 93.0E-18 140.0E-15 15.51 165.00 1064.00 






18 290.0E-15 16.11 146.00 906.00 






18 1.1E-12 24.90 61.00 245.00 




GOA_23.02.2017_10h01 4.0E-15 6.0E-12 18.04 103.00 571.00 




GOA_23.02.2017_10h01 5.8E-15 8.8E-12 16.56 125.00 755.00 











15 190.0E-12 18.61 86.00 462.00 






15 250.0E-12 18.16 91.00 501.00 
GO:0006357 







15 840.0E-12 12.46 249.00 1999.00 






15 940.0E-12 12.20 269.00 2205.00 




GOA_23.02.2017_10h01 2.7E-12 4.1E-9 12.53 230.00 1836.00 




GOA_23.02.2017_10h01 4.0E-12 6.0E-9 17.36 88.00 507.00 
GO:1905114 





GOA_23.02.2017_10h01 5.4E-12 8.2E-9 16.32 101.00 619.00 




GOA_23.02.2017_10h01 5.8E-12 8.7E-9 12.93 199.00 1539.00 
GO:0045944 
positive regulation of transcription from RNA 
polymerase II promoter 8 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.9E-12 10.0E-9 13.85 158.00 1141.00 




GOA_23.02.2017_10h01 8.2E-12 12.0E-9 13.04 192.00 1472.00 




GOA_23.02.2017_10h01 16.0E-12 24.0E-9 23.71 46.00 194.00 




GOA_23.02.2017_10h01 18.0E-12 27.0E-9 16.30 97.00 595.00 
GO:0045935 
positive regulation of nucleobase-containing 




GOA_23.02.2017_10h01 20.0E-12 31.0E-9 12.36 224.00 1813.00 




GOA_23.02.2017_10h01 66.0E-12 99.0E-9 15.12 111.00 734.00 




GOA_23.02.2017_10h01 84.0E-12 120.0E-9 14.65 121.00 826.00 






12 270.0E-9 12.02 229.00 1905.00 






12 600.0E-9 19.22 59.00 307.00 
GO:0010557 







12 810.0E-9 12.11 212.00 1751.00 






12 1.1E-6 17.33 70.00 404.00 






12 1.3E-6 14.10 120.00 851.00 




GOA_23.02.2017_10h01 1.1E-9 1.6E-6 14.13 119.00 842.00 




GOA_23.02.2017_10h01 1.2E-9 1.9E-6 13.38 140.00 1046.00 




GOA_23.02.2017_10h01 1.2E-9 1.9E-6 13.38 140.00 1046.00 




GOA_23.02.2017_10h01 9.6E-9 14.0E-6 17.66 59.00 334.00 
GO:0000122 
negative regulation of transcription from RNA 




GOA_23.02.2017_10h01 10.0E-9 15.0E-6 13.83 112.00 810.00 




GOA_23.02.2017_10h01 25.0E-9 37.0E-6 29.49 23.00 78.00 
GO:2000113 





GOA_23.02.2017_10h01 35.0E-9 51.0E-6 12.15 168.00 1383.00 
GO:0010558 





GOA_23.02.2017_10h01 46.0E-9 68.0E-6 11.98 176.00 1469.00 
GO:0000976 





GOA_23.02.2017_10h01 48.0E-9 71.0E-6 14.18 96.00 677.00 




GOA_23.02.2017_10h01 51.0E-9 76.0E-6 13.95 100.00 717.00 
GO:0090287 





GOA_23.02.2017_10h01 80.0E-9 110.0E-6 18.36 47.00 256.00 




GOA_23.02.2017_10h01 88.0E-9 130.0E-6 14.09 94.00 667.00 




GOA_23.02.2017_10h01 110.0E-9 160.0E-6 44.83 13.00 29.00 
 




GOA_23.02.2017_10h01 110.0E-9 170.0E-6 12.39 145.00 1170.00 
GO:0000977 
RNA polymerase II regulatory region sequence-




GOA_23.02.2017_10h01 120.0E-9 180.0E-6 14.41 85.00 590.00 
GO:0004360 Axon guidance 
3.7212
464 KEGG_01.03.2017 130.0E-9 190.0E-6 20.57 36.00 175.00 




GOA_23.02.2017_10h01 130.0E-9 190.0E-6 21.57 33.00 153.00 




GOA_23.02.2017_10h01 130.0E-9 200.0E-6 17.33 52.00 300.00 
GO:1903507 





GOA_23.02.2017_10h01 140.0E-9 200.0E-6 12.27 149.00 1214.00 




GOA_23.02.2017_10h01 160.0E-9 240.0E-6 12.10 155.00 1281.00 




GOA_23.02.2017_10h01 190.0E-9 280.0E-6 17.50 49.00 280.00 




GOA_23.02.2017_10h01 290.0E-9 430.0E-6 11.60 180.00 1552.00 




GOA_23.02.2017_10h01 350.0E-9 520.0E-6 12.84 117.00 911.00 




GOA_23.02.2017_10h01 520.0E-9 760.0E-6 17.72 45.00 254.00 




GOA_23.02.2017_10h01 780.0E-9 1.1E-3 18.72 38.00 203.00 




GOA_23.02.2017_10h01 800.0E-9 1.1E-3 14.97 66.00 441.00 
GO:0045934 
negative regulation of nucleobase-containing 




GOA_23.02.2017_10h01 950.0E-9 1.3E-3 11.59 167.00 1441.00 




GOA_23.02.2017_10h01 1.0E-6 1.4E-3 20.53 31.00 151.00 




GOA_23.02.2017_10h01 1.0E-6 1.5E-3 18.57 39.00 210.00 




GOA_23.02.2017_10h01 1.0E-6 1.5E-3 11.23 194.00 1727.00 




GOA_23.02.2017_10h01 1.3E-6 1.9E-3 27.54 19.00 69.00 




GOA_23.02.2017_10h01 1.6E-6 2.4E-3 27.14 19.00 70.00 




GOA_23.02.2017_10h01 1.6E-6 2.4E-3 18.45 38.00 206.00 
GO:2000112 





GOA_23.02.2017_10h01 1.6E-6 2.4E-3 9.87 411.00 4166.00 




GOA_23.02.2017_10h01 2.1E-6 3.1E-3 11.94 136.00 1139.00 




GOA_23.02.2017_10h01 2.3E-6 3.3E-3 9.77 431.00 4411.00 




GOA_23.02.2017_10h01 2.7E-6 3.9E-3 18.23 37.00 203.00 
GO:0000987 





GOA_23.02.2017_10h01 2.9E-6 4.3E-3 15.20 57.00 375.00 




GOA_23.02.2017_10h01 3.0E-6 4.4E-3 9.89 389.00 3933.00 
GO:0090090 





GOA_23.02.2017_10h01 3.7E-6 5.3E-3 18.86 33.00 175.00 




GOA_23.02.2017_10h01 3.9E-6 5.6E-3 9.84 398.00 4045.00 
GO:0000978 
RNA polymerase II core promoter proximal region 




GOA_23.02.2017_10h01 5.3E-6 7.6E-3 15.15 55.00 363.00 




GOA_23.02.2017_10h01 5.4E-6 7.8E-3 21.82 24.00 110.00 




GOA_23.02.2017_10h01 5.5E-6 8.0E-3 9.89 372.00 3763.00 




GOA_23.02.2017_10h01 6.0E-6 8.8E-3 9.61 462.00 4809.00 




GOA_23.02.2017_10h01 6.0E-6 8.8E-3 9.61 462.00 4809.00 




GOA_23.02.2017_10h01 6.5E-6 9.5E-3 19.61 30.00 153.00 




GOA_23.02.2017_10h01 6.9E-6 9.9E-3 9.87 374.00 3791.00 
GO:0032330 regulation of chondrocyte differentiation 2 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.9E-6 10.0E-3 29.41 15.00 51.00 









GOA_23.02.2017_10h01 9.0E-6 13.0E-3 9.53 475.00 4982.00 














GOA_23.02.2017_10h01 10.0E-6 14.0E-3 9.16 665.00 7258.00 




GOA_23.02.2017_10h01 12.0E-6 17.0E-3 9.77 384.00 3930.00 




GOA_23.02.2017_10h01 13.0E-6 19.0E-3 24.66 18.00 73.00 




GOA_23.02.2017_10h01 14.0E-6 20.0E-3 9.48 485.00 5118.00 




GOA_23.02.2017_10h01 14.0E-6 21.0E-3 13.97 63.00 451.00 




GOA_23.02.2017_10h01 15.0E-6 21.0E-3 16.09 42.00 261.00 









GOA_23.02.2017_10h01 16.0E-6 23.0E-3 10.51 224.00 2131.00 




GOA_23.02.2017_10h01 16.0E-6 23.0E-3 17.35 34.00 196.00 




GOA_23.02.2017_10h01 18.0E-6 25.0E-3 13.06 79.00 605.00 
 




GOA_23.02.2017_10h01 23.0E-6 32.0E-3 34.38 11.00 32.00 




GOA_23.02.2017_10h01 23.0E-6 33.0E-3 13.20 73.00 553.00 




GOA_23.02.2017_10h01 23.0E-6 33.0E-3 13.96 61.00 437.00 
GO:0010769 





GOA_23.02.2017_10h01 24.0E-6 35.0E-3 15.69 43.00 274.00 




GOA_23.02.2017_10h01 28.0E-6 40.0E-3 12.45 91.00 731.00 




GOA_23.02.2017_10h01 28.0E-6 40.0E-3 15.52 43.00 277.00 




GOA_23.02.2017_10h01 28.0E-6 40.0E-3 15.52 43.00 277.00 
GO:0004310 Wnt signaling pathway 
1.3665
315 KEGG_01.03.2017 30.0E-6 43.0E-3 18.88 27.00 143.00 




GOA_23.02.2017_10h01 33.0E-6 47.0E-3 9.64 393.00 4077.00 
 
B 











Group PValue Corrected 










GOA_23.02.2017_10h01 26.0E-12 12.0E-9 7.9E+0 1.7E-9 12.0E-9 [3, 4] Group11 4.57 
GO:0048468 cell development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 130.0E-12 21.0E-9 7.7E+0 57.0E-12 790.0E-12 [3, 4, 5] Group13 4.24 
GO:0000904 
cell morphogenesis 
involved in differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-12 27.0E-9 7.6E+0 2.5E-9 12.0E-9 [4, 5, 6] Group10 6.23 
GO:0000904 
cell morphogenesis 
involved in differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-12 27.0E-9 7.6E+0 57.0E-12 790.0E-12 [4, 5, 6] Group13 6.23 
GO:0007409 axonogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 13.0E-9 1.2E-6 5.9E+0 2.5E-9 12.0E-9 
[6, 7, 8, 9, 
10, 11, 12] Group10 6.71 
GO:0048699 generation of neurons 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 18.0E-9 1.2E-6 5.9E+0 57.0E-12 790.0E-12 [6, 7] Group13 4.37 
GO:0007409 axonogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 13.0E-9 1.2E-6 5.9E+0 57.0E-12 790.0E-12 
[6, 7, 8, 9, 
10, 11, 12] Group13 6.71 
GO:0050770 regulation of axonogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 11.0E-9 1.3E-6 5.9E+0 57.0E-12 790.0E-12 
[6, 7, 8, 9, 
10, 11, 12, 





GOA_23.02.2017_10h01 18.0E-9 1.4E-6 5.9E+0 57.0E-12 790.0E-12 [3, 4] Group13 4.83 
GO:0045595 
regulation of cell 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 30.0E-9 1.4E-6 5.9E+0 57.0E-12 790.0E-12 [3, 4, 5] Group13 4.20 
GO:0030182 neuron differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 23.0E-9 1.4E-6 5.9E+0 57.0E-12 790.0E-12 [5, 7, 8] Group13 4.50 
GO:0000902 cell morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 29.0E-9 1.5E-6 5.8E+0 57.0E-12 790.0E-12 [4, 5] Group13 4.97 
GO:2000026 
regulation of multicellular 
organismal development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 58.0E-9 1.9E-6 5.7E+0 57.0E-12 790.0E-12 [3, 4] Group13 4.02 
GO:0022008 neurogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 52.0E-9 1.9E-6 5.7E+0 57.0E-12 790.0E-12 [5, 6] Group13 4.23 
GO:0048667 
cell morphogenesis 
involved in neuron 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 50.0E-9 2.0E-6 5.7E+0 2.5E-9 12.0E-9 
[5, 6, 7, 8, 
9, 10] Group10 5.95 
GO:0030030 cell projection organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 47.0E-9 2.0E-6 5.7E+0 57.0E-12 790.0E-12 [3] Group13 4.32 
GO:0048667 
cell morphogenesis 
involved in neuron 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 50.0E-9 2.0E-6 5.7E+0 57.0E-12 790.0E-12 
[5, 6, 7, 8, 





GOA_23.02.2017_10h01 110.0E-9 3.3E-6 5.5E+0 2.5E-9 12.0E-9 
[5, 6, 7, 8, 
10, 11] Group10 5.65 
GO:0050767 regulation of neurogenesis 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 110.0E-9 3.3E-6 5.5E+0 57.0E-12 790.0E-12 
[5, 6, 7, 8, 
10, 11] Group13 5.65 
GO:0032990 cell part morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 130.0E-9 3.4E-6 5.5E+0 2.5E-9 12.0E-9 [4, 5] Group10 5.51 
GO:0032990 cell part morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 130.0E-9 3.4E-6 5.5E+0 57.0E-12 790.0E-12 [4, 5] Group13 5.51 
GO:0045664 
regulation of neuron 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 130.0E-9 3.5E-6 5.5E+0 57.0E-12 790.0E-12 [6, 7, 8, 9] Group13 5.71 
GO:0051960 
regulation of nervous 
system development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 120.0E-9 3.6E-6 5.4E+0 57.0E-12 790.0E-12 [4, 5, 6] Group13 5.08 
GO:0007010 cytoskeleton organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 170.0E-9 4.0E-6 5.4E+0 1.7E-9 12.0E-9 [4] Group11 4.42 
GO:0048666 neuron development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 210.0E-9 5.0E-6 5.3E+0 57.0E-12 790.0E-12 
[4, 5, 6, 8, 
9] Group13 4.61 
GO:0060284 
regulation of cell 
development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 260.0E-9 5.6E-6 5.3E+0 57.0E-12 790.0E-12 [4, 5, 6] Group13 4.94 
GO:0010769 
regulation of cell 
morphogenesis involved in 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 360.0E-9 7.5E-6 5.1E+0 57.0E-12 790.0E-12 [5, 6, 7] Group13 7.66 
GO:0090132 epithelium migration 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 570.0E-9 11.0E-6 5.0E+0 2.8E-9 9.8E-9 
[4, 5, 6, 7, 





GOA_23.02.2017_10h01 570.0E-9 11.0E-6 5.0E+0 57.0E-12 790.0E-12 
[4, 5, 6, 7, 
9, 10] Group13 4.75 
GO:0010975 
regulation of neuron 
projection development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 730.0E-9 13.0E-6 4.9E+0 57.0E-12 790.0E-12 
[5, 6, 7, 8, 
9, 10, 11] Group13 6.12 
GO:0040012 regulation of locomotion 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 1.2E-6 21.0E-6 4.7E+0 1.7E-9 12.0E-9 [4, 5] Group11 5.27 
GO:0022604 
regulation of cell 
morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 1.4E-6 23.0E-6 4.6E+0 57.0E-12 790.0E-12 [4, 5, 6] Group13 5.91 
 
 216 GO:0016477 cell migration 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 1.5E-6 24.0E-6 4.6E+0 2.5E-9 12.0E-9 [3, 4, 5] Group10 4.05 
GO:0016477 cell migration 
GO_BiologicalProcess-






GOA_23.02.2017_10h01 3.5E-6 55.0E-6 4.3E+0 1.7E-9 12.0E-9 [4, 5] Group11 6.65 
GO:0022603 
regulation of anatomical 
structure morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 3.8E-6 57.0E-6 4.2E+0 57.0E-12 790.0E-12 [3, 4] Group13 4.38 





GOA_23.02.2017_10h01 4.2E-6 61.0E-6 4.2E+0 1.7E-9 12.0E-9 [3] Group11 4.84 
GO:0004360 Axon guidance KEGG_01.03.2017 4.3E-6 61.0E-6 4.2E+0 57.0E-12 790.0E-12 [-1] Group13 8.57 
GO:2000145 regulation of cell motility 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 4.7E-6 64.0E-6 4.2E+0 750.0E-9 2.1E-6 [3, 4, 5] Group12 4.71 
GO:0005205 Proteoglycans in cancer KEGG_01.03.2017 6.2E-6 83.0E-6 4.1E+0 6.2E-6 14.0E-6 [-1] Group03 7.88 
GO:0051270 
regulation of cellular 
component movement 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.8E-6 88.0E-6 4.1E+0 750.0E-9 2.1E-6 [3, 4] Group12 4.55 
GO:0008092 cytoskeletal protein binding 
GO_MolecularFunction-
GOA_23.02.2017_10h01 7.0E-6 89.0E-6 4.1E+0 1.7E-9 12.0E-9 [3] Group11 4.45 
GO:0043005 neuron projection 
GO_CellularComponent-
GOA_23.02.2017_10h01 10.0E-6 120.0E-6 3.9E+0 2.8E-9 9.8E-9 [3, 4] Group09 4.22 
GO:0010632 
regulation of epithelial cell 
migration 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 9.8E-6 120.0E-6 3.9E+0 750.0E-9 2.1E-6 
[3, 4, 5, 6, 
7, 8] Group12 8.02 
GO:0043005 neuron projection 
GO_CellularComponent-
GOA_23.02.2017_10h01 10.0E-6 120.0E-6 3.9E+0 57.0E-12 790.0E-12 [3, 4] Group13 4.22 
GO:0003779 actin binding 
GO_MolecularFunction-
GOA_23.02.2017_10h01 11.0E-6 130.0E-6 3.9E+0 1.7E-9 12.0E-9 [4] Group11 5.65 
GO:0031344 
regulation of cell projection 
organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 12.0E-6 140.0E-6 3.9E+0 57.0E-12 790.0E-12 [4, 5] Group13 5.02 
GO:0045596 
negative regulation of cell 
differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 13.0E-6 140.0E-6 3.9E+0 57.0E-12 790.0E-12 [3, 4, 5, 6] Group13 4.80 
GO:0002418 
immune response to tumor 
cell 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 14.0E-6 150.0E-6 3.8E+0 1.7E-9 12.0E-9 [3] Group11 4.97 
GO:0044463 cell projection part 
GO_CellularComponent-
GOA_23.02.2017_10h01 16.0E-6 160.0E-6 3.8E+0 2.8E-9 9.8E-9 [2, 3, 4] Group09 4.11 
GO:0030334 regulation of cell migration 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 15.0E-6 160.0E-6 3.8E+0 750.0E-9 2.1E-6 [4, 5, 6] Group12 4.65 
GO:0044463 cell projection part 
GO_CellularComponent-
GOA_23.02.2017_10h01 16.0E-6 160.0E-6 3.8E+0 57.0E-12 790.0E-12 [2, 3, 4] Group13 4.11 
GO:0051093 
negative regulation of 
developmental process 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 19.0E-6 180.0E-6 3.7E+0 57.0E-12 790.0E-12 [2, 3, 4] Group13 4.36 
GO:0005874 microtubule 
GO_CellularComponent-
GOA_23.02.2017_10h01 20.0E-6 200.0E-6 3.7E+0 1.7E-9 12.0E-9 
[5, 6, 7, 8, 
9, 10] Group11 5.60 
GO:0001052 
Role of Abl in Robo-Slit 
signaling REACTOME_Pathways_01.03.2017 21.0E-6 210.0E-6 3.7E+0 21.0E-6 38.0E-6 [-1] Group04 44.44 
GO:0070886 




GOA_23.02.2017_10h01 21.0E-6 210.0E-6 3.7E+0 35.0E-6 55.0E-6 
[6, 7, 8, 9, 
10, 11] Group07 44.44 
GO:0051961 




GOA_23.02.2017_10h01 27.0E-6 260.0E-6 3.6E+0 57.0E-12 790.0E-12 
[3, 4, 5, 6, 
7] Group13 6.43 
GO:0001525 angiogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 32.0E-6 290.0E-6 3.5E+0 750.0E-9 2.1E-6 
[3, 4, 5, 7, 





GOA_23.02.2017_10h01 38.0E-6 350.0E-6 3.5E+0 750.0E-9 2.1E-6 [4, 5, 6] Group12 5.85 
GO:0048646 
anatomical structure 
formation involved in 
morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 46.0E-6 400.0E-6 3.4E+0 750.0E-9 2.1E-6 [2, 3, 4] Group12 4.05 
GO:0051493 
regulation of cytoskeleton 
organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 50.0E-6 440.0E-6 3.4E+0 1.7E-9 12.0E-9 [5, 6] Group11 5.16 
GO:1903729 
regulation of plasma 
membrane organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 59.0E-6 490.0E-6 3.3E+0 59.0E-6 83.0E-6 [4, 5, 6] Group02 10.84 
GO:0030424 axon 
GO_CellularComponent-
GOA_23.02.2017_10h01 57.0E-6 490.0E-6 3.3E+0 2.8E-9 9.8E-9 [4, 5] Group09 5.24 
GO:0030424 axon 
GO_CellularComponent-
GOA_23.02.2017_10h01 57.0E-6 490.0E-6 3.3E+0 57.0E-12 790.0E-12 [4, 5] Group13 5.24 
GO:0007026 




GOA_23.02.2017_10h01 60.0E-6 500.0E-6 3.3E+0 60.0E-6 77.0E-6 
[5, 6, 7, 8, 
9, 10] Group00 23.81 
GO:0010721 
negative regulation of cell 
development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 68.0E-6 550.0E-6 3.3E+0 57.0E-12 790.0E-12 [4, 5, 6, 7] Group13 6.00 
GO:0060548 
negative regulation of cell 
death 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 78.0E-6 620.0E-6 3.2E+0 70.0E-6 82.0E-6 [3, 4, 5] Group08 4.07 
GO:0031589 cell-substrate adhesion 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 87.0E-6 660.0E-6 3.2E+0 35.0E-6 55.0E-6 [3] Group07 5.69 
GO:1901215 
negative regulation of 
neuron death 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 85.0E-6 670.0E-6 3.2E+0 750.0E-9 2.1E-6 
[3, 4, 6, 7, 
8, 9] Group12 4.82 
GO:0070997 neuron death 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 94.0E-6 700.0E-6 3.2E+0 70.0E-6 82.0E-6 [4] Group08 5.65 
GO:0001952 
regulation of cell-matrix 
adhesion 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 100.0E-6 740.0E-6 3.1E+0 2.8E-9 9.8E-9 [3, 4] Group09 4.35 
GO:0015631 tubulin binding 
GO_MolecularFunction-
GOA_23.02.2017_10h01 100.0E-6 760.0E-6 3.1E+0 1.7E-9 12.0E-9 [4] Group11 5.79 
GO:0006935 chemotaxis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-6 780.0E-6 3.1E+0 2.5E-9 12.0E-9 [3, 4] Group10 4.64 
GO:0006935 chemotaxis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-6 780.0E-6 3.1E+0 750.0E-9 2.1E-6 [3, 4] Group12 4.64 
GO:0006935 chemotaxis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-6 780.0E-6 3.1E+0 57.0E-12 790.0E-12 [3, 4] Group13 4.64 
GO:0050919 negative chemotaxis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 120.0E-6 830.0E-6 3.1E+0 120.0E-6 120.0E-6 [4, 5] Group05 20.83 
GO:0008017 microtubule binding 
GO_MolecularFunction-
GOA_23.02.2017_10h01 120.0E-6 850.0E-6 3.1E+0 1.7E-9 12.0E-9 [5] Group11 6.44 
GO:0007548 sex differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 130.0E-6 920.0E-6 3.0E+0 130.0E-6 130.0E-6 [3, 4] Group01 5.88 
 
 217 GO:0002040 sprouting angiogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 140.0E-6 940.0E-6 3.0E+0 750.0E-9 2.1E-6 
[4, 5, 6, 8, 





























GO:0007399 nervous system development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 78.0E-9 45.0E-6 4.3E+0 13.0E-9 880.0E-9 [4, 5] Group69 4.61 109.00 
GO:0009653 anatomical structure morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 200.0E-9 58.0E-6 4.2E+0 200.0E-9 4.4E-6 [2, 3] Group39 4.47 114.00 
GO:0098590 plasma membrane region 
GO_CellularComponent-
GOA_23.02.2017_10h01 900.0E-9 170.0E-6 3.8E+0 1.4E-6 18.0E-6 
[2, 3, 4, 
5, 6] Group52 5.50 57.00 
GO:0006928 movement of cell or subcellular component 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 1.6E-6 230.0E-6 3.6E+0 2.9E-6 32.0E-6 [3] Group62 4.56 93.00 
GO:0000053 
Neurotransmitter Receptor Binding And 
Downstream Transmission In The  
Postsynaptic Cell 
REACTOME_Pathways_0
1.03.2017 3.8E-6 440.0E-6 3.4E+0 6.1E-6 58.0E-6 [-1] Group63 7.62 26.00 
GO:0000054 Transmission across Chemical Synapses 
REACTOME_Pathways_0
1.03.2017 3.8E-6 440.0E-6 3.4E+0 6.1E-6 58.0E-6 [-1] Group63 7.62 26.00 
GO:0000055 Neuronal System 
REACTOME_Pathways_0
1.03.2017 3.8E-6 440.0E-6 3.4E+0 6.1E-6 58.0E-6 [-1] Group63 7.62 26.00 
GO:0001844 GABA A (rho) receptor activation 
REACTOME_Pathways_0
1.03.2017 3.8E-6 440.0E-6 3.4E+0 6.1E-6 58.0E-6 [-1] Group63 7.62 26.00 
GO:0001845 GABA receptor activation 
REACTOME_Pathways_0
1.03.2017 3.8E-6 440.0E-6 3.4E+0 6.1E-6 58.0E-6 [-1] Group63 7.62 26.00 
GO:0048699 generation of neurons 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 15.0E-6 1.1E-3 3.0E+0 13.0E-9 880.0E-9 [6, 7] Group69 4.71 69.00 
GO:0035239 tube morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 20.0E-6 1.2E-3 2.9E+0 260.0E-6 1.2E-3 [3, 4, 5] Group51 6.93 26.00 
GO:0042995 cell projection 
GO_CellularComponent-
GOA_23.02.2017_10h01 14.0E-6 1.2E-3 2.9E+0 32.0E-6 260.0E-6 [2, 3] Group58 4.41 88.00 
GO:0048468 cell development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 12.0E-6 1.2E-3 2.9E+0 13.0E-9 880.0E-9 [3, 4, 5] Group69 4.39 89.00 
GO:0030182 neuron differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 20.0E-6 1.2E-3 2.9E+0 13.0E-9 880.0E-9 [5, 7, 8] Group69 4.80 64.00 
GO:0022008 neurogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 26.0E-6 1.3E-3 2.9E+0 13.0E-9 880.0E-9 [5, 6] Group69 4.61 72.00 
GO:0035295 tube development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 55.0E-6 2.1E-3 2.7E+0 260.0E-6 1.2E-3 [3, 4] Group51 5.75 36.00 
GO:0048870 cell motility 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 53.0E-6 2.2E-3 2.7E+0 2.9E-6 32.0E-6 [2, 3, 4] Group62 4.52 70.00 
GO:1902495 transmembrane transporter complex 
GO_CellularComponent-
GOA_23.02.2017_10h01 51.0E-6 2.3E-3 2.6E+0 1.1E-3 3.5E-3 
[2, 3, 4, 
5] Group68 7.01 23.00 
GO:0098794 postsynapse 
GO_CellularComponent-
GOA_23.02.2017_10h01 50.0E-6 2.4E-3 2.6E+0 1.4E-6 18.0E-6 [2, 3] Group52 6.36 28.00 
GO:0002521 leukocyte differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 71.0E-6 2.5E-3 2.6E+0 1.2E-3 3.7E-3 
[5, 6, 7, 
8] Group56 6.07 30.00 
GO:0030224 monocyte differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 74.0E-6 2.5E-3 2.6E+0 650.0E-6 2.3E-3 
[7, 8, 9, 
10] Group67 18.42 7.00 
GO:0043005 neuron projection 
GO_CellularComponent-
GOA_23.02.2017_10h01 93.0E-6 3.0E-3 2.5E+0 32.0E-6 260.0E-6 [3, 4] Group58 4.89 51.00 
GO:0030030 cell projection organization 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 110.0E-6 3.2E-3 2.5E+0 13.0E-9 880.0E-9 [3] Group69 4.53 65.00 
GO:0005033 Nicotine addiction KEGG_01.03.2017 100.0E-6 3.2E-3 2.5E+0 150.0E-9 5.0E-6 [-1] Group70 17.50 7.00 
GO:0004727 GABAergic synapse KEGG_01.03.2017 160.0E-6 4.3E-3 2.4E+0 150.0E-9 5.0E-6 [-1] Group70 11.36 10.00 
GO:0048666 neuron development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 160.0E-6 4.4E-3 2.4E+0 13.0E-9 880.0E-9 
[4, 5, 6, 
8, 9] Group69 4.79 51.00 
GO:0044463 cell projection part 
GO_CellularComponent-
GOA_23.02.2017_10h01 190.0E-6 4.5E-3 2.3E+0 32.0E-6 260.0E-6 [2, 3, 4] Group58 4.75 52.00 
GO:0002573 myeloid leukocyte differentiation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 180.0E-6 4.5E-3 2.3E+0 650.0E-6 2.3E-3 
[6, 7, 8, 
9] Group67 7.88 16.00 
GO:0005032 Morphine addiction KEGG_01.03.2017 220.0E-6 4.5E-3 2.3E+0 150.0E-9 5.0E-6 [-1] Group70 10.99 10.00 
GO:0007267 cell-cell signaling 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 240.0E-6 4.6E-3 2.3E+0 240.0E-6 1.3E-3 [3] Group42 4.30 72.00 
GO:0044224 juxtaparanode region of axon 
GO_CellularComponent-
GOA_23.02.2017_10h01 240.0E-6 4.6E-3 2.3E+0 600.0E-6 2.3E-3 
[4, 5, 6, 
7, 8] Group57 33.33 4.00 
GO:0007163 
establishment or maintenance of cell 
polarity 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 210.0E-6 4.7E-3 2.3E+0 210.0E-6 1.3E-3 [3] Group19 8.11 15.00 
GO:1990778 protein localization to cell periphery 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 230.0E-6 4.7E-3 2.3E+0 25.0E-3 25.0E-3 [5] Group53 7.20 18.00 
GO:0090002 
establishment of protein localization to 
plasma membrane 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 260.0E-6 4.7E-3 2.3E+0 25.0E-3 25.0E-3 [5, 6, 7] Group53 8.78 13.00 
GO:0034702 ion channel complex 
GO_CellularComponent-
GOA_23.02.2017_10h01 180.0E-6 4.7E-3 2.3E+0 1.1E-3 3.5E-3 
[3, 4, 5, 
6] Group68 6.92 20.00 
GO:0007417 central nervous system development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 210.0E-6 4.7E-3 2.3E+0 13.0E-9 880.0E-9 [4, 5, 6] Group69 4.84 48.00 
GO:0060562 epithelial tube morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 280.0E-6 4.9E-3 2.3E+0 110.0E-6 820.0E-6 [4, 5, 6] Group66 6.51 22.00 
GO:0097458 neuron part 
GO_CellularComponent-
GOA_23.02.2017_10h01 290.0E-6 5.0E-3 2.3E+0 32.0E-6 260.0E-6 [2, 3] Group58 4.42 63.00 
GO:0045211 postsynaptic membrane 
GO_CellularComponent-
GOA_23.02.2017_10h01 400.0E-6 6.0E-3 2.2E+0 1.4E-6 18.0E-6 
[3, 4, 5, 
6, 7, 8] Group52 7.11 17.00 
GO:0004360 Axon guidance KEGG_01.03.2017 400.0E-6 6.1E-3 2.2E+0 400.0E-6 1.7E-3 [-1] Group13 8.00 14.00 
GO:0016477 cell migration 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 370.0E-6 6.2E-3 2.2E+0 2.9E-6 32.0E-6 [3, 4, 5] Group62 4.41 62.00 
GO:0072073 kidney epithelium development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 380.0E-6 6.2E-3 2.2E+0 110.0E-6 820.0E-6 
[4, 5, 6, 
7, 8] Group66 8.44 13.00 
GO:0007044 cell-substrate junction assembly 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 400.0E-6 6.3E-3 2.2E+0 140.0E-6 980.0E-6 [5] Group60 10.20 10.00 
GO:0003779 actin binding 
GO_MolecularFunction-
GOA_23.02.2017_10h01 460.0E-6 6.5E-3 2.2E+0 2.7E-3 6.6E-3 [4] Group59 5.88 25.00 
 
 218 GO:0031252 cell leading edge 
GO_CellularComponent-
GOA_23.02.2017_10h01 450.0E-6 6.6E-3 2.2E+0 140.0E-6 980.0E-6 [2, 3] Group60 6.12 24.00 
GO:0010464 
regulation of mesenchymal cell 
proliferation 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 500.0E-6 7.0E-3 2.2E+0 500.0E-6 2.0E-3 [4, 5] Group25 16.22 6.00 
GO:2000026 
regulation of multicellular organismal 
development 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 530.0E-6 7.2E-3 2.1E+0 13.0E-9 880.0E-9 [3, 4] Group69 4.13 75.00 
GO:0048729 tissue morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 590.0E-6 7.9E-3 2.1E+0 450.0E-9 7.4E-6 [3, 4] Group55 5.19 34.00 
GO:0097060 synaptic membrane 
GO_CellularComponent-
GOA_23.02.2017_10h01 690.0E-6 8.9E-3 2.1E+0 1.4E-6 18.0E-6 
[2, 3, 4, 
5, 6, 7] Group52 6.35 20.00 
GO:0001464 
Interactions of neurexins and neuroligins at 
synapses 
REACTOME_Pathways_0
1.03.2017 780.0E-6 9.6E-3 2.0E+0 150.0E-9 5.0E-6 [-1] Group70 11.27 8.00 
GO:0001465 Protein-protein interactions at synapses 
REACTOME_Pathways_0
1.03.2017 780.0E-6 9.6E-3 2.0E+0 150.0E-9 5.0E-6 [-1] Group70 11.27 8.00 
GO:0032989 cellular component morphogenesis 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 770.0E-6 9.7E-3 2.0E+0 13.0E-9 880.0E-9 [3, 4] Group69 4.55 49.00 
 
Table 3.4 | NPC-specific loops GO. 
(A) Gene ontology enrichment terms and details for genes in NPC-specific loops. 
(B) Gene ontology enrichment terms and details for genes in significant NPC 
loops that are lost in neurons. Negative log(FDR) from Benjamini-Hochberg 
correction. (C) Gene ontology enrichment terms and details for genes in 
significant NPC loops that are lost in glia. Negative log(FDR) from Benjamini-



































Table 6Table 3.5 | Glia- specific loops GO 
GOID GOTerm 
Neg 
log(P) Ontology Source Term PValue 
Term PValue Corrected with 













GOA_23.02.2017_10h01 1.4E-24 2.5E-21 20.6 8.36 213 2549 




GOA_23.02.2017_10h01 980.0E-21 1.7E-15 14.8 9.53 127 1333 




GOA_23.02.2017_10h01 1.5E-18 2.8E-15 14.6 8.29 168 2026 




GOA_23.02.2017_10h01 6.3E-18 11.0E-15 14.0 7.83 185 2363 









GOA_23.02.2017_10h01 1.3E-15 2.3E-12 11.6 8.51 133 1562 
GO:0007167 





GOA_23.02.2017_10h01 1.9E-15 3.5E-12 11.5 9.67 101 1044 




GOA_23.02.2017_10h01 2.5E-15 4.5E-12 11.3 6.28 296 4711 




GOA_23.02.2017_10h01 3.5E-15 6.1E-12 11.2 11.05 78 706 
GO:0030154 cell differentiation 11 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.0E-15 10.0E-12 11.0 6.50 261 4013 
GO:0007169 





GOA_23.02.2017_10h01 17.0E-15 30.0E-12 10.5 10.73 78 727 




GOA_23.02.2017_10h01 18.0E-15 33.0E-12 10.5 9.64 95 985 




GOA_23.02.2017_10h01 29.0E-15 51.0E-12 10.3 6.03 319 5288 




GOA_23.02.2017_10h01 35.0E-15 62.0E-12 10.2 6.36 267 4199 
GO:0048667 





GOA_23.02.2017_10h01 63.0E-15 110.0E-12 10.0 11.56 66 571 




GOA_23.02.2017_10h01 89.0E-15 150.0E-12 9.8 9.20 99 1076 
GO:0048646 





GOA_23.02.2017_10h01 170.0E-15 310.0E-12 9.5 9.26 96 1037 




GOA_23.02.2017_10h01 390.0E-15 690.0E-12 9.2 11.43 63 551 




GOA_23.02.2017_10h01 750.0E-15 1.3E-9 8.9 9.02 96 1064 




GOA_23.02.2017_10h01 840.0E-15 1.4E-9 8.9 7.45 152 2041 




GOA_23.02.2017_10h01 2.4E-12 4.3E-9 8.4 9.56 82 858 




GOA_23.02.2017_10h01 5.1E-12 8.9E-9 8.1 8.89 93 1046 
GO:0009888 tissue development 8 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.0E-12 10.0E-9 8.0 7.36 146 1983 
GO:0072358 cardiovascular system development 8 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 5.9E-12 10.0E-9 8.0 10.32 68 659 




GOA_23.02.2017_10h01 9.9E-12 17.0E-9 7.8 10.50 65 619 




GOA_23.02.2017_10h01 13.0E-12 23.0E-9 7.6 10.40 65 625 




GOA_23.02.2017_10h01 14.0E-12 26.0E-9 7.6 9.97 70 702 




GOA_23.02.2017_10h01 18.0E-12 32.0E-9 7.5 8.80 90 1023 




GOA_23.02.2017_10h01 19.0E-12 33.0E-9 7.5 10.41 64 615 




GOA_23.02.2017_10h01 19.0E-12 33.0E-9 7.5 10.41 64 615 




GOA_23.02.2017_10h01 23.0E-12 41.0E-9 7.4 6.35 220 3464 




GOA_23.02.2017_10h01 23.0E-12 41.0E-9 7.4 6.35 220 3464 




GOA_23.02.2017_10h01 27.0E-12 47.0E-9 7.3 6.60 193 2924 




GOA_23.02.2017_10h01 27.0E-12 47.0E-9 7.3 6.60 193 2924 




GOA_23.02.2017_10h01 27.0E-12 47.0E-9 7.3 6.60 193 2924 




GOA_23.02.2017_10h01 38.0E-12 66.0E-9 7.2 9.05 82 906 




GOA_23.02.2017_10h01 39.0E-12 68.0E-9 7.2 9.20 79 859 
GO:2000145 regulation of cell motility 7 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 58.0E-12 100.0E-9 7.0 9.43 74 785 




GOA_23.02.2017_10h01 100.0E-12 180.0E-9 6.7 9.82 66 672 




GOA_23.02.2017_10h01 190.0E-12 330.0E-9 6.5 5.65 319 5645 




GOA_23.02.2017_10h01 190.0E-12 330.0E-9 6.5 5.65 319 5645 




GOA_23.02.2017_10h01 190.0E-12 330.0E-9 6.5 5.65 319 5645 




GOA_23.02.2017_10h01 190.0E-12 330.0E-9 6.5 10.58 57 539 




GOA_23.02.2017_10h01 200.0E-12 360.0E-9 6.4 5.78 291 5037 




GOA_23.02.2017_10h01 200.0E-12 360.0E-9 6.4 5.78 291 5037 
 









GOA_23.02.2017_10h01 260.0E-12 450.0E-9 6.3 11.04 51 462 




GOA_23.02.2017_10h01 310.0E-12 540.0E-9 6.3 9.44 69 731 




GOA_23.02.2017_10h01 360.0E-12 630.0E-9 6.2 6.46 188 2909 




GOA_23.02.2017_10h01 360.0E-12 630.0E-9 6.2 6.46 188 2909 




GOA_23.02.2017_10h01 480.0E-12 830.0E-9 6.1 6.28 204 3247 




GOA_23.02.2017_10h01 480.0E-12 830.0E-9 6.1 6.28 204 3247 




GOA_23.02.2017_10h01 480.0E-12 830.0E-9 6.1 6.28 204 3247 




GOA_23.02.2017_10h01 550.0E-12 950.0E-9 6.0 7.94 100 1260 




GOA_23.02.2017_10h01 550.0E-12 950.0E-9 6.0 7.94 100 1260 




GOA_23.02.2017_10h01 570.0E-12 990.0E-9 6.0 14.05 34 242 




GOA_23.02.2017_10h01 820.0E-12 1.4E-6 5.9 6.24 206 3300 




GOA_23.02.2017_10h01 820.0E-12 1.4E-6 5.9 6.24 206 3300 




GOA_23.02.2017_10h01 820.0E-12 1.4E-6 5.9 6.24 206 3300 




GOA_23.02.2017_10h01 980.0E-12 1.7E-6 5.8 9.27 67 723 









GOA_23.02.2017_10h01 1.1E-9 2.0E-6 5.7 4.92 558 11349 




GOA_23.02.2017_10h01 1.2E-9 2.1E-6 5.7 9.71 60 618 




GOA_23.02.2017_10h01 1.3E-9 2.3E-6 5.6 6.41 183 2857 
GO:0010604 





GOA_23.02.2017_10h01 2.2E-9 3.9E-6 5.4 6.27 192 3061 




GOA_23.02.2017_10h01 2.6E-9 4.6E-6 5.3 7.35 114 1550 
GO:0051240 





GOA_23.02.2017_10h01 2.7E-9 4.7E-6 5.3 7.35 114 1552 
GO:0051240 





GOA_23.02.2017_10h01 2.7E-9 4.7E-6 5.3 7.35 114 1552 




GOA_23.02.2017_10h01 2.9E-9 5.0E-6 5.3 6.16 204 3311 




GOA_23.02.2017_10h01 3.0E-9 5.3E-6 5.3 6.60 158 2393 




GOA_23.02.2017_10h01 3.0E-9 5.3E-6 5.3 6.60 158 2393 









GOA_23.02.2017_10h01 3.2E-9 5.5E-6 5.3 10.62 48 452 




GOA_23.02.2017_10h01 3.4E-9 5.9E-6 5.2 9.95 55 553 




GOA_23.02.2017_10h01 3.8E-9 6.5E-6 5.2 7.23 117 1619 




GOA_23.02.2017_10h01 3.8E-9 6.5E-6 5.2 7.23 117 1619 
GO:0010557 





GOA_23.02.2017_10h01 4.2E-9 7.3E-6 5.1 7.08 124 1751 









GOA_23.02.2017_10h01 5.7E-9 9.8E-6 5.0 4.66 676 14515 
GO:0048729 tissue morphogenesis 5 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.2E-9 10.0E-6 5.0 9.31 61 655 
GO:0048729 tissue morphogenesis 5 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.2E-9 10.0E-6 5.0 9.31 61 655 




GOA_23.02.2017_10h01 6.9E-9 11.0E-6 5.0 8.17 81 991 




GOA_23.02.2017_10h01 6.9E-9 11.0E-6 5.0 8.17 81 991 




GOA_23.02.2017_10h01 7.4E-9 12.0E-6 4.9 8.60 71 826 




GOA_23.02.2017_10h01 7.4E-9 12.0E-6 4.9 8.60 71 826 




GOA_23.02.2017_10h01 10.0E-9 18.0E-6 4.7 6.91 128 1853 




GOA_23.02.2017_10h01 11.0E-9 20.0E-6 4.7 5.41 334 6170 




GOA_23.02.2017_10h01 11.0E-9 20.0E-6 4.7 5.41 334 6170 
GO:0022603 





GOA_23.02.2017_10h01 14.0E-9 23.0E-6 4.6 8.07 81 1004 




GOA_23.02.2017_10h01 13.0E-9 23.0E-6 4.6 7.53 97 1289 




GOA_23.02.2017_10h01 14.0E-9 24.0E-6 4.6 6.82 132 1935 
GO:0051173 





GOA_23.02.2017_10h01 14.0E-9 24.0E-6 4.6 6.83 132 1933 




GOA_23.02.2017_10h01 14.0E-9 24.0E-6 4.6 7.31 105 1436 




GOA_23.02.2017_10h01 14.0E-9 25.0E-6 4.6 8.00 83 1037 




GOA_23.02.2017_10h01 18.0E-9 31.0E-6 4.5 9.27 58 626 
 




GOA_23.02.2017_10h01 18.0E-9 31.0E-6 4.5 9.27 58 626 




GOA_23.02.2017_10h01 19.0E-9 32.0E-6 4.5 7.55 94 1245 




GOA_23.02.2017_10h01 18.0E-9 32.0E-6 4.5 5.84 231 3955 




GOA_23.02.2017_10h01 18.0E-9 32.0E-6 4.5 5.84 231 3955 




GOA_23.02.2017_10h01 18.0E-9 32.0E-6 4.5 5.84 231 3955 




GOA_23.02.2017_10h01 19.0E-9 33.0E-6 4.5 6.86 126 1836 




GOA_23.02.2017_10h01 20.0E-9 34.0E-6 4.5 12.75 32 251 




GOA_23.02.2017_10h01 21.0E-9 35.0E-6 4.5 8.23 75 911 




GOA_23.02.2017_10h01 21.0E-9 35.0E-6 4.5 8.23 75 911 




GOA_23.02.2017_10h01 21.0E-9 36.0E-6 4.4 12.23 34 278 




GOA_23.02.2017_10h01 30.0E-9 52.0E-6 4.3 7.40 98 1324 




GOA_23.02.2017_10h01 34.0E-9 57.0E-6 4.2 9.24 55 595 




GOA_23.02.2017_10h01 48.0E-9 82.0E-6 4.1 12.55 31 247 
GO:0031328 





GOA_23.02.2017_10h01 49.0E-9 83.0E-6 4.1 6.72 128 1905 




GOA_23.02.2017_10h01 50.0E-9 84.0E-6 4.1 6.06 188 3100 




GOA_23.02.2017_10h01 54.0E-9 93.0E-6 4.0 4.65 660 14198 




GOA_23.02.2017_10h01 55.0E-9 93.0E-6 4.0 6.36 155 2437 




GOA_23.02.2017_10h01 59.0E-9 99.0E-6 4.0 8.23 70 851 




GOA_23.02.2017_10h01 59.0E-9 99.0E-6 4.0 8.23 70 851 




GOA_23.02.2017_10h01 70.0E-9 110.0E-6 4.0 11.08 37 334 




GOA_23.02.2017_10h01 68.0E-9 110.0E-6 4.0 9.98 45 451 




GOA_23.02.2017_10h01 69.0E-9 110.0E-6 4.0 14.81 24 162 




GOA_23.02.2017_10h01 70.0E-9 110.0E-6 4.0 9.09 55 605 




GOA_23.02.2017_10h01 75.0E-9 120.0E-6 3.9 13.90 26 187 




GOA_23.02.2017_10h01 84.0E-9 140.0E-6 3.9 10.53 40 380 




GOA_23.02.2017_10h01 86.0E-9 140.0E-6 3.9 6.23 165 2649 




GOA_23.02.2017_10h01 84.0E-9 140.0E-6 3.9 10.53 40 380 
GO:0051962 





GOA_23.02.2017_10h01 87.0E-9 140.0E-6 3.9 9.60 48 500 




GOA_23.02.2017_10h01 100.0E-9 180.0E-6 3.7 12.96 28 216 
GO:0090287 





GOA_23.02.2017_10h01 110.0E-9 180.0E-6 3.7 12.11 31 256 




GOA_23.02.2017_10h01 110.0E-9 190.0E-6 3.7 8.05 72 894 




GOA_23.02.2017_10h01 110.0E-9 190.0E-6 3.7 8.05 72 894 




GOA_23.02.2017_10h01 110.0E-9 190.0E-6 3.7 8.05 72 894 




GOA_23.02.2017_10h01 130.0E-9 210.0E-6 3.7 18.18 18 99 




GOA_23.02.2017_10h01 130.0E-9 220.0E-6 3.7 6.13 172 2805 




GOA_23.02.2017_10h01 130.0E-9 220.0E-6 3.7 6.13 172 2805 




GOA_23.02.2017_10h01 130.0E-9 220.0E-6 3.7 6.13 172 2805 




GOA_23.02.2017_10h01 130.0E-9 220.0E-6 3.7 6.13 172 2805 




GOA_23.02.2017_10h01 180.0E-9 300.0E-6 3.5 5.24 348 6639 




GOA_23.02.2017_10h01 190.0E-9 320.0E-6 3.5 5.31 326 6143 




GOA_23.02.2017_10h01 200.0E-9 330.0E-6 3.5 22.58 14 62 




GOA_23.02.2017_10h01 200.0E-9 340.0E-6 3.5 8.34 63 755 




GOA_23.02.2017_10h01 200.0E-9 340.0E-6 3.5 8.34 63 755 




GOA_23.02.2017_10h01 200.0E-9 340.0E-6 3.5 16.13 20 124 
GO:0038084 





GOA_23.02.2017_10h01 210.0E-9 360.0E-6 3.4 33.33 10 30 




GOA_23.02.2017_10h01 230.0E-9 390.0E-6 3.4 8.23 65 790 




GOA_23.02.2017_10h01 230.0E-9 390.0E-6 3.4 8.23 65 790 




GOA_23.02.2017_10h01 250.0E-9 420.0E-6 3.4 10.87 35 322 




GOA_23.02.2017_10h01 280.0E-9 460.0E-6 3.3 10.65 36 338 




GOA_23.02.2017_10h01 290.0E-9 490.0E-6 3.3 12.08 29 240 
 




GOA_23.02.2017_10h01 300.0E-9 500.0E-6 3.3 5.47 275 5031 




GOA_23.02.2017_10h01 300.0E-9 500.0E-6 3.3 5.47 275 5031 




GOA_23.02.2017_10h01 300.0E-9 500.0E-6 3.3 5.47 275 5031 




GOA_23.02.2017_10h01 350.0E-9 590.0E-6 3.2 10.18 39 383 




GOA_23.02.2017_10h01 360.0E-9 600.0E-6 3.2 6.24 150 2403 
GO:2000026 





GOA_23.02.2017_10h01 370.0E-9 610.0E-6 3.2 6.62 120 1814 
GO:2000026 





GOA_23.02.2017_10h01 370.0E-9 610.0E-6 3.2 6.62 120 1814 
GO:2000026 





GOA_23.02.2017_10h01 370.0E-9 610.0E-6 3.2 6.62 120 1814 
GO:0045944 
positive regulation of transcription from RNA 




GOA_23.02.2017_10h01 370.0E-9 620.0E-6 3.2 7.36 84 1141 




GOA_23.02.2017_10h01 390.0E-9 660.0E-6 3.2 8.31 61 734 




GOA_23.02.2017_10h01 390.0E-9 660.0E-6 3.2 8.31 61 734 




GOA_23.02.2017_10h01 420.0E-9 700.0E-6 3.2 12.44 27 217 
GO:0000981 
RNA polymerase II transcription factor activity, 




GOA_23.02.2017_10h01 420.0E-9 700.0E-6 3.2 8.28 61 737 




GOA_23.02.2017_10h01 450.0E-9 750.0E-6 3.1 9.90 40 404 




GOA_23.02.2017_10h01 450.0E-9 750.0E-6 3.1 5.54 252 4552 




GOA_23.02.2017_10h01 450.0E-9 750.0E-6 3.1 5.54 252 4552 




GOA_23.02.2017_10h01 460.0E-9 760.0E-6 3.1 9.18 47 512 




GOA_23.02.2017_10h01 460.0E-9 760.0E-6 3.1 12.39 27 218 




GOA_23.02.2017_10h01 460.0E-9 760.0E-6 3.1 11.84 29 245 




GOA_23.02.2017_10h01 490.0E-9 820.0E-6 3.1 6.01 172 2860 




GOA_23.02.2017_10h01 560.0E-9 930.0E-6 3.0 10.13 38 375 




GOA_23.02.2017_10h01 560.0E-9 940.0E-6 3.0 10.86 33 304 
 
Table 3.5 | Glia-specific loops GO. 
Gene ontology enrichment terms and details for genes in glia-specific loops (See 
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Table 7Table 3.6 | GM12878 lymphoblastoid-specific loops GO 
GOID GOTerm Neg log(P) Ontology Source 
Term 
PValue 
Term PValue Corrected with 
Bonferroni step down 
% Associated 
Genes Nr. Genes 
Total genes in 
term 
GO:0044444 cytoplasmic part 11.7 
GO_CellularComponent-
GOA_23.02.2017_10h01 1.1E-15 2.1E-12 17.24 1624 9421 
GO:0005829 cytosol 8.6 
GO_CellularComponent-
GOA_23.02.2017_10h01 1.3E-12 2.5E-9 18.27 910 4982 
GO:0043547 positive regulation of GTPase activity 5.4 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 2.0E-9 3.8E-6 23.62 163 690 
GO:0006464 cellular protein modification process 5.2 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 25.0E-9 48.0E-6 16.39 1762 10749 
GO:0015031 protein transport 4.3 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 26.0E-9 50.0E-6 19.33 405 2095 
GO:0018193 peptidyl-amino acid modification 4.2 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 35.0E-9 66.0E-6 20.66 264 1278 
GO:0015833 peptide transport 4.1 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 40.0E-9 75.0E-6 19.25 410 2130 
GO:0044446 intracellular organelle part 4.0 
GO_CellularComponent-
GOA_23.02.2017_10h01 51.0E-9 95.0E-6 16.64 1481 8901 
GO:0032555 purine ribonucleotide binding 3.4 
GO_MolecularFunction-
GOA_23.02.2017_10h01 220.0E-9 410.0E-6 19.19 379 1975 
GO:0051223 regulation of protein transport 3.3 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 250.0E-9 460.0E-6 21.73 178 819 
GO:0005654 nucleoplasm 3.2 
GO_CellularComponent-
GOA_23.02.2017_10h01 310.0E-9 580.0E-6 17.99 619 3441 
GO:0032559 adenyl ribonucleotide binding 3.2 
GO_MolecularFunction-
GOA_23.02.2017_10h01 360.0E-9 670.0E-6 19.58 316 1614 
GO:0030554 adenyl nucleotide binding 3.1 
GO_MolecularFunction-
GOA_23.02.2017_10h01 390.0E-9 730.0E-6 19.56 318 1626 
GO:0090087 regulation of peptide transport 3.0 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 510.0E-9 970.0E-6 21.44 182 849 
GO:0006468 protein phosphorylation 3.0 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 540.0E-9 1.0E-3 19.04 376 1975 
GO:1902531 
regulation of intracellular signal 
transduction 3.0 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 620.0E-9 1.1E-3 19.16 355 1853 
GO:0044428 nuclear part 2.7 
GO_CellularComponent-
GOA_23.02.2017_10h01 970.0E-9 1.8E-3 17.46 770 4411 
GO:0030097 hemopoiesis 2.6 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 1.4E-6 2.7E-3 21.52 164 762 
GO:0048534 
hematopoietic or lymphoid organ 
development 2.4 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 2.1E-6 3.9E-3 21.24 171 805 
GO:0009968 
negative regulation of signal 
transduction 2.4 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 2.3E-6 4.3E-3 20.02 239 1194 
GO:0005524 ATP binding 2.3 
GO_MolecularFunction-
GOA_23.02.2017_10h01 2.5E-6 4.7E-3 19.29 304 1576 
GO:0050708 regulation of protein secretion 2.3 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 2.5E-6 4.7E-3 23.62 103 436 
GO:0002791 regulation of peptide secretion 2.0 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 5.1E-6 9.6E-3 23.06 107 464 
GO:0051247 
positive regulation of protein metabolic 
process 2.0 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 5.3E-6 9.9E-3 19.07 312 1636 
GO:0004015 Rap1 signaling pathway 2.0 KEGG_01.03.2017 6.2E-6 11.0E-3 27.14 57 210 
GO:0031981 nuclear lumen 2.0 
GO_CellularComponent-
GOA_23.02.2017_10h01 6.4E-6 11.0E-3 17.40 704 4045 
GO:0019932 second-messenger-mediated signaling 1.9 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 6.9E-6 12.0E-3 25.77 67 260 
GO:0007169 
transmembrane receptor protein 
tyrosine kinase signaling pathway 1.8 
GO_BiologicalProcess-





GOA_23.02.2017_10h01 8.7E-6 16.0E-3 66.67 10 15 
GO:0032270 
positive regulation of cellular protein 
metabolic process 1.7 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 11.0E-6 20.0E-3 19.08 292 1530 
GO:0031399 
regulation of protein modification 
process 1.7 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 11.0E-6 21.0E-3 18.75 333 1776 
GO:0009306 protein secretion 1.7 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 11.0E-6 21.0E-3 22.06 120 544 
GO:0048666 neuron development 1.5 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 18.0E-6 34.0E-3 19.83 211 1064 
GO:0002790 peptide secretion 1.5 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 19.0E-6 35.0E-3 21.70 125 576 
GO:0007167 
enzyme linked receptor protein signaling 
pathway 1.4 
GO_BiologicalProcess-
GOA_23.02.2017_10h01 23.0E-6 43.0E-3 19.83 207 1044 
 
Table 3.6 | GM12878 lymphoblastoid-specific loops GO. 
Gene ontology enrichment terms and details for genes in GM12878-specific 
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Table 8Table 3.7 | TAD s expanded  in neurons compared  to glia 
chr(Neu TAD) x1(Neu TAD) x2(Neu TAD) No. Overlap Glia TADs chr (Glia Gene) y1 (Glia Gene ) y2 (Glia Gene) Gene ID (ENSG) 
Gene 
Symbol Strand Gene length (bp) 
chr2 139600000 143750000 11 chr2 139654893 139656744 ENSG00000229104 YY1P2 + 1851 
chr2 139600000 143750000 11 chr2 141750111 141750228 ENSG00000201892 Y_RNA + 117 
chr2 139600000 143750000 11 chr2 141924825 141924926 ENSG00000252015 U6 - 101 
chr2 139600000 143750000 11 chr2 143635194 143799885 ENSG00000115919 KYNU + 114806 
chr2 139600000 143750000 11 chr2 140988995 142889270 ENSG00000168702 LRP1B - 1900275 
chr2 140425000 143750000 11 chr2 141750111 141750228 ENSG00000201892 Y_RNA + 117 
chr2 140425000 143750000 11 chr2 141924825 141924926 ENSG00000252015 U6 - 101 
chr2 140425000 143750000 11 chr2 143635194 143799885 ENSG00000115919 KYNU + 114806 
chr2 140425000 143750000 11 chr2 140988995 142889270 ENSG00000168702 LRP1B - 1900275 
chr2 139600000 142950000 10 chr2 139654893 139656744 ENSG00000229104 YY1P2 + 1851 
chr2 139600000 142950000 10 chr2 141750111 141750228 ENSG00000201892 Y_RNA + 117 
chr2 139600000 142950000 10 chr2 141924825 141924926 ENSG00000252015 U6 - 101 
chr2 139600000 142950000 10 chr2 140988995 142889270 ENSG00000168702 LRP1B - 1900275 
chr18 25175000 28550000 9 chr18 25373549 25373648 n/a Mir_384 n/a 99 
chr18 25175000 28550000 9 chr18 25613650 25613747 n/a Mir_340 n/a 97 
chr18 25175000 28550000 9 chr18 27878875 27878926 n/a MIR302F n/a 51 
chr18 25175000 28550000 9 chr18 25530929 25757445 ENSG00000170558 CDH2 - 226516 
chr18 25175000 28550000 9 chr18 24916342 25175128 ENSG00000264151 AK127888 - 128 
chr9 80925000 85725000 9 chr9 82478897 82478939 n/a DQ575560 n/a 42 
chr9 80925000 85725000 9 chr9 82479022 82479053 n/a DQ583878 n/a 31 
chr9 80925000 85725000 9 chr9 82479147 82479179 n/a DQ589820 n/a 32 
chr9 80925000 85725000 9 chr9 82479196 82479300 n/a DQ580124 n/a 104 
chr9 80925000 85725000 9 chr9 82479444 82479479 n/a DQ595182 n/a 35 
chr9 80925000 85725000 9 chr9 82479496 82479529 n/a DQ596925 n/a 33 
chr9 80925000 85725000 9 chr9 82479564 82479595 n/a DQ597713 n/a 31 
chr9 80925000 85725000 9 chr9 82479638 82479675 n/a DQ586158 n/a 37 
chr9 80925000 85725000 9 chr9 82479836 82479872 n/a DQ588659 n/a 36 
chr9 80925000 85725000 9 chr9 82479911 82479966 n/a DQ599976 n/a 55 
chr9 80925000 85725000 9 chr9 82480085 82480149 n/a DQ574305 n/a 64 
chr9 80925000 85725000 9 chr9 82480265 82480311 n/a DQ600106 n/a 46 
chr9 80925000 85725000 9 chr9 82480444 82480513 n/a DQ574306 n/a 69 
chr9 80925000 85725000 9 chr9 82480639 82480689 n/a DQ599155 n/a 50 
chr9 80925000 85725000 9 chr9 82480842 82480885 n/a DQ574330 n/a 43 
chr9 80925000 85725000 9 chr9 82481004 82481059 n/a DQ579956 n/a 55 
chr9 80925000 85725000 9 chr9 82481263 82481303 n/a DQ594965 n/a 40 
chr9 80925000 85725000 9 chr9 82481394 82481432 n/a DQ596802 n/a 38 
chr9 80925000 85725000 9 chr9 82481509 82481544 n/a DQ574826 n/a 35 
chr9 80925000 85725000 9 chr9 82481703 82481771 n/a DQ592136 n/a 68 
chr9 80925000 85725000 9 chr9 82482216 82482251 n/a DQ577348 n/a 35 
chr9 80925000 85725000 9 chr9 82482361 82482391 n/a DQ593172 n/a 30 
chr9 80925000 85725000 9 chr9 82482630 82482673 n/a DQ592375 n/a 43 
chr9 80925000 85725000 9 chr9 82483105 82483135 n/a DQ570523 n/a 30 
chr9 80925000 85725000 9 chr9 82483941 82483980 n/a DQ573195 n/a 39 
chr9 80925000 85725000 9 chr9 82973117 82973151 n/a DQ591664 n/a 34 
chr9 80925000 85725000 9 chr9 84528351 84534842 ENSG00000240632 
SPATA31D5
P + 6491 
chr9 80925000 85725000 9 chr9 84531745 84531773 n/a DQ592725 n/a 28 
chr9 80925000 85725000 9 chr9 84532087 84532118 n/a DQ577940 n/a 31 
chr9 80925000 85725000 9 chr9 84533136 84533203 n/a DQ578305 n/a 67 
chr9 80925000 85725000 9 chr9 84534683 84534718 n/a DQ582032 n/a 35 
chr9 80925000 85725000 9 chr9 84535666 84535704 n/a DQ584769 n/a 38 
chr9 80925000 85725000 9 chr9 84543342 84549913 ENSG00000189357 SPATA31D4 + 6571 
chr9 80925000 85725000 9 chr9 84547133 84547164 n/a DQ577940 n/a 31 
chr9 80925000 85725000 9 chr9 84548208 84548275 n/a DQ578305 n/a 67 
chr9 80925000 85725000 9 chr9 84549755 84549790 n/a DQ582032 n/a 35 
chr9 80925000 85725000 9 chr9 84550738 84550776 n/a DQ584769 n/a 38 
chr9 80925000 85725000 9 chr9 84558414 84565009 ENSG00000186788 SPATA31D3 + 6595 
chr9 80925000 85725000 9 chr9 84562225 84562256 n/a DQ577940 n/a 31 
chr9 80925000 85725000 9 chr9 84563300 84563367 n/a DQ578305 n/a 67 
chr9 80925000 85725000 9 chr9 84891466 84891571 n/a Mir_544 n/a 105 
chr9 80925000 85725000 9 chr9 85045810 85045838 n/a DQ588544 n/a 28 
chr9 80925000 85725000 9 chr9 85202301 85202353 n/a Mir_1302 n/a 52 
chr9 80925000 85725000 9 chr9 80912058 80945009 ENSG00000135069 PSAT1 + 20009 
chr9 80925000 85725000 9 chr9 84304627 84391814 ENSG00000233926 BC036431 + 87187 
chr9 80925000 85725000 9 chr9 84545140 84592004 ENSG00000267559 AK097447 - 46864 
chr9 80925000 85725000 9 chr9 84603686 84610171 ENSG00000214929 SPATA31D1 + 6485 
chr9 80925000 85725000 9 chr9 85594499 85678043 ENSG00000165105 RASEF - 83544 
chr9 80925000 85725000 9 chr9 82186877 82341656 ENSG00000106829 TLE4 + 154779 
chr9 80925000 85725000 9 chr9 84198597 84303596 ENSG00000196781 TLE1 - 104999 
chr10 60100000 62425000 8 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2519 
chr10 60100000 62425000 8 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60100000 62425000 8 chr10 61821742 61822047 n/a 
Metazoa_SR
P n/a 305 
chr10 60100000 62425000 8 chr10 61841498 61841612 ENSG00000202190 Y_RNA + 114 
chr10 60100000 62425000 8 chr10 60094738 60130513 ENSG00000072401 UBE2D1 + 30513 
chr10 60100000 62425000 8 chr10 60144902 60158990 ENSG00000108064 TFAM + 14088 
chr10 60100000 62425000 8 chr10 61410521 61469649 ENSG00000165449 SLC16A9 - 59128 
chr10 60100000 62425000 8 chr10 61496747 61513203 ENSG00000227877 LINC00948 - 16456 
chr10 60100000 62425000 8 chr10 61715187 61720671 ENSG00000235931 C10orf40 - 5484 
chr10 60100000 62425000 8 chr10 60272903 60588845 ENSG00000122870 BICC1 + 315942 
chr10 60100000 62425000 8 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60100000 62425000 8 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr10 60100000 62425000 8 chr10 61548505 61666414 ENSG00000108091 CCDC6 - 117909 
chr10 60100000 62425000 8 chr10 61786055 62149634 ENSG00000151150 ANK3 - 363579 
chr3 58525000 62275000 8 chr3 59956575 59958982 n/a NPCR n/a 2407 
chr3 58525000 62275000 8 chr3 60842060 60842277 ENSG00000212211 U3 - 217 
chr3 58525000 62275000 8 chr3 61068514 61068637 n/a 5S_rRNA n/a 123 
 
 225 
chr3 58525000 62275000 8 chr3 58549844 58563491 ENSG00000168309 FAM107A - 13647 
chr3 58525000 62275000 8 chr3 58619669 58652561 ENSG00000198643 FAM3D - 32892 
chr3 58525000 62275000 8 chr3 58727736 59035715 ENSG00000163689 C3orf67 - 307979 
chr3 58525000 62275000 8 chr3 58810196 59004819 ENSG00000242428 AK090895 + 194623 
chr3 58525000 62275000 8 chr3 62247493 62304622 ENSG00000241472 PTPRG-AS1 - 27507 
chr3 58525000 62275000 8 chr3 59735035 61237133 ENSG00000189283 FHIT - 1502098 
chr3 58525000 62275000 8 chr3 61547242 62280573 ENSG00000144724 PTPRG + 727758 
chr4 175250000 177250000 8 chr4 175344945 175345015 ENSG00000265846 MIR4276 + 70 
chr4 175250000 177250000 8 chr4 175474212 175474248 n/a HH834010 n/a 36 
chr4 175250000 177250000 8 chr4 175848510 175848545 n/a HH834010 n/a 35 
chr4 175250000 177250000 8 chr4 177019313 177019436 ENSG00000201516 SNORA51 + 123 
chr4 175250000 177250000 8 chr4 175411327 175444049 ENSG00000164120 HPGD - 32722 
chr4 175250000 177250000 8 chr4 176711457 176733340 ENSG00000249106 BC038536 + 21883 
chr4 175250000 177250000 8 chr4 177105724 177116822 ENSG00000150628 SPATA4 - 11098 
chr4 175250000 177250000 8 chr4 177134825 177190373 ENSG00000164122 ASB5 - 55548 
chr4 175250000 177250000 8 chr4 177241089 177253396 ENSG00000129128 SPCS3 + 8911 
chr4 175250000 177250000 8 chr4 175205054 175254531 ENSG00000164118 CEP44 + 4531 
chr4 175250000 177250000 8 chr4 175563197 175750465 ENSG00000145451 GLRA3 - 187268 
chr4 175250000 177250000 8 chr4 175750818 175791938 ENSG00000168594 AK093264 + 41120 
chr4 175250000 177250000 8 chr4 175839508 175899331 ENSG00000168594 ADAM29 + 59823 
chr4 175250000 177250000 8 chr4 176554087 176923842 ENSG00000150625 GPM6A - 369755 
chr4 175250000 177250000 8 chr4 176986984 177103979 ENSG00000150627 WDR17 + 116995 
chr5 162950000 167650000 8 chr5 165036445 165036684 ENSG00000252794 7SK + 239 
chr5 162950000 167650000 8 chr5 167460095 167460210 ENSG00000253065 SNORA40 - 115 
chr5 162950000 167650000 8 chr5 163781145 164029423 ENSG00000241956 BC011998 + 248278 
chr5 162950000 167650000 8 chr5 166711842 167691162 ENSG00000145934 TENM2 + 938158 
chr1 215800000 218375000 7 chr1 216825011 216825068 n/a Mir_598 n/a 57 
chr1 215800000 218375000 7 chr1 218066241 218094146 ENSG00000231814 LINC00210 + 27905 
chr1 215800000 218375000 7 chr1 216676587 216896814 ENSG00000196482 ESRRG - 220227 
chr1 215800000 218375000 7 chr1 217603833 217804409 ENSG00000092978 GPATCH2 - 200576 
chr1 215800000 218375000 7 chr1 217804694 218040484 ENSG00000162814 SPATA17 + 235790 
chr1 215800000 218375000 7 chr1 215796235 216596738 ENSG00000042781 USH2A - 796738 
chr1 71550000 75175000 7 chr1 72259914 72302695 ENSG00000228853 NEGR1-IT1 - 42781 
chr1 71550000 75175000 7 chr1 75043113 75091782 ENSG00000234497 CR627203 + 48669 
chr1 71550000 75175000 7 chr1 75171171 75199092 ENSG00000116791 CRYZ - 3829 
chr1 71550000 75175000 7 chr1 71547006 71703406 ENSG00000229956 
ZRANB2-
AS2 + 153406 
chr1 71550000 75175000 7 chr1 73771852 73804560 ENSG00000233973 BC041341 + 32708 
chr1 71550000 75175000 7 chr1 74491701 74663871 ENSG00000162620 LRRIQ3 - 172170 
chr1 71550000 75175000 7 chr1 74663895 75010116 ENSG00000116783 
FPGT-
TNNI3K + 346221 
chr1 71550000 75175000 7 chr1 75033794 75139422 ENSG00000178965 C1orf173 - 105628 
chr1 71550000 75175000 7 chr1 71868624 72748405 ENSG00000172260 NEGR1 - 879781 
chr10 65600000 69550000 7 chr10 66585284 66586634 ENSG00000216740 ANXA2P3 + 1350 
chr10 65600000 69550000 7 chr10 66585343 66585369 n/a DJ439558 n/a 26 
chr10 65600000 69550000 7 chr10 66586101 66586126 n/a DJ439576 n/a 25 
chr10 65600000 69550000 7 chr10 66586203 66586227 n/a DJ439561 n/a 24 
chr10 65600000 69550000 7 chr10 68254456 68254557 ENSG00000252203 SnoU40 + 101 
chr10 65600000 69550000 7 chr10 69524260 69524407 n/a HI650153 n/a 147 
chr10 65600000 69550000 7 chr10 68685791 68860867 ENSG00000198739 LRRTM3 + 175076 
chr10 65600000 69550000 7 chr10 67679724 69455949 ENSG00000183230 CTNNA3 - 1776225 
chr12 96925000 98800000 7 chr12 97490690 97490764 n/a 
TRNA_Pseu
do n/a 74 
chr12 96925000 98800000 7 chr12 97506929 97507042 n/a Mir_584 n/a 113 
chr12 96925000 98800000 7 chr12 97866326 97868402 n/a AK129935 n/a 2076 
chr12 96925000 98800000 7 chr12 97885686 97885756 ENSG00000221479 MIR1251 + 70 
chr12 96925000 98800000 7 chr12 97945914 97946006 ENSG00000251844 
SnoMe28S_
Am2634 - 92 
chr12 96925000 98800000 7 chr12 97957589 97957689 ENSG00000207586 MIR135A2 + 100 
chr12 96925000 98800000 7 chr12 98389160 98389226 ENSG00000263890 MIR4303 - 66 
chr12 96925000 98800000 7 chr12 98752079 98752163 n/a Mir_548 n/a 84 
chr12 96925000 98800000 7 chr12 96883352 96934765 ENSG00000188596 C12orf55 + 9765 
chr12 96925000 98800000 7 chr12 97301000 97347469 ENSG00000139350 NEDD1 + 46469 
chr12 96925000 98800000 7 chr12 98123825 98150295 ENSG00000257501 LOC643711 - 26470 
chr12 96925000 98800000 7 chr12 96933914 97024429 ENSG00000188596 AX747187 + 90515 
chr12 96925000 98800000 7 chr12 97041752 97159032 ENSG00000188596 C12orf63 + 117280 
chr12 96925000 98800000 7 chr12 97858798 97927544 ENSG00000255794 RMST + 68746 
chr16 63375000 66400000 7 chr16 65420321 65420381 n/a JB153694 n/a 60 
chr16 63375000 66400000 7 chr16 66335711 66335843 ENSG00000201999 5S_rRNA + 132 
chr16 63375000 66400000 7 chr16 65318401 65610203 ENSG00000261742 LINC00922 - 291802 
chr16 63375000 66400000 7 chr16 64980682 65155919 ENSG00000140937 CDH11 - 175237 
chr2 140500000 142900000 7 chr2 141750111 141750228 ENSG00000201892 Y_RNA + 117 
chr2 140500000 142900000 7 chr2 141924825 141924926 ENSG00000252015 U6 - 101 
chr2 140500000 142900000 7 chr2 140988995 142889270 ENSG00000168702 LRP1B - 1900275 
chr2 33875000 37175000 7 chr2 33951127 33953284 ENSG00000239649 MYADML - 2157 
chr2 33875000 37175000 7 chr2 34628738 34628822 ENSG00000212025 Mir_548 - 84 
chr2 33875000 37175000 7 chr2 36581891 36582713 n/a 
LOC1002889
11 n/a 822 
chr2 33875000 37175000 7 chr2 36779403 36825332 ENSG00000171055 FEZ2 - 45929 
chr2 33875000 37175000 7 chr2 36923832 37041937 ENSG00000205221 VIT + 118105 
chr2 33875000 37175000 7 chr2 37064840 37193615 ENSG00000115808 STRN - 110160 
chr2 33875000 37175000 7 chr2 36583369 36778278 ENSG00000150938 CRIM1 + 194909 
chr2 62125000 64150000 7 chr2 62432960 62433052 ENSG00000266097 MIR5192 + 92 
chr2 62125000 64150000 7 chr2 62489521 62489806 ENSG00000239958 
Metazoa_SR
P - 285 
chr2 62125000 64150000 7 chr2 62727355 62733604 ENSG00000186889 TMEM17 - 6249 
chr2 62125000 64150000 7 chr2 62953770 62953875 ENSG00000252436 Y_RNA - 105 
chr2 62125000 64150000 7 chr2 63271099 63274846 ENSG00000231609 
LOC1001322
15 - 3747 
chr2 62125000 64150000 7 chr2 63277936 63284966 ENSG00000115507 OTX1 + 7030 
chr2 62125000 64150000 7 chr2 63344985 63346677 ENSG00000242412 DBIL5P2 - 1692 
chr2 62125000 64150000 7 chr2 62296587 62374016 ENSG00000229839 BC071802 - 77429 
chr2 62125000 64150000 7 chr2 62423261 62451866 ENSG00000170340 B3GNT2 + 28605 
chr2 62125000 64150000 7 chr2 62839006 62889763 ENSG00000226622 BC038779 - 50757 
chr2 62125000 64150000 7 chr2 62132802 62363205 ENSG00000173163 COMMD1 + 230403 
chr2 62125000 64150000 7 chr2 62933000 63273621 ENSG00000115504 EHBP1 + 340621 
chr2 62125000 64150000 7 chr2 63348534 63815867 ENSG00000143951 WDPCP - 467333 
chr2 62125000 64150000 7 chr2 63816284 63834330 ENSG00000014641 MDH1 + 18046 
 
 226 
chr2 62125000 64150000 7 chr2 64069013 64118696 ENSG00000169764 UGP2 + 49683 
chr2 62125000 64150000 7 chr2 64119666 64246214 ENSG00000143952 VPS54 - 30334 
chr4 181975000 184250000 7 chr4 182756017 182756261 ENSG00000251742 7SK - 244 
chr4 181975000 184250000 7 chr4 183060158 183065668 ENSG00000177822 MGC45800 - 5510 
chr4 181975000 184250000 7 chr4 183090445 183090531 ENSG00000221227 MIR1305 + 86 
chr4 181975000 184250000 7 chr4 183469811 183469932 ENSG00000252343 U2 + 121 
chr4 181975000 184250000 7 chr4 184018173 184020352 ENSG00000251359 WWC2-AS2 - 2179 
chr4 181975000 184250000 7 chr4 184090500 184090570 ENSG00000252702 U7 - 70 
chr4 181975000 184250000 7 chr4 184239219 184241927 ENSG00000177300 CLDN22 - 2708 
chr4 181975000 184250000 7 chr4 184242916 184243579 ENSG00000185758 CLDN24 - 663 
chr4 181975000 184250000 7 chr4 183811243 183838630 ENSG00000129187 DCTD - 27387 
chr4 181975000 184250000 7 chr4 183958817 183961272 ENSG00000230219 FAM92A1P2 + 2455 
chr4 181975000 184250000 7 chr4 181985242 182080302 ENSG00000248197 LINC00290 - 95060 
chr4 181975000 184250000 7 chr4 182896308 183006289 ENSG00000177822 AK056196 - 109981 
chr4 181975000 184250000 7 chr4 184020462 184241929 ENSG00000151718 WWC2 + 221467 
chr4 181975000 184250000 7 chr4 184154780 184161787 ENSG00000251128 BX537950 - 7007 
chr4 181975000 184250000 7 chr4 183245098 183724177 ENSG00000218336 TENM3 + 479079 
chr9 6775000 9925000 7 chr9 6834701 6835011 ENSG00000230581 DQ580140 + 310 
chr9 6775000 9925000 7 chr9 7167235 7167357 n/a Mir_584 n/a 122 
chr9 6775000 9925000 7 chr9 8858133 8861724 ENSG00000225706 AK094342 + 3591 
chr9 6775000 9925000 7 chr9 8888135 8888207 ENSG00000251699 SNORD27 + 72 
chr9 6775000 9925000 7 chr9 9442059 9442347 ENSG00000265735 
Metazoa_SR
P + 288 
chr9 6775000 9925000 7 chr9 7796490 7799799 ENSG00000137038 C9orf123 - 3309 
chr9 6775000 9925000 7 chr9 6757640 7175648 ENSG00000107077 KDM4C + 400648 
chr9 6775000 9925000 7 chr9 8314245 10612723 ENSG00000153707 PTPRD - 1610755 
chr1 95650000 98950000 6 chr1 95699710 95712781 ENSG00000122481 RWDD3 + 13071 
chr1 95650000 98950000 6 chr1 95970531 95970615 ENSG00000216037 Mir_548 - 84 
chr1 95650000 98950000 6 chr1 97161411 97161723 ENSG00000223229 7SK - 312 
chr1 95650000 98950000 6 chr1 98510798 98510907 ENSG00000225206 MIR2682 - 109 
chr1 95650000 98950000 6 chr1 95582893 95663161 ENSG00000152078 TMEM56 + 13161 
chr1 95650000 98950000 6 chr1 95975895 95981020 ENSG00000228971 BC067883 + 5125 
chr1 95650000 98950000 6 chr1 98453555 98515249 ENSG00000225206 MIR137HG - 61694 
chr1 95650000 98950000 6 chr1 95628774 95699538 ENSG00000226026 AK090700 - 49538 
chr1 95650000 98950000 6 chr1 95940292 95944912 ENSG00000233907 FLJ31662 + 4620 
chr1 95650000 98950000 6 chr1 97187174 97280605 ENSG00000117569 PTBP2 + 93431 
chr1 95650000 98950000 6 chr1 97543299 98386615 ENSG00000188641 DPYD - 843316 
chr1 95650000 98950000 6 chr1 97561478 97788511 ENSG00000232878 DPYD-AS1 + 227033 
chr1 95650000 98950000 6 chr1 98676266 98738214 ENSG00000226053 LOC729987 + 61948 
chr10 60100000 61800000 6 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2519 
chr10 60100000 61800000 6 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60100000 61800000 6 chr10 60094738 60130513 ENSG00000072401 UBE2D1 + 30513 
chr10 60100000 61800000 6 chr10 60144902 60158990 ENSG00000108064 TFAM + 14088 
chr10 60100000 61800000 6 chr10 61410521 61469649 ENSG00000165449 SLC16A9 - 59128 
chr10 60100000 61800000 6 chr10 61496747 61513203 ENSG00000227877 LINC00948 - 16456 
chr10 60100000 61800000 6 chr10 61715187 61720671 ENSG00000235931 C10orf40 - 5484 
chr10 60100000 61800000 6 chr10 60272903 60588845 ENSG00000122870 BICC1 + 315942 
chr10 60100000 61800000 6 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60100000 61800000 6 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr10 60100000 61800000 6 chr10 61548505 61666414 ENSG00000108091 CCDC6 - 117909 
chr10 60100000 61800000 6 chr10 61786055 62149634 ENSG00000151150 ANK3 - 13945 
chr11 34475000 36525000 6 chr11 35639734 35642421 ENSG00000179431 FJX1 + 2687 
chr11 34475000 36525000 6 chr11 35835881 35839556 ENSG00000261355 DQ573949 + 3675 
chr11 34475000 36525000 6 chr11 35887569 35887666 n/a Mir_652 n/a 97 
chr11 34475000 36525000 6 chr11 36031647 36031754 ENSG00000263389 MIR3973 + 107 
chr11 34475000 36525000 6 chr11 34500341 34535347 ENSG00000135374 ELF5 - 35006 
chr11 34475000 36525000 6 chr11 34654010 34684834 ENSG00000135373 EHF + 30824 
chr11 34475000 36525000 6 chr11 34903842 34937939 ENSG00000149089 APIP - 34097 
chr11 34475000 36525000 6 chr11 34963383 34963467 ENSG00000251862 MIR1343 + 84 
chr11 34475000 36525000 6 chr11 35160416 35253949 ENSG00000026508 CD44 + 93533 
chr11 34475000 36525000 6 chr11 36084833 36099448 n/a BC036209 n/a 14615 
chr11 34475000 36525000 6 chr11 36505316 36531863 ENSG00000175104 TRAF6 - 19684 
chr11 34475000 36525000 6 chr11 34460471 34493607 ENSG00000121691 CAT + 18607 
chr11 34475000 36525000 6 chr11 34937676 35017675 ENSG00000110435 PDHX + 79999 
chr11 34475000 36525000 6 chr11 35272751 35441105 ENSG00000110436 SLC1A2 - 168354 
chr11 34475000 36525000 6 chr11 35453375 35547176 ENSG00000149090 PAMR1 - 93801 
chr11 34475000 36525000 6 chr11 35684352 35830930 ENSG00000166326 TRIM44 + 146578 
chr11 34475000 36525000 6 chr11 35965611 36252841 ENSG00000179241 LDLRAD3 + 287230 
chr11 34475000 36525000 6 chr11 36293841 36310999 ENSG00000110442 COMMD9 - 17158 
chr11 34475000 36525000 6 chr11 36397534 36486754 ENSG00000135362 PRR5L + 89220 
chr12 31475000 32850000 6 chr12 31477249 31478879 ENSG00000177340 FLJ13224 + 1630 
chr12 31475000 32850000 6 chr12 31516414 31522235 ENSG00000256232 BC039477 - 5821 
chr12 31475000 32850000 6 chr12 31747026 31747140 ENSG00000252390 U5 - 114 
chr12 31475000 32850000 6 chr12 31944118 31945175 ENSG00000188375 H3F3C - 1057 
chr12 31475000 32850000 6 chr12 32146772 32146802 n/a RNU6-78P n/a 30 
chr12 31475000 32850000 6 chr12 31742856 31768285 ENSG00000255867 
DENND5B-
AS1 + 25429 
chr12 31475000 32850000 6 chr12 31812608 31822016 ENSG00000139160 METTL20 + 9408 
chr12 31475000 32850000 6 chr12 32832136 32898584 ENSG00000087470 DNM1L + 17864 
chr12 31475000 32850000 6 chr12 31535156 31743952 ENSG00000170456 DENND5B - 208796 
chr12 31475000 32850000 6 chr12 31824070 31882108 ENSG00000151743 AMN1 - 58038 
chr12 31475000 32850000 6 chr12 32112352 32146043 ENSG00000174718 KIAA1551 + 33691 
chr12 31475000 32850000 6 chr12 32655040 32798984 ENSG00000139132 FGD4 + 143944 
chr12 31475000 32850000 6 chr12 31433519 31479159 ENSG00000139146 FAM60A - 4159 
chr12 31475000 32850000 6 chr12 32260184 32531141 ENSG00000151746 BICD1 + 270957 
chr12 58300000 62625000 6 chr12 59762831 59762932 ENSG00000212599 U6 - 101 
chr12 58300000 62625000 6 chr12 58335444 58351052 ENSG00000166896 XRCC6BP1 + 15608 
chr12 58300000 62625000 6 chr12 59265936 59314319 ENSG00000139263 LRIG3 - 48383 
chr12 58300000 62625000 6 chr12 58325231 58329947 ENSG00000257698 
LOC1005068
44 - 4716 
chr12 58300000 62625000 6 chr12 58959742 59175498 ENSG00000257259 AK093124 - 215756 
chr12 58300000 62625000 6 chr12 59989820 60183635 ENSG00000118596 SLC16A7 + 193815 
chr12 58300000 62625000 6 chr12 62102028 62586620 ENSG00000198673 FAM19A2 - 484592 
chr13 30025000 31700000 6 chr13 30050651 30061887 ENSG00000179141 MTUS2-AS1 - 11236 
chr13 30025000 31700000 6 chr13 31032878 31040081 ENSG00000189403 HMGB1 - 7203 
chr13 30025000 31700000 6 chr13 31248100 31248174 n/a TRNA_Asn n/a 74 
chr13 30025000 31700000 6 chr13 31377342 31384782 ENSG00000237879 LINC00398 + 7440 
chr13 30025000 31700000 6 chr13 30446749 30462542 ENSG00000224329 LINC00297 - 15793 
 
 227 
chr13 30025000 31700000 6 chr13 30510667 30524625 ENSG00000122043 LINC00544 + 13958 
chr13 30025000 31700000 6 chr13 31480311 31499709 ENSG00000102802 MEDAG + 19398 
chr13 30025000 31700000 6 chr13 31506833 31549153 ENSG00000175664 TEX26 + 42320 
chr13 30025000 31700000 6 chr13 29598747 30080084 ENSG00000132938 MTUS2 + 55084 
chr13 30025000 31700000 6 chr13 30083550 30169825 ENSG00000139514 SLC7A1 - 86275 
chr13 30025000 31700000 6 chr13 30776766 30881191 ENSG00000102781 KATNAL1 - 104425 
chr13 30025000 31700000 6 chr13 30914406 30948036 ENSG00000238121 LINC00426 - 33630 
chr13 30025000 31700000 6 chr13 31191829 31233686 ENSG00000132952 USPL1 + 41857 
chr13 30025000 31700000 6 chr13 31287614 31338565 ENSG00000132965 ALOX5AP + 50951 
chr13 30025000 31700000 6 chr13 30338544 30424820 ENSG00000122042 UBL3 - 86276 
chr13 30025000 31700000 6 chr13 31456971 31506745 ENSG00000224743 TEX26-AS1 - 49774 
 
Table 3.7 | TADs expanded in neurons compared to glia. 
TAD calls in neurons that encompass multiple TADs in glia (Table 3.7) and NPCs 
(Table 3.8). Chr(Neu TAD), x1 (Neu TAD), x2 (Neu TAD) – coordinates for TADs 
in neurons; No. Overlap Glia TADs, number of TADs in glia that overlap with the 
TAD called in neurons (columns A-C). Chr(Glia/NPC gene), x1 (Glia/NPC gene), 
x2 (Glia/NPC gene) – coordinates for genes located in TADs in column D in glia  
(Table 3.7) and NPCs (Table 3.8), respectively. Gene ID (ENSG), ENSEMBL 




































Table 9Table 3.8 | TAD s expanded  in neurons compared  to NPC  
chr(Ne
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chr10 60100000 62425000 9 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2519 
chr10 60100000 62425000 9 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60100000 62425000 9 chr10 61821742 61822047 n/a Metazoa_SRP n/a 305 
chr10 60100000 62425000 9 chr10 61841498 61841612 ENSG00000202190 Y_RNA + 114 
chr10 60100000 62425000 9 chr10 60094738 60130513 ENSG00000072401 UBE2D1 + 30513 
chr10 60100000 62425000 9 chr10 60144902 60158990 ENSG00000108064 TFAM + 14088 
chr10 60100000 62425000 9 chr10 61410521 61469649 ENSG00000165449 SLC16A9 - 59128 
chr10 60100000 62425000 9 chr10 61496747 61513203 ENSG00000227877 LINC00948 - 16456 
chr10 60100000 62425000 9 chr10 61715187 61720671 ENSG00000235931 C10orf40 - 5484 
chr10 60100000 62425000 9 chr10 60272903 60588845 ENSG00000122870 BICC1 + 315942 
chr10 60100000 62425000 9 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60100000 62425000 9 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr10 60100000 62425000 9 chr10 61548505 61666414 ENSG00000108091 CCDC6 - 117909 
chr10 60100000 62425000 9 chr10 61786055 62149634 ENSG00000151150 ANK3 - 363579 
chr6 20525000 24375000 8 chr6 20567407 20567491 n/a Mir_548 n/a 84 
chr6 20525000 24375000 8 chr6 22134830 22147422 ENSG00000260455 LOC729177 - 12592 
chr6 20525000 24375000 8 chr6 22569677 22570750 ENSG00000112273 HDGFL1 + 1073 
chr6 20525000 24375000 8 chr6 24357130 24358512 ENSG00000146049 KAAG1 + 1382 
chr6 20525000 24375000 8 chr6 21593971 21598849 ENSG00000124766 SOX4 + 4878 
chr6 20525000 24375000 8 chr6 22287472 22303082 ENSG00000172179 PRL - 15610 
chr6 20525000 24375000 8 chr6 24126413 24147757 ENSG00000152954 NRSN1 + 21344 
chr6 20525000 24375000 8 chr6 22146882 22194616 ENSG00000272168 LINC00340 + 47734 
chr6 20525000 24375000 8 chr6 24171982 24358280 ENSG00000146038 DCDC2 - 186298 
chr6 20525000 24375000 8 chr6 20534687 21232634 ENSG00000145996 CDKAL1 + 697947 
chr6 20525000 24375000 8 chr6 21666674 22194616 ENSG00000272168 LINC00340 + 527942 
chr9 6775000 9925000 8 chr9 6834701 6835011 ENSG00000230581 DQ580140 + 310 
chr9 6775000 9925000 8 chr9 7167235 7167357 n/a Mir_584 n/a 122 
chr9 6775000 9925000 8 chr9 8858133 8861724 ENSG00000225706 AK094342 + 3591 
chr9 6775000 9925000 8 chr9 8888135 8888207 ENSG00000251699 SNORD27 + 72 
chr9 6775000 9925000 8 chr9 9442059 9442347 ENSG00000265735 Metazoa_SRP + 288 
chr9 6775000 9925000 8 chr9 7796490 7799799 ENSG00000137038 C9orf123 - 3309 
chr9 6775000 9925000 8 chr9 6757640 7175648 ENSG00000107077 KDM4C + 400648 
chr9 6775000 9925000 8 chr9 8314245 10612723 ENSG00000153707 PTPRD - 1610755 
chr10 60100000 61800000 7 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2519 
chr10 60100000 61800000 7 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60100000 61800000 7 chr10 60094738 60130513 ENSG00000072401 UBE2D1 + 30513 
chr10 60100000 61800000 7 chr10 60144902 60158990 ENSG00000108064 TFAM + 14088 
chr10 60100000 61800000 7 chr10 61410521 61469649 ENSG00000165449 SLC16A9 - 59128 
chr10 60100000 61800000 7 chr10 61496747 61513203 ENSG00000227877 LINC00948 - 16456 
chr10 60100000 61800000 7 chr10 61715187 61720671 ENSG00000235931 C10orf40 - 5484 
chr10 60100000 61800000 7 chr10 60272903 60588845 ENSG00000122870 BICC1 + 315942 
chr10 60100000 61800000 7 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60100000 61800000 7 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr10 60100000 61800000 7 chr10 61548505 61666414 ENSG00000108091 CCDC6 - 117909 
chr10 60100000 61800000 7 chr10 61786055 62149634 ENSG00000151150 ANK3 - 13945 
chr4 52675000 55125000 7 chr4 53578620 53580305 ENSG00000226950 DANCR + 1685 
chr4 52675000 55125000 7 chr4 53578848 53578914 ENSG00000264585 MIR4449 + 66 
chr4 52675000 55125000 7 chr4 53579415 53579537 ENSG00000212588 SNORA26 + 122 
chr4 52675000 55125000 7 chr4 53609683 53617807 ENSG00000226887 ERVMER34-1 - 8124 
chr4 52675000 55125000 7 chr4 53728494 53733002 ENSG00000128045 RASL11B + 4508 
chr4 52675000 55125000 7 chr4 54851665 54853449 ENSG00000229585 RPL21P44 - 1784 
chr4 52675000 55125000 7 chr4 54966247 54968122 ENSG00000180613 GSX2 + 1875 
chr4 52675000 55125000 7 chr4 52709275 52783003 ENSG00000109184 DCUN1D4 + 73728 
chr4 52675000 55125000 7 chr4 52859865 52883786 ENSG00000188993 LRRC66 - 23921 
chr4 52675000 55125000 7 chr4 52886860 52904485 ENSG00000163069 SGCB - 17625 
chr4 52675000 55125000 7 chr4 53656160 53681631 ENSG00000250302 LOC152578 + 25471 
chr4 52675000 55125000 7 chr4 53811820 53824254 ENSG00000248115 AK055055 + 12434 
chr4 52675000 55125000 7 chr4 54294193 54326103 ENSG00000145216 FIP1L1 + 31910 
chr4 52675000 55125000 7 chr4 54366243 54389443 ENSG00000250930 LNX1-AS1 + 23200 
chr4 52675000 55125000 7 chr4 54459122 54471548 ENSG00000248494 LNX1-AS2 + 12426 
chr4 52675000 55125000 7 chr4 55095263 55164412 ENSG00000134853 PDGFRA + 29737 
chr4 52675000 55125000 7 chr4 52917592 52963458 ENSG00000163071 SPATA18 + 45866 
chr4 52675000 55125000 7 chr4 53739150 54232242 ENSG00000184178 SCFD2 - 493092 
chr4 52675000 55125000 7 chr4 54326436 54457753 ENSG00000072201 LNX1 - 131317 
chr4 52675000 55125000 7 chr4 54875957 54930815 ENSG00000109220 CHIC2 - 54858 
chr4 52675000 55125000 7 chr4 53457126 53525502 ENSG00000109189 USP46 - 68376 
chr5 162950000 167650000 7 chr5 165036445 165036684 ENSG00000252794 7SK + 239 
chr5 162950000 167650000 7 chr5 167460095 167460210 ENSG00000253065 SNORA40 - 115 
chr5 162950000 167650000 7 chr5 163781145 164029423 ENSG00000241956 BC011998 + 248278 
chr5 162950000 167650000 7 chr5 166711842 167691162 ENSG00000145934 TENM2 + 938158 
chr9 97300000 99100000 7 chr9 97572243 97572339 ENSG00000252153 MIR2278 + 96 
chr9 97300000 99100000 7 chr9 97781172 97784562 ENSG00000148120 AL137535 + 3390 
chr9 97300000 99100000 7 chr9 97847489 97848370 ENSG00000207563 MIR23B + 881 
chr9 97300000 99100000 7 chr9 97848295 97848376 ENSG00000207617 MIR3074 - 81 
chr9 97300000 99100000 7 chr9 97884155 97886342 n/a BC041030 n/a 2187 
chr9 97300000 99100000 7 chr9 98225890 98232301 n/a LOC100507346 n/a 6411 
chr9 97300000 99100000 7 chr9 98680445 98680471 ENSG00000237631 DQ588075 + 26 
chr9 97300000 99100000 7 chr9 98782013 98784037 ENSG00000225194 LINC00092 - 2024 
chr9 97300000 99100000 7 chr9 97317422 97330409 ENSG00000231806 BC080653 + 12987 
chr9 97300000 99100000 7 chr9 97321002 97356075 ENSG00000130957 FBP2 - 35073 
chr9 97300000 99100000 7 chr9 98205263 98270831 ENSG00000185920 PTCH1 - 65568 
chr9 97300000 99100000 7 chr9 98568369 98638259 ENSG00000175611 LINC00476 - 69890 
chr9 97300000 99100000 7 chr9 98868942 98878693 n/a LOC158434 n/a 9751 
chr9 97300000 99100000 7 chr9 98997588 99064434 ENSG00000130948 HSD17B3 - 66846 
chr9 97300000 99100000 7 chr9 97365420 97401923 ENSG00000165140 FBP1 - 36503 
 
 229 
chr9 97300000 99100000 7 chr9 97521930 97849500 ENSG00000148120 C9orf3 + 327570 
chr9 97300000 99100000 7 chr9 97861335 98079991 ENSG00000158169 FANCC - 218656 
chr9 97300000 99100000 7 chr9 98637899 98731122 ENSG00000182150 ERCC6L2 + 93223 
chr9 97300000 99100000 7 chr9 98828120 98864194 ENSG00000237212 LOC158435 + 36074 
chr9 97300000 99100000 7 chr9 99082987 99145992 ENSG00000130958 SLC35D2 - 17013 
chr1 71550000 75175000 6 chr1 72259914 72302695 ENSG00000228853 NEGR1-IT1 - 42781 
chr1 71550000 75175000 6 chr1 75043113 75091782 ENSG00000234497 CR627203 + 48669 
chr1 71550000 75175000 6 chr1 75171171 75199092 ENSG00000116791 CRYZ - 3829 
chr1 71550000 75175000 6 chr1 71547006 71703406 ENSG00000229956 ZRANB2-AS2 + 153406 
chr1 71550000 75175000 6 chr1 73771852 73804560 ENSG00000233973 BC041341 + 32708 
chr1 71550000 75175000 6 chr1 74491701 74663871 ENSG00000162620 LRRIQ3 - 172170 
chr1 71550000 75175000 6 chr1 74663895 75010116 ENSG00000116783 FPGT-TNNI3K + 346221 
chr1 71550000 75175000 6 chr1 75033794 75139422 ENSG00000178965 C1orf173 - 105628 
chr1 71550000 75175000 6 chr1 71868624 72748405 ENSG00000172260 NEGR1 - 879781 
chr1 95650000 98950000 6 chr1 95699710 95712781 ENSG00000122481 RWDD3 + 13071 
chr1 95650000 98950000 6 chr1 95970531 95970615 ENSG00000216037 Mir_548 - 84 
chr1 95650000 98950000 6 chr1 97161411 97161723 ENSG00000223229 7SK - 312 
chr1 95650000 98950000 6 chr1 98510798 98510907 ENSG00000225206 MIR2682 - 109 
chr1 95650000 98950000 6 chr1 95582893 95663161 ENSG00000152078 TMEM56 + 13161 
chr1 95650000 98950000 6 chr1 95975895 95981020 ENSG00000228971 BC067883 + 5125 
chr1 95650000 98950000 6 chr1 98453555 98515249 ENSG00000225206 MIR137HG - 61694 
chr1 95650000 98950000 6 chr1 95628774 95699538 ENSG00000226026 AK090700 - 49538 
chr1 95650000 98950000 6 chr1 95940292 95944912 ENSG00000233907 FLJ31662 + 4620 
chr1 95650000 98950000 6 chr1 97187174 97280605 ENSG00000117569 PTBP2 + 93431 
chr1 95650000 98950000 6 chr1 97543299 98386615 ENSG00000188641 DPYD - 843316 
chr1 95650000 98950000 6 chr1 97561478 97788511 ENSG00000232878 DPYD-AS1 + 227033 
chr1 95650000 98950000 6 chr1 98676266 98738214 ENSG00000226053 LOC729987 + 61948 
chr10 60225000 61375000 6 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2519 
chr10 60225000 61375000 6 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60225000 61375000 6 chr10 60272903 60588845 ENSG00000122870 BICC1 + 315942 
chr10 60225000 61375000 6 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60225000 61375000 6 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr10 60475000 61375000 6 chr10 60474774 60477293 ENSG00000183055 FAM133CP + 2293 
chr10 60475000 61375000 6 chr10 61019597 61019717 n/a Mir_584 n/a 120 
chr10 60475000 61375000 6 chr10 60272903 60588845 ENSG00000122870 BICC1 + 113845 
chr10 60475000 61375000 6 chr10 60936347 61007534 ENSG00000165443 PHYHIPL + 71187 
chr10 60475000 61375000 6 chr10 61005888 61122352 ENSG00000148541 FAM13C - 116464 
chr12 69725000 72125000 6 chr12 69978501 69978603 ENSG00000264405 MIR3913-1 - 102 
chr12 69725000 72125000 6 chr12 69978502 69978602 n/a MIR3913-2 n/a 100 
chr12 69725000 72125000 6 chr12 70002344 70004942 ENSG00000198812 LRRC10 - 2598 
chr12 69725000 72125000 6 chr12 70195707 70195791 n/a Mir_548 n/a 84 
chr12 69725000 72125000 6 chr12 71300696 71300798 ENSG00000207387 Y_RNA + 102 
chr12 69725000 72125000 6 chr12 71869656 71869910 n/a 7SK n/a 254 
chr12 69725000 72125000 6 chr12 69742133 69748013 ENSG00000090382 LYZ + 5880 
chr12 69725000 72125000 6 chr12 69753531 69784576 ENSG00000127337 YEATS4 + 31045 
chr12 69725000 72125000 6 chr12 69864128 69973562 ENSG00000166225 FRS2 + 109434 
chr12 69725000 72125000 6 chr12 70047388 70093196 ENSG00000127325 BEST3 - 45808 
chr12 69725000 72125000 6 chr12 70132630 70216984 ENSG00000127328 RAB3IP + 84354 
chr12 69725000 72125000 6 chr12 70320436 70352503 ENSG00000166268 C12orf28 + 32067 
chr12 69725000 72125000 6 chr12 70910631 71031220 ENSG00000127329 PTPRB - 120589 
chr12 69725000 72125000 6 chr12 71518876 71551779 ENSG00000127324 TSPAN8 - 32903 
chr12 69725000 72125000 6 chr12 72003378 72057749 ENSG00000133858 ZFC3H1 - 54371 
chr12 69725000 72125000 6 chr12 72057676 72074428 ENSG00000173451 THAP2 + 16752 
chr12 69725000 72125000 6 chr12 69979207 69995357 ENSG00000166226 CCT2 + 16150 
chr12 69725000 72125000 6 chr12 70107414 70132348 ENSG00000247131 BC042465 - 24934 
chr12 69725000 72125000 6 chr12 70636773 70748773 ENSG00000111596 CNOT2 + 112000 
chr12 69725000 72125000 6 chr12 70760061 70828072 ENSG00000135643 KCNMB4 + 68011 
chr12 69725000 72125000 6 chr12 70861864 70932592 ENSG00000258168 BC031864 + 70728 
chr12 69725000 72125000 6 chr12 71833549 71980088 ENSG00000139292 LGR5 + 146539 
chr12 69725000 72125000 6 chr12 72079877 72097839 ENSG00000139291 TMEM19 + 17962 
chr12 69725000 72125000 6 chr12 71031852 71314584 ENSG00000153233 PTPRR - 282732 
chr12 96925000 98800000 6 chr12 97490690 97490764 n/a TRNA_Pseudo n/a 74 
chr12 96925000 98800000 6 chr12 97506929 97507042 n/a Mir_584 n/a 113 
chr12 96925000 98800000 6 chr12 97866326 97868402 n/a AK129935 n/a 2076 
chr12 96925000 98800000 6 chr12 97885686 97885756 ENSG00000221479 MIR1251 + 70 
chr12 96925000 98800000 6 chr12 97945914 97946006 ENSG00000251844 
SnoMe28S_Am263
4 - 92 
chr12 96925000 98800000 6 chr12 97957589 97957689 ENSG00000207586 MIR135A2 + 100 
chr12 96925000 98800000 6 chr12 98389160 98389226 ENSG00000263890 MIR4303 - 66 
chr12 96925000 98800000 6 chr12 98752079 98752163 n/a Mir_548 n/a 84 
chr12 96925000 98800000 6 chr12 96883352 96934765 ENSG00000188596 C12orf55 + 9765 
chr12 96925000 98800000 6 chr12 97301000 97347469 ENSG00000139350 NEDD1 + 46469 
chr12 96925000 98800000 6 chr12 98123825 98150295 ENSG00000257501 LOC643711 - 26470 
chr12 96925000 98800000 6 chr12 96933914 97024429 ENSG00000188596 AX747187 + 90515 
chr12 96925000 98800000 6 chr12 97041752 97159032 ENSG00000188596 C12orf63 + 117280 
chr12 96925000 98800000 6 chr12 97858798 97927544 ENSG00000255794 RMST + 68746 
chr14 25850000 29100000 6 chr14 26641372 26641456 ENSG00000212037 Mir_548 - 84 
chr14 25850000 29100000 6 chr14 27377847 27377931 ENSG00000265165 MIR4307 + 84 
chr14 25850000 29100000 6 chr14 29063026 29063048 ENSG00000257662 DD413682 + 22 
chr14 25850000 29100000 6 chr14 28081793 28108842 ENSG00000258548 LINC00645 + 27049 
chr14 25850000 29100000 6 chr14 26915088 27066960 ENSG00000139910 NOVA1 - 151872 
chr14 25850000 29100000 6 chr14 27791205 28142425 ENSG00000258932 BC148262 - 351220 
chr16 78125000 80550000 6 chr16 79627744 79634622 ENSG00000178573 MAF - 6878 
chr16 78125000 80550000 6 chr16 78133326 79246564 ENSG00000186153 WWOX + 1113238 
chr18 49100000 51725000 6 chr18 51105992 51107426 ENSG00000260433 BC034434 - 1434 
chr18 49100000 51725000 6 chr18 51677970 51751158 ENSG00000134046 MBD2 - 47030 
chr18 49100000 51725000 6 chr18 49866541 51062273 ENSG00000187323 DCC + 1195732 
chr18 49350000 51725000 6 chr18 51105992 51107426 ENSG00000260433 BC034434 - 1434 
chr18 49350000 51725000 6 chr18 51677970 51751158 ENSG00000134046 MBD2 - 47030 
chr18 49350000 51725000 6 chr18 49866541 51062273 ENSG00000187323 DCC + 1195732 
chr2 103425000 105550000 6 chr2 103486031 103486051 n/a DD413674 n/a 20 
chr2 103425000 105550000 6 chr2 105471968 105473471 ENSG00000198914 POU3F3 + 1503 
chr2 103425000 105550000 6 chr2 105481954 105488840 ENSG00000229743 AK095498 - 6886 
chr2 103425000 105550000 6 chr2 104995307 105024790 n/a LOC100287010 n/a 29483 
chr2 103425000 105550000 6 chr2 105363094 105374177 ENSG00000234177 LOC284998 - 11083 
chr2 103425000 105550000 6 chr2 105421882 105467934 ENSG00000233639 LOC100506421 - 46052 
chr2 103425000 105550000 6 chr2 103378489 103434138 ENSG00000170417 TMEM182 + 9138 
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chr2 103425000 105550000 6 chr2 105050804 105129215 ENSG00000235597 LOC150568 + 78411 
chr2 188350000 190325000 6 chr2 189162218 189162315 ENSG00000207951 MIR561 + 97 
chr2 188350000 190325000 6 chr2 189842817 189842886 ENSG00000221502 MIR1245A + 69 
chr2 188350000 190325000 6 chr2 189842819 189842887 n/a MIR1245B n/a 68 
chr2 188350000 190325000 6 chr2 189860355 189860418 n/a MIR3606 n/a 63 
chr2 188350000 190325000 6 chr2 189997761 189997837 ENSG00000264725 MIR3129 - 76 
chr2 188350000 190325000 6 chr2 189598464 189654831 ENSG00000174325 DIRC1 - 56367 
chr2 188350000 190325000 6 chr2 189839098 189877472 ENSG00000168542 COL3A1 + 38374 
chr2 188350000 190325000 6 chr2 188328957 188419219 ENSG00000003436 TFPI - 69219 
chr2 188350000 190325000 6 chr2 189156395 189460652 ENSG00000144366 GULP1 + 304257 
chr2 188350000 190325000 6 chr2 189896640 190044605 ENSG00000204262 COL5A2 - 147965 
chr2 188350000 190325000 6 chr2 190306158 190340264 ENSG00000115368 WDR75 + 18842 
chr2 33875000 37175000 6 chr2 33951127 33953284 ENSG00000239649 MYADML - 2157 
chr2 33875000 37175000 6 chr2 34628738 34628822 ENSG00000212025 Mir_548 - 84 
chr2 33875000 37175000 6 chr2 36581891 36582713 n/a LOC100288911 n/a 822 
chr2 33875000 37175000 6 chr2 36779403 36825332 ENSG00000171055 FEZ2 - 45929 
chr2 33875000 37175000 6 chr2 36923832 37041937 ENSG00000205221 VIT + 118105 
chr2 33875000 37175000 6 chr2 37064840 37193615 ENSG00000115808 STRN - 110160 
chr2 33875000 37175000 6 chr2 36583369 36778278 ENSG00000150938 CRIM1 + 194909 
chr2 39550000 42025000 6 chr2 39620662 39620759 ENSG00000252239 U6 - 97 
chr2 39550000 42025000 6 chr2 41559792 41559915 n/a Mir_584 n/a 123 
chr2 39550000 42025000 6 chr2 39741286 39828484 ENSG00000231312 LOC728730 + 87198 
chr2 39550000 42025000 6 chr2 39893034 39945104 ENSG00000152154 TMEM178A + 52070 
chr2 39550000 42025000 6 chr2 39476406 39664453 ENSG00000011566 MAP4K3 - 114453 
chr2 39550000 42025000 6 chr2 39963199 40006416 ENSG00000138050 THUMPD2 - 43217 
chr2 39550000 42025000 6 chr2 40144773 40482349 ENSG00000227028 SLC8A1-AS1 + 337576 
chr2 39550000 42025000 6 chr2 40339285 40657444 ENSG00000183023 SLC8A1 - 318159 
chr2 62125000 64150000 6 chr2 62432960 62433052 ENSG00000266097 MIR5192 + 92 
chr2 62125000 64150000 6 chr2 62489521 62489806 ENSG00000239958 Metazoa_SRP - 285 
chr2 62125000 64150000 6 chr2 62727355 62733604 ENSG00000186889 TMEM17 - 6249 
chr2 62125000 64150000 6 chr2 62953770 62953875 ENSG00000252436 Y_RNA - 105 
chr2 62125000 64150000 6 chr2 63271099 63274846 ENSG00000231609 LOC100132215 - 3747 
chr2 62125000 64150000 6 chr2 63277936 63284966 ENSG00000115507 OTX1 + 7030 
chr2 62125000 64150000 6 chr2 63344985 63346677 ENSG00000242412 DBIL5P2 - 1692 
chr2 62125000 64150000 6 chr2 62296587 62374016 ENSG00000229839 BC071802 - 77429 
chr2 62125000 64150000 6 chr2 62423261 62451866 ENSG00000170340 B3GNT2 + 28605 
chr2 62125000 64150000 6 chr2 62839006 62889763 ENSG00000226622 BC038779 - 50757 
chr2 62125000 64150000 6 chr2 62132802 62363205 ENSG00000173163 COMMD1 + 230403 
chr2 62125000 64150000 6 chr2 62933000 63273621 ENSG00000115504 EHBP1 + 340621 
chr2 62125000 64150000 6 chr2 63348534 63815867 ENSG00000143951 WDPCP - 467333 
chr2 62125000 64150000 6 chr2 63816284 63834330 ENSG00000014641 MDH1 + 18046 
chr2 62125000 64150000 6 chr2 64069013 64118696 ENSG00000169764 UGP2 + 49683 
chr2 62125000 64150000 6 chr2 64119666 64246214 ENSG00000143952 VPS54 - 30334 
chr21 30400000 32450000 6 chr21 30552745 30552960 ENSG00000212479 U3 - 215 
chr21 30400000 32450000 6 chr21 31538240 31538971 ENSG00000156282 CLDN17 - 731 
chr21 30400000 32450000 6 chr21 31581468 31584101 ENSG00000227342 LINC00307 - 2633 
chr21 30400000 32450000 6 chr21 31661462 31661832 ENSG00000232263 KRTAP25-1 - 370 
chr21 30400000 32450000 6 chr21 31691449 31692607 ENSG00000197683 KRTAP26-1 - 1158 
chr21 30400000 32450000 6 chr21 31709330 31710012 ENSG00000206107 KRTAP27-1 - 682 
chr21 30400000 32450000 6 chr21 31720716 31720924 ENSG00000186980 KRTAP23-1 - 208 
chr21 30400000 32450000 6 chr21 31743708 31744557 ENSG00000182816 KRTAP13-2 - 849 
chr21 30400000 32450000 6 chr21 31747611 31747696 ENSG00000265007 MIR4327 - 85 
chr21 30400000 32450000 6 chr21 31797710 31798230 ENSG00000240432 KRTAP13-3 - 520 
chr21 30400000 32450000 6 chr21 31802593 31803076 ENSG00000186971 KRTAP13-4 + 483 
chr21 30400000 32450000 6 chr21 31812645 31813098 ENSG00000186970 KRTAP15-1 + 453 
chr21 30400000 32450000 6 chr21 31852363 31852636 ENSG00000184351 KRTAP19-1 - 273 
chr21 30400000 32450000 6 chr21 31859508 31859667 ENSG00000186965 KRTAP19-2 - 159 
chr21 30400000 32450000 6 chr21 31863781 31864275 ENSG00000244025 KRTAP19-3 - 494 
chr21 30400000 32450000 6 chr21 31869173 31869428 ENSG00000186967 KRTAP19-4 - 255 
chr21 30400000 32450000 6 chr21 31874189 31874408 ENSG00000186977 KRTAP19-5 - 219 
chr21 30400000 32450000 6 chr21 31913853 31914181 ENSG00000186925 KRTAP19-6 - 328 
chr21 30400000 32450000 6 chr21 31933416 31933608 ENSG00000244362 KRTAP19-7 - 192 
chr21 30400000 32450000 6 chr21 31962423 31962716 ENSG00000206106 KRTAP22-2 - 293 
chr21 30400000 32450000 6 chr21 31971004 31971193 ENSG00000186930 KRTAP6-2 - 189 
chr21 30400000 32450000 6 chr21 31973439 31973586 ENSG00000186924 KRTAP22-1 + 147 
chr21 30400000 32450000 6 chr21 31986004 31986223 ENSG00000184724 KRTAP6-1 - 219 
chr21 30400000 32450000 6 chr21 31988773 31988944 ENSG00000244624 KRTAP20-1 + 171 
chr21 30400000 32450000 6 chr21 31992945 31993169 ENSG00000206105 KRTAP20-4 + 224 
chr21 30400000 32450000 6 chr21 32007582 32007780 ENSG00000184032 KRTAP20-2 + 198 
chr21 30400000 32450000 6 chr21 32015182 32015455 ENSG00000206104 KRTAP20-3 + 273 
chr21 30400000 32450000 6 chr21 32090842 32091095 ENSG00000231068 KRTAP21-3 - 253 
chr21 30400000 32450000 6 chr21 32119268 32119520 ENSG00000187026 KRTAP21-2 - 252 
chr21 30400000 32450000 6 chr21 32127456 32127696 ENSG00000187005 KRTAP21-1 - 240 
chr21 30400000 32450000 6 chr21 32185014 32185570 ENSG00000183640 KRTAP8-1 - 556 
chr21 30400000 32450000 6 chr21 32201357 32202051 ENSG00000256386 KRTAP7-1 - 694 
chr21 30400000 32450000 6 chr21 32252963 32253874 ENSG00000182591 KRTAP11-1 - 911 
chr21 30400000 32450000 6 chr21 32410477 32410795 ENSG00000206102 KRTAP19-8 - 318 
chr21 30400000 32450000 6 chr21 30428647 30446010 ENSG00000156261 CCT8 - 17363 
chr21 30400000 32450000 6 chr21 30565814 30660526 ENSG00000215533 LINC00189 + 94712 
chr21 30400000 32450000 6 chr21 30671219 30718469 ENSG00000156273 BACH1 + 47250 
chr21 30400000 32450000 6 chr21 30968359 31003067 ENSG00000183653 GRIK1-AS2 + 34708 
chr21 30400000 32450000 6 chr21 31120493 31136325 ENSG00000174680 GRIK1-AS1 + 15832 
chr21 30400000 32450000 6 chr21 31653626 31655276 ENSG00000188694 KRTAP24-1 - 1650 
chr21 30400000 32450000 6 chr21 31768391 31769138 ENSG00000198390 KRTAP13-1 + 747 
chr21 30400000 32450000 6 chr21 31964758 31965374 ENSG00000212938 KRTAP6-3 + 616 
chr21 30400000 32450000 6 chr21 30452872 30548202 ENSG00000156265 MAP3K7CL + 95330 
chr21 30400000 32450000 6 chr21 30925865 31312282 ENSG00000171189 GRIK1 - 386417 
chr21 30400000 32450000 6 chr21 31586323 31588469 ENSG00000156284 CLDN8 - 2146 
chr21 30400000 32450000 6 chr21 30396937 30426807 ENSG00000156256 USP16 + 26807 
chr3 180425000 182400000 6 chr3 180586548 180588578 ENSG00000114416 BC034416 + 2030 
chr3 180425000 182400000 6 chr3 180701497 180707562 ENSG00000205981 DNAJC19 - 6065 
chr3 180425000 182400000 6 chr3 180949524 180949631 ENSG00000206932 U6 + 107 
chr3 180425000 182400000 6 chr3 181413636 181413690 n/a JA611300 n/a 54 
chr3 180425000 182400000 6 chr3 181429711 181432223 ENSG00000181449 SOX2 + 2512 
chr3 180425000 182400000 6 chr3 181686246 181686469 ENSG00000252257 7SK + 223 
chr3 180425000 182400000 6 chr3 181723101 181725535 n/a DQ571917 n/a 2434 
chr3 180425000 182400000 6 chr3 180630233 180700539 ENSG00000114416 FXR1 + 70306 
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chr3 180425000 182400000 6 chr3 181670166 181721828 ENSG00000242512 BC036236 + 51662 
chr3 180425000 182400000 6 chr3 180425376 180587966 ENSG00000145075 DKFZp434A128 - 162590 
chr3 180425000 182400000 6 chr3 182164757 182204150 ENSG00000241098 FLJ46066 - 39393 
chr3 180425000 182400000 6 chr3 180774467 181460013 ENSG00000242808 SOX2-OT + 685546 
chr3 58525000 62275000 6 chr3 59956575 59958982 n/a NPCR n/a 2407 
chr3 58525000 62275000 6 chr3 60842060 60842277 ENSG00000212211 U3 - 217 
chr3 58525000 62275000 6 chr3 61068514 61068637 n/a 5S_rRNA n/a 123 
chr3 58525000 62275000 6 chr3 58549844 58563491 ENSG00000168309 FAM107A - 13647 
chr3 58525000 62275000 6 chr3 58619669 58652561 ENSG00000198643 FAM3D - 32892 
chr3 58525000 62275000 6 chr3 58727736 59035715 ENSG00000163689 C3orf67 - 307979 
chr3 58525000 62275000 6 chr3 58810196 59004819 ENSG00000242428 AK090895 + 194623 
chr3 58525000 62275000 6 chr3 62247493 62304622 ENSG00000241472 PTPRG-AS1 - 27507 
chr3 58525000 62275000 6 chr3 59735035 61237133 ENSG00000189283 FHIT - 1502098 
chr3 58525000 62275000 6 chr3 61547242 62280573 ENSG00000144724 PTPRG + 727758 
 
Table 3.8 | TADs expanded in neurons compared to NPC. 
TAD calls in neurons that encompass multiple TADs in glia (Table 3.7) and NPCs 
(Table 3.8). Chr(Neu TAD), x1 (Neu TAD), x2 (Neu TAD) – coordinates for TADs 
in neurons; No. Overlap NPC TADs, number of TADs in NPC that overlap with 
the TAD called in neurons (columns A-C). Chr(Glia/NPC gene), x1 (Glia/NPC 
gene), x2 (Glia/NPC gene) – coordinates for genes located in TADs in column D 
in glia  (Table 3.7) and NPCs (Table 3.8), respectively. Gene ID (ENSG), 
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Table 10Table 3.9 | Loops anchored in sch izophrenia ( SZ) risk sequence. 
NEURONS             
Riskchr Risk start Risk end Risk overlap chr1 x1 x2 chr2 y1 y2 GliafdrDonut NeufdrDonut NPCfdrDonut 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104660000 104665000 0.4254983 0.06027781 0.14398974 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104660000 104665000 0.4254983 0.06027781 0.14398974 
chr18 52747689 53804156 5000 chr18 53075000 53080000 chr18 54240000 54245000 1.2518088 0.05274656 0.44168428 
chr2 200547937 201309547 10000 chr2 199180000 199190000 chr2 200720000 200730000 0.51119745 2.03E-08 0.30081078 
chr2 200547937 201309547 10000 chr2 200320000 200330000 chr2 200720000 200730000 1.5162903 0.00013409 1.5750872 
chr22 39840130 40091818 10000 chr22 39720000 39730000 chr22 39910000 39920000 0.7976765 6.04E-05 0.8887403 
chr4 176717618 176904037 10000 chr4 176480000 176490000 chr4 176730000 176740000 1.0397903 6.22E-05 1.0504069 
chr5 87676693 88195380 5000 chr5 88025000 88030000 chr5 88595000 88600000 1.1398252 0 1.3084083 
chr5 88580998 88748452 5000 chr5 88025000 88030000 chr5 88595000 88600000 1.1398252 0 1.3084083 
chr5 137838122 137948140 10000 chr5 137930000 137940000 chr5 138200000 138210000 1.2840025 1.70E-05 1.7241881 
chr6 24988105 33842877 10000 chr6 25260000 25270000 chr6 25590000 25600000 0.20888025 0.05431648 0.40973878 
chr6 24988105 33842877 10000 chr6 25260000 25270000 chr6 25590000 25600000 0.20888025 0.05431648 0.40973878 
chr6 24988105 33842877 5000 chr6 26120000 26125000 chr6 27110000 27115000 1.0039818 0 1.2458384 
chr6 24988105 33842877 5000 chr6 26120000 26125000 chr6 27110000 27115000 1.0039818 0 1.2458384 
chr6 24988105 33842877 10000 chr6 28460000 28470000 chr6 28630000 28640000 1.5588554 5.11E-05 0.98528725 
chr6 24988105 33842877 10000 chr6 28460000 28470000 chr6 28630000 28640000 1.5588554 5.11E-05 0.98528725 
chr7 110850439 111180544 10000 chr7 108260000 108270000 chr7 111120000 111130000 1.4305197 0.01244852 1.6058803 
             
GLIA             
Riskchr Risk start Risk end Risk overlap chr1 x1 x2 chr2 y1 y2 GliafdrDonut NeufdrDonut NPCfdrDonut 
chr1 8392592 8701288 10000 chr1 8430000 8440000 chr1 8770000 8780000 3.85E-06 0.44497925 0.7925938 
chr1 98341152 98559093 9093 chr1 98550000 98560000 chr1 98660000 98670000 0.00097779 1.5657233 1.7241881 
chr1 149998923 150214166 5000 chr1 149935000 149940000 chr1 150020000 150025000 2.52E-05 1.060373 0.8423837 
chr1 200253612 200269903 9903 chr1 200260000 200270000 chr1 200450000 200460000 0.00100757 1.5745742 1.0504069 
chr10 104570118 105059896 10000 chr10 104480000 104490000 chr10 104810000 104820000 0.00022482 0.90376765 0.3040932 
chr10 104570118 105059896 5000 chr10 104485000 104490000 chr10 104665000 104670000 0.01798354 1.2801908 0.9664832 
chr10 104570118 105059896 5000 chr10 104485000 104490000 chr10 104660000 104665000 6.75E-05 0.5831852 0.1140143 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104675000 104680000 0.00142198 1.3248246 1.3478131 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104675000 104680000 0.00142198 1.3248246 1.3478131 
chr10 104570118 105059896 10000 chr10 104850000 104860000 chr10 105000000 105010000 0.00171292 1.5044254 0.85600626 
chr10 104570118 105059896 10000 chr10 104850000 104860000 chr10 105000000 105010000 0.00171292 1.5044254 0.85600626 
chr11 113317745 113451229 10000 chr11 113420000 113430000 chr11 113480000 113490000 0.00300015 1.1429281 1.0907023 
chr12 123447928 123902361 10000 chr12 123520000 123530000 chr12 123710000 123720000 2.77E-08 1.508456 0.630625 
chr12 123447928 123902361 10000 chr12 123520000 123530000 chr12 123710000 123720000 2.77E-08 1.508456 0.630625 
chr13 79855297 80162555 10000 chr13 80130000 80140000 chr13 80930000 80940000 3.23E-05 0.90376765 0.17745346 
chr14 30000405 30190316 5000 chr14 30015000 30020000 chr14 30680000 30685000 1.14E-06 1.363864 0.44168428 
chr15 82827938 83391537 10000 chr15 83250000 83260000 chr15 83650000 83660000 0.00023944 1.5335083 1.2896612 
chr15 84703470 85392298 5000 chr15 85130000 85135000 chr15 85585000 85590000 0.07324936 1.363864 0.24052724 
chr16 29924422 30117253 5000 chr16 29710000 29715000 chr16 30030000 30035000 0.08700617 1.3652908 1.2216492 
chr16 29924422 30117253 10000 chr16 30070000 30080000 chr16 30400000 30410000 0.00022482 1.5745742 1.688994 
chr16 67708897 68305708 5000 chr16 67550000 67555000 chr16 67960000 67965000 0 1 1.3505517 
chr16 67708897 68305708 5000 chr16 67850000 67855000 chr16 67960000 67965000 0.01798354 1.3262548 0.5672295 
chr16 67708897 68305708 5000 chr16 67850000 67855000 chr16 67960000 67965000 0.01798354 1.3262548 0.5672295 
chr16 67708897 68305708 10000 chr16 68120000 68130000 chr16 68360000 68370000 0.00817463 1.5335083 1.6341001 
chr16 67708897 68305708 5000 chr16 68290000 68295000 chr16 68360000 68365000 0.02715562 1.0222301 0.21247724 
chr17 17649172 17967397 10000 chr17 17810000 17820000 chr17 17930000 17940000 8.20E-07 1.1149824 0.52612877 
chr17 17649172 17967397 10000 chr17 17810000 17820000 chr17 17930000 17940000 8.20E-07 1.1149824 0.52612877 
chr17 17649172 17967397 5000 chr17 17825000 17830000 chr17 17870000 17875000 0.00082981 1.521011 0.96269846 
chr17 17649172 17967397 5000 chr17 17825000 17830000 chr17 17870000 17875000 0.00082981 1.521011 0.96269846 
chr18 52747689 53804156 5000 chr18 53170000 53175000 chr18 53205000 53210000 0.00299272 1.6471775 1.3091516 
chr18 52747689 53804156 5000 chr18 53170000 53175000 chr18 53205000 53210000 0.00299272 1.6471775 1.3091516 
chr19 19358332 19657632 5000 chr19 19255000 19260000 chr19 19600000 19605000 0 1.061395 1.3407764 
chr2 57950104 58484172 10000 chr2 58130000 58140000 chr2 58460000 58470000 0.05253198 1.5455453 1.6341001 
chr2 57950104 58484172 10000 chr2 58130000 58140000 chr2 58460000 58470000 0.05253198 1.5455453 1.6341001 
chr2 57950104 58484172 10000 chr2 58350000 58360000 chr2 58670000 58680000 2.43E-08 1.5479501 0.5771854 
chr2 198146381 198940251 5000 chr2 197975000 197980000 chr2 198245000 198250000 9.33E-05 1.3912318 0.1050422 
chr2 198146381 198940251 5000 chr2 198055000 198060000 chr2 198175000 198180000 0.06144834 0.9483586 0.7659539 
chr2 198146381 198940251 5000 chr2 198055000 198060000 chr2 198175000 198180000 0.06144834 0.9483586 0.7659539 
chr2 200547937 201309547 5000 chr2 200835000 200840000 chr2 201560000 201565000 2.32E-05 0.110981 0.6510733 
chr22 39840130 40091818 10000 chr22 39800000 39810000 chr22 39890000 39900000 0.00029721 1.1993746 1.4838825 
chr22 42315790 42689370 10000 chr22 42360000 42370000 chr22 42480000 42490000 0.02962909 1.5869178 0.1819355 
chr22 42315790 42689370 10000 chr22 42360000 42370000 chr22 42480000 42490000 0.02962909 1.5869178 0.1819355 
chr3 17221017 17888256 5000 chr3 17300000 17305000 chr3 17455000 17460000 0.00032593 1.3415203 0.19510272 
chr3 17221017 17888256 5000 chr3 17300000 17305000 chr3 17455000 17460000 0.00032593 1.3415203 0.19510272 
chr3 36843149 36945794 5000 chr3 36770000 36775000 chr3 36895000 36900000 0.00071711 1.3308439 1.3718083 
chr3 52965713 53175017 10000 chr3 52880000 52890000 chr3 53090000 53100000 8.95E-05 0.84550905 0.504883 
chr3 135807609 136615268 5000 chr3 135785000 135790000 chr3 136470000 136475000 0.00010323 0.27722827 0.44168428 
chr3 135807609 136615268 5000 chr3 135790000 135795000 chr3 136475000 136480000 0.00967255 1.312808 0.18504989 
chr3 180571624 181207851 5000 chr3 180510000 180515000 chr3 180890000 180895000 0.00659433 1.1958251 1.3511878 
chr3 180571624 181207851 5000 chr3 181040000 181045000 chr3 181405000 181410000 0.00071711 1.1443537 1.1120648 
chr4 170357792 170646003 10000 chr4 169930000 169940000 chr4 170480000 170490000 2.37E-09 1.3162088 0.7925938 
chr5 87676693 88195380 10000 chr5 87070000 87080000 chr5 87840000 87850000 3.70E-05 0.22795595 0.40951368 
chr5 87676693 88195380 10000 chr5 87680000 87690000 chr5 87780000 87790000 0.00987681 1.4089538 0.95696616 
chr5 87676693 88195380 10000 chr5 87680000 87690000 chr5 87780000 87790000 0.00987681 1.4089538 0.95696616 
chr5 137838122 137948140 5000 chr5 137910000 137915000 chr5 138600000 138605000 0.00010323 0.5248362 0.11458015 
chr6 24988105 33842877 5000 chr6 26610000 26615000 chr6 27050000 27055000 0.09176145 1.1728417 0.3633115 
chr6 24988105 33842877 5000 chr6 26610000 26615000 chr6 27050000 27055000 0.09176145 1.1728417 0.3633115 
chr6 24988105 33842877 10000 chr6 27140000 27150000 chr6 27430000 27440000 9.69E-05 1.5393742 0.3642763 
chr6 24988105 33842877 10000 chr6 27140000 27150000 chr6 27430000 27440000 9.69E-05 1.5393742 0.3642763 
chr6 24988105 33842877 5000 chr6 28235000 28240000 chr6 28300000 28305000 0.04845583 1.2806816 1.1394541 
chr6 24988105 33842877 5000 chr6 28235000 28240000 chr6 28300000 28305000 0.04845583 1.2806816 1.1394541 
chr6 24988105 33842877 5000 chr6 30710000 30715000 chr6 30845000 30850000 3.10E-05 0.768764 0.21247724 
chr6 24988105 33842877 5000 chr6 30710000 30715000 chr6 30845000 30850000 3.10E-05 0.768764 0.21247724 
chr6 24988105 33842877 5000 chr6 31645000 31650000 chr6 31800000 31805000 0.00290042 0.14871757 0.6141024 
chr6 24988105 33842877 5000 chr6 31645000 31650000 chr6 31800000 31805000 0.00290042 0.14871757 0.6141024 
chr6 24988105 33842877 5000 chr6 32085000 32090000 chr6 32120000 32125000 4.14E-05 1.1549484 0.14398974 
chr6 24988105 33842877 5000 chr6 32085000 32090000 chr6 32120000 32125000 4.14E-05 1.1549484 0.14398974 
 
 233 
chr6 24988105 33842877 10000 chr6 32850000 32860000 chr6 32900000 32910000 6.56E-06 1.5971392 0.20099184 
chr6 24988105 33842877 10000 chr6 32850000 32860000 chr6 32900000 32910000 6.56E-06 1.5971392 0.20099184 
chr6 24988105 33842877 10000 chr6 32850000 32860000 chr6 32900000 32910000 6.56E-06 1.5971392 0.20099184 
chr6 24988105 33842877 10000 chr6 32850000 32860000 chr6 32900000 32910000 6.56E-06 1.5971392 0.20099184 
chr6 24988105 33842877 10000 chr6 32980000 32990000 chr6 33040000 33050000 2.64E-05 1.601542 0.26288363 
chr6 24988105 33842877 10000 chr6 32980000 32990000 chr6 33040000 33050000 2.64E-05 1.601542 0.26288363 
chr6 84264202 84409255 10000 chr6 84320000 84330000 chr6 84920000 84930000 8.82E-06 1.5061508 0.8328693 
chr7 86403263 86948073 5000 chr7 86560000 86565000 chr7 86770000 86775000 0.00199059 1.3308439 1.3042823 
chr7 86403263 86948073 5000 chr7 86560000 86565000 chr7 86770000 86775000 0.00199059 1.3308439 1.3042823 
chr7 104597669 105063372 5000 chr7 104620000 104625000 chr7 104655000 104660000 0.00326091 1.0854295 1.2470313 
chr7 104597669 105063372 5000 chr7 104620000 104625000 chr7 104655000 104660000 0.00326091 1.0854295 1.2470313 
chr8 26190836 26279173 5000 chr8 26230000 26235000 chr8 26305000 26310000 0.00317194 1.3397491 0.4989114 
chr8 38014429 38310910 10000 chr8 37960000 37970000 chr8 38240000 38250000 0.00277824 1.5559133 0.5771854 
chr8 89221915 89462854 10000 chr8 88700000 88710000 chr8 89330000 89340000 0.00277824 0.55052704 0.17356487 
             
NPCs             
Riskchr Risk start Risk end Risk overlap chr1 x1 x2 chr2 y1 y2 GliafdrDonut NeufdrDonut NPCfdrDonut 
chr1 8392592 8701288 10000 chr1 8070000 8080000 chr1 8400000 8410000 0.19700903 1.5615494 0.01706708 
chr1 8392592 8701288 10000 chr1 8470000 8480000 chr1 8780000 8790000 1.5955924 1.3734437 0.00030532 
chr1 8392592 8701288 10000 chr1 8520000 8530000 chr1 8570000 8580000 0.47351536 1.8601022 0.00419528 
chr1 8392592 8701288 10000 chr1 8520000 8530000 chr1 8570000 8580000 0.47351536 1.8601022 0.00419528 
chr1 98341152 98559093 5000 chr1 97710000 97715000 chr1 98515000 98520000 1.2857124 1.1945096 7.96E-09 
chr1 98341152 98559093 10000 chr1 98290000 98300000 chr1 98510000 98520000 0.3418393 0.22795595 3.03E-06 
chr1 149998923 150214166 5000 chr1 149930000 149935000 chr1 150155000 150160000 1.046633 1.3828198 0.00012025 
chr1 200253612 200269903 6388 chr1 200250000 200260000 chr1 200450000 200460000 0.14504352 0.84550905 5.19E-05 
chr1 243503764 243685760 5000 chr1 243505000 243510000 chr1 244010000 244015000 1.0040472 1.3334736 6.39E-07 
chr1 243503764 243685760 10000 chr1 243630000 243640000 chr1 244210000 244220000 0.2424752 1.5495831 0.00119237 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104665000 104670000 0.11233018 0.6618322 3.07E-05 
chr10 104570118 105059896 5000 chr10 104590000 104595000 chr10 104665000 104670000 0.11233018 0.6618322 3.07E-05 
chr11 24367339 24412992 5000 chr11 23560000 23565000 chr11 24405000 24410000 0.8606538 1.3652908 6.39E-07 
chr11 30240470 30395895 5000 chr11 30365000 30370000 chr11 30940000 30945000 0.61549026 0.12672402 7.96E-09 
chr11 46342942 46751495 10000 chr11 46260000 46270000 chr11 46550000 46560000 0.51119745 0.6351586 0.00517559 
chr11 65378028 65485218 10000 chr11 65470000 65480000 chr11 65760000 65770000 0.96181405 1.4031175 0.0005021 
chr11 65378028 65485218 5218 chr11 65480000 65490000 chr11 65750000 65760000 1.5454209 0.18674426 0.01933173 
chr11 113317745 113451229 10000 chr11 112080000 112090000 chr11 113400000 113410000 1.4454288 1.5345914 0.00173531 
chr12 2321868 2523772 5000 chr12 2165000 2170000 chr12 2390000 2395000 0.9105591 1.3828198 1.94E-05 
chr12 39448519 39533484 10000 chr12 38530000 38540000 chr12 39490000 39500000 1.4776708 1.3464317 0.00176357 
chr12 39448519 39533484 5000 chr12 39300000 39305000 chr12 39495000 39500000 0.18078998 0.5831852 5.75E-08 
chr12 39448519 39533484 5000 chr12 39315000 39320000 chr12 39495000 39500000 0.10347593 0.82978237 0.00040699 
chr12 57483524 57682956 5000 chr12 57400000 57405000 chr12 57500000 57505000 1.2518088 1.3637018 0.05757648 
chr12 57483524 57682956 5000 chr12 57405000 57410000 chr12 57505000 57510000 1.3117417 0.768764 6.82E-07 
chr12 57483524 57682956 5000 chr12 57460000 57465000 chr12 57500000 57505000 0.6582037 0.29175246 2.68E-09 
chr12 57483524 57682956 5000 chr12 57515000 57520000 chr12 57570000 57575000 0.31741977 1.6471775 4.71E-07 
chr12 57483524 57682956 5000 chr12 57515000 57520000 chr12 57570000 57575000 0.31741977 1.6471775 4.71E-07 
chr12 57483524 57682956 5000 chr12 57515000 57520000 chr12 57570000 57575000 0.31741977 1.6471775 4.71E-07 
chr12 57483524 57682956 5000 chr12 57515000 57520000 chr12 57570000 57575000 0.31741977 1.6471775 4.71E-07 
chr12 57483524 57682956 5000 chr12 57605000 57610000 chr12 57640000 57645000 1.2080998 0.21955356 0.00049333 
chr12 57483524 57682956 5000 chr12 57605000 57610000 chr12 57640000 57645000 1.2080998 0.21955356 0.00049333 
chr12 103361112 103382325 3888 chr12 103360000 103365000 chr12 103405000 103410000 1.0532553 1.406275 0.00465611 
chr12 123447928 123902361 10000 chr12 123450000 123460000 chr12 123630000 123640000 0.48641446 0.14620744 0.00015493 
chr12 123447928 123902361 10000 chr12 123450000 123460000 chr12 123630000 123640000 0.48641446 0.14620744 0.00015493 
chr12 123447928 123902361 5000 chr12 123755000 123760000 chr12 124065000 124070000 0.5114943 1.0074358 2.63E-06 
chr14 30000405 30190316 5000 chr14 29220000 29225000 chr14 30005000 30010000 0.4999548 1.1687775 0.00664212 
chr14 30000405 30190316 5000 chr14 30010000 30015000 chr14 30680000 30685000 0.61155725 1.312808 6.39E-07 
chr14 30000405 30190316 10000 chr14 30020000 30030000 chr14 30910000 30920000 1.0302607 1.5480927 0.02061128 
chr14 59864362 60033892 10000 chr14 59950000 59960000 chr14 60380000 60390000 1.5195316 0.6351586 2.58E-09 
chr14 59864362 60033892 10000 chr14 59970000 59980000 chr14 60640000 60650000 1.217849 1.4720036 7.04E-05 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104445000 104450000 0.38935196 1.214352 0.05757648 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104375000 104380000 0.75055546 1.3912318 5.85E-14 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104375000 104380000 0.75055546 1.3912318 5.85E-14 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104375000 104380000 0.75055546 1.3912318 5.85E-14 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104375000 104380000 0.75055546 1.3912318 5.85E-14 
chr14 104188920 104537680 5000 chr14 104270000 104275000 chr14 104445000 104450000 0.38935196 1.214352 0.05757648 
chr15 40566759 40602256 5000 chr15 40570000 40575000 chr15 40610000 40615000 1.265262 0.5248362 0.08441468 
chr15 84703470 85392298 10000 chr15 82530000 82540000 chr15 84760000 84770000 0.5006912 0.7435584 0.00023499 
chr15 84703470 85392298 10000 chr15 85120000 85130000 chr15 85470000 85480000 0.5458053 0.84550905 0.0005021 
chr16 58538662 58684945 5000 chr16 58565000 58570000 chr16 58610000 58615000 0.15176348 0.78110456 2.92E-06 
chr16 58538662 58684945 5000 chr16 58565000 58570000 chr16 58610000 58615000 0.15176348 0.78110456 2.92E-06 
chr16 67708897 68305708 10000 chr16 67840000 67850000 chr16 67960000 67970000 0.14010376 1.5178461 0.00205718 
chr16 67708897 68305708 10000 chr16 67840000 67850000 chr16 68070000 68080000 0.5458053 0.2988238 2.33E-05 
chr16 67708897 68305708 10000 chr16 67840000 67850000 chr16 67960000 67970000 0.14010376 1.5178461 0.00205718 
chr16 67708897 68305708 10000 chr16 67840000 67850000 chr16 68070000 68080000 0.5458053 0.2988238 2.33E-05 
chr16 67708897 68305708 10000 chr16 68120000 68130000 chr16 68250000 68260000 0.10775846 0.77173877 0.0001776 
chr16 67708897 68305708 10000 chr16 68120000 68130000 chr16 68250000 68260000 0.10775846 0.77173877 0.0001776 
chr17 17649172 17967397 5000 chr17 17575000 17580000 chr17 17760000 17765000 1.0688708 1.3500707 2.69E-05 
chr17 17649172 17967397 5000 chr17 17580000 17585000 chr17 17760000 17765000 0.10347593 0.5248362 0.00024168 
chr17 17649172 17967397 10000 chr17 17710000 17720000 chr17 17760000 17770000 1.2335014 1.7054206 5.20E-10 
chr17 17649172 17967397 10000 chr17 17710000 17720000 chr17 17760000 17770000 1.2335014 1.7054206 5.20E-10 
chr17 17649172 17967397 5000 chr17 17715000 17720000 chr17 17760000 17765000 1.2496098 1.2806816 1.86E-08 
chr17 17649172 17967397 5000 chr17 17715000 17720000 chr17 17760000 17765000 1.2496098 1.2806816 1.86E-08 
chr17 17649172 17967397 5000 chr17 17795000 17800000 chr17 17935000 17940000 1.0495049 0.5248362 5.57E-05 
chr17 17649172 17967397 5000 chr17 17795000 17800000 chr17 17935000 17940000 1.0495049 0.5248362 5.57E-05 
chr17 17649172 17967397 5000 chr17 17795000 17800000 chr17 17935000 17940000 1.0495049 0.5248362 5.57E-05 
chr17 17649172 17967397 5000 chr17 17795000 17800000 chr17 17935000 17940000 1.0495049 0.5248362 5.57E-05 
chr18 52747689 53804156 5000 chr18 53080000 53085000 chr18 54240000 54245000 0.5891176 1.3511385 4.20E-06 
chr18 52747689 53804156 10000 chr18 53250000 53260000 chr18 54240000 54250000 0.1354248 0.2903848 1.89E-05 
chr19 19358332 19657632 10000 chr19 19640000 19650000 chr19 20060000 20070000 0.9354744 0.35116497 6.07E-07 
chr19 50106208 50182697 10000 chr19 50010000 50020000 chr19 50170000 50180000 0.14845291 0.45033494 3.03E-06 
chr2 57950104 58484172 10000 chr2 57980000 57990000 chr2 58460000 58470000 1.173447 1.5335083 0.00251959 
chr2 57950104 58484172 10000 chr2 57980000 57990000 chr2 58460000 58470000 1.173447 1.5335083 0.00251959 
chr2 57950104 58484172 10000 chr2 58130000 58140000 chr2 58780000 58790000 1.5449245 1.2797885 0.00020904 
chr2 57950104 58484172 5000 chr2 58135000 58140000 chr2 58670000 58675000 1.2857124 1.1327559 0.00071491 
chr2 198146381 198940251 10000 chr2 197160000 197170000 chr2 198240000 198250000 1.4342196 1.5084682 8.24E-05 
chr2 198146381 198940251 5000 chr2 197710000 197715000 chr2 198270000 198275000 1.2287014 1.34677 2.69E-05 
chr2 198146381 198940251 10000 chr2 197760000 197770000 chr2 198260000 198270000 1.173447 1.3162088 7.00E-09 
chr2 198146381 198940251 10000 chr2 197790000 197800000 chr2 198170000 198180000 1.0634867 0.14082912 0.00205718 
chr2 198146381 198940251 5000 chr2 198055000 198060000 chr2 198245000 198250000 0.11233018 1.0938406 0.00040699 
chr2 198146381 198940251 5000 chr2 198055000 198060000 chr2 198245000 198250000 0.11233018 1.0938406 0.00040699 
 
 234 
chr2 198146381 198940251 5000 chr2 198275000 198280000 chr2 198350000 198355000 0.33233196 1.1542732 0.00040699 
chr2 198146381 198940251 5000 chr2 198275000 198280000 chr2 198350000 198355000 0.33233196 1.1542732 0.00040699 
chr2 198146381 198940251 5000 chr2 198365000 198370000 chr2 198570000 198575000 0.5114943 1.3262548 8.71E-06 
chr2 198146381 198940251 5000 chr2 198365000 198370000 chr2 198570000 198575000 0.5114943 1.3262548 8.71E-06 
chr2 200547937 201309547 5000 chr2 199175000 199180000 chr2 200605000 200610000 1.2815038 0.25484702 0.00180604 
chr2 200547937 201309547 5000 chr2 200565000 200570000 chr2 200605000 200610000 0.884727 1.3637018 0.00103107 
chr2 200547937 201309547 5000 chr2 200565000 200570000 chr2 200605000 200610000 0.884727 1.3637018 0.00103107 
chr22 41408754 41684093 5000 chr22 41345000 41350000 chr22 41415000 41420000 1.0219431 1.3248246 0.00267979 
chr22 41408754 41684093 10000 chr22 41550000 41560000 chr22 42030000 42040000 1.4649647 1.3464317 2.30E-05 
chr22 42315790 42689370 10000 chr22 42350000 42360000 chr22 42480000 42490000 1.5955924 1.5869178 3.77E-05 
chr22 42315790 42689370 10000 chr22 42350000 42360000 chr22 42480000 42490000 1.5955924 1.5869178 3.77E-05 
chr3 10800703 10807667 4297 chr3 10800000 10805000 chr3 11100000 11105000 1.2339293 0.5064022 7.70E-10 
chr3 10800703 10807667 6964 chr3 10800000 10810000 chr3 10920000 10930000 1.4067187 1.5559133 0.00251959 
chr3 17221017 17888256 5000 chr3 16640000 16645000 chr3 17455000 17460000 0.7089102 1.1532058 4.27E-06 
chr3 17221017 17888256 10000 chr3 17290000 17300000 chr3 17880000 17890000 0.4119865 0.86441755 0.01132488 
chr3 17221017 17888256 8256 chr3 17290000 17300000 chr3 17880000 17890000 0.4119865 0.86441755 0.01132488 
chr3 17221017 17888256 10000 chr3 17300000 17310000 chr3 17880000 17890000 1.069242 1.3684161 0.00194236 
chr3 17221017 17888256 8256 chr3 17300000 17310000 chr3 17880000 17890000 1.069242 1.3684161 0.00194236 
chr3 17221017 17888256 5000 chr3 17470000 17475000 chr3 17875000 17880000 0.34376985 1.0329467 1.63E-05 
chr3 17221017 17888256 5000 chr3 17470000 17475000 chr3 17875000 17880000 0.34376985 1.0329467 1.63E-05 
chr3 52965713 53175017 10000 chr3 52880000 52890000 chr3 53100000 53110000 0.31834856 1.5495831 4.66E-05 
chr3 63792668 64003983 10000 chr3 62600000 62610000 chr3 63800000 63810000 1.2053969 0.6132447 0.00451189 
chr3 135807609 136615268 5000 chr3 135920000 135925000 chr3 135965000 135970000 0.31253472 1.3427322 0.03763996 
chr3 135807609 136615268 5000 chr3 135920000 135925000 chr3 135965000 135970000 0.31253472 1.3427322 0.03763996 
chr3 135807609 136615268 10000 chr3 135970000 135980000 chr3 136460000 136470000 1.579057 1.3394774 0.00162069 
chr3 135807609 136615268 10000 chr3 135970000 135980000 chr3 136460000 136470000 1.579057 1.3394774 0.00162069 
chr3 135807609 136615268 10000 chr3 136110000 136120000 chr3 136720000 136730000 1.5838375 1.5335083 0.06340116 
chr3 135807609 136615268 5000 chr3 136265000 136270000 chr3 136470000 136475000 1.2750337 1.269171 7.88E-06 
chr3 135807609 136615268 5000 chr3 136265000 136270000 chr3 136470000 136475000 1.2750337 1.269171 7.88E-06 
chr3 180571624 181207851 5000 chr3 180705000 180710000 chr3 180890000 180895000 0.884727 1.1728417 5.75E-08 
chr3 180571624 181207851 5000 chr3 180705000 180710000 chr3 180890000 180895000 0.884727 1.1728417 5.75E-08 
chr3 180571624 181207851 10000 chr3 180770000 180780000 chr3 181430000 181440000 1.4305197 1.5375824 2.30E-05 
chr3 180571624 181207851 10000 chr3 181170000 181180000 chr3 181320000 181330000 1.5225048 1.5741836 3.97E-05 
chr4 103001649 103198082 10000 chr4 102080000 102090000 chr4 103180000 103190000 0.31834856 1.5084682 6.39E-11 
chr4 143742567 143883013 10000 chr4 143200000 143210000 chr4 143760000 143770000 0.2424752 1.466538 0.00010735 
chr4 170357792 170646003 10000 chr4 170180000 170190000 chr4 170400000 170410000 0.26364303 1.4433368 0.0005892 
chr4 170357792 170646003 10000 chr4 170530000 170540000 chr4 170970000 170980000 0.51119745 0.4597334 4.66E-05 
chr5 49441779 49884022 10000 chr5 46320000 46330000 chr5 49500000 49510000 74.00363 196.37476 9.41E-08 
chr5 49441779 49884022 10000 chr5 46320000 46330000 chr5 49500000 49510000 74.00363 196.37476 9.41E-08 
chr5 87676693 88195380 5000 chr5 86705000 86710000 chr5 87685000 87690000 1.2059175 1.0492826 0.00019324 
chr5 87676693 88195380 5000 chr5 87240000 87245000 chr5 87690000 87695000 1.3303624 1.2508715 2.52E-08 
chr5 87676693 88195380 5000 chr5 87240000 87245000 chr5 87960000 87965000 1.0688708 1.2623683 1.84E-09 
chr5 87676693 88195380 5000 chr5 87440000 87445000 chr5 87840000 87845000 0.5114943 1.1590292 0.00024168 
chr5 87676693 88195380 10000 chr5 87500000 87510000 chr5 87960000 87970000 0.10775846 0.84550905 6.22E-13 
chr5 87676693 88195380 5000 chr5 87690000 87695000 chr5 87840000 87845000 0.38935196 0.5064022 8.71E-06 
chr5 87676693 88195380 5000 chr5 87690000 87695000 chr5 87840000 87845000 0.38935196 0.5064022 8.71E-06 
chr5 87676693 88195380 5000 chr5 87695000 87700000 chr5 87780000 87785000 0.11233018 1.34677 2.15E-06 
chr5 87676693 88195380 5000 chr5 87695000 87700000 chr5 87780000 87785000 0.11233018 1.34677 2.15E-06 
chr5 87676693 88195380 5000 chr5 87710000 87715000 chr5 87765000 87770000 0.6582037 1.3248246 0.01746155 
chr5 87676693 88195380 5000 chr5 87710000 87715000 chr5 87765000 87770000 0.6582037 1.3248246 0.01746155 
chr5 87676693 88195380 5000 chr5 87780000 87785000 chr5 87960000 87965000 0.500902 0.12672402 8.71E-06 
chr5 87676693 88195380 5000 chr5 87780000 87785000 chr5 87960000 87965000 0.500902 0.12672402 8.71E-06 
chr5 87676693 88195380 5000 chr5 87850000 87855000 chr5 87950000 87955000 1.2184821 1.269171 2.63E-06 
chr5 87676693 88195380 5000 chr5 87850000 87855000 chr5 87950000 87955000 1.2184821 1.269171 2.63E-06 
chr5 137838122 137948140 1878 chr5 137785000 137790000 chr5 137835000 137840000 0.4254983 1.2680601 7.56E-12 
chr6 24988105 33842877 5000 chr6 24855000 24860000 chr6 25060000 25065000 1.0038705 0.9483586 0.02084518 
chr6 24988105 33842877 5000 chr6 24860000 24865000 chr6 25015000 25020000 0.8402052 1.4453112 0.00296772 
chr6 24988105 33842877 5000 chr6 25220000 25225000 chr6 25600000 25605000 0.6925214 1.3397491 6.44E-12 
chr6 24988105 33842877 10000 chr6 25220000 25230000 chr6 25880000 25890000 1.4305197 1.5657233 0.00011976 
chr6 24988105 33842877 5000 chr6 25220000 25225000 chr6 25600000 25605000 0.6925214 1.3397491 6.44E-12 
chr6 24988105 33842877 10000 chr6 25220000 25230000 chr6 25880000 25890000 1.4305197 1.5657233 0.00011976 
chr6 24988105 33842877 5000 chr6 25270000 25275000 chr6 25490000 25495000 0.11233018 1.3367205 0.00588869 
chr6 24988105 33842877 5000 chr6 25270000 25275000 chr6 25490000 25495000 0.11233018 1.3367205 0.00588869 
chr6 24988105 33842877 5000 chr6 25275000 25280000 chr6 25485000 25490000 0.6925214 1.1728417 0.00117906 
chr6 24988105 33842877 5000 chr6 25275000 25280000 chr6 25485000 25490000 0.6925214 1.1728417 0.00117906 
chr6 24988105 33842877 10000 chr6 26170000 26180000 chr6 26570000 26580000 0.74615896 1.5682914 0.01017091 
chr6 24988105 33842877 10000 chr6 26170000 26180000 chr6 26570000 26580000 0.74615896 1.5682914 0.01017091 
chr6 24988105 33842877 10000 chr6 26330000 26340000 chr6 27040000 27050000 1.5449245 0.8654066 1.48E-06 
chr6 24988105 33842877 10000 chr6 26330000 26340000 chr6 27040000 27050000 1.5449245 0.8654066 1.48E-06 
chr6 24988105 33842877 10000 chr6 26810000 26820000 chr6 58210000 58220000 3.5411448 22.384825 7.29E-16 
chr6 24988105 33842877 10000 chr6 26810000 26820000 chr6 58210000 58220000 3.5411448 22.384825 7.29E-16 
chr6 24988105 33842877 5000 chr6 27120000 27125000 chr6 27860000 27865000 0.32161906 0.5831852 0.00068245 
chr6 24988105 33842877 5000 chr6 27120000 27125000 chr6 27860000 27865000 0.32161906 0.5831852 0.00068245 
chr6 24988105 33842877 5000 chr6 27155000 27160000 chr6 27755000 27760000 1.2981611 1.3262548 8.30E-05 
chr6 24988105 33842877 5000 chr6 27155000 27160000 chr6 27755000 27760000 1.2981611 1.3262548 8.30E-05 
chr6 24988105 33842877 10000 chr6 27480000 27490000 chr6 27550000 27560000 1.3893585 1.6099682 3.71E-05 
chr6 24988105 33842877 10000 chr6 27480000 27490000 chr6 27550000 27560000 1.3893585 1.6099682 3.71E-05 
chr6 24988105 33842877 10000 chr6 27650000 27660000 chr6 27860000 27870000 1.3705888 1.3260291 1.89E-05 
chr6 24988105 33842877 10000 chr6 27650000 27660000 chr6 27860000 27870000 1.3705888 1.3260291 1.89E-05 
chr6 24988105 33842877 5000 chr6 28105000 28110000 chr6 28190000 28195000 0.75055546 1.3637018 0.00267979 
chr6 24988105 33842877 5000 chr6 28105000 28110000 chr6 28190000 28195000 0.75055546 1.3637018 0.00267979 
chr6 24988105 33842877 10000 chr6 28460000 28470000 chr6 28650000 28660000 0.1354248 0.45033494 1.03E-05 
chr6 24988105 33842877 10000 chr6 28460000 28470000 chr6 28650000 28660000 0.1354248 0.45033494 1.03E-05 
chr6 24988105 33842877 10000 chr6 28650000 28660000 chr6 29550000 29560000 0.13810997 0.15189412 6.27E-06 
chr6 24988105 33842877 10000 chr6 28650000 28660000 chr6 29550000 29560000 0.13810997 0.15189412 6.27E-06 
chr6 24988105 33842877 5000 chr6 29810000 29815000 chr6 29975000 29980000 0.38935196 1.3514338 1.04E-06 
chr6 24988105 33842877 5000 chr6 29810000 29815000 chr6 29975000 29980000 0.38935196 1.3514338 1.04E-06 
chr6 24988105 33842877 5000 chr6 29815000 29820000 chr6 29975000 29980000 0.16963711 0.49460578 3.02E-06 
chr6 24988105 33842877 5000 chr6 29815000 29820000 chr6 29975000 29980000 0.16963711 0.49460578 3.02E-06 
chr6 24988105 33842877 5000 chr6 30450000 30455000 chr6 30565000 30570000 0.61549026 1.2254188 0.00023257 
chr6 24988105 33842877 5000 chr6 30450000 30455000 chr6 30565000 30570000 0.61549026 1.2254188 0.00023257 
chr6 24988105 33842877 10000 chr6 30500000 30510000 chr6 31050000 31060000 0.10125773 1.2104888 1.76E-05 
chr6 24988105 33842877 10000 chr6 30500000 30510000 chr6 31050000 31060000 0.10125773 1.2104888 1.76E-05 
chr6 24988105 33842877 5000 chr6 31510000 31515000 chr6 31630000 31635000 1.2857124 0.76937705 0.00682281 
chr6 24988105 33842877 5000 chr6 31510000 31515000 chr6 31630000 31635000 1.2857124 0.76937705 0.00682281 
chr6 24988105 33842877 5000 chr6 31760000 31765000 chr6 31800000 31805000 0.9526036 1.4984149 0.00296772 
chr6 24988105 33842877 5000 chr6 31760000 31765000 chr6 31800000 31805000 0.9526036 1.4984149 0.00296772 
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chr6 24988105 33842877 10000 chr6 32080000 32090000 chr6 32140000 32150000 0.44272268 1.6237167 4.96E-05 
chr6 24988105 33842877 10000 chr6 32080000 32090000 chr6 32140000 32150000 0.44272268 1.6237167 4.96E-05 
chr6 24988105 33842877 5000 chr6 32380000 32385000 chr6 32665000 32670000 0.38935196 0.5867754 4.44E-10 
chr6 24988105 33842877 10000 chr6 32380000 32390000 chr6 32830000 32840000 0.8012636 1.1520559 1.76E-05 
chr6 24988105 33842877 10000 chr6 32380000 32390000 chr6 32830000 32840000 0.8012636 1.1520559 1.76E-05 
chr6 24988105 33842877 5000 chr6 32380000 32385000 chr6 32665000 32670000 0.38935196 0.5867754 4.44E-10 
chr6 24988105 33842877 10000 chr6 32380000 32390000 chr6 32830000 32840000 0.8012636 1.1520559 1.76E-05 
chr6 24988105 33842877 10000 chr6 32380000 32390000 chr6 32830000 32840000 0.8012636 1.1520559 1.76E-05 
chr6 24988105 33842877 5000 chr6 32850000 32855000 chr6 32940000 32945000 0.4254983 1.3397491 0.01301809 
chr6 24988105 33842877 5000 chr6 32850000 32855000 chr6 32925000 32930000 0.58261454 1.3912318 5.14E-07 
chr6 24988105 33842877 5000 chr6 32850000 32855000 chr6 32925000 32930000 0.58261454 1.3912318 5.14E-07 
chr6 24988105 33842877 5000 chr6 32850000 32855000 chr6 32940000 32945000 0.4254983 1.3397491 0.01301809 
chr6 24988105 33842877 5000 chr6 33550000 33555000 chr6 33675000 33680000 0.21398759 0.18502843 1.39E-07 
chr6 24988105 33842877 5000 chr6 33550000 33555000 chr6 33675000 33680000 0.21398759 0.18502843 1.39E-07 
chr6 24988105 33842877 5000 chr6 33735000 33740000 chr6 33995000 34000000 0.16174258 1.214352 0.00071491 
chr6 24988105 33842877 5000 chr6 33735000 33740000 chr6 34120000 34125000 1.2104913 0.17672323 6.03E-05 
chr6 24988105 33842877 5000 chr6 33735000 33740000 chr6 34120000 34125000 1.2104913 0.17672323 6.03E-05 
chr6 84264202 84409255 10000 chr6 84320000 84330000 chr6 84930000 84940000 0.21959442 0.31036413 0.0002823 
chr7 86403263 86948073 5000 chr7 86565000 86570000 chr7 86780000 86785000 0.32161906 1.0722134 0.00021275 
chr7 86403263 86948073 5000 chr7 86565000 86570000 chr7 86780000 86785000 0.32161906 1.0722134 0.00021275 
chr7 86403263 86948073 10000 chr7 86690000 86700000 chr7 87580000 87590000 74.00363 1.4095246 0.04428426 
chr8 18396405 18429406 9406 chr8 18050000 18060000 chr8 18420000 18430000 1.4860443 1.1758273 1.23E-07 
chr8 26190836 26279173 5000 chr8 26230000 26235000 chr8 26510000 26515000 0.34376985 1.2175577 0.00071491 
chr8 27327841 27453762 3762 chr8 27170000 27175000 chr8 27450000 27455000 0.7089102 1.3237675 5.86E-05 
chr8 27327841 27453762 3762 chr8 27170000 27175000 chr8 27450000 27455000 0.7089102 1.3237675 5.86E-05 
chr8 38014429 38310910 10000 chr8 37630000 37640000 chr8 38020000 38030000 1.3000284 0.2903848 4.66E-05 
chr8 38014429 38310910 5000 chr8 37975000 37980000 chr8 38030000 38035000 1.2364298 1.3860595 3.32E-06 
chr8 38014429 38310910 5000 chr8 37975000 37980000 chr8 38030000 38035000 1.2364298 1.3860595 3.32E-06 
chr8 38014429 38310910 5000 chr8 38035000 38040000 chr8 38575000 38580000 0.34376985 1.0722134 0.00021275 
chr8 60475926 60954059 5000 chr8 59630000 59635000 chr8 60835000 60840000 0.10347593 1.2623683 2.74E-05 
chr8 60475926 60954059 5000 chr8 59720000 59725000 chr8 60830000 60835000 0.8606538 0.8023862 9.22E-05 
chr8 89221915 89462854 10000 chr8 87710000 87720000 chr8 89330000 89340000 1.3222934 0.45391688 3.55E-07 
chr9 101065115 101076627 1627 chr9 101075000 101080000 chr9 101535000 101540000 0.17700288 1.2175577 5.86E-05 
 
Table 3.9 | Loops anchored in schizophrenia (SZ) risk sequence. 
Cell-type-specific HiCCUPS loops (i.e., FDR < 0.1 in one cell type and FDR > 0.1 
in the remaining two) overlapping SZ risk-associated GWAS loci in at least one 
anchor. Riskchr, Risk start, Risk end = coordinates of SZ risk locus overlapping 
loop anchor; Risk overlap = # bp overlap between loop anchor and risk locus; 
chr1, x1, x2 = anchor 1 coordinates; chr2, y1, y2 = anchor 2 coordinates; 
Glia/Neu/NPC-fdrDonut = HiCCUPS FDR value from the "donut" local 
neighborhood.          
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8890000 RERE|0|- 1.57E+00 2.25E+00 1.78E+00 – – – primary 
rs2015



































1|- 6.28E+00 7.76E+00 1.82E+00 – – – primary 
rs3522



















44 0.15 – – adult primary 
rs1865



















11|+ 1.33E+00 2.21E-01 4.18E-01 
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ganglia)  – adult conditional 
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|0|- 7.46E-03 7.35E-02 2.19E-01 – – – primary 
rs1093
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13038|I|- 3.52E+00 5.98E+00 4.65E+00 – – – primary 
rs3935



















































































































1|- 8.66E-01 9.55E-01 6.07E-01 – – – primary 
rs4072

















56 – – – primary 
rs7298


































0-1|+ 2.81E+00 5.43E+00 
1.442334
63 – – – primary 
rs5023















26 9.12E-01 5.46E-01 – – – primary 
rs2004

















77 – – – primary 
 
Table 3.10 | Chromosomal contacts anchored in SZ GWAS co-localized 
eQTLs.  
HiC interactions overlapping GWAS co-localized eQTL SNP-gene pairs (Dobbyn 
et al., 2018). Columns A-E are from Dobbyn et al (2018) Table 2. eSNP, eQTL 
SNP; Chr, GWAS Locus Start and GWAS Locus End together indicate the 
coordinates for the corresponding risk locus within which the eSNP resides; 
Gene, the gene corresponding to the eSNP; eSNP position, coordinate of the 
eSNP in hg19; ROI, region of interest corresponding to the SZ risk loci; 
anchor.bin.coord, coordinate of the 10kb used as anchor in the binomial test for 
significant interactions; anchor.bin.genes, genes overlapping the 10kb anchor 
bin; target.bin.coord, coordinate of the 10kb queried as a  target of the anchor in 
the binomial test for significant interactions; target.bin.genes, genes overlapping 
the 10kb target bin; Glia, NPC, Neuron columns refer to the log (q-value) for each 
interaction determined by binomial statistics.       
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Table 12Table 3.11 |  Gene- level sing le- SNP eQTLs for clustered PCDH  
      Genotype 0 (n=150) Genotype 1 (n=277) Genotype 2 (n=152) 
Ensembl ID Gene ID Gene Start (bp) Gene End (bp) p-value p-adjusted Mean SE Mean SE Mean SE 
ENSG00000250120 PCDHA10 140235595 140391929 2.40E-14 1.61E-12 -0.9450845 0.14005154 -0.3220529 0.0469093 -0.018637 0.03260897 
ENSG00000204962 PCDHA8 140220907 140391929 5.52E-13 3.70E-11 -1.562385 0.04569762 -1.315371 0.03233461 -1.085131 0.04282544 
ENSG00000204963 PCDHA7 140213969 140391929 2.03E-11 1.36E-09 -1.2849008 0.04151695 -1.0832615 0.02988216 -0.9140139 0.04085353 
ENSG00000204969 PCDHA2 140174444 140391929 1.87E-09 1.25E-07 -1.263745 0.03214275 -1.1634137 0.02443782 -0.9951632 0.0306389 
ENSG00000239389 PCDHA13 140261793 140391929 2.65E-08 1.78E-06 -0.3379225 0.03420221 -0.4584249 0.02614051 -0.5841679 0.03465996 
ENSG00000204967 PCDHA4 140186659 140391929 1.28E-05 0.0008576 -0.0940208 0.03133687 0.07152288 0.02254759 0.08552427 0.03129946 
ENSG00000204961 PCDHA9 140227048 140391929 0.0003829 0.0256543 -0.8885906 0.13530321 -0.531843 0.04152144 -0.4422395 0.04931668 
ENSG00000249158 PCDHA11 140248689 140391929 0.0008857 0.0593419 0.4383577 0.03023422 0.5256985 0.02074671 0.5673561 0.02727161 
ENSG00000204970 PCDHA1 140165876 140391929 0.2997 1 -1.168368 0.03560745 -1.212149 0.02525289 -1.238437 0.03251574 
ENSG00000255408 PCDHA3 140180783 140391929 0.09267 1 -0.3266051 0.02698158 -0.2652614 0.02019158 -0.2768451 0.03101834 
ENSG00000204965 PCDHA5 140201222 140391929 0.3493 1 0.01375301 0.03100332 0.06426113 0.02347947 0.044756 0.03029636 
ENSG00000081842 PCDHA6 140207563 140391929 0.4351 1 -0.0261231 0.0399647 -0.0368595 0.02697582 -0.0722259 0.03390551 
ENSG00000249034 AC005609.1 140240341 140243224 0.8416 1 -1.651762 0.06461126 -1.734715 0.0462817 -1.657964 0.06411573 
ENSG00000251664 PCDHA12 140255058 140391929 0.01968 1 -0.5597011 0.03440314 -0.4958071 0.02650548 -0.4345344 0.03334305 
ENSG00000248383 PCDHAC1 140306302 140391929 0.04019 1 0.1123253 0.04139802 0.1829496 0.02673045 0.2158291 0.03283328 
ENSG00000243232 PCDHAC2 140345820 140391936 0.589 1 2.361629 0.03826713 2.376794 0.03004392 2.326327 0.03968978 
ENSG00000112852 PCDHB2 140474227 140476962 0.3131 1 0.6907204 0.03089572 0.6421203 0.02787192 0.6447874 0.0344836 
ENSG00000272154 AC005754.7 140479829 140481794 0.881 1 -0.0156119 0.04615792 0.05565437 0.03715139 -0.0173929 0.06464357 
ENSG00000113205 PCDHB3 140480234 140483406 0.02615 1 0.4022594 0.03103061 0.3829122 0.0218286 0.3135084 0.02927212 
ENSG00000272108 AC005754.8 140498262 140500347 0.04383 1 0.6543306 0.04894567 0.5441159 0.03794151 0.5393526 0.05292806 
ENSG00000081818 PCDHB4 140501581 140505201 0.8963 1 1.841228 0.02971057 1.815392 0.02339597 1.810416 0.03254467 
ENSG00000113209 PCDHB5 140514800 140517703 0.224 1 1.567102 0.02299553 1.549667 0.02068541 1.51964 0.02580371 
ENSG00000113211 PCDHB6 140529683 140532868 0.3184 1 0.265684 0.03583055 0.2689495 0.02605475 0.3133934 0.03659252 
ENSG00000255622 PCDHB17 140535577 140538639 0.7226 1 -0.3756098 0.04920646 -0.4890143 0.03970313 -0.4072474 0.05548462 
ENSG00000113212 PCDHB7 140552243 140555957 0.3499 1 0.4885163 0.03826745 0.4943283 0.03128195 0.5439796 0.04520774 
ENSG00000120322 PCDHB8 140557371 140560081 0.9269 1 0.01001523 0.04438598 -0.0132715 0.03983904 0.02598359 0.05385032 
ENSG00000196963 PCDHB16 140560980 140565793 0.4212 1 0.02597449 0.04194141 -0.0275194 0.03339609 0.09018198 0.04660624 
ENSG00000177839 PCDHB9 140566893 140571111 0.03744 1 0.674292 0.0381622 0.7036802 0.02482808 0.7873397 0.03631906 
ENSG00000120324 PCDHB10 140571942 140575215 0.0332 1 1.550995 0.02669294 1.558507 0.01814735 1.626481 0.02711403 
ENSG00000197479 PCDHB11 140579183 140582618 0.7363 1 1.24371 0.02766519 1.198184 0.02279798 1.224654 0.02874177 
ENSG00000120328 PCDHB12 140588269 140591696 0.5195 1 1.578292 0.02579869 1.568764 0.01984231 1.613458 0.02583847 
ENSG00000187372 PCDHB13 140593509 140596993 0.5773 1 1.144594 0.03861705 1.117381 0.02907133 1.186299 0.04333161 
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ENSG00000120327 PCDHB14 140602931 140605858 0.6245 1 2.37246 0.01787361 2.345718 0.01396584 2.359431 0.01816899 
ENSG00000146001 PCDHB18 140613938 140617101 0.7843 1 0.5287241 0.04483872 0.4868465 0.03350162 0.556907 0.04718459 
ENSG00000262096 PCDHB19P 140619518 140621864 0.6678 1 0.5610128 0.05018575 0.5222347 0.036843 0.6020646 0.04864062 
ENSG00000113248 PCDHB15 140625147 140627799 0.2016 1 1.275723 0.02478772 1.259874 0.02024715 1.326387 0.0259284 
ENSG00000178913 TAF7 140698057 140700330 0.6472 1 5.287593 0.02872701 5.307101 0.02267996 5.242052 0.03666379 
ENSG00000272070 AC005618.6 140705777 140708924 0.3824 1 0.2658314 0.02889967 0.2744418 0.02361841 0.2928478 0.03017335 
ENSG00000204956 PCDHGA1 140710252 140892546 0.08634 1 -0.9367046 0.04188522 -0.8589053 0.0321514 -0.8368188 0.03893686 
ENSG00000081853 PCDHGA2 140718539 140892546 0.3214 1 -0.4044892 0.04268331 -0.4066491 0.03242702 -0.3469972 0.03727468 
ENSG00000254245 PCDHGA3 140723601 140892546 0.699 1 0.10353173 0.04510637 0.08295321 0.03484245 0.15444447 0.0494062 
ENSG00000254221 PCDHGB1 140729828 140892546 0.05279 1 0.372262 0.03450643 0.3869631 0.02540657 0.4593994 0.03457968 
ENSG00000262576 PCDHGA4 140734768 140892546 0.6408 1 -0.0668598 0.03192729 -0.0684422 0.02606557 -0.0257894 0.03763937 
ENSG00000253910 PCDHGB2 140739703 140892546 0.01694 1 0.3736417 0.037329 0.4069007 0.03197805 0.5231219 0.04426136 
ENSG00000253485 PCDHGA5 140743898 140892546 0.6391 1 -0.401642 0.03938976 -0.373267 0.03426557 -0.3313155 0.0488054 
ENSG00000262209 PCDHGB3 140749831 140892546 0.1391 1 -0.9051775 0.04431799 -0.8966564 0.03587637 -0.7654312 0.05014739 
ENSG00000253731 PCDHGA6 140753651 140892546 0.6019 1 -0.3094883 0.0401174 -0.2804153 0.03370213 -0.3146994 0.05037824 
ENSG00000253537 PCDHGA7 140762467 140892546 0.485 1 -0.4691286 0.03963365 -0.4766255 0.03066884 -0.4103881 0.04403638 
ENSG00000253953 PCDHGB4 140767452 140892546 0.2756 1 -0.4760418 0.03919649 -0.4802712 0.02919548 -0.412954 0.04021008 
ENSG00000253767 PCDHGA8 140772381 140892546 0.363 1 -0.9928499 0.05395769 -0.9891268 0.0443002 -0.8983144 0.06304307 
ENSG00000261934 PCDHGA9 140782520 140892546 0.419 1 0.7850766 0.03107475 0.7785777 0.0252662 0.8391602 0.03686301 
ENSG00000253305 PCDHGB6 140787770 140892546 0.438 1 0.08134237 0.04342428 0.09391992 0.03328246 0.14412456 0.04685704 
ENSG00000253846 PCDHGA10 140792743 140892546 0.9656 1 0.7094627 0.03317664 0.7157928 0.02714398 0.7139836 0.03741461 
ENSG00000254122 PCDHGB7 140797427 140892546 0.2273 1 -0.0062796 0.04391279 0.0008358 0.03474804 0.10182631 0.05136511 
ENSG00000253873 PCDHGA11 140800762 140891835 0.7571 1 0.1503583 0.03974685 0.1630275 0.03141137 0.1841329 0.04277974 
ENSG00000248449 PCDHGB8P 140805853 140808219 0.4083 1 0.1226163 0.05903111 0.0846888 0.0463076 0.2108079 0.06345998 
ENSG00000253159 PCDHGA12 140810185 140892546 0.5601 1 0.4870029 0.04397322 0.4898922 0.03426719 0.521935 0.04629193 
ENSG00000240184 PCDHGC3 140855580 140892542 0.246 1 3.335496 0.04493861 3.390439 0.03367271 3.400317 0.04292565 
ENSG00000242419 PCDHGC4 140864741 140892546 0.6337 1 1.511794 0.04101957 1.537931 0.02512287 1.522494 0.03315068 
ENSG00000240764 PCDHGC5 140868808 140892546 0.8556 1 2.872448 0.04664224 2.888523 0.03236965 2.84832 0.04243448 
ENSG00000131504 DIAPH1 140894583 140998622 0.8943 1 2.475123 0.02367114 2.446633 0.01934177 2.486694 0.02561167 
ENSG00000248106 AC005609.2 140143695 140144406 NA NA NA NA NA NA NA NA 
ENSG00000249504 PCDHA14 140240860 140243104 NA NA NA NA NA NA NA NA 
ENSG00000171815 PCDHB1 140430979 140433512 NA NA NA NA NA NA NA NA 
ENSG00000120329 SLC25A2 140682196 140683612 NA NA NA NA NA NA NA NA 
ENSG00000255729 AC005618.1 140699661 140700339 NA NA NA NA NA NA NA NA 
ENSG00000242020 RN7SL68P 140858883 140859190 NA NA NA NA NA NA NA NA 
 
Table 3.11 | Gene-level single-SNP eQTLs for clustered PCDH. 
 
 240 Gene-level single-SNP eQTL analysis testing for association of clustered PCDH 
gene expression with SZ risk SNP rs111896713. Significant genes are 
highlighted in green.         
    
 
Table 13Table 3.12 |  Locus- specific chromosomal contact s in  fetal brain  compared to hiPSC-derived cells 
bp credsnp indexsnp R_to_index hgnc_CP hgnc_GZ hgnc_ES hgnc_IMR90 NPC Neuron Glia 
103573575 rs10860949 rs10860964 0.976583         ASCL1, C12orf42 NA NA 
103574202 rs7306170 rs10860964 0.910154         ASCL1, C12orf42 NA NA 
103575583 rs10778221 rs10860964 0.973776 C12orf42 NA NA NA ASCL1, C12orf42 NA NA 
103575787 rs10860950 rs10860964 0.936245 C12orf42 NA NA NA ASCL1, C12orf42 NA NA 
68377126 rs5937157 rs5937157 1 EFNB1 NA NA NA EFNB1 NA EFNB1 
68377204 rs62606711 rs5937157 0.912256 EFNB1 NA NA NA EFNB1 NA EFNB1 
68377205 rs62606712 rs5937157 0.90829 EFNB1 NA NA NA EFNB1 NA EFNB1 
68377485 rs2361468 rs5937157 0.993235 EFNB1 NA NA NA EFNB1 NA EFNB1 
68377499 rs2885287 rs5937157 0.993235 EFNB1 NA NA NA EFNB1 NA EFNB1 
68379039 rs5937159 rs5937157 0.92888 EFNB1 NA NA NA EFNB1 NA EFNB1 
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OX2 NA NA SOX2, SOX-OT SOX2, SOX-OT SOX2, SOX-OT, FLJ46066 
113364647 rs4245150 rs2514218 0.952883 DRD2 DRD2 NA NA TTC12 TTC12 TTC12 
113364691 rs17602038 rs2514218 0.952883 DRD2 DRD2 NA NA TTC12 TTC12 TTC12 
113364803 rs4938021 rs2514218 0.952883 DRD2 DRD2 NA NA TTC12 TTC12 TTC12 
113365084 rs4936275 rs2514218 0.952883 DRD2 DRD2 NA NA TTC12 TTC12 TTC12 
113365141 rs4936276 rs2514218 0.952883 DRD2 DRD2 NA NA TTC12 TTC12 TTC12 




























































































































































































































































































































































































































































































Table 3.12 | Locus-specific chromosomal contacts in fetal brain compared 
to hiPSC-derived cells. 
Comparison of genes identified as interacting with 36 credible SNPs of interest 
(Won et al., 2016) between fetal brain and hiPSC Hi-C interactions. Credsnp, 
credible SNP called by CAVIAR; indexsnp, index SNP of the haplotype in which 
 
 242 credible SNP lies; R_to_index, correlation between credible SNP and its index 
SNP; hgnc_CP, gene interacting with credible SNP in cortical plate samples; 
hgnc_GZ, gene interacting with credible SNP in germinal zone samples; 
hgnc_ES, gene interacting with credible SNP in embryonic stem cell samples; 
hgnc_IMR90, gene interacting with credible SNP in IMR90 samples; NPC, 













































Table 14Table 3.13 |  Oligonucleotide sequences for  gRN A in vitro transcription  
ID TYPE COORDINATES (Region, gRNA) gRNA SEQUENCE 
REVERSE 


























































































































































































































































































































































































































































































































































































































































































            
Cas9 
ID TYPE COORDINATES (Region, gRNA) gRNA SEQUENCE 
REVERSE 
























































gacagacatc PCDH rs12659129 
         
 
































































AGAGTGGTCATTC ASCL1 rs10860950 




















ggcactaatt MATR3 rs11957778 







































CCGAAATGTCCTT EFNB1 rs2885287 













ggagttcgcagt EP300 rs9607768 
 
Table 3.13 | Oligonucleotide sequences for gRNA in vitro transcription. 
Oligos used to generate gRNAs through in vitro transcription (IVT). ID, unique 
oligo name; Type, condition of the experiment; Name, contains coordinate and 
strand information (from Benchling); Sequence, gRNA sequence; F1 and R1 
Primer, blue corresponds to T7 Promoter sequence (F1) and tracrRNA (R1) as 





















































Table 3.14 | qPCR primer sequences for RNA quantification in CRISPR 
experiments. 
Primer sequences to measure gene expression of target genes from CRISPR 






















Table 16Table 3.15 |  Genes located in  cell-t ype specific SZ r isk associated  chromosomal cont act s 
Genes located in 10kb bins corresponding to specific 
interactions anchored in PGC2 loci 
  
Genes located in 10kb bins corresponding to specific 
interactions anchored in PGC2+ CLOZUK loci  
  
Genes located in 10kb bins corresponding to specific interactions anchored 
in PGC2+ CLOZUK loci; with clusters of co-localized genes (e.g., PCDH) 
randomly removed such that only one gene is present 







AADAT  ABCB9  ABCB9  AADAT  ABCB9  ABCB9  AADAT  ABCB9  ABCB9   
ADSS  ACTR5  ADSL  ABCD3  ACTG1P17  ADSL  ABCD3  ACTG1P17  ADSL   
AKT3  ADAMTS9-AS2 ADSS  ACTR8  ACTR5  ADSS  ACTR8  ACTR5  ADSS   
AMBRA1  ADAMTSL3  AKT3  ADGRG6  ACTR8  AKT3  ADGRG6  ACTR8  AKT3   
ANKRD44  ADGRA3  ANKHD1  ADSS  ADAMTS9-AS2 ALMS1  ADSS  ADAMTS9-AS2 ALMS1   
ANP32E  ADIG  
ANKHD1-
EIF4EBP3 AIG1  ADAMTSL3  ALMS1P1  AIG1  ADAMTSL3  ALMS1P1   
AOX1  ADSS  ANKRD44  AKT3  ADGRA3  ANKHD1  AKT3  ADGRA3  ANKHD1   
AOX2P  AKAP13  AOX1  ALAS1  ADIG  
ANKHD1-
EIF4EBP3 ALAS1  ADIG  ANKHD1-EIF4EBP3  
AP1S3  AKT3  AOX2P  ALMS1  ADSS  ANKRD44  ALMS1  ADSS  ANKRD44   
ARNT  AMBRA1  ARL6IP4  ALMS1P1  AIG1  AOX1  ALMS1P1  AIG1  AOX1   
ASB5  ANKRD44  ARTN  AMBRA1  AKAP13  AOX2P  AMBRA1  AKAP13  AOX2P   
ASTN1  ANP32E  ATF7IP2  ANKRD44  AKT3  AP3B2  ANKRD44  AKT3  AP3B2   
ATP2A2  AP1S3  BOLA2  ANKRD45  ALAS1  ARL6IP4  ANKRD45  ALAS1  ARL6IP4   
ATP6V0A2  ARHGAP40  BOLL  ANP32E  ALKBH5  ARTN  ANP32E  ALKBH5  ARTN   
B4GALT2  ARL6IP4  C12orf65  AOX1  ALMS1  ATF7IP2  AOX1  ALMS1  ATF7IP2   
BANK1  ASTN1  C1orf100  AOX2P  ALMS1P1  AUP1  AOX2P  ALMS1P1  AUP1   
BNIPL  ATG13  C1orf101  AP1S3  AMBRA1  BOLA2  AP1S3  AMBRA1  BOLA2   
BOLL  ATPAF2  C2orf69  ARL14  ANKRD44  BOLL  ARL14  ANKRD44  BOLL   
BRD8  ATXN7  C7orf50  ARNT  ANKRD45  BRINP3  ARNT  ANKRD45  BRINP3   
BRINP2  BAHD1  CCDC150  ASB5  ANP32E  C12orf65  ASB5  ANP32E  C12orf65   
C11orf49  BAZ2A  CCDC39  ASH2L  AP1S3  C1orf100  ASH2L  AP1S3  C1orf100   
C1orf101  BOLA2  CD46  ASTN1  AP3B2  C1orf101  ASTN1  AP3B2  C1orf101   
C2orf69  BOLL  CNBD1  ATP2A2  ARHGAP15  C2orf69  ATP2A2  ARHGAP15  C2orf69   
C4BPA  BRINP2  CNKSR2  ATP6V0A2  ARHGAP40  C7orf50  ATP6V0A2  ARHGAP40  C7orf50   
C7orf31  C1orf100  CNTN4  B4GALT2  ARL6IP4  CCDC150  B4GALT2  ARL6IP4  CCDC150   
CA6  C1orf101  COQ10B  BANK1  ASTN1  CCDC39  BANK1  ASTN1  CCDC39   
CACNA1C  C1orf116  CSMD1  BNIPL  ATG13  CCT7  BNIPL  ATG13  CCT7   
CACNA1D  C2orf69  CTNND1  BOLA3  ATPAF2  CD46  BOLA3  ATPAF2  CD46   
CBR4  C2orf82  CUL3  BOLA3-AS1  ATXN7  CHRM3  BOLA3-AS1  ATXN7  CHRM3   
CCDC150  C3orf49  DHX35  BOLL  BAHD1  CNBD1  BOLL  BAHD1  CNBD1   
CCDC24  C7orf50  DNAH10  BRD8  BAZ2A  CNKSR2  BRD8  BAZ2A  CNKSR2   
CCDC30  CA6  DOCK10  BRINP2  BNIP3L  CNTN4  BRINP2  BNIP3L  CNTN4   
CCDC39  CA8  DPP4  BRINP3  BOLA2  COQ10B  BRINP3  BOLA2  COQ10B   
CD46  CACNA1C  DPYD  C11orf49  BOLL  CPEB1-AS1  C11orf49  BOLL  CPEB1-AS1   
CDC25C  CACNA1C-AS4 EP300  C1orf101  BRINP2  CSMD1  C1orf101  BRINP2  CSMD1   
CEP170  CACNA1C-IT3 ERMAP  C2orf69  BRINP3  CTNND1  C2orf69  BRINP3  CTNND1   
CETN3  CBR4  FAM57B  C4BPA  C1orf100  CUL3  C4BPA  C1orf100  CUL3   
CFAP57  CCDC150  FAM83D  C7orf31  C1orf101  DAAM1  C7orf31  C1orf101  DAAM1   
CHST12  CCDC39  FANCL  CA6  C1orf116  DHX35  CA6  C1orf116  DHX35   
CLCN3  CCDC62  FAT2  CACNA1C  C2orf69  DNAH10  CACNA1C  C2orf69  DNAH10   
CLIP1  CD46  FCAMR  CACNA1D  C2orf78  DOCK10  CACNA1D  C2orf78  DOCK10   
CLU  CDC20  FLJ40288  CACNA2D3  C2orf82  DPP4  CACNA2D3  C2orf82  DPP4   
CNKSR2  CDC25C  FLJ46066  CBR4  C3orf49  DPYD  CBR4  C3orf49  DPYD   
COQ10B  CDHR3  FPGT-TNNI3K CCDC150  C7orf50  DQX1  CCDC150  C7orf50  DQX1   
CREB3L2  CEP162  GALNT10  CCDC24  CA6  EMX1  CCDC24  CA6  EMX1   
CSMD1  CHRNA3  GBA3  CCDC30  CA8  EP300  CCDC30  CA8  EP300   
CUL3  CNKSR2  GIGYF2  CCDC39  CACNA1C  ERMAP  CCDC39  CACNA1C  ERMAP   
CYP26B1  CNNM2  GPER1  CCNH  CACNA1C-AS4 EXOC6B  CCNH  CACNA1C-AS4 EXOC6B   
CYSTM1  COQ10B  GPM6A  CD46  CACNA1C-IT3 FAM57B  CD46  CACNA1C-IT3 FAM57B   
DAZL  COX20  GPX5  CDC25C  CACNA1D  FAM83D  CDC25C  CACNA1D  FAM83D   
DDX60L  CR1L  GRAMD1B  CENPL  CACYBP  FANCL  CENPL  CACYBP  FANCL   
DENR  CREB3L1  GRIA1  CEP170  CBR4  FAT2  CEP170  CBR4  FAT2   
DESI2  CSMD1  GRIN2A  CETN3  CCDC150  FCAMR  CETN3  CCDC150  FCAMR   
DFNA5  CTNNA1  HCN1  CFAP57  CCDC39  FLJ40288  CFAP57  CCDC39  FLJ40288   
DGKD  CTNND1  HECW2  CHDH  CCDC62  FLJ46066  CHDH  CCDC62  FLJ46066   
DGKZ  CTRL  HIRIP3  CHST12  CCT7  FOXP1  CHST12  CCT7  FOXP1   
DNAJC18  CTSS  HSPE1-MOB4 CLCN3  CD46  FPGT-TNNI3K CLCN3  CD46  FPGT-TNNI3K  
DNAJC19  CUL3  IMMP2L  CLIP1  CDC20  GALNT10  CLIP1  CDC20  GALNT10   
DOCK10  CYP26B1  INO80E  CLU  CDC25C  GALNT15  CLU  CDC25C  GALNT15   
DPH3  DDX60L  ITGA9  CMTR2  CDHR3  GBA3  CMTR2  CDHR3  GBA3   
DPP4  DESI2  JUND  CNKSR2  CENPL  GIGYF2  CNKSR2  CENPL  GIGYF2   
DPYD  DGKD  KCNJ13  COQ10B  CEP162  GPER1  COQ10B  CEP162  GPER1   
DPYD-AS1  DGKZ  KDM4A  CREB3L2  CHDH  GPM6A  CREB3L2  CHDH  GPM6A   
DUS2  DIS3L2  KMT5A  CSGALNACT1 CHRNA3  GPX5  CSGALNACT1 CHRNA3  GPX5   
EBNA1BP2  DNAJC19  LINC01122  CSMD1  CNKSR2  GRAMD1B  CSMD1  CNKSR2  GRAMD1B   
EFHD1  DOCK10  LOC100507091 CUL3  CNNM2  GRIA1  CUL3  CNNM2  GRIA1   
EIF2B1  DPEP3  LOC606724  CYP26B1  COQ10B  GRIN2A  CYP26B1  COQ10B  GRIN2A   
EIF3B  DPH3  LOC613038  CYSTM1  COX20  HCN1  CYSTM1  COX20  HCN1   
EP300  DPYD  LOC729987  DARS2  CPEB1  HECW2  DARS2  CPEB1  HECW2   
EPB41  DPYD-AS1  LRRIQ3  DAZL  CPEB1-AS1  HIRIP3  DAZL  CPEB1-AS1  HIRIP3   
EPC2  DUS2  LSMEM1  DCP1A  CR1L  HSPE1-MOB4 DCP1A  CR1L  HSPE1-MOB4  
EPHB1  DYSF  MAD1L1  DCTN1  CREB3L1  HTRA2  DCTN1  CREB3L1  HTRA2   
ERI3  EFHD1  MAN2A1  DCTN1-AS1  CSMD1  HYDIN  DCTN1-AS1  CSMD1  HYDIN   
ESAM  EIF4E2  MAPK3  DDX60L  CTNNA1  IBTK  DDX60L  CTNNA1  IBTK   
ETF1  ELOVL1  MBTPS2  DENR  CTNND1  IMMP2L  DENR  CTNND1  IMMP2L   
FAM114A2  ENO1  MEF2C  DESI2  CTRL  INO80E  DESI2  CTRL  INO80E   
FAM13B  EPC2  MIR137  DFNA5  CTSS  ITGA9  DFNA5  CTSS  ITGA9   
FAM53C  ERI3  MIR137HG  DGKD  CUL3  JUND  DGKD  CUL3  JUND   
FANCL  FAM124B  MIR2682  DGKZ  CYP26B1  KCNJ13  DGKZ  CYP26B1  KCNJ13   
FAT2  FAM53C  MIR29C  DNAJC18  DARS2  KDM4A  DNAJC18  DARS2  KDM4A   
 
 248 
FCHSD1  FAM57B  MIR3188  DNAJC19  DCDC1  KLHL20  DNAJC19  DCDC1  KLHL20   
FER  FANCL  MIR3714  DOCK10  DCDC5  KMT5A  DOCK10  DCDC5  KMT5A   
FLJ46066  FLJ46066  MIR4304  DPH3  DCP1A  LINC00461  DPH3  DCP1A  LINC00461   
FPGT-TNNI3K FPGT-TNNI3K MKL1  DPP4  DCTN1  LINC01122  DPP4  DCTN1  LINC01122   
FTCDNL1  FSIP2  MOB4  DPYD  DDHD2  LOC100506023 DPYD  DDHD2  LOC100506023  
FXR1  FTCDNL1  MPHOSPH9  DPYD-AS1  DDX60L  LOC100507091 DPYD-AS1  DDX60L  LOC100507091  
GALNT10  FXR1  MPP6  DUS2  DESI2  LOC153910  DUS2  DESI2  LOC153910   
GALNT15  G3BP1  MYLPF  EBNA1BP2  DGKD  LOC440704  EBNA1BP2  DGKD  LOC440704   
GATAD2A  GABBR1  MYO1A  EFHD1  DGKZ  LOC606724  EFHD1  DGKZ  LOC606724   
GBF1  GALNT10  NDUFA13  EIF2B1  DIS3L2  LOC613038  EIF2B1  DIS3L2  LOC613038   
GFRA3  GATAD2A  NEK1  EIF3B  DNAJC19  LOC729987  EIF3B  DNAJC19  LOC729987   
GIGYF2  GFRA3  NFATC3  EMB  DNAJC6  LOXL3  EMB  DNAJC6  LOXL3   
GLRA1  GID4  NLGN4X  EMX1  DOCK10  LRRIQ3  EMX1  DOCK10  LRRIQ3   
GPM6A  GIGYF2  NMUR2  EP300  DPEP3  LSMEM1  EP300  DPEP3  LSMEM1   
GPX5  GLRA1  NRN1L  EPB41  DPH3  MAD1L1  EPB41  DPH3  MAD1L1   
GPX6  GPM6A  NUGGC  EPC2  DPYD  MAN2A1  EPC2  DPYD  MAN2A1   
GRIA1  GPX5  OGFOD2  EPHB1  DPYD-AS1  MAPK3  EPHB1  DPYD-AS1  MAPK3   
GRIN2A  GRIA1  OR1S1  ERI3  DUS2  MBTPS2  ERI3  DUS2  MBTPS2   
GTF2H3  GRIN2A  OR1S2  ESAM  DUSP11  MEF2C  ESAM  DUSP11  MEF2C   
GTF3C3  GRM3  OR8B3  ETF1  DYSF  MIR137  ETF1  DYSF  MIR137   
HCN1  H6PD  OR9Q1  EXOC6B  EFHD1  MIR137HG  EXOC6B  EFHD1  MIR137HG   
HDAC3  HARS  PAPPA2  FAM114A2  EGR4  MIR2682  FAM114A2  EGR4  MIR2682   
HECW2  HARS2  PDE6D  FAM13B  EIF4E2  MIR29C  FAM13B  EIF4E2  MIR29C   
HPF1  HCN1  PITPNM2  FAM53C  ELOVL1  MIR3188  FAM53C  ELOVL1  MIR3188   
HSPA9  HECW2  PLCL1  FANCL  EMX1  MIR3714  FANCL  EMX1  MIR3714   
HSPD1  HSPA9  PLCL2  FAT2  ENO1  MIR4304  FAT2  ENO1  MIR4304   
HSPE1-MOB4 IL19  PLD5  FCHSD1  EPC2  MIR9-2  FCHSD1  EPC2  MIR9-2   
IK  INPP5D  PLEKHO1  FER  EPHA7  MKL1  FER  EPHA7  MKL1   
IL19  IPO11  PLXNA4  FGFR1  EPN2  MOB1A  FGFR1  EPN2  MOB1A   
IMMP2L  ITIH1  PPP1R16B  FLJ46066  EPN2-IT1  MOB4  FLJ46066  EPN2-IT1  MOB4   
INPP5D  ITIH3  PSKH1  FPGT-TNNI3K ERI3  MPHOSPH9  FPGT-TNNI3K ERI3  MPHOSPH9   
IQCE  ITIH4  PTCHD1-AS  FTCDNL1  EXOC6B  MPP6  FTCDNL1  EXOC6B  MPP6   
IQCF1  KCNH7  PTPRF  FXR1  FAM124B  MYLPF  FXR1  FAM124B  MYLPF   
ITGA9  KCNJ13  RERE  GAB1  FAM53C  MYO1A  GAB1  FAM53C  MYO1A   
ITIH3  KDM4A  RFTN2  GALNT10  FAM57B  NAT8  GALNT10  FAM57B  NAT8   
ITIH4  KMT2E  RILPL1  GALNT15  FANCL  NDUFA13  GALNT15  FANCL  NDUFA13   
KCNH7  KMT2E-AS1  RNF220  GATAD2A  FBXO41  NEK1  GATAD2A  FBXO41  NEK1   
KCNJ13  LAPTM5  SAP30L-AS1  GBF1  FLJ46066  NFATC3  GBF1  FLJ46066  NFATC3   
KDM3B  LINC00634  SATB2  GFRA3  FOXP1  NLGN4X  GFRA3  FOXP1  NLGN4X   
KDM4A  LINC00698  SBNO1  GIGYF2  FPGT-TNNI3K NMUR2  GIGYF2  FPGT-TNNI3K NMUR2   
KMT2E  LINC01004  SDCCAG8  GLRA1  FRMD8  NRN1L  GLRA1  FRMD8  NRN1L   
KNTC1  LINC01122  SF3B1  GPM6A  FSIP2  NUGGC  GPM6A  FSIP2  NUGGC   
LINC01122  LOC100129620 SH3RF1  GPR52  FTCDNL1  OGFOD2  GPR52  FTCDNL1  OGFOD2   
LOC100129620 LOC100652758 SLC4A10  GPX5  FXR1  OPCML  GPX5  FXR1  OPCML   
LOC100130452 LOC339529  SLC6A9  GPX6  G3BP1  OR1S1  GPX6  G3BP1  OR1S1   
LOC100130880 LOC339862  SLX1A  GRIA1  GABBR1  OR1S2  GRIA1  GABBR1  OR1S2   
LOC100506085 LOC606724  SLX1B-SULT1A4 GRIN2A  GALNT10  OR8B3  GRIN2A  GALNT10  OR8B3   
LOC100507091 LOC613038  SMG1P2  GTF2H3  GALNT15  OR9Q1  GTF2H3  GALNT15  OR9Q1   
LOC100507140 LOC642423  SMS  GTF3C3  GAS5  PAPPA2  GTF3C3  GAS5  PAPPA2   
LOC148696  LRP1  SNAP91  GUSBP5  GAS5-AS1  PDE4B  GUSBP5  GAS5-AS1  PDE4B   
LOC339529  LRRIQ3  SOX2-OT  HCN1  GATAD2A  PDE6D  HCN1  GATAD2A  PDE6D   
LOC339862  LYPD6B  ST3GAL3  HDAC3  GFRA3  PGM3  HDAC3  GFRA3  PGM3   
LOC729987  MAD1L1  STK31  HECW2  GID4  PITPNM2  HECW2  GID4  PITPNM2   
LRRC43  MAN2A1  TAOK2  HPF1  GIGYF2  PLCL1  HPF1  GIGYF2  PLCL1   
LRRIQ3  MARS  TBC1D10B  HSPA9  GLRA1  PLCL2  HSPA9  GLRA1  PLCL2   
LYPD6  MBTPS2  TBC1D5  HSPD1  GLT8D1  PLD5  HSPD1  GLT8D1  PLD5   
MAD1L1  MDK  TCF4  HSPE1-MOB4 GNL3  PLEKHO1  HSPE1-MOB4 GNL3  PLEKHO1   
MAN2A1  MED8  TMX2-CTNND1 HYDIN  GPM6A  PLXNA4  HYDIN  GPM6A  PLXNA4   
MARS2  MIR137HG  TNFRSF9  IK  GPR52  PPP1R16B  IK  GPR52  PPP1R16B   
MAU2  MIR22  TNNI3K  IL17RB  GPX5  PSKH1  IL17RB  GPX5  PSKH1   
MBTPS2  MIR22HG  TNRC6B  IL19  GRIA1  PTCHD1-AS  IL19  GRIA1  PTCHD1-AS   
MDK  MIR29C  TOX  IMMP2L  GRIN2A  PTPRF  IMMP2L  GRIN2A  PTPRF   
MFAP3  MIR339  TRANK1  INO80B  GRM3  RABGAP1L  INO80B  GRM3  RABGAP1L   
MIR137HG  MIR33B  TSSK6  INO80B-WBP1 H6PD  RC3H1  INO80B-WBP1 H6PD  RC3H1   
MIR2682  MIR4677  TTYH3  INPP4B  HARS  RERE  INPP4B  HARS  RERE   
MIR3160-1  MIR4688  UGT1A10  INPP5D  HARS2  RFTN2  INPP5D  HARS2  RFTN2   
MIR3160-2  MIR548A2  UGT1A4  IQCE  HCN1  RILPL1  IQCE  HCN1  RILPL1   
MIR4688  MOG  UGT1A5  IQCF1  HDAC2  RNF220  IQCF1  HDAC2  RNF220   
MOB4  MPHOSPH9  UGT1A6  ITGA9  HECW2  SAP30L-AS1  ITGA9  HECW2  SAP30L-AS1   
MPHOSPH9  MPL  UGT1A7  ITIH3  HIVEP2  SATB2  ITIH3  HIVEP2  SATB2   
MPP6  MRAP2  UGT1A8  ITIH4  HSPA9  SBNO1  ITIH4  HSPA9  SBNO1   
MUSTN1  MSL2  UGT1A9  KCNH7  IL17RB  SDCCAG8  KCNH7  IL17RB  SDCCAG8   
MYO1A  MUSTN1  UNCX  KCNJ13  IL19  SF3B1  KCNJ13  IL19  SF3B1   
MYOT  MYO1A  USP40  KDM3B  IL34  SFXN5  KDM3B  IL34  SFXN5   
NCAN  NDUFA4L2  UTS2  KDM4A  INO80B  SH3RF1  KDM4A  INO80B  SH3RF1   
NCK1  NEK1  VPS45  KLHL20  INO80B-WBP1 SLC4A10  KLHL20  INO80B-WBP1 SLC4A10   
NEK1  NEK4  VRK2  KLHL29  INPP4B  SLC4A5  KLHL29  INPP4B  SLC4A5   
NFATC3  NEMP1  WDFY1  KMT2E  INPP5D  SLC6A9  KMT2E  INPP5D  SLC6A9   
NLGN4X  NFATC3  YJEFN3  KNTC1  IPO11  SLC9C2  KNTC1  IPO11  SLC9C2   
NME5  NGEF  ZNF165  LINC00461  ITIH1  SLX1A  LINC00461  ITIH1  SLX1A   
NMUR2  NLGN4X  ZNF48  LINC01122  ITIH3  SLX1B-SULT1A4 LINC01122  ITIH3  SLX1B-SULT1A4  
NOSIP  NT5C2  ZNF691  LOC100129620 ITIH4  SMG1P2  LOC100129620 ITIH4  SMG1P2   
NPY6R  NT5M  ZNF804A  LOC100130452 JAK1  SMS  LOC100130452 JAK1  SMS   
NT5C2  NYAP2  ZSCAN16-AS1 LOC100130880 KAT5  SNAP91  LOC100130880 KAT5  SNAP91   
NUBP1  OGFOD2  ZSWIM6  LOC100506023 KCNH7  SOX2-OT  LOC100506023 KCNH7  SOX2-OT   
NYAP2  P2RX3    LOC100506085 KCNJ13  ST3GAL3  LOC100506085 KCNJ13  ST3GAL3   
OR2B2  PALLD    LOC100507091 KDM4A  STAB2  LOC100507091 KDM4A  STAB2   
ORC5  PARK7    LOC100507140 KLHL29  STK31  LOC100507140 KLHL29  STK31   
OTUD7B  PBRM1    LOC148696  KMT2E  TAOK2  LOC148696  KMT2E  TAOK2   
OXNAD1  PCCB    LOC339529  KMT2E-AS1  TBC1D10B  LOC339529  KMT2E-AS1  TBC1D10B   
PAIP2B  PCDHA1    LOC339862  LAPTM5  TBC1D5  LOC339862  LAPTM5  TBC1D5   
PALLD  PCDHA10    LOC440704  LEPR  TCF4  LOC440704  LEPR  TCF4   
PCCB  PCDHA11    LOC729987  LINC00634  TMEM161B-AS1 LOC729987  LINC00634  TMEM161B-AS1  
PCDHA1  PCDHA12    LOC730159  LINC00698  TMX2-CTNND1 LOC730159  LINC00698  TMX2-CTNND1  
PCDHA10  PCDHA13    LRRC43  LINC01004  TNFRSF9  LRRC43  LINC01004  TNFRSF9   
PCDHA11  PCDHA2    LRRIQ3  LINC01122  TNNI3K  LRRIQ3  LINC01122  TNNI3K   
PCDHA12  PCDHA3    LYPD6  LOC100129620 TNRC6B  LYPD6  LOC100129620 TNRC6B   
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PCDHA13  PCDHA4    M1AP  LOC100506023 TOX  M1AP  LOC100506023 TOX   
PCDHA2  PCDHA5    MAD1L1  LOC100652758 TRANK1  MAD1L1  LOC100652758 TRANK1   
PCDHA3  PCDHA6    MAN2A1  LOC338963  TSSK6  MAN2A1  LOC338963  TSSK6   
PCDHA4  PCDHA7    MARS2  LOC339529  TTYH3  MARS2  LOC339529  TTYH3   
PCDHA5  PCDHA8    MAU2  LOC339862  UGT1A10  MAU2  LOC339862  UGT1A10   
PCDHA6  PCDHA9    MBTPS2  LOC440704  UGT1A4  MBTPS2  LOC440704  UGT1A5   
PCDHA7  PCDHAC1    MDK  LOC606724  UGT1A5  MDK  LOC606724  UGT1A8   
PCDHA8  PCDHAC2    MEF2C  LOC613038  UGT1A6  MEF2C  LOC613038  UNCX   
PCDHA9  PCDHGA1    MFAP3  LOC642423  UGT1A7  MFAP3  LOC642423  USP40   
PCDHAC1  PCDHGA10    MIR137HG  LRP1  UGT1A8  MIR137HG  LRP1  UTS2   
PCDHAC2  PCDHGA11    MIR2682  LRRIQ3  UGT1A9  MIR2682  LRRIQ3  VPS45   
PCDHGA1  PCDHGA12    MIR3160-1  LYPD6B  UNCX  MIR3160-1  LYPD6B  VRK2   
PCDHGA10  PCDHGA2    MIR3160-2  MAD1L1  USP40  MIR3160-2  MAD1L1  WDFY1   
PCDHGA11  PCDHGA3    MIR4688  MAN2A1  UTS2  MIR4688  MAN2A1  YJEFN3   
PCDHGA12  PCDHGA4    MOB4  MAP3K11  VPS45  MOB4  MAP3K11  ZNF165   
PCDHGA2  PCDHGA5    MPHOSPH9  MARS  VRK2  MPHOSPH9  MARS  ZNF48   
PCDHGA3  PCDHGA6    MPP6  MBTPS2  WDFY1  MPP6  MBTPS2  ZNF691   
PCDHGA4  PCDHGA7    MSRA  MDK  YJEFN3  MSRA  MDK  ZNF804A   
PCDHGA5  PCDHGA8    MUSTN1  MED8  ZNF165  MUSTN1  MED8  ZSCAN16-AS1  
PCDHGA6  PCDHGA9    MYO1A  MEF2C  ZNF48  MYO1A  MEF2C  ZSWIM6   
PCDHGA7  PCDHGB1    MYOT  MIR137HG  ZNF691  MYOT  MIR137HG     
PCDHGA8  PCDHGB2    NAT8  MIR22  ZNF804A  NAT8  MIR22     
PCDHGA9  PCDHGB3    NCAN  MIR22HG  ZSCAN16-AS1 NCAN  MIR22HG     
PCDHGB1  PCDHGB4    NCK1  MIR29C  ZSWIM6  NCK1  MIR29C     
PCDHGB2  PCDHGB5    NEK1  MIR339    NEK1  MIR339     
PCDHGB3  PCDHGB6    NFATC3  MIR33B    NFATC3  MIR33B     
PCDHGB4  PCDHGB7    NISCH  MIR4677    NISCH  MIR4677     
PCDHGB5  PCDHGC3    NLGN4X  MIR4688    NLGN4X  MIR4688     
PCDHGB6  PCGF6    NME5  MIR548A2    NME5  MIR548A2     
PCDHGB7  PDE4D    NMUR2  MIR548AI    NMUR2  MIR548AI     
PCGF6  PDE6D    NOSIP  MOG    NOSIP  MOG     
PDE4D  PEMT    NPY6R  MOGS    NPY6R  MOGS     
PER3  PEX5L    NT5C2  MPHOSPH9    NT5C2  MPHOSPH9     
PEX5L  PFKFB2    NTM  MPL    NTM  MPL     
PGAP1  PGAP1    NUBP1  MRAP2    NUBP1  MRAP2     
PHEX  PGM3    NYAP2  MRPS14    NYAP2  MRPS14     
PHF21A  PHEX    OPCML  MSL2    OPCML  MSL2     
PIH1D1  PHF21A    OR2B2  MSRA    OR2B2  MSRA     
PITPNM2  PITPNM2    ORC5  MUSTN1    ORC5  MUSTN1     
PKD2L2  PLCB2    OTUD7B  MYO15A    OTUD7B  MYO15A     
PLCL1  PLCL1    OXNAD1  MYO1A    OXNAD1  MYO1A     
PLCL2  PLCL2    PAIP2B  NAT8    PAIP2B  NAT8     
PLD5  PLD5    PALLD  NDUFA4L2    PALLD  NDUFA4L2     
PLEKHO1  PLEKHO1    PARP8  NEK1    PARP8  NEK1     
PLPPR5  PLPPR5    PCCB  NEK4    PCCB  NEK4     
PLXNA2  PLXNA2    PCDHA1  NEMP1    PCDHA1  NEMP1     
PODXL  POLDIP3    PCDHA10  NFATC3    PCDHAC1  NFATC3     
PPARGC1A  PPARGC1A    PCDHA11  NGEF    PCDHGA2  NGEF     
PPIH  PPP2R3A    PCDHA12  NLGN4X    PCGF6  NLGN4X     
PPP1CC  PRUNE1    PCDHA13  NT5C2    PDE4B  NT5C2     
PPP2R3A  PSKH1    PCDHA2  NT5M    PDE4D  NT5M     
PSMD14  PSMB10    PCDHA3  NTM    PDGFRL  NTM     
PTCHD1-AS  PSMG3    PCDHA4  NYAP2    PER3  NYAP2     
PTPRF  PSMG3-AS1    PCDHA5  OGFOD2    PEX5L  OGFOD2     
RAD54L2  PTBP2    PCDHA6  OPCML    PGAP1  OPCML     
RANBP10  PTCHD1-AS    PCDHA7  OXNAD1    PHEX  OXNAD1     
RANGAP1  PTPRF    PCDHA8  P2RX3    PHF21A  P2RX3     
RASAL2  R3HDM2    PCDHA9  PALLD    PIH1D1  PALLD     
REEP2  RAI1    PCDHAC1  PARK7    PITPNM2  PARK7     
RELL2  RASAL2    PCDHAC2  PBRM1    PKD2L2  PBRM1     
RERE  RERE    PCDHGA1  PCCB    PLCL1  PCCB     
RFTN1  RFTN1    PCDHGA10  PCDHA1    PLCL2  PCDHA1     
RFTN2  RFTN2    PCDHGA11  PCDHA10    PLD5  PCDHAC1     
RILPL2  RNF220    PCDHGA12  PCDHA11    PLEKHO1  PCDHGA10     
RPRD2  RPS6KA3    PCDHGA2  PCDHA12    PLPPR5  PCGF6     
RPS6KA3  RRP7BP    PCDHGA3  PCDHA13    PLXNA2  PCNX3     
RSRC2  RTN4RL1    PCDHGA4  PCDHA2    POC1A  PDE4B     
SAP30L-AS1  RTN4RL2    PCDHGA5  PCDHA3    PODXL  PDE4D     
SATB1  RWDD2A    PCDHGA6  PCDHA4    PPARGC1A  PDE6D     
SATB2  SAP30L-AS1    PCDHGA7  PCDHA5    PPIH  PEMT     
SBNO1  SATB2    PCDHGA8  PCDHA6    PPM1L  PEX5L     
SCG2  SBNO1    PCDHGA9  PCDHA7    PPP1CC  PFKFB2     
SDCCAG8  SDCCAG8    PCDHGB1  PCDHA8    PPP2R2A  PGAP1     
SEC16B  SEMA3G    PCDHGB2  PCDHA9    PPP2R3A  PGM3     
SF3B1  SEMA6C    PCDHGB3  PCDHAC1    PRDX6  PHEX     
SGO2  SERHL2    PCDHGB4  PCDHAC2    PSD3  PHF21A     
SH3RF1  SERPINE2    PCDHGB5  PCDHGA1    PSMD14  PITPNM2     
SLC17A7  SERPINF1    PCDHGB6  PCDHGA10    PTCHD1-AS  PLCB2     
SLC25A42  SF3B1    PCDHGB7  PCDHGA11    PTPRF  PLCL1     
SLC2A5  SFMBT1    PCGF6  PCDHGA12    RABGAP1L  PLCL2     
SLC35G2  SFXN2    PDE4B  PCDHGA2    RAD54L2  PLD5     
SLC39A8  SH3GL3    PDE4D  PCDHGA3    RANBP10  PLEKHO1     
SLC4A10  SH3PXD2A    PDGFRL  PCDHGA4    RANGAP1  PLPPR5     
SLC6A9  SLC12A4    PER3  PCDHGA5    RASA1  PLXNA2     
SMPX  SLC25A33    PEX5L  PCDHGA6    RASAL2  POC1A     
SMS  SLC2A5    PGAP1  PCDHGA7    RC3H1  POLDIP3     
SNTB2  SLC2A7    PHEX  PCDHGA8    REEP2  PPARGC1A     
SNX7  SLC35G2    PHF21A  PCDHGA9    RELL2  PPP2R2A     
SNX8  SLC4A10    PIH1D1  PCDHGB1    RERE  PPP2R3A     
SOX2  SLX1A    PITPNM2  PCDHGB2    RFT1  PRADC1     
SOX2-OT  SLX1B-SULT1A4   PKD2L2  PCDHGB3    RFTN1  PRKCB     
SPATA24  SMG1P2    PLCL1  PCDHGB4    RFTN2  PRKD1     
SRPK2  SMG6    PLCL2  PCDHGB5    RILPL2  PRUNE1     
ST3GAL3  SMPX    PLD5  PCDHGB6    RPRD2  PSD3     
STAG1  SMS    PLEKHO1  PCDHGB7    RPS6KA3  PSKH1     
STK31  SNAP91    PLPPR5  PCDHGC3    RSRC2  PSMB10     
SUGP1  SNORD32B    PLXNA2  PCGF6    RTKN  PSMG3     
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SUGP2  SNORD63    POC1A  PCNX3    SAP30L-AS1  PSMG3-AS1     
TAF5  SNX7    PODXL  PDE4B    SATB1  PTBP2     
TBC1D5  SNX8    PPARGC1A  PDE4D    SATB2  PTCHD1-AS     
TCF4  SOX2    PPIH  PDE6D    SBNO1  PTPRF     
TCTN2  SOX2-OT    PPM1L  PEMT    SCG2  R3HDM2     
TFAMP1  SPARC    PPP1CC  PEX5L    SDCCAG8  RAI1     
TKT  SPATS2L    PPP2R2A  PFKFB2    SEC16B  RASAL2     
TMEFF2  SREBF1    PPP2R3A  PGAP1    SEMA3G  RERE     
TMEM110  SRPK2    PRDX6  PGM3    SEMA4F  RFTN1     
TMEM110-
MUSTN1 SRR    PSD3  PHEX    SERPINC1  RFTN2     
TMTC1  SSRP1    PSMD14  PHF21A    SF3B1  RNF220     
TNNI3K  ST3GAL3    PTCHD1-AS  PITPNM2    SFMBT1  RPS6KA3     
TRANK1  STAC3    PTPRF  PLCB2    SFXN5  RRP7BP     
TSPAN9  STAG1    RABGAP1L  PLCL1    SGO2  RTN4RL1     
TVP23A  STAT6    RAD54L2  PLCL2    SH3RF1  RTN4RL2     
TYW5  SUFU    RANBP10  PLD5    SLC17A7  RWDD2A     
UGT1A10  SYNPR    RANGAP1  PLEKHO1    SLC25A42  SAP30L-AS1     
UGT1A6  TAF5    RASA1  PLPPR5    SLC2A5  SATB2     
UGT1A7  TBC1D5    RASAL2  PLXNA2    SLC35G2  SBNO1     
UGT1A8  THOC7    RC3H1  POC1A    SLC39A8  SDCCAG8     
UGT1A9  TLCD2    REEP2  POLDIP3    SLC4A10  SEMA3G     
UTP4  TLR9    RELL2  PPARGC1A    SLC4A5  SEMA6C     
VPS33A  TMEFF2    RERE  PPP2R2A    SLC6A9  SERHL2     
VPS45  TMEM110    RFT1  PPP2R3A    SLC9C2  SERPINE2     
VRK2  
TMEM110-
MUSTN1   RFTN1  PRADC1    SMPX  SERPINF1     
VSIG2  TMEM161A    RFTN2  PRKCB    SMS  SF3B1     
WBP1L  TMX2-CTNND1   RILPL2  PRKD1    SNTB2  SFMBT1     
WDR55  TNNI3K    RPRD2  PRUNE1    SNX7  SFXN2     
ZBED9  TOM1L2    RPS6KA3  PSD3    SNX8  SH3GL3     
ZBTB18  TOX    RSRC2  PSKH1    SOX2  SH3PXD2A     
ZKSCAN4  TTC14    RTKN  PSMB10    SOX2-OT  SLC12A4     
ZNF391  TWF2    SAP30L-AS1  PSMG3    SPATA24  SLC25A33     
ZNF804A  TYW5    SATB1  PSMG3-AS1    SRPK2  SLC2A5     
ZSCAN23  USP40    SATB2  PTBP2    ST3GAL3  SLC2A7     
ZSWIM6  VPS37B    SBNO1  PTCHD1-AS    STAG1  SLC35G2     
  VPS45    SCG2  PTPRF    STK31  SLC4A10     
  VRK2    SDCCAG8  R3HDM2    SUGP1  SLX1A     
  VTRNA1-1    SEC16B  RAI1    SUGP2  SLX1B-SULT1A4    
  WBP1L    SEMA3G  RASAL2    TAF5  SMG1P2     
  WDFY1    SEMA4F  RERE    TBC1D5  SMG6     
  WDR81    SERPINC1  RFTN1    TCF4  SMPX     
  YY2    SF3B1  RFTN2    TCTN2  SMS     
  ZBED9    SFMBT1  RNF220    TET3  SNAP91     
  ZBTB18    SFXN5  RPS6KA3    TFAMP1  SNORD32B     
  ZDHHC5    SGO2  RRP7BP    TKT  SNORD63     
  ZFP57    SH3RF1  RTN4RL1    TMEFF2  SNX7     
  ZKSCAN3    SLC17A7  RTN4RL2    TMEM110  SNX8     
  ZMAT2    SLC25A42  RWDD2A    TMEM110-MUSTN1 SOX2     
  ZNF592    SLC2A5  SAP30L-AS1    TMTC1  SOX2-OT     
  ZNF804A    SLC35G2  SATB2    TNFSF4  SPARC     
  ZSCAN12    SLC39A8  SBNO1    TNN  SPATS2L     
  ZSCAN23    SLC4A10  SDCCAG8    TNNC1  SREBF1     
  ZSCAN31    SLC4A5  SEMA3G    TNNI3K  SRPK2     
  ZSWIM6    SLC6A9  SEMA6C    TNR  SRR     
      SLC9C2  SERHL2    TRANK1  SSRP1     
      SMPX  SERPINE2    TSPAN9  ST3GAL3     
      SMS  SERPINF1    TVP23A  STAC3     
      SNTB2  SF3B1    TYW5  STAG1     
      SNX7  SFMBT1    UGT1A5  STAT6     
      SNX8  SFXN2    UGT1A8  SUFU     
      SOX2  SH3GL3    UGT1A10  SYNPR     
      SOX2-OT  SH3PXD2A    USP38  TAF5     
      SPATA24  SLC12A4    UTP4  TBC1D5     
      SRPK2  SLC25A33    VPS33A  THOC7     
      ST3GAL3  SLC2A5    VPS45  TLCD2     
      STAG1  SLC2A7    VRK2  TLR9     
      STK31  SLC35G2    VSIG2  TMEFF2     
      SUGP1  SLC4A10    WBP1L  TMEM110     
      SUGP2  SLX1A    WDR55  TMEM110-MUSTN1    
      TAF5  SLX1B-SULT1A4   WHSC1L1  TMEM161A     
      TBC1D5  SMG1P2    ZBED9  TMX2-CTNND1    
      TCF4  SMG6    ZBTB18  TNNI3K     
      TCTN2  SMPX    ZBTB37  TOM1L2     
      TET3  SMS    ZEB2  TOX     
      TFAMP1  SNAP91    ZKSCAN4  TTC14     
      TKT  SNORD32B    ZNF391  TWF2     
      TMEFF2  SNORD63    ZNF804A  TYW5     
      TMEM110  SNX7    ZSCAN23  USP40     
      
TMEM110-
MUSTN1 SNX8    ZSWIM6  VPS37B     
      TMTC1  SOX2           
      TNFSF4  SOX2-OT           
      TNN  SPARC           
      TNNC1  SPATS2L           
      TNNI3K  SREBF1           
      TNR  SRPK2           
      TRANK1  SRR           
      TSPAN9  SSRP1           
      TVP23A  ST3GAL3           
      TYW5  STAC3           
      UGT1A10  STAG1           
      UGT1A6  STAT6           
      UGT1A7  SUFU           
      UGT1A8  SYNPR           
      UGT1A9  TAF5           
      USP38  TBC1D5           
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      UTP4  THOC7           
      VPS33A  TLCD2           
      VPS45  TLR9           
      VRK2  TMEFF2           
      VSIG2  TMEM110           
      WBP1L  
TMEM110-
MUSTN1          
      WDR55  TMEM161A           
      WHSC1L1  TMX2-CTNND1          
      ZBED9  TNNI3K           
      ZBTB18  TOM1L2           
      ZBTB37  TOX           
      ZEB2  TTC14           
      ZKSCAN4  TWF2           
      ZNF391  TYW5           
      ZNF804A  USP40           
      ZSCAN23  VPS37B           
      ZSWIM6             
 








































Table 17Table 3.16 |  GO for genes in SZ risk- associated chromosomal cont act s 
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GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO_BiologicalProcess-GOA_23.02.2017_10h01 18.0E-33 1.6E-30 29.79588 22.09 36.00 
GO:0098609 cell-cell adhesion GO_BiologicalProcess-GOA_23.02.2017_10h01 750.0E-18 68.0E-15 13.1674911 5.64 47.00 
GO:0051552 flavone metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 3.5E-9 310.0E-9 6.50863831 83.33 5.00 
GO:0032594 protein transport within lipid bilayer GO_BiologicalProcess-GOA_23.02.2017_10h01 32.0E-9 2.8E-6 5.55284197 62.50 5.00 
GO:1904224 negative regulation of glucuronosyltransferase activity GO_BiologicalProcess-GOA_23.02.2017_10h01 32.0E-9 2.8E-6 5.55284197 62.50 5.00 
GO:0052697 xenobiotic glucuronidation GO_BiologicalProcess-GOA_23.02.2017_10h01 71.0E-9 6.2E-6 5.20760831 55.56 5.00 
GO:0052696 flavonoid glucuronidation GO_BiologicalProcess-GOA_23.02.2017_10h01 28.0E-6 2.5E-3 2.60205999 60.00 3.00 
GO:0000053 Ascorbate and aldarate metabolism KEGG_01.03.2017 37.0E-6 3.1E-3 2.50863831 18.52 5.00 
GO:0000830 Retinol metabolism KEGG_01.03.2017 40.0E-6 3.4E-3 2.46852108 10.77 7.00 
GO:0000983 Drug metabolism KEGG_01.03.2017 48.0E-6 4.0E-3 2.39794001 13.04 6.00 
GO:0000040 Pentose and glucuronate interconversions KEGG_01.03.2017 110.0E-6 9.7E-3 2.01322827 14.71 5.00 
GO:0015020 glucuronosyltransferase activity GO_MolecularFunction-GOA_23.02.2017_10h01 110.0E-6 9.7E-3 2.01322827 14.71 5.00 
GO:0010677 negative regulation of cellular carbohydrate metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 130.0E-6 11.0E-3 1.95860731 10.91 6.00 
GO:0000860 Porphyrin and chlorophyll metabolism KEGG_01.03.2017 320.0E-6 26.0E-3 1.58502665 11.90 5.00 
GO:0000210 Glucuronidation REACTOME_Pathways_01.03.2017 350.0E-6 28.0E-3 1.55284197 16.67 4.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 400.0E-6 31.0E-3 1.50863831 8.96 6.00 
GO:0005031 Amphetamine addiction KEGG_01.03.2017 430.0E-6 34.0E-3 1.46852108 8.82 6.00 
GO:0000982 Drug metabolism KEGG_01.03.2017 500.0E-6 39.0E-3 1.40893539 8.57 6.00 
GO:0051001 negative regulation of nitric-oxide synthase activity GO_BiologicalProcess-GOA_23.02.2017_10h01 580.0E-6 44.0E-3 1.35654732 25.00 3.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 590.0E-6 44.0E-3 1.35654732 6.15 8.00 
GO:0007062 sister chromatid cohesion GO_BiologicalProcess-GOA_23.02.2017_10h01 620.0E-6 45.0E-3 1.34678749 6.11 8.00 
GO:0004024 cAMP signaling pathway KEGG_01.03.2017 610.0E-6 45.0E-3 1.34678749 5.05 10.00 
        
NEURON        
















GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules GO_BiologicalProcess-GOA_23.02.2017_10h01 57.0E-33 13.0E-30 28.9E+0 22.09 36.00 
GO:0005509 calcium ion binding GO_MolecularFunction-GOA_23.02.2017_10h01 970.0E-18 230.0E-15 12.6E+0 6.02 45.00 
GO:0007399 nervous system development GO_BiologicalProcess-GOA_23.02.2017_10h01 23.0E-15 5.7E-12 11.2E+0 3.51 83.00 
GO:0098609 cell-cell adhesion GO_BiologicalProcess-GOA_23.02.2017_10h01 52.0E-15 12.0E-12 10.9E+0 5.40 45.00 
GO:0007267 cell-cell signaling GO_BiologicalProcess-GOA_23.02.2017_10h01 3.9E-12 950.0E-12 9.0E+0 3.76 63.00 
GO:0031226 intrinsic component of plasma membrane GO_CellularComponent-GOA_23.02.2017_10h01 72.0E-12 17.0E-9 7.8E+0 3.58 61.00 
GO:0005887 integral component of plasma membrane GO_CellularComponent-GOA_23.02.2017_10h01 290.0E-12 69.0E-9 7.2E+0 3.56 58.00 
GO:0044459 plasma membrane part GO_CellularComponent-GOA_23.02.2017_10h01 21.0E-9 5.1E-6 5.3E+0 2.79 77.00 
GO:0043169 cation binding GO_MolecularFunction-GOA_23.02.2017_10h01 22.0E-9 5.3E-6 5.3E+0 2.44 107.00 
GO:0048731 system development GO_BiologicalProcess-GOA_23.02.2017_10h01 35.0E-9 8.2E-6 5.1E+0 2.38 112.00 
GO:0007275 multicellular organism development GO_BiologicalProcess-GOA_23.02.2017_10h01 990.0E-9 230.0E-6 3.6E+0 2.21 117.00 
GO:0036477 somatodendritic compartment GO_CellularComponent-GOA_23.02.2017_10h01 15.0E-6 3.5E-3 2.5E+0 3.67 27.00 
GO:0030425 dendrite GO_CellularComponent-GOA_23.02.2017_10h01 87.0E-6 20.0E-3 1.7E+0 3.91 20.00 
GO:0043005 neuron projection GO_CellularComponent-GOA_23.02.2017_10h01 99.0E-6 22.0E-3 1.7E+0 3.07 32.00 
GO:0044297 cell body GO_CellularComponent-GOA_23.02.2017_10h01 190.0E-6 44.0E-3 1.4E+0 3.68 20.00 
        
GLIA        
















GO:0052697 xenobiotic glucuronidation GO_BiologicalProcess-GOA_23.02.2017_10h01 31.0E-15 930.0E-15 12.0E+0 77.78 7.00 
GO:1904224 negative regulation of glucuronosyltransferase activity GO_BiologicalProcess-GOA_23.02.2017_10h01 3.5E-12 100.0E-12 10.0E+0 75.00 6.00 
GO:0000053 Ascorbate and aldarate metabolism KEGG_01.03.2017 690.0E-12 19.0E-9 7.7E+0 25.93 7.00 
GO:0000983 Drug metabolism KEGG_01.03.2017 1.2E-9 33.0E-9 7.5E+0 17.39 8.00 
GO:0000040 Pentose and glucuronate interconversions KEGG_01.03.2017 4.0E-9 100.0E-9 7.0E+0 20.59 7.00 
GO:0000210 Glucuronidation REACTOME_Pathways_01.03.2017 15.0E-9 380.0E-9 6.4E+0 25.00 6.00 
GO:0000860 Porphyrin and chlorophyll metabolism KEGG_01.03.2017 19.0E-9 460.0E-9 6.3E+0 16.67 7.00 
GO:0000830 Retinol metabolism KEGG_01.03.2017 21.0E-9 490.0E-9 6.3E+0 12.31 8.00 
GO:0000982 Drug metabolism KEGG_01.03.2017 39.0E-9 860.0E-9 6.1E+0 11.43 8.00 
GO:0000140 Steroid hormone biosynthesis KEGG_01.03.2017 190.0E-9 4.0E-6 5.4E+0 12.07 7.00 
GO:0000980 Metabolism of xenobiotics by cytochrome P450 KEGG_01.03.2017 1.0E-6 21.0E-6 4.7E+0 9.46 7.00 
GO:0005204 Chemical carcinogenesis KEGG_01.03.2017 2.1E-6 40.0E-6 4.4E+0 8.54 7.00 
GO:0045833 negative regulation of lipid metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 3.7E-6 66.0E-6 4.2E+0 7.87 7.00 
GO:0008194 UDP-glycosyltransferase activity GO_MolecularFunction-GOA_23.02.2017_10h01 11.0E-6 190.0E-6 3.7E+0 5.44 8.00 
GO:0010675 regulation of cellular carbohydrate metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 92.0E-6 1.4E-3 2.9E+0 4.79 7.00 
GO:0000205 Phase II conjugation REACTOME_Pathways_01.03.2017 100.0E-6 1.5E-3 2.8E+0 5.83 6.00 
GO:0000208 Cytosolic sulfonation of small molecules REACTOME_Pathways_01.03.2017 100.0E-6 1.5E-3 2.8E+0 5.83 6.00 
GO:0042440 pigment metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 190.0E-6 2.7E-3 2.6E+0 6.76 5.00 
GO:0001972 retinoic acid binding GO_MolecularFunction-GOA_23.02.2017_10h01 270.0E-6 3.6E-3 2.4E+0 16.67 3.00 
GO:0043197 dendritic spine GO_CellularComponent-GOA_23.02.2017_10h01 460.0E-6 5.5E-3 2.3E+0 4.41 6.00 
GO:0004520 Adherens junction KEGG_01.03.2017 1.8E-3 14.0E-3 1.9E+0 5.56 4.00 
GO:0004662 B cell receptor signaling pathway KEGG_01.03.2017 14.0E-3 14.0E-3 1.9E+0 4.23 3.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 1.4E-3 15.0E-3 1.8E+0 5.97 4.00 
GO:0001464 Interactions of neurexins and neuroligins at synapses REACTOME_Pathways_01.03.2017 1.7E-3 15.0E-3 1.8E+0 5.63 4.00 
GO:0001465 Protein-protein interactions at synapses REACTOME_Pathways_01.03.2017 1.7E-3 15.0E-3 1.8E+0 5.63 4.00 
GO:0001073 Unblocking of NMDA receptor, glutamate binding and activation REACTOME_Pathways_01.03.2017 1.7E-3 17.0E-3 1.8E+0 9.09 3.00 
GO:0001082 CREB phosphorylation through the activation of CaMKII REACTOME_Pathways_01.03.2017 1.7E-3 17.0E-3 1.8E+0 9.09 3.00 
GO:0001733 SALM protein interactions at the synapses REACTOME_Pathways_01.03.2017 1.7E-3 17.0E-3 1.8E+0 9.09 3.00 
GO:0051310 metaphase plate congression GO_BiologicalProcess-GOA_23.02.2017_10h01 6.2E-3 18.0E-3 1.7E+0 5.77 3.00 
GO:0000521 Neurophilin interactions with VEGF and VEGFR REACTOME_Pathways_01.03.2017 3.2E-3 22.0E-3 1.7E+0 7.32 3.00 
GO:0000973 Sema3A PAK dependent Axon repulsion REACTOME_Pathways_01.03.2017 3.2E-3 22.0E-3 1.7E+0 7.32 3.00 
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GO:0000974 SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion REACTOME_Pathways_01.03.2017 3.2E-3 22.0E-3 1.7E+0 7.32 3.00 
GO:0001093 Signal transduction by L1 REACTOME_Pathways_01.03.2017 3.2E-3 22.0E-3 1.7E+0 7.32 3.00 
GO:0021879 forebrain neuron differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 11.0E-3 23.0E-3 1.6E+0 4.62 3.00 
GO:0005211 Renal cell carcinoma KEGG_01.03.2017 11.0E-3 23.0E-3 1.6E+0 4.62 3.00 
GO:0000556 Nuclear Events (kinase and transcription factor activation) REACTOME_Pathways_01.03.2017 5.9E-3 23.0E-3 1.6E+0 5.88 3.00 
GO:0000558 ERK/MAPK targets REACTOME_Pathways_01.03.2017 5.9E-3 23.0E-3 1.6E+0 5.88 3.00 
GO:0000564 CREB phosphorylation REACTOME_Pathways_01.03.2017 5.9E-3 23.0E-3 1.6E+0 5.88 3.00 
GO:0001116 MAPK targets/ Nuclear events mediated by MAP kinases REACTOME_Pathways_01.03.2017 5.9E-3 23.0E-3 1.6E+0 5.88 3.00 
GO:0001291 CD209 (DC-SIGN) signaling REACTOME_Pathways_01.03.2017 5.9E-3 23.0E-3 1.6E+0 5.88 3.00 
GO:0000493 Pre-NOTCH Processing in Golgi REACTOME_Pathways_01.03.2017 4.1E-3 25.0E-3 1.6E+0 6.67 3.00 
GO:0000494 Pre-NOTCH Expression and Processing REACTOME_Pathways_01.03.2017 4.1E-3 25.0E-3 1.6E+0 6.67 3.00 
GO:0030071 regulation of mitotic metaphase/anaphase transition GO_BiologicalProcess-GOA_23.02.2017_10h01 5.3E-3 26.0E-3 1.6E+0 6.12 3.00 
        
NPC (PGC2 + CLOZUK)       
















GO:0032594 protein transport within lipid bilayer GO_BiologicalProcess-GOA_23.02.2017_10h01 59.0E-9 8.6E-6 5.1E+0 62.50 5.00 
GO:0051552 flavone metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 82.0E-6 6.0E-3 2.2E+0 50.00 3.00 
GO:0004261 Adrenergic signaling in cardiomyocytes KEGG_01.03.2017 120.0E-6 6.1E-3 2.2E+0 6.94 10.00 
GO:0004261 Adrenergic signaling in cardiomyocytes KEGG_01.03.2017 120.0E-6 6.1E-3 2.2E+0 6.94 10.00 
GO:0004261 Adrenergic signaling in cardiomyocytes KEGG_01.03.2017 120.0E-6 6.1E-3 2.2E+0 6.94 10.00 
GO:0052697 xenobiotic glucuronidation GO_BiologicalProcess-GOA_23.02.2017_10h01 330.0E-6 6.9E-3 2.2E+0 33.33 3.00 
GO:0007062 sister chromatid cohesion GO_BiologicalProcess-GOA_23.02.2017_10h01 290.0E-6 7.2E-3 2.1E+0 6.87 9.00 
GO:0005891 voltage-gated calcium channel complex GO_CellularComponent-GOA_23.02.2017_10h01 510.0E-6 7.4E-3 2.1E+0 12.20 5.00 
GO:0004024 cAMP signaling pathway KEGG_01.03.2017 410.0E-6 7.5E-3 2.1E+0 5.56 11.00 
GO:0004024 cAMP signaling pathway KEGG_01.03.2017 410.0E-6 7.5E-3 2.1E+0 5.56 11.00 
GO:0014888 striated muscle adaptation GO_BiologicalProcess-GOA_23.02.2017_10h01 570.0E-6 7.6E-3 2.1E+0 11.90 5.00 
GO:0014888 striated muscle adaptation GO_BiologicalProcess-GOA_23.02.2017_10h01 570.0E-6 7.6E-3 2.1E+0 11.90 5.00 
GO:0044450 microtubule organizing center part GO_CellularComponent-GOA_23.02.2017_10h01 480.0E-6 7.8E-3 2.1E+0 5.88 10.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 280.0E-6 8.1E-3 2.1E+0 6.92 9.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 280.0E-6 8.1E-3 2.1E+0 6.92 9.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 280.0E-6 8.1E-3 2.1E+0 6.92 9.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 760.0E-6 9.3E-3 2.0E+0 8.96 6.00 
GO:0005031 Amphetamine addiction KEGG_01.03.2017 820.0E-6 9.3E-3 2.0E+0 8.82 6.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 760.0E-6 9.3E-3 2.0E+0 8.96 6.00 
GO:0005031 Amphetamine addiction KEGG_01.03.2017 820.0E-6 9.3E-3 2.0E+0 8.82 6.00 
GO:0005814 centriole GO_CellularComponent-GOA_23.02.2017_10h01 960.0E-6 10.0E-3 2.0E+0 6.45 8.00 
GO:0051393 alpha-actinin binding GO_MolecularFunction-GOA_23.02.2017_10h01 270.0E-6 10.0E-3 2.0E+0 13.89 5.00 
GO:0035641 locomotory exploration behavior GO_BiologicalProcess-GOA_23.02.2017_10h01 1.6E-3 14.0E-3 1.9E+0 20.00 3.00 
GO:0031011 Ino80 complex GO_CellularComponent-GOA_23.02.2017_10h01 1.6E-3 14.0E-3 1.9E+0 20.00 3.00 
GO:0000819 sister chromatid segregation GO_BiologicalProcess-GOA_23.02.2017_10h01 1.5E-3 14.0E-3 1.9E+0 4.74 11.00 
GO:0000775 chromosome, centromeric region GO_CellularComponent-GOA_23.02.2017_10h01 1.6E-3 14.0E-3 1.9E+0 5.03 10.00 
GO:0050651 dermatan sulfate proteoglycan biosynthetic process GO_BiologicalProcess-GOA_23.02.2017_10h01 1.6E-3 14.0E-3 1.9E+0 20.00 3.00 
GO:0070603 SWI/SNF superfamily-type complex GO_CellularComponent-GOA_23.02.2017_10h01 2.0E-3 15.0E-3 1.8E+0 7.41 6.00 
GO:0006446 regulation of translational initiation GO_BiologicalProcess-GOA_23.02.2017_10h01 2.1E-3 15.0E-3 1.8E+0 7.32 6.00 
GO:0005410 Hypertrophic cardiomyopathy (HCM) KEGG_01.03.2017 2.3E-3 15.0E-3 1.8E+0 7.23 6.00 
GO:0015020 glucuronosyltransferase activity GO_MolecularFunction-GOA_23.02.2017_10h01 2.1E-3 15.0E-3 1.8E+0 11.76 4.00 
GO:0005410 Hypertrophic cardiomyopathy (HCM) KEGG_01.03.2017 2.3E-3 15.0E-3 1.8E+0 7.23 6.00 
GO:0072523 purine-containing compound catabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 2.5E-3 15.0E-3 1.8E+0 8.62 5.00 
GO:0002190 cap-independent translational initiation GO_BiologicalProcess-GOA_23.02.2017_10h01 2.0E-3 16.0E-3 1.8E+0 18.75 3.00 
GO:1903510 mucopolysaccharide metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 3.5E-3 17.0E-3 1.8E+0 5.83 7.00 
GO:0030220 platelet formation GO_BiologicalProcess-GOA_23.02.2017_10h01 2.9E-3 17.0E-3 1.8E+0 16.67 3.00 
GO:0019932 second-messenger-mediated signaling GO_BiologicalProcess-GOA_23.02.2017_10h01 3.6E-3 17.0E-3 1.8E+0 4.23 11.00 
GO:0009066 aspartate family amino acid metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 3.3E-3 18.0E-3 1.7E+0 8.06 5.00 
GO:0005414 Dilated cardiomyopathy KEGG_01.03.2017 3.5E-3 18.0E-3 1.7E+0 6.67 6.00 
GO:0014898 cardiac muscle hypertrophy in response to stress GO_BiologicalProcess-GOA_23.02.2017_10h01 3.9E-3 18.0E-3 1.7E+0 15.00 3.00 
GO:0000830 Retinol metabolism KEGG_01.03.2017 4.1E-3 18.0E-3 1.7E+0 7.69 5.00 
GO:0072509 divalent inorganic cation transmembrane transporter activity GO_MolecularFunction-GOA_23.02.2017_10h01 3.1E-3 18.0E-3 1.7E+0 4.92 9.00 
GO:0005414 Dilated cardiomyopathy KEGG_01.03.2017 3.5E-3 18.0E-3 1.7E+0 6.67 6.00 
GO:0055119 relaxation of cardiac muscle GO_BiologicalProcess-GOA_23.02.2017_10h01 3.4E-3 18.0E-3 1.7E+0 15.79 3.00 
GO:0071871 response to epinephrine GO_BiologicalProcess-GOA_23.02.2017_10h01 3.4E-3 18.0E-3 1.7E+0 15.79 3.00 
GO:0072509 divalent inorganic cation transmembrane transporter activity GO_MolecularFunction-GOA_23.02.2017_10h01 3.1E-3 18.0E-3 1.7E+0 4.92 9.00 
GO:0004602 glutathione peroxidase activity GO_MolecularFunction-GOA_23.02.2017_10h01 4.5E-3 19.0E-3 1.7E+0 14.29 3.00 
GO:0048872 homeostasis of number of cells GO_BiologicalProcess-GOA_23.02.2017_10h01 4.8E-3 19.0E-3 1.7E+0 4.07 11.00 
GO:0030641 regulation of cellular pH GO_BiologicalProcess-GOA_23.02.2017_10h01 4.5E-3 19.0E-3 1.7E+0 6.32 6.00 
GO:0035966 response to topologically incorrect protein GO_BiologicalProcess-GOA_23.02.2017_10h01 4.3E-3 19.0E-3 1.7E+0 4.69 9.00 
GO:0000140 RORA activates gene expression REACTOME_Pathways_01.03.2017 5.3E-3 19.0E-3 1.7E+0 7.25 5.00 
GO:0000141 BMAL1:CLOCK,NPAS2 activates circadian gene expression REACTOME_Pathways_01.03.2017 5.3E-3 19.0E-3 1.7E+0 7.25 5.00 
GO:0000979 Circadian Clock REACTOME_Pathways_01.03.2017 5.3E-3 19.0E-3 1.7E+0 7.25 5.00 
GO:0000860 Porphyrin and chlorophyll metabolism KEGG_01.03.2017 4.7E-3 19.0E-3 1.7E+0 9.52 4.00 
GO:0004022 cGMP-PKG signaling pathway KEGG_01.03.2017 5.3E-3 19.0E-3 1.7E+0 4.91 8.00 
GO:0004022 cGMP-PKG signaling pathway KEGG_01.03.2017 5.3E-3 19.0E-3 1.7E+0 4.91 8.00 
GO:0006555 methionine metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 5.2E-3 20.0E-3 1.7E+0 13.64 3.00 
GO:0043501 skeletal muscle adaptation GO_BiologicalProcess-GOA_23.02.2017_10h01 6.7E-3 20.0E-3 1.7E+0 12.50 3.00 
GO:0043501 skeletal muscle adaptation GO_BiologicalProcess-GOA_23.02.2017_10h01 6.7E-3 20.0E-3 1.7E+0 12.50 3.00 
GO:0001464 Interactions of neurexins and neuroligins at synapses REACTOME_Pathways_01.03.2017 5.9E-3 20.0E-3 1.7E+0 7.04 5.00 
GO:0001465 Protein-protein interactions at synapses REACTOME_Pathways_01.03.2017 5.9E-3 20.0E-3 1.7E+0 7.04 5.00 
GO:0035637 multicellular organismal signaling GO_BiologicalProcess-GOA_23.02.2017_10h01 6.5E-3 20.0E-3 1.7E+0 4.39 9.00 
GO:0043501 skeletal muscle adaptation GO_BiologicalProcess-GOA_23.02.2017_10h01 6.7E-3 20.0E-3 1.7E+0 12.50 3.00 
GO:0030552 cAMP binding GO_MolecularFunction-GOA_23.02.2017_10h01 6.7E-3 20.0E-3 1.7E+0 12.50 3.00 
GO:0043197 dendritic spine GO_CellularComponent-GOA_23.02.2017_10h01 6.9E-3 21.0E-3 1.7E+0 5.15 7.00 
GO:0002062 chondrocyte differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 7.7E-3 21.0E-3 1.7E+0 5.66 6.00 
GO:0045948 positive regulation of translational initiation GO_BiologicalProcess-GOA_23.02.2017_10h01 5.9E-3 21.0E-3 1.7E+0 13.04 3.00 
GO:0000776 kinetochore GO_CellularComponent-GOA_23.02.2017_10h01 7.4E-3 21.0E-3 1.7E+0 5.07 7.00 
GO:0051788 response to misfolded protein GO_BiologicalProcess-GOA_23.02.2017_10h01 5.9E-3 21.0E-3 1.7E+0 13.04 3.00 
GO:0030206 chondroitin sulfate biosynthetic process GO_BiologicalProcess-GOA_23.02.2017_10h01 7.5E-3 21.0E-3 1.7E+0 12.00 3.00 
GO:0042440 pigment metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 7.1E-3 21.0E-3 1.7E+0 6.76 5.00 
GO:0071300 cellular response to retinoic acid GO_BiologicalProcess-GOA_23.02.2017_10h01 7.1E-3 21.0E-3 1.7E+0 6.76 5.00 
GO:0000983 Drug metabolism KEGG_01.03.2017 6.5E-3 21.0E-3 1.7E+0 8.70 4.00 
GO:0042440 pigment metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 7.1E-3 21.0E-3 1.7E+0 6.76 5.00 
GO:0005412 Arrhythmogenic right ventricular cardiomyopathy (ARVC) KEGG_01.03.2017 6.3E-3 21.0E-3 1.7E+0 6.94 5.00 
GO:0019722 calcium-mediated signaling GO_BiologicalProcess-GOA_23.02.2017_10h01 6.3E-3 21.0E-3 1.7E+0 4.76 8.00 
GO:0004931 Insulin resistance KEGG_01.03.2017 8.1E-3 22.0E-3 1.7E+0 5.61 6.00 
GO:0006941 striated muscle contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 8.3E-3 22.0E-3 1.7E+0 4.55 8.00 
GO:0022406 membrane docking GO_BiologicalProcess-GOA_23.02.2017_10h01 9.4E-3 23.0E-3 1.6E+0 4.44 8.00 
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GO:0004260 Cardiac muscle contraction KEGG_01.03.2017 8.8E-3 23.0E-3 1.6E+0 6.41 5.00 
GO:0008287 protein serine/threonine phosphatase complex GO_CellularComponent-GOA_23.02.2017_10h01 9.4E-3 23.0E-3 1.6E+0 7.84 4.00 
GO:0000053 Ascorbate and aldarate metabolism KEGG_01.03.2017 9.3E-3 23.0E-3 1.6E+0 11.11 3.00 
GO:0060078 regulation of postsynaptic membrane potential GO_BiologicalProcess-GOA_23.02.2017_10h01 9.0E-3 23.0E-3 1.6E+0 4.90 7.00 
GO:0004260 Cardiac muscle contraction KEGG_01.03.2017 8.8E-3 23.0E-3 1.6E+0 6.41 5.00 
GO:0008287 protein serine/threonine phosphatase complex GO_CellularComponent-GOA_23.02.2017_10h01 9.4E-3 23.0E-3 1.6E+0 7.84 4.00 
GO:0061337 cardiac conduction GO_BiologicalProcess-GOA_23.02.2017_10h01 9.0E-3 23.0E-3 1.6E+0 4.90 7.00 
GO:0055117 regulation of cardiac muscle contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 8.8E-3 23.0E-3 1.6E+0 6.41 5.00 
GO:0005231 excitatory extracellular ligand-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000223 Mitochondrial biogenesis REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000260 Mitochondrial transcription initiation REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000673 Transcriptional activation of mitochondrial biogenesis REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0001680 Transcription from mitochondrial promoters REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000223 Mitochondrial biogenesis REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000260 Mitochondrial transcription initiation REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000673 Transcriptional activation of mitochondrial biogenesis REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0001680 Transcription from mitochondrial promoters REACTOME_Pathways_01.03.2017 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0008194 UDP-glycosyltransferase activity GO_MolecularFunction-GOA_23.02.2017_10h01 10.0E-3 24.0E-3 1.6E+0 4.76 7.00 
GO:0015276 ligand-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 10.0E-3 24.0E-3 1.6E+0 4.79 7.00 
GO:0005231 excitatory extracellular ligand-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 10.0E-3 24.0E-3 1.6E+0 7.69 4.00 
GO:0000480 Glutathione metabolism KEGG_01.03.2017 11.0E-3 26.0E-3 1.6E+0 7.41 4.00 
GO:0070252 actin-mediated cell contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 11.0E-3 26.0E-3 1.6E+0 5.17 6.00 
GO:0070252 actin-mediated cell contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 11.0E-3 26.0E-3 1.6E+0 5.17 6.00 
GO:0006479 protein methylation GO_BiologicalProcess-GOA_23.02.2017_10h01 12.0E-3 27.0E-3 1.6E+0 4.23 8.00 
GO:0001491 Regulation of TP53 Activity through Acetylation REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0035967 cellular response to topologically incorrect protein GO_BiologicalProcess-GOA_23.02.2017_10h01 12.0E-3 27.0E-3 1.6E+0 4.58 7.00 
GO:0000579 Chondroitin sulfate biosynthesis REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0000580 Dermatan sulfate biosynthesis REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0000585 CS/DS degradation REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0000852 Defective CHST3 causes SEDCJD REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0000853 Defective CHST14 causes EDS, musculocontractural type REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0000854 Defective CHSY1 causes TPBS REACTOME_Pathways_01.03.2017 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0001964 startle response GO_BiologicalProcess-GOA_23.02.2017_10h01 12.0E-3 27.0E-3 1.6E+0 10.00 3.00 
GO:0086065 cell communication involved in cardiac conduction GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 27.0E-3 1.6E+0 7.14 4.00 
GO:0086065 cell communication involved in cardiac conduction GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 27.0E-3 1.6E+0 7.14 4.00 
GO:0032733 positive regulation of interleukin-10 production GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 28.0E-3 1.6E+0 9.68 3.00 
GO:0032733 positive regulation of interleukin-10 production GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 28.0E-3 1.6E+0 9.68 3.00 
GO:0032733 positive regulation of interleukin-10 production GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 28.0E-3 1.6E+0 9.68 3.00 
GO:0006937 regulation of muscle contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 13.0E-3 28.0E-3 1.6E+0 4.52 7.00 
GO:0051216 cartilage development GO_BiologicalProcess-GOA_23.02.2017_10h01 15.0E-3 30.0E-3 1.5E+0 4.08 8.00 
GO:0001782 B cell homeostasis GO_BiologicalProcess-GOA_23.02.2017_10h01 14.0E-3 30.0E-3 1.5E+0 9.38 3.00 
GO:0001065 Golgi Associated Vesicle Biogenesis REACTOME_Pathways_01.03.2017 16.0E-3 30.0E-3 1.5E+0 4.80 6.00 
GO:0001474 Signaling by BRAF and RAF fusions REACTOME_Pathways_01.03.2017 16.0E-3 30.0E-3 1.5E+0 4.80 6.00 
GO:0001477 Oncogenic MAPK signaling REACTOME_Pathways_01.03.2017 16.0E-3 30.0E-3 1.5E+0 4.80 6.00 
GO:0030173 integral component of Golgi membrane GO_CellularComponent-GOA_23.02.2017_10h01 14.0E-3 30.0E-3 1.5E+0 6.90 4.00 
GO:0032743 positive regulation of interleukin-2 production GO_BiologicalProcess-GOA_23.02.2017_10h01 14.0E-3 30.0E-3 1.5E+0 9.38 3.00 
GO:0004110 Cell cycle KEGG_01.03.2017 15.0E-3 31.0E-3 1.5E+0 4.84 6.00 
GO:0006370 7-methylguanosine mRNA capping GO_BiologicalProcess-GOA_23.02.2017_10h01 16.0E-3 31.0E-3 1.5E+0 9.09 3.00 
GO:0000287 Rev-mediated nuclear export of HIV RNA REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0000350 Export of Viral Ribonucleoproteins from Nucleus REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0000358 NEP/NS2 Interacts with the Cellular Export Machinery REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0000417 Interactions of Rev with host cellular proteins REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0000685 Downregulation of TGF-beta receptor signaling REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0000686 TGF-beta receptor signaling activates SMADs REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0001124 HuR (ELAVL1) binds and stabilizes mRNA REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0001549 Cyclin A/B1 associated events during G2/M transition REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 5.49 5.00 
GO:0001073 Unblocking of NMDA receptor, glutamate binding and activation REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 9.09 3.00 
GO:0001082 CREB phosphorylation through the activation of CaMKII REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 9.09 3.00 
GO:0001733 SALM protein interactions at the synapses REACTOME_Pathways_01.03.2017 16.0E-3 31.0E-3 1.5E+0 9.09 3.00 
GO:0005244 voltage-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 16.0E-3 31.0E-3 1.5E+0 4.02 8.00 
GO:0005244 voltage-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 16.0E-3 31.0E-3 1.5E+0 4.02 8.00 
GO:0071354 cellular response to interleukin-6 GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 32.0E-3 1.5E+0 8.82 3.00 
GO:0098739 import across plasma membrane GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 32.0E-3 1.5E+0 8.82 3.00 
GO:0001662 behavioral fear response GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 32.0E-3 1.5E+0 8.82 3.00 
GO:0042100 B cell proliferation GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 32.0E-3 1.5E+0 5.38 5.00 
GO:0000040 Pentose and glucuronate interconversions KEGG_01.03.2017 17.0E-3 32.0E-3 1.5E+0 8.82 3.00 
GO:0043620 regulation of DNA-templated transcription in response to stress GO_BiologicalProcess-GOA_23.02.2017_10h01 18.0E-3 33.0E-3 1.5E+0 4.69 6.00 
GO:0002823 
negative regulation of adaptive immune response based on somatic 
recombination of immune receptors built from immunoglobulin 
superfamily domains GO_BiologicalProcess-GOA_23.02.2017_10h01 19.0E-3 33.0E-3 1.5E+0 8.57 3.00 
GO:0008376 acetylgalactosaminyltransferase activity GO_MolecularFunction-GOA_23.02.2017_10h01 19.0E-3 33.0E-3 1.5E+0 8.57 3.00 
GO:0050777 negative regulation of immune response GO_BiologicalProcess-GOA_23.02.2017_10h01 19.0E-3 34.0E-3 1.5E+0 4.62 6.00 
GO:0050777 negative regulation of immune response GO_BiologicalProcess-GOA_23.02.2017_10h01 19.0E-3 34.0E-3 1.5E+0 4.62 6.00 
GO:0004713 Circadian entrainment KEGG_01.03.2017 20.0E-3 35.0E-3 1.5E+0 5.21 5.00 
GO:0004713 Circadian entrainment KEGG_01.03.2017 20.0E-3 35.0E-3 1.5E+0 5.21 5.00 
GO:0006901 vesicle coating GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 36.0E-3 1.4E+0 6.15 4.00 
GO:0005211 Renal cell carcinoma KEGG_01.03.2017 21.0E-3 36.0E-3 1.4E+0 6.15 4.00 
GO:0032729 positive regulation of interferon-gamma production GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 36.0E-3 1.4E+0 6.15 4.00 
GO:0015698 inorganic anion transport GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 36.0E-3 1.4E+0 4.12 7.00 
GO:0030968 endoplasmic reticulum unfolded protein response GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 36.0E-3 1.4E+0 4.55 6.00 
GO:0032729 positive regulation of interferon-gamma production GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 36.0E-3 1.4E+0 6.15 4.00 
GO:0001756 somitogenesis GO_BiologicalProcess-GOA_23.02.2017_10h01 24.0E-3 39.0E-3 1.4E+0 5.88 4.00 
GO:0048199 vesicle targeting, to, from or within Golgi GO_BiologicalProcess-GOA_23.02.2017_10h01 24.0E-3 39.0E-3 1.4E+0 5.88 4.00 
GO:0006986 response to unfolded protein GO_BiologicalProcess-GOA_23.02.2017_10h01 24.0E-3 39.0E-3 1.4E+0 4.02 7.00 
GO:1901863 positive regulation of muscle tissue development GO_BiologicalProcess-GOA_23.02.2017_10h01 24.0E-3 39.0E-3 1.4E+0 5.88 4.00 
GO:0004360 Axon guidance KEGG_01.03.2017 24.0E-3 40.0E-3 1.4E+0 4.00 7.00 
GO:0015103 inorganic anion transmembrane transporter activity GO_MolecularFunction-GOA_23.02.2017_10h01 24.0E-3 40.0E-3 1.4E+0 4.38 6.00 
GO:0006821 chloride transport GO_BiologicalProcess-GOA_23.02.2017_10h01 27.0E-3 42.0E-3 1.4E+0 4.81 5.00 
GO:0000982 Drug metabolism KEGG_01.03.2017 27.0E-3 42.0E-3 1.4E+0 5.71 4.00 
GO:0005033 Nicotine addiction KEGG_01.03.2017 27.0E-3 42.0E-3 1.4E+0 7.50 3.00 
GO:0006821 chloride transport GO_BiologicalProcess-GOA_23.02.2017_10h01 27.0E-3 42.0E-3 1.4E+0 4.81 5.00 
GO:0018023 peptidyl-lysine trimethylation GO_BiologicalProcess-GOA_23.02.2017_10h01 28.0E-3 44.0E-3 1.4E+0 7.32 3.00 
GO:0001072 Post NMDA receptor activation events REACTOME_Pathways_01.03.2017 28.0E-3 44.0E-3 1.4E+0 7.32 3.00 
GO:0001083 CREB phosphorylation through the activation of Ras REACTOME_Pathways_01.03.2017 28.0E-3 44.0E-3 1.4E+0 7.32 3.00 
GO:0001085 
Activation of NMDA receptor upon glutamate binding and postsynaptic 
events REACTOME_Pathways_01.03.2017 28.0E-3 44.0E-3 1.4E+0 7.32 3.00 
GO:0001086 Ras activation uopn Ca2+ infux through NMDA receptor REACTOME_Pathways_01.03.2017 28.0E-3 44.0E-3 1.4E+0 7.32 3.00 
GO:0004520 Adherens junction KEGG_01.03.2017 29.0E-3 45.0E-3 1.3E+0 5.56 4.00 
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GO:0000777 condensed chromosome kinetochore GO_CellularComponent-GOA_23.02.2017_10h01 30.0E-3 46.0E-3 1.3E+0 4.67 5.00 
GO:0000218 Signaling by NOTCH REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000549 Signaling by NOTCH1 REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000550 Signaling by NOTCH2 REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000654 Activated NOTCH1 Transmits Signal to the Nucleus REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000743 Signaling by NOTCH1 PEST Domain Mutants in Cancer REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000744 Signaling by NOTCH1 in Cancer REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000746 Constitutive Signaling by NOTCH1 PEST Domain Mutants REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000756 Signaling by NOTCH1 HD Domain Mutants in Cancer REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000757 Constitutive Signaling by NOTCH1 HD Domain Mutants REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000765 Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000766 Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:0000768 NOTCH2 Activation and Transmission of Signal to the Nucleus REACTOME_Pathways_01.03.2017 31.0E-3 46.0E-3 1.3E+0 4.63 5.00 
GO:1903779 regulation of cardiac conduction GO_BiologicalProcess-GOA_23.02.2017_10h01 31.0E-3 46.0E-3 1.3E+0 5.48 4.00 
GO:0051489 regulation of filopodium assembly GO_BiologicalProcess-GOA_23.02.2017_10h01 32.0E-3 47.0E-3 1.3E+0 6.98 3.00 
GO:0006904 vesicle docking involved in exocytosis GO_BiologicalProcess-GOA_23.02.2017_10h01 32.0E-3 47.0E-3 1.3E+0 6.98 3.00 
GO:0008135 translation factor activity, RNA binding GO_MolecularFunction-GOA_23.02.2017_10h01 32.0E-3 47.0E-3 1.3E+0 4.59 5.00 
GO:0006661 phosphatidylinositol biosynthetic process GO_BiologicalProcess-GOA_23.02.2017_10h01 34.0E-3 48.0E-3 1.3E+0 4.05 6.00 
GO:0021549 cerebellum development GO_BiologicalProcess-GOA_23.02.2017_10h01 35.0E-3 48.0E-3 1.3E+0 4.50 5.00 
GO:0031571 mitotic G1 DNA damage checkpoint GO_BiologicalProcess-GOA_23.02.2017_10h01 35.0E-3 48.0E-3 1.3E+0 5.26 4.00 
GO:0048678 response to axon injury GO_BiologicalProcess-GOA_23.02.2017_10h01 35.0E-3 48.0E-3 1.3E+0 5.26 4.00 
GO:0051304 chromosome separation GO_BiologicalProcess-GOA_23.02.2017_10h01 33.0E-3 48.0E-3 1.3E+0 5.33 4.00 
GO:0004973 Carbohydrate digestion and absorption KEGG_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0000309 Complement cascade REACTOME_Pathways_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0000310 Lectin pathway of complement activation REACTOME_Pathways_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0000311 Initial triggering of complement REACTOME_Pathways_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0000313 Creation of C4 and C2 activators REACTOME_Pathways_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0000759 
Ficolins bind to repetitive carbohydrate structures on the target cell 
surface REACTOME_Pathways_01.03.2017 34.0E-3 48.0E-3 1.3E+0 6.82 3.00 
GO:0003022 Basal transcription factors KEGG_01.03.2017 36.0E-3 49.0E-3 1.3E+0 6.67 3.00 
GO:0033555 multicellular organismal response to stress GO_BiologicalProcess-GOA_23.02.2017_10h01 36.0E-3 49.0E-3 1.3E+0 5.19 4.00 
GO:0032580 Golgi cisterna membrane GO_CellularComponent-GOA_23.02.2017_10h01 36.0E-3 49.0E-3 1.3E+0 5.19 4.00 
GO:0000493 Pre-NOTCH Processing in Golgi REACTOME_Pathways_01.03.2017 36.0E-3 49.0E-3 1.3E+0 6.67 3.00 
GO:0000494 Pre-NOTCH Expression and Processing REACTOME_Pathways_01.03.2017 36.0E-3 49.0E-3 1.3E+0 6.67 3.00 
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GO:0097346 INO80-type complex GO_CellularComponent-GOA_23.02.2017_10h01 830.0E-9 52.0E-6 4.3E+0 27.27 6.00 
GO:0070603 SWI/SNF superfamily-type complex GO_CellularComponent-GOA_23.02.2017_10h01 520.0E-9 66.0E-6 4.2E+0 12.35 10.00 
GO:0044297 cell body GO_CellularComponent-GOA_23.02.2017_10h01 5.2E-6 220.0E-6 3.7E+0 4.41 24.00 
GO:0006338 chromatin remodeling GO_BiologicalProcess-GOA_23.02.2017_10h01 8.2E-6 260.0E-6 3.6E+0 7.50 12.00 
GO:0098794 postsynapse GO_CellularComponent-GOA_23.02.2017_10h01 21.0E-6 380.0E-6 3.4E+0 4.55 20.00 
GO:0043025 neuronal cell body GO_CellularComponent-GOA_23.02.2017_10h01 21.0E-6 450.0E-6 3.3E+0 4.40 21.00 
GO:0030425 dendrite GO_CellularComponent-GOA_23.02.2017_10h01 19.0E-6 490.0E-6 3.3E+0 4.30 22.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 37.0E-6 600.0E-6 3.2E+0 7.69 10.00 
GO:0004728 Dopaminergic synapse KEGG_01.03.2017 37.0E-6 600.0E-6 3.2E+0 7.69 10.00 
GO:0042578 phosphoric ester hydrolase activity GO_MolecularFunction-GOA_23.02.2017_10h01 45.0E-6 630.0E-6 3.2E+0 4.62 18.00 
GO:0031011 Ino80 complex GO_CellularComponent-GOA_23.02.2017_10h01 69.0E-6 880.0E-6 3.1E+0 26.67 4.00 
GO:0032526 response to retinoic acid GO_BiologicalProcess-GOA_23.02.2017_10h01 92.0E-6 1.0E-3 3.0E+0 7.69 9.00 
GO:0071300 cellular response to retinoic acid GO_BiologicalProcess-GOA_23.02.2017_10h01 150.0E-6 1.6E-3 2.8E+0 9.46 7.00 
GO:0090568 nuclear transcriptional repressor complex GO_CellularComponent-GOA_23.02.2017_10h01 290.0E-6 2.8E-3 2.6E+0 13.16 5.00 
GO:0090568 nuclear transcriptional repressor complex GO_CellularComponent-GOA_23.02.2017_10h01 290.0E-6 2.8E-3 2.6E+0 13.16 5.00 
GO:0071229 cellular response to acid chemical GO_BiologicalProcess-GOA_23.02.2017_10h01 370.0E-6 3.4E-3 2.5E+0 5.39 11.00 
GO:0005891 voltage-gated calcium channel complex GO_CellularComponent-GOA_23.02.2017_10h01 420.0E-6 3.5E-3 2.5E+0 12.20 5.00 
GO:0005891 voltage-gated calcium channel complex GO_CellularComponent-GOA_23.02.2017_10h01 420.0E-6 3.5E-3 2.5E+0 12.20 5.00 
GO:0005031 Amphetamine addiction KEGG_01.03.2017 660.0E-6 4.2E-3 2.4E+0 8.82 6.00 
GO:0014069 postsynaptic density GO_CellularComponent-GOA_23.02.2017_10h01 630.0E-6 4.2E-3 2.4E+0 5.07 11.00 
GO:0005031 Amphetamine addiction KEGG_01.03.2017 660.0E-6 4.2E-3 2.4E+0 8.82 6.00 
GO:0014069 postsynaptic density GO_CellularComponent-GOA_23.02.2017_10h01 630.0E-6 4.2E-3 2.4E+0 5.07 11.00 
GO:0004152 AMPK signaling pathway KEGG_01.03.2017 620.0E-6 4.4E-3 2.4E+0 6.61 8.00 
GO:0004152 AMPK signaling pathway KEGG_01.03.2017 620.0E-6 4.4E-3 2.4E+0 6.61 8.00 
GO:0004973 Carbohydrate digestion and absorption KEGG_01.03.2017 590.0E-6 4.6E-3 2.3E+0 11.36 5.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 610.0E-6 4.6E-3 2.3E+0 8.96 6.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 610.0E-6 4.6E-3 2.3E+0 8.96 6.00 
GO:0004973 Carbohydrate digestion and absorption KEGG_01.03.2017 590.0E-6 4.6E-3 2.3E+0 11.36 5.00 
GO:0000118 histone deacetylase complex GO_CellularComponent-GOA_23.02.2017_10h01 1.0E-3 6.3E-3 2.2E+0 8.11 6.00 
GO:0000118 histone deacetylase complex GO_CellularComponent-GOA_23.02.2017_10h01 1.0E-3 6.3E-3 2.2E+0 8.11 6.00 
GO:0004931 Insulin resistance KEGG_01.03.2017 1.4E-3 7.0E-3 2.2E+0 6.54 7.00 
GO:0045211 postsynaptic membrane GO_CellularComponent-GOA_23.02.2017_10h01 1.3E-3 7.0E-3 2.2E+0 4.60 11.00 
GO:0005231 excitatory extracellular ligand-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 1.2E-3 7.0E-3 2.2E+0 9.62 5.00 
GO:0004931 Insulin resistance KEGG_01.03.2017 1.4E-3 7.0E-3 2.2E+0 6.54 7.00 
GO:0001101 response to acid chemical GO_BiologicalProcess-GOA_23.02.2017_10h01 1.2E-3 7.1E-3 2.1E+0 4.01 14.00 
GO:0043197 dendritic spine GO_CellularComponent-GOA_23.02.2017_10h01 1.3E-3 7.1E-3 2.1E+0 5.88 8.00 
GO:0004725 Cholinergic synapse KEGG_01.03.2017 1.8E-3 8.2E-3 2.1E+0 6.25 7.00 
GO:0004725 Cholinergic synapse KEGG_01.03.2017 1.8E-3 8.2E-3 2.1E+0 6.25 7.00 
GO:0004925 Aldosterone synthesis and secretion KEGG_01.03.2017 1.7E-3 8.3E-3 2.1E+0 7.32 6.00 
GO:0060078 regulation of postsynaptic membrane potential GO_BiologicalProcess-GOA_23.02.2017_10h01 1.8E-3 8.4E-3 2.1E+0 5.59 8.00 
GO:0000422 mitophagy GO_BiologicalProcess-GOA_23.02.2017_10h01 2.1E-3 8.7E-3 2.1E+0 7.06 6.00 
GO:0004724 Glutamatergic synapse KEGG_01.03.2017 2.0E-3 8.8E-3 2.1E+0 6.14 7.00 
GO:0004724 Glutamatergic synapse KEGG_01.03.2017 2.0E-3 8.8E-3 2.1E+0 6.14 7.00 
GO:0051393 alpha-actinin binding GO_MolecularFunction-GOA_23.02.2017_10h01 2.3E-3 9.1E-3 2.0E+0 11.11 4.00 
GO:0051393 alpha-actinin binding GO_MolecularFunction-GOA_23.02.2017_10h01 2.3E-3 9.1E-3 2.0E+0 11.11 4.00 
GO:0030224 monocyte differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 2.8E-3 10.0E-3 2.0E+0 10.53 4.00 
GO:0000257 Post-translational modification: synthesis of GPI-anchored proteins REACTOME_Pathways_01.03.2017 2.8E-3 10.0E-3 2.0E+0 6.67 6.00 
GO:0016575 histone deacetylation GO_BiologicalProcess-GOA_23.02.2017_10h01 2.7E-3 10.0E-3 2.0E+0 6.74 6.00 
GO:0004070 Phosphatidylinositol signaling system KEGG_01.03.2017 4.1E-3 12.0E-3 1.9E+0 6.19 6.00 
GO:0000706 SeMet incorporation into proteins REACTOME_Pathways_01.03.2017 4.0E-3 12.0E-3 1.9E+0 9.52 4.00 
GO:0000889 Cytosolic tRNA aminoacylation REACTOME_Pathways_01.03.2017 4.0E-3 12.0E-3 1.9E+0 9.52 4.00 
GO:0000890 tRNA Aminoacylation REACTOME_Pathways_01.03.2017 4.0E-3 12.0E-3 1.9E+0 9.52 4.00 
GO:0071869 response to catecholamine GO_BiologicalProcess-GOA_23.02.2017_10h01 3.7E-3 12.0E-3 1.9E+0 9.76 4.00 
GO:0035258 steroid hormone receptor binding GO_MolecularFunction-GOA_23.02.2017_10h01 3.5E-3 12.0E-3 1.9E+0 6.38 6.00 
GO:0071869 response to catecholamine GO_BiologicalProcess-GOA_23.02.2017_10h01 3.7E-3 12.0E-3 1.9E+0 9.76 4.00 
GO:0004070 Phosphatidylinositol signaling system KEGG_01.03.2017 4.1E-3 12.0E-3 1.9E+0 6.19 6.00 
GO:0008081 phosphoric diester hydrolase activity GO_MolecularFunction-GOA_23.02.2017_10h01 4.3E-3 13.0E-3 1.9E+0 6.12 6.00 
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GO:0004024 cAMP signaling pathway KEGG_01.03.2017 4.0E-3 13.0E-3 1.9E+0 4.55 9.00 
GO:0008081 phosphoric diester hydrolase activity GO_MolecularFunction-GOA_23.02.2017_10h01 4.3E-3 13.0E-3 1.9E+0 6.12 6.00 
GO:0004713 Circadian entrainment KEGG_01.03.2017 3.9E-3 13.0E-3 1.9E+0 6.25 6.00 
GO:0004024 cAMP signaling pathway KEGG_01.03.2017 4.0E-3 13.0E-3 1.9E+0 4.55 9.00 
GO:0004713 Circadian entrainment KEGG_01.03.2017 3.9E-3 13.0E-3 1.9E+0 6.25 6.00 
GO:0044450 microtubule organizing center part GO_CellularComponent-GOA_23.02.2017_10h01 5.3E-3 15.0E-3 1.8E+0 4.71 8.00 
GO:0016581 NuRD complex GO_CellularComponent-GOA_23.02.2017_10h01 5.2E-3 15.0E-3 1.8E+0 13.04 3.00 
GO:0016581 NuRD complex GO_CellularComponent-GOA_23.02.2017_10h01 5.2E-3 15.0E-3 1.8E+0 13.04 3.00 
GO:0031103 axon regeneration GO_BiologicalProcess-GOA_23.02.2017_10h01 5.6E-3 16.0E-3 1.8E+0 8.70 4.00 
GO:0043523 regulation of neuron apoptotic process GO_BiologicalProcess-GOA_23.02.2017_10h01 5.8E-3 16.0E-3 1.8E+0 4.29 9.00 
GO:0030552 cAMP binding GO_MolecularFunction-GOA_23.02.2017_10h01 5.9E-3 16.0E-3 1.8E+0 12.50 3.00 
GO:0030552 cAMP binding GO_MolecularFunction-GOA_23.02.2017_10h01 5.9E-3 16.0E-3 1.8E+0 12.50 3.00 
GO:0004812 aminoacyl-tRNA ligase activity GO_MolecularFunction-GOA_23.02.2017_10h01 7.6E-3 19.0E-3 1.7E+0 8.00 4.00 
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity GO_MolecularFunction-GOA_23.02.2017_10h01 8.3E-3 19.0E-3 1.7E+0 11.11 3.00 
GO:0004261 Adrenergic signaling in cardiomyocytes KEGG_01.03.2017 7.5E-3 19.0E-3 1.7E+0 4.86 7.00 
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity GO_MolecularFunction-GOA_23.02.2017_10h01 8.3E-3 19.0E-3 1.7E+0 11.11 3.00 
GO:0004261 Adrenergic signaling in cardiomyocytes KEGG_01.03.2017 7.5E-3 19.0E-3 1.7E+0 4.86 7.00 
GO:0021549 cerebellum development GO_BiologicalProcess-GOA_23.02.2017_10h01 7.9E-3 20.0E-3 1.7E+0 5.41 6.00 
GO:0010508 positive regulation of autophagy GO_BiologicalProcess-GOA_23.02.2017_10h01 8.2E-3 20.0E-3 1.7E+0 5.36 6.00 
GO:0015276 ligand-gated ion channel activity GO_MolecularFunction-GOA_23.02.2017_10h01 8.0E-3 20.0E-3 1.7E+0 4.79 7.00 
GO:0051306 mitotic sister chromatid separation GO_BiologicalProcess-GOA_23.02.2017_10h01 9.3E-3 21.0E-3 1.7E+0 7.55 4.00 
GO:0004435 phosphatidylinositol phospholipase C activity GO_MolecularFunction-GOA_23.02.2017_10h01 9.2E-3 21.0E-3 1.7E+0 10.71 3.00 
GO:1903599 positive regulation of mitophagy GO_BiologicalProcess-GOA_23.02.2017_10h01 10.0E-3 22.0E-3 1.7E+0 10.34 3.00 
GO:0006418 tRNA aminoacylation for protein translation GO_BiologicalProcess-GOA_23.02.2017_10h01 9.9E-3 22.0E-3 1.7E+0 7.41 4.00 
GO:0000289 Activation of AKT2 REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0000847 Integrin alphaIIb beta3 signaling REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0000929 CTLA4 inhibitory signaling REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0001088 RSK activation REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0001177 VEGFR2 mediated vascular permeability REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0001685 Platelet Aggregation (Plug Formation) REACTOME_Pathways_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0004911 Insulin secretion KEGG_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0004911 Insulin secretion KEGG_01.03.2017 10.0E-3 23.0E-3 1.6E+0 5.88 5.00 
GO:0001491 Regulation of TP53 Activity through Acetylation REACTOME_Pathways_01.03.2017 11.0E-3 24.0E-3 1.6E+0 10.00 3.00 
GO:0001491 Regulation of TP53 Activity through Acetylation REACTOME_Pathways_01.03.2017 11.0E-3 24.0E-3 1.6E+0 10.00 3.00 
GO:0001491 Regulation of TP53 Activity through Acetylation REACTOME_Pathways_01.03.2017 11.0E-3 24.0E-3 1.6E+0 10.00 3.00 
GO:0001491 Regulation of TP53 Activity through Acetylation REACTOME_Pathways_01.03.2017 11.0E-3 24.0E-3 1.6E+0 10.00 3.00 
GO:0006473 protein acetylation GO_BiologicalProcess-GOA_23.02.2017_10h01 12.0E-3 25.0E-3 1.6E+0 4.08 8.00 
GO:0004727 GABAergic synapse KEGG_01.03.2017 12.0E-3 25.0E-3 1.6E+0 5.68 5.00 
GO:0004727 GABAergic synapse KEGG_01.03.2017 12.0E-3 25.0E-3 1.6E+0 5.68 5.00 
GO:0030426 growth cone GO_CellularComponent-GOA_23.02.2017_10h01 13.0E-3 26.0E-3 1.6E+0 4.32 7.00 
GO:0005814 centriole GO_CellularComponent-GOA_23.02.2017_10h01 13.0E-3 26.0E-3 1.6E+0 4.84 6.00 
GO:0016836 hydro-lyase activity GO_MolecularFunction-GOA_23.02.2017_10h01 12.0E-3 26.0E-3 1.6E+0 6.90 4.00 
GO:0004211 Longevity regulating pathway KEGG_01.03.2017 14.0E-3 26.0E-3 1.6E+0 5.49 5.00 
GO:0072523 purine-containing compound catabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 12.0E-3 26.0E-3 1.6E+0 6.90 4.00 
GO:1901657 glycosyl compound metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 14.0E-3 27.0E-3 1.6E+0 4.29 7.00 
GO:1903578 regulation of ATP metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 15.0E-3 27.0E-3 1.6E+0 6.56 4.00 
GO:0001065 Golgi Associated Vesicle Biogenesis REACTOME_Pathways_01.03.2017 13.0E-3 27.0E-3 1.6E+0 4.80 6.00 
GO:0001474 Signaling by BRAF and RAF fusions REACTOME_Pathways_01.03.2017 13.0E-3 27.0E-3 1.6E+0 4.80 6.00 
GO:0001477 Oncogenic MAPK signaling REACTOME_Pathways_01.03.2017 13.0E-3 27.0E-3 1.6E+0 4.80 6.00 
GO:1903578 regulation of ATP metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 15.0E-3 27.0E-3 1.6E+0 6.56 4.00 
GO:0004022 cGMP-PKG signaling pathway KEGG_01.03.2017 14.0E-3 27.0E-3 1.6E+0 4.29 7.00 
GO:0001073 Unblocking of NMDA receptor, glutamate binding and activation REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0001082 CREB phosphorylation through the activation of CaMKII REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0001733 SALM protein interactions at the synapses REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0004022 cGMP-PKG signaling pathway KEGG_01.03.2017 14.0E-3 27.0E-3 1.6E+0 4.29 7.00 
GO:0001073 Unblocking of NMDA receptor, glutamate binding and activation REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0001082 CREB phosphorylation through the activation of CaMKII REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0001733 SALM protein interactions at the synapses REACTOME_Pathways_01.03.2017 14.0E-3 27.0E-3 1.6E+0 9.09 3.00 
GO:0009066 aspartate family amino acid metabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 15.0E-3 28.0E-3 1.6E+0 6.45 4.00 
GO:0004914 Progesterone-mediated oocyte maturation KEGG_01.03.2017 17.0E-3 30.0E-3 1.5E+0 5.21 5.00 
GO:0030902 hindbrain development GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 30.0E-3 1.5E+0 4.14 7.00 
GO:2001252 positive regulation of chromosome organization GO_BiologicalProcess-GOA_23.02.2017_10h01 18.0E-3 30.0E-3 1.5E+0 4.09 7.00 
GO:1901983 regulation of protein acetylation GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 30.0E-3 1.5E+0 6.25 4.00 
GO:0005143 African trypanosomiasis KEGG_01.03.2017 17.0E-3 30.0E-3 1.5E+0 8.57 3.00 
GO:1901983 regulation of protein acetylation GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 30.0E-3 1.5E+0 6.25 4.00 
GO:0005143 African trypanosomiasis KEGG_01.03.2017 17.0E-3 30.0E-3 1.5E+0 8.57 3.00 
GO:1901983 regulation of protein acetylation GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 30.0E-3 1.5E+0 6.25 4.00 
GO:1903169 regulation of calcium ion transmembrane transport GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 30.0E-3 1.5E+0 4.55 6.00 
GO:0005143 African trypanosomiasis KEGG_01.03.2017 17.0E-3 30.0E-3 1.5E+0 8.57 3.00 
GO:0051427 hormone receptor binding GO_MolecularFunction-GOA_23.02.2017_10h01 19.0E-3 31.0E-3 1.5E+0 4.05 7.00 
GO:0000970 Aminoacyl-tRNA biosynthesis KEGG_01.03.2017 19.0E-3 32.0E-3 1.5E+0 6.06 4.00 
GO:0000230 Purine metabolism KEGG_01.03.2017 20.0E-3 32.0E-3 1.5E+0 4.00 7.00 
GO:0001425 DNA Damage Recognition in GG-NER REACTOME_Pathways_01.03.2017 21.0E-3 32.0E-3 1.5E+0 7.89 3.00 
GO:0006306 DNA methylation GO_BiologicalProcess-GOA_23.02.2017_10h01 19.0E-3 32.0E-3 1.5E+0 6.06 4.00 
GO:0000230 Purine metabolism KEGG_01.03.2017 20.0E-3 32.0E-3 1.5E+0 4.00 7.00 
GO:0030594 neurotransmitter receptor activity GO_MolecularFunction-GOA_23.02.2017_10h01 20.0E-3 32.0E-3 1.5E+0 5.00 5.00 
GO:0004723 Retrograde endocannabinoid signaling KEGG_01.03.2017 21.0E-3 33.0E-3 1.5E+0 4.95 5.00 
GO:0086003 cardiac muscle cell contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 33.0E-3 1.5E+0 5.88 4.00 
GO:0004723 Retrograde endocannabinoid signaling KEGG_01.03.2017 21.0E-3 33.0E-3 1.5E+0 4.95 5.00 
GO:0086003 cardiac muscle cell contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 21.0E-3 33.0E-3 1.5E+0 5.88 4.00 
GO:0000140 RORA activates gene expression REACTOME_Pathways_01.03.2017 22.0E-3 34.0E-3 1.5E+0 5.80 4.00 
GO:0000141 BMAL1:CLOCK,NPAS2 activates circadian gene expression REACTOME_Pathways_01.03.2017 22.0E-3 34.0E-3 1.5E+0 5.80 4.00 
GO:0000979 Circadian Clock REACTOME_Pathways_01.03.2017 22.0E-3 34.0E-3 1.5E+0 5.80 4.00 
GO:0006304 DNA modification GO_BiologicalProcess-GOA_23.02.2017_10h01 22.0E-3 34.0E-3 1.5E+0 4.85 5.00 
GO:0043044 ATP-dependent chromatin remodeling GO_BiologicalProcess-GOA_23.02.2017_10h01 22.0E-3 34.0E-3 1.5E+0 5.80 4.00 
GO:0000260 Glycine, serine and threonine metabolism KEGG_01.03.2017 24.0E-3 35.0E-3 1.5E+0 7.50 3.00 
GO:1901658 glycosyl compound catabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 24.0E-3 35.0E-3 1.5E+0 7.50 3.00 
GO:0003300 cardiac muscle hypertrophy GO_BiologicalProcess-GOA_23.02.2017_10h01 26.0E-3 36.0E-3 1.4E+0 5.56 4.00 
GO:0004662 B cell receptor signaling pathway KEGG_01.03.2017 24.0E-3 36.0E-3 1.4E+0 5.63 4.00 
GO:0009166 nucleotide catabolic process GO_BiologicalProcess-GOA_23.02.2017_10h01 26.0E-3 36.0E-3 1.4E+0 5.56 4.00 
GO:0001464 Interactions of neurexins and neuroligins at synapses REACTOME_Pathways_01.03.2017 24.0E-3 36.0E-3 1.4E+0 5.63 4.00 
GO:0001465 Protein-protein interactions at synapses REACTOME_Pathways_01.03.2017 24.0E-3 36.0E-3 1.4E+0 5.63 4.00 
GO:0004662 B cell receptor signaling pathway KEGG_01.03.2017 24.0E-3 36.0E-3 1.4E+0 5.63 4.00 
GO:0005161 Hepatitis B KEGG_01.03.2017 25.0E-3 37.0E-3 1.4E+0 4.17 6.00 
GO:0001072 Post NMDA receptor activation events REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0001083 CREB phosphorylation through the activation of Ras REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
 
 257 GO:0001085 
Activation of NMDA receptor upon glutamate binding and postsynaptic 
events REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0001086 Ras activation uopn Ca2+ infux through NMDA receptor REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0005161 Hepatitis B KEGG_01.03.2017 25.0E-3 37.0E-3 1.4E+0 4.17 6.00 
GO:0001072 Post NMDA receptor activation events REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0001083 CREB phosphorylation through the activation of Ras REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0001085 
Activation of NMDA receptor upon glutamate binding and postsynaptic 
events REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0001086 Ras activation uopn Ca2+ infux through NMDA receptor REACTOME_Pathways_01.03.2017 25.0E-3 37.0E-3 1.4E+0 7.32 3.00 
GO:0004407 histone deacetylase activity GO_MolecularFunction-GOA_23.02.2017_10h01 27.0E-3 38.0E-3 1.4E+0 7.14 3.00 
GO:0043524 negative regulation of neuron apoptotic process GO_BiologicalProcess-GOA_23.02.2017_10h01 28.0E-3 39.0E-3 1.4E+0 4.05 6.00 
GO:0004918 Thyroid hormone synthesis KEGG_01.03.2017 28.0E-3 39.0E-3 1.4E+0 5.41 4.00 
GO:0004918 Thyroid hormone synthesis KEGG_01.03.2017 28.0E-3 39.0E-3 1.4E+0 5.41 4.00 
GO:0006497 protein lipidation GO_BiologicalProcess-GOA_23.02.2017_10h01 30.0E-3 41.0E-3 1.4E+0 4.00 6.00 
GO:0055117 regulation of cardiac muscle contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 33.0E-3 45.0E-3 1.3E+0 5.13 4.00 
GO:0055117 regulation of cardiac muscle contraction GO_BiologicalProcess-GOA_23.02.2017_10h01 33.0E-3 45.0E-3 1.3E+0 5.13 4.00 
GO:0032204 regulation of telomere maintenance GO_BiologicalProcess-GOA_23.02.2017_10h01 35.0E-3 46.0E-3 1.3E+0 5.06 4.00 
GO:0004919 Thyroid hormone signaling pathway KEGG_01.03.2017 35.0E-3 46.0E-3 1.3E+0 4.31 5.00 
GO:0004919 Thyroid hormone signaling pathway KEGG_01.03.2017 35.0E-3 46.0E-3 1.3E+0 4.31 5.00 
GO:0004919 Thyroid hormone signaling pathway KEGG_01.03.2017 35.0E-3 46.0E-3 1.3E+0 4.31 5.00 
GO:0000197 Inositol phosphate metabolism REACTOME_Pathways_01.03.2017 36.0E-3 47.0E-3 1.3E+0 6.38 3.00 
GO:0000453 Synthesis of IP2, IP, and Ins in the cytosol REACTOME_Pathways_01.03.2017 36.0E-3 47.0E-3 1.3E+0 6.38 3.00 
GO:0004071 Sphingolipid signaling pathway KEGG_01.03.2017 37.0E-3 47.0E-3 1.3E+0 4.24 5.00 
GO:1901019 regulation of calcium ion transmembrane transporter activity GO_BiologicalProcess-GOA_23.02.2017_10h01 36.0E-3 47.0E-3 1.3E+0 5.00 4.00 
GO:0004071 Sphingolipid signaling pathway KEGG_01.03.2017 37.0E-3 47.0E-3 1.3E+0 4.24 5.00 
GO:0001754 eye photoreceptor cell differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 38.0E-3 48.0E-3 1.3E+0 6.25 3.00 
GO:0043204 perikaryon GO_CellularComponent-GOA_23.02.2017_10h01 38.0E-3 48.0E-3 1.3E+0 4.20 5.00 
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GO:0052697 xenobiotic glucuronidation GO_BiologicalProcess-GOA_23.02.2017_10h01 48.0E-6 1.4E-3 2.9E+0 33.33 3.00 
GO:0008081 phosphoric diester hydrolase activity GO_MolecularFunction-GOA_23.02.2017_10h01 180.0E-6 1.8E-3 2.7E+0 6.12 6.00 
GO:0043197 dendritic spine GO_CellularComponent-GOA_23.02.2017_10h01 160.0E-6 2.4E-3 2.6E+0 5.15 7.00 
GO:0002285 lymphocyte activation involved in immune response GO_BiologicalProcess-GOA_23.02.2017_10h01 400.0E-6 3.0E-3 2.5E+0 4.43 7.00 
GO:0000983 Drug metabolism KEGG_01.03.2017 610.0E-6 3.7E-3 2.4E+0 8.70 4.00 
GO:0004114 3',5'-cyclic-nucleotide phosphodiesterase activity GO_MolecularFunction-GOA_23.02.2017_10h01 1.5E-3 5.6E-3 2.3E+0 11.11 3.00 
GO:0004435 phosphatidylinositol phospholipase C activity GO_MolecularFunction-GOA_23.02.2017_10h01 1.6E-3 5.6E-3 2.3E+0 10.71 3.00 
GO:0000053 Ascorbate and aldarate metabolism KEGG_01.03.2017 1.5E-3 5.6E-3 2.3E+0 11.11 3.00 
GO:0004520 Adherens junction KEGG_01.03.2017 3.2E-3 5.8E-3 2.2E+0 5.56 4.00 
GO:0001464 Interactions of neurexins and neuroligins at synapses REACTOME_Pathways_01.03.2017 3.1E-3 5.8E-3 2.2E+0 5.63 4.00 
GO:0001465 Protein-protein interactions at synapses REACTOME_Pathways_01.03.2017 3.1E-3 5.8E-3 2.2E+0 5.63 4.00 
GO:0000982 Drug metabolism KEGG_01.03.2017 2.9E-3 5.9E-3 2.2E+0 5.71 4.00 
GO:0001073 Unblocking of NMDA receptor, glutamate binding and activation REACTOME_Pathways_01.03.2017 2.7E-3 6.2E-3 2.2E+0 9.09 3.00 
GO:0001082 CREB phosphorylation through the activation of CaMKII REACTOME_Pathways_01.03.2017 2.7E-3 6.2E-3 2.2E+0 9.09 3.00 
GO:0001733 SALM protein interactions at the synapses REACTOME_Pathways_01.03.2017 2.7E-3 6.2E-3 2.2E+0 9.09 3.00 
GO:0002292 T cell differentiation involved in immune response GO_BiologicalProcess-GOA_23.02.2017_10h01 1.4E-3 6.3E-3 2.2E+0 6.90 4.00 
GO:0000040 Pentose and glucuronate interconversions KEGG_01.03.2017 2.9E-3 6.3E-3 2.2E+0 8.82 3.00 
GO:0004720 Long-term potentiation KEGG_01.03.2017 2.5E-3 6.3E-3 2.2E+0 5.97 4.00 
GO:0032206 positive regulation of telomere maintenance GO_BiologicalProcess-GOA_23.02.2017_10h01 1.3E-3 6.5E-3 2.2E+0 7.14 4.00 
GO:0001782 B cell homeostasis GO_BiologicalProcess-GOA_23.02.2017_10h01 2.4E-3 6.7E-3 2.2E+0 9.38 3.00 
GO:0000830 Retinol metabolism KEGG_01.03.2017 2.2E-3 6.8E-3 2.2E+0 6.15 4.00 
GO:0000521 Neurophilin interactions with VEGF and VEGFR REACTOME_Pathways_01.03.2017 5.0E-3 8.4E-3 2.1E+0 7.32 3.00 
GO:0000973 Sema3A PAK dependent Axon repulsion REACTOME_Pathways_01.03.2017 5.0E-3 8.4E-3 2.1E+0 7.32 3.00 
GO:0000974 SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion REACTOME_Pathways_01.03.2017 5.0E-3 8.4E-3 2.1E+0 7.32 3.00 
GO:0001093 Signal transduction by L1 REACTOME_Pathways_01.03.2017 5.0E-3 8.4E-3 2.1E+0 7.32 3.00 
GO:0000860 Porphyrin and chlorophyll metabolism KEGG_01.03.2017 5.4E-3 8.5E-3 2.1E+0 7.14 3.00 
GO:0000493 Pre-NOTCH Processing in Golgi REACTOME_Pathways_01.03.2017 6.5E-3 9.8E-3 2.0E+0 6.67 3.00 
GO:0000494 Pre-NOTCH Expression and Processing REACTOME_Pathways_01.03.2017 6.5E-3 9.8E-3 2.0E+0 6.67 3.00 
GO:0030071 regulation of mitotic metaphase/anaphase transition GO_BiologicalProcess-GOA_23.02.2017_10h01 8.3E-3 11.0E-3 2.0E+0 6.12 3.00 
GO:0042093 T-helper cell differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 8.3E-3 11.0E-3 2.0E+0 6.12 3.00 
GO:0001776 leukocyte homeostasis GO_BiologicalProcess-GOA_23.02.2017_10h01 9.0E-3 12.0E-3 1.9E+0 4.17 4.00 
GO:0051310 metaphase plate congression GO_BiologicalProcess-GOA_23.02.2017_10h01 9.7E-3 12.0E-3 1.9E+0 5.77 3.00 
GO:0000556 Nuclear Events (kinase and transcription factor activation) REACTOME_Pathways_01.03.2017 9.2E-3 12.0E-3 1.9E+0 5.88 3.00 
GO:0000558 ERK/MAPK targets REACTOME_Pathways_01.03.2017 9.2E-3 12.0E-3 1.9E+0 5.88 3.00 
GO:0000564 CREB phosphorylation REACTOME_Pathways_01.03.2017 9.2E-3 12.0E-3 1.9E+0 5.88 3.00 
GO:0001116 MAPK targets/ Nuclear events mediated by MAP kinases REACTOME_Pathways_01.03.2017 9.2E-3 12.0E-3 1.9E+0 5.88 3.00 
GO:0001291 CD209 (DC-SIGN) signaling REACTOME_Pathways_01.03.2017 9.2E-3 12.0E-3 1.9E+0 5.88 3.00 
GO:0000480 Glutathione metabolism KEGG_01.03.2017 10.0E-3 13.0E-3 1.9E+0 5.56 3.00 
GO:0000140 Steroid hormone biosynthesis KEGG_01.03.2017 13.0E-3 15.0E-3 1.8E+0 5.17 3.00 
GO:0021879 forebrain neuron differentiation GO_BiologicalProcess-GOA_23.02.2017_10h01 17.0E-3 19.0E-3 1.7E+0 4.62 3.00 
GO:0002312 B cell activation involved in immune response GO_BiologicalProcess-GOA_23.02.2017_10h01 18.0E-3 19.0E-3 1.7E+0 4.55 3.00 
GO:0005211 Renal cell carcinoma KEGG_01.03.2017 17.0E-3 19.0E-3 1.7E+0 4.62 3.00 
GO:0004662 B cell receptor signaling pathway KEGG_01.03.2017 22.0E-3 23.0E-3 1.6E+0 4.23 3.00 
GO:0000980 Metabolism of xenobiotics by cytochrome P450 KEGG_01.03.2017 25.0E-3 25.0E-3 1.6E+0 4.05 3.00 
 
Table 3.16 | GO for genes in SZ risk-associated chromosomal contacts. 
GO enrichment of genes in Table 3.15 See description of Table 3.2-3.6 for 
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1 EIF2B1 1 PCDHA1 1 ANKRD44 1 PHF21A 1 EPC2 1 SNAP91 1 ITIH4 1 BAHD1 1 ADSS 
2 CUL3 2 FSIP2 2 SNAP91 2 ZBTB18 2 DIS3L2 2 ANKRD44 2 SLC2A5 2 CUL3 2 MOB4 
3 MARS2 3 PCDHA2 3 BRINP3 3 FANCL 3 SFMBT1 3 GRAMD1B 3 ITIH3 3 BAZ2A 3 CUL3 
4 DNAJC19 4 CSMD1 4 ZNF804A 4 MAD1L1 4 NLGN4X 4 ZNF804A 4 SEC16B 4 TAF5 4 NFATC3 
5 ORC5 5 PCDHA11 5 RABGAP1L 5 KDM4A 5 KMT2E 5 SLC4A10 5 CACNA1D 5 SF3B1 5 SF3B1 
6 ZEB2 6 CHRNA3 6 LINC01122 6 KDM3B 6 SEMA6C 6 LINC01122 6 HECW2 6 ACTR5 6 ADSL 
7 PHF21A 7 ATPAF2 7 SLC4A10 7 SOX2-OT 7 NT5M 7 TCF4 7 PPP2R3A 7 POLDIP3 7 EP300 
8 ZBTB18 8 PCDHGA10 8 MIR137HG 8 SAP30L-AS1 8 PLCL2 8 
ANKHD1-
EIF4EBP3 8 SH3RF1 8 ANP32E 8 RNF220 
9 ITGA9 9 IL17RB 9 GRAMD1B 9 ARNT 9 PLPPR5 9 C1orf100 9 TCTN2 9 CDC20 9 ANKHD1 
10 ALMS1 10 PSMG3-AS1 10 OPCML 10 FXR1 10 PBRM1 10 CSMD1 10 CLCN3 10 CDC25C 10 UTS2 
11 TET3 11 C3orf49 11 CSMD1 11 CD46 11 RAI1 11 PLD5 11 CLU 11 DNAJC19 11 HECW2 
12 CCDC150 12 PPP2R3A 12 HECW2 12 EPB41 12 RNF220 12 HECW2 12 CACNA1C 12 THOC7 12 MEF2C 
13 MPHOSPH9 13 BRINP3 13 PLD5 13 RAD54L2 13 PLEKHO1 13 UTS2 13 PDE4D 13 SUFU 13 TCF4 
14 KNTC1 14 FBXO41 14 DOCK10 14 RPS6KA3 14 RERE 14 
PTCHD1-
AS 14 GPM6A 14 MAD1L1 14 GRIN2A 
15 POC1A 15 LINC01122 15 CHRM3 15 RSRC2 15 INPP5D 15 CCDC39 15 DNAJC18 15 RNF220 15 PLXNA4 
16 ANP32E 16 GRM3 16 GPM6A 16 GTF3C3 16 GIGYF2 16 ZNF165 16 NT5C2 16 PHF21A 16 MAPK3 
17 CDC25C 17 PCDHGA1 17 TRANK1 17 SBNO1 17 SOX2 17 PITPNM2 17 GRIN2A 17 AKT3 17 GRIA1 
18 SGO2 18 PCDHA6 18 GALNT15 18 TAF5 18 FAM53C 18 RILPL1 18 OXNAD1 18 SEMA6C 18 JUND 
19 CENPL 19 PCDHA8 19 PDE4B 19 PPP1CC 19 PTPRF 19 COQ10B 19 HSPA9 19 NT5M 19 SH3RF1 
20 PPIH 20 PCDHA7 20 PTCHD1-AS 20 SF3B1 20 
FPGT-
TNNI3K 20 JUND 20 CYP26B1 20 STAG1 20 AOX1 
21 BRD8 21 PCDHA9 21 UTS2 21 DESI2 21 AKT3 21 ARTN 21 UGT1A7 21 CEP162 21 GPER1 
22 SUGP1 22 PCDHAC1 22 C1orf100 22 NFATC3 22 RRP7BP 22 SH3RF1 22 UGT1A10 22 H6PD 22 NMUR2 
23 CD46 23 PLD5 23 EMX1 23 PCGF6 23 SERHL2 23 NEK1 23 UGT1A9 23 PSKH1 23 DPP4 
24 EPB41 24 KCNH7 24 ALMS1P1 24 NOSIP 24 
SAP30L-
AS1 24 GRIN2A 24 UGT1A8 24 CTNND1 24 CNKSR2 
25 RSRC2 25 SYNPR 25 NAT8 25 PPIH 25 SATB2 25 PLXNA4 25 UGT1A6 25 SREBF1 25 UGT1A9 
26 GTF3C3 26 CA8 26 HYDIN 26 CETN3 26 ZBTB18 26 MEF2C 26 SDCCAG8 26 ENO1 26 UGT1A5 
27 SBNO1 27 FTCDNL1 27 SLC9C2 27 SMS 27 PHF21A 27 TRANK1 27 PPARGC1A 27 GATAD2A 27 UGT1A8 
28 PPP1CC 28 NTM 28 NEK1 28 KNTC1 28 CBR4 28 DOCK10 28 CA6 28 HARS 28 UGT1A4 
29 SF3B1 29 OPCML 29 GRIN2A 29 ANP32E 29 COX20 29 GPM6A 29 AOX1 29 ZMAT2 29 UGT1A6 
30 TAF5 30 ARHGAP40 30 PLXNA4 30 CDC25C 30 ZSCAN23 30 CNKSR2 30 CLIP1 30 AMBRA1 30 UGT1A10 
31 ZSWIM6 31 MIR137HG 31 MEF2C 31 SGO2 31 SMG1P2 31 DPP4 31 ASB5 31 PLCB2 31 UGT1A7 
32 RAD54L2 32 EFHD1 32 SDCCAG8 32 CCDC150 32 PLCB2 32 PLCL2 32 ST3GAL3 32 MED8   
33 RPS6KA3 33 SERPINE2 33 ARTN 33 MPHOSPH9 33 SLC35G2 33 ABCB9 33 CREB3L2 33 ADSS   
34 RANGAP1 34 PCDHGA2 34 SH3RF1 34 BRD8 34 ARL6IP4 34 FAM57B 34 PCCB 34 MARS   
35 SUGP2 35 PCDHGA8 35 PITPNM2 35 SUGP1 35 PLXNA2 35 PLCL1 35 GRIA1 35 PSMG3   
36 ARNT 36 PCDHGA9 36 STAB2 36 SNTB2 36 TOX 36 FAT2 36 HDAC3 36 SH3GL3   
37 FXR1 37 NDUFA4L2 37 KCNJ13 37 ZSWIM6 37 RASAL2 37 PPP1R16B 37 PPIH 37 HECW2   
38 MDK 38 STAC3 38 NDUFA13 38 RANGAP1 38 PCDHGA6 38 
TMX2-
CTNND1 38 SUGP1 38 CA8   
39 NCK1 39 IL19 39 SLC4A5 39 SUGP2 39 PCDHGB3 39 LSMEM1 39 GATAD2A 39 SDCCAG8   
40 TKT 40 ITIH1 40 YJEFN3 40 EIF2B1 40 PCDHGA4 40 YJEFN3 40 UTP4 40 PPP2R3A   
41 NUBP1 41 BOLL 41 JUND 41 CUL3 41 PCDHGA5 41 NDUFA13 41 PSMD14 41 GRM3   
42 HDAC3 42 EGR4 42 COQ10B 42 MARS2 42 SERPINF1 42 KCNJ13 42 EP300 42 WDR81   
43 PIH1D1 43 SDCCAG8 43 RILPL1 43 MOB4 43 TMEM110 43 MIR137HG 43 MAD1L1 43 NT5C2   
44 PSMD14 44 PCDHA10 44 PGM3 44 AMBRA1 44 DPYD 44 BOLL 44 CUL3 44 GRIN2A   
45 EIF3B 45 PCDHA5 45 LSMEM1 45 ZKSCAN4 45 P2RX3 45 NUGGC 45 DNAJC19 45 ITIH4   
46 GATAD2A 46 MIR339 46 
TMX2-
CTNND1 46 TYW5 46 PTBP2 46 GBA3 46 ARNT 46 SLC2A5   
47 SNX7 47 SMPX 47 KLHL20 47 GIGYF2 47 RTN4RL2 47 MIR4304 47 SNTB2 47 ITIH3   
48 CETN3 48 CYP26B1 48 ERMAP 48 INPP5D 48 PGAP1 48 GPX5 48 RANGAP1 48 GABBR1   
49 FGFR1 49 ADIG 49 SFXN5 49 RASAL2 49 TYW5 49 UGT1A9 49 EPB41 49 SNAP91   
50 PPP2R2A 50 MIR548AI 50 TBC1D10B 50 VSIG2 50 C2orf69 50 UGT1A5 50 RPS6KA3 50 PFKFB2   
51 DESI2 51 NT5C2 51 USP40 51 ITGA9 51 ZSCAN12 51 UGT1A8 51 TAF5 51 CACNA1C   
52 NFATC3 52 ALMS1P1 52 VRK2 52 C2orf69 52 CD46 52 UGT1A4 52 PPP1CC 52 PDE4D   
53 SMS 53 NAT8 53 EXOC6B 53 PGAP1 53 MSL2 53 OR9Q1 53 SF3B1 53 DGKD   
54 NOSIP 54 PHEX 54 MBTPS2 54 ADSS 54 SBNO1 54 FCAMR 54 BRD8 54 MPL   
55 PCGF6 55 TOM1L2 55 MAPK3 55 ETF1 55 BAZ2A 55 UGT1A7 55 KNTC1 55 PPARGC1A   
56 FAM53C 56 MSRA 56 GRIA1 56 HSPD1 56 ZSWIM6 56 UGT1A6 56 ANP32E 56 HSPA9   
57 DUS2 57 NEK1 57 MAN2A1 57 MDK 57 TAF5 57 UGT1A10 57 SGO2 57 HARS2   
58 RFT1 58 CCDC39 58 IMMP2L 58 NCK1 58 ACTR5 58 OR1S2 58 CDC25C 58 ATG13   
59 PRDX6 59 ANKRD45 59 ST3GAL3 59 TKT 59 RPS6KA3 59 FLJ40288 59 AKT3 59 SLC12A4   
60 ADSS 60 DCDC1 60 AUP1 60 DUS2 60 KMT2E-AS1 60 STK31 60 PHF21A 60 CTNNA1   
61 ETF1 61 PTCHD1-AS 61 GALNT10 61 SNX7 61 GID4 61 SDCCAG8 61 KMT2E 61 PLXNA2   
62 HSPD1 62 FAM124B 62 GPER1 62 ORC5 62 FXR1 62 CNBD1 62 PLCL2 62 PDE6D   
63 FANCL 63 ITIH4 63 MKL1 63 DNAJC19 63 WDFY1 63 TNNI3K 63 NCAN 63 DGKZ   
64 MAD1L1 64 C1orf100 64 SLC6A9 64 HPF1 64 BAHD1 64 MPP6 64 EPHB1 64 GRIA1   
65 KDM4A 65 CR1L 65 TNRC6B 65 ATP6V0A2 65 CUL3 65 DNAH10 65 CHST12 65 CA6   
66 KDM3B 66 CTSS 66 TCF4 66 EP300 66 DESI2 66 C12orf65 66 RPRD2 66 IL19   
67 SOX2-OT 67 DOCK10 67 CCDC39 67 RANBP10 67 POLDIP3 67 C7orf50 67 MAU2 67 MBTPS2   
68 STAG1 68 LRP1 68 ZNF165 68 PSMD14 68 NFATC3 68 CTNND1 68 B4GALT2 68 SEMA3G   
69 HPF1 69 PFKFB2 69 GBA3 69 UTP4 69 SF3B1 69 TTYH3 69 NLGN4X 69 CREB3L1   
70 ASH2L 70 CPEB1 70 NUGGC 70 EIF3B 70 
MPHOSPH
9 70 PSKH1 70 DPYD 70 DYSF   
71 DARS2 71 JAK1 71 BOLL 71 GATAD2A 71 CCDC150 71 VPS45 71 NCK1 71 SPARC   
72 VPS45 72 AIG1 72 MIR4304 72 NUBP1 72 ANP32E 72 TBC1D5 72 ADSS 72 PSMB10   
73 ABCD3 73 PDE4B 73 NMUR2 73 HDAC3 73 NEMP1 73 PLEKHO1 73 HSPD1 73 ATXN7   
74 TBC1D5 74 PDE4D 74 
ANKHD1-
EIF4EBP3 74 PIH1D1 74 G3BP1 74 RERE 74 EBNA1BP2     
75 B4GALT2 75 HIVEP2 75 HCN1 75 MAU2 75 CDC25C 75 NLGN4X 75 GTF2H3     
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76 MAU2 76 CACNA1C 76 PAPPA2 76 B4GALT2 76 CDC20 76 TAOK2 76 EPC2     
77 ADGRG6 77 
CACNA1C-
AS4 77 OR9Q1 77 TBC1D5 77 PCGF6 77 GALNT10 77 STAG1     
78 SOX2 78 CACNA1C-IT3 78 CNBD1 78 VPS45 78 SSRP1 78 MKL1       
79 CMTR2 79 GALNT15 79 STK31 79 AADAT 79 IPO11 79 GPER1       
80 RANBP10 80 PRUNE1 80 FCAMR 80 EPC2 80 SOX2-OT 80 MAPK3       
81 ATP6V0A2 81 
ADAMTS9-
AS2 81 UGT1A7 81 STAG1 81 MAD1L1 81 GRIA1       
82 EP300 82 EPN2 82 UGT1A6 82 DENR 82 VPS37B 82 MAN2A1       
83 FPGT-TNNI3K 83 GPM6A 83 UGT1A4 83 VPS33A 83 DNAJC19 83 IMMP2L       
84 PTPRF 84 TMEFF2 84 OR1S2 84 DPYD 84 KDM4A 84 ST3GAL3       
85 OXNAD1 85 EMX1 85 UGT1A10 85 TMEM110 85 SUFU 85 UNCX       
86 PODXL 86 PCDHGA12 86 UGT1A8 86 SATB2 86 FANCL 86 TNFRSF9       
87 AADAT 87 MEF2C 87 UGT1A5 87 
TMEM110-
MUSTN1 87 SFXN2 87 AOX1       
88 EPC2 88 PCDHGA11 88 UGT1A9 88 PLXNA2 88 THOC7 88 NRN1L       
89 SLC39A8 89 DGKD 89 CNTN4 89 PCDHGB1 89 AMBRA1 89 MBTPS2       
90 CHST12 90 SLC2A5 90 SLX1A 90 PCDHGB2 90 HARS 90 VRK2       
91 GFRA3 91 ITIH3 91 MYO1A 91 PCDHGA6 91 EIF4E2 91 USP40       
92 LYPD6 92 PRKCB 92 AOX2P 92 PCDHGB3 92 PSMG3 92 LRRIQ3       
93 NLGN4X 93 CDHR3 93 MYLPF 93 PCDHGA4 93 MARS 93 BOLA2       
94 SATB1 94 LINC00634 94 UNCX 94 PCDHGA5 94 MED8 94 OGFOD2       
95 PLEKHO1 95 PCDHAC2 95 TNFRSF9 95 SLC39A8 95 ADSS 95 ERMAP       
96 RERE 96 BRINP2 96 AOX1 96 CHST12 96 SLC25A33 96 TBC1D10B       
97 RPRD2 97 CACNA1D 97 NRN1L 97 GFRA3 97 DPH3 97 SLC6A9       
98 SAP30L-AS1 98 KLHL29 98 RFTN2 98 LYPD6 98 ZMAT2 98 TNRC6B       
99 DPYD 99 PCDHA4 99 LINC00461 99 NLGN4X 99 PARK7 99 NMUR2       
100 SATB2 100 SH3PXD2A 100 
TMEM161B-
AS1 100 SATB1 100 TWF2 100 HCN1       
101 M1AP 101 GRIN2A 101 PLEKHO1 101 PLEKHO1 101 C7orf50 101 PAPPA2       
102 SLC35G2 102 MRAP2 102 RERE 102 RERE 102 PDE6D 102 C2orf69       
103 EMB 103 INO80B 103 NLGN4X 103 RPRD2 103 H6PD 103 CUL3       
104 RASAL2 104 SLC2A7 104 TAOK2 104 DPP4 104 PSKH1 104 SBNO1       
105 VSIG2 105 TLR9 105 TNNI3K 105 PLCL2 105 CTNND1 105 WDFY1       
106 TYW5 106 PPARGC1A 106 CNKSR2 106 CEP170 106 SREBF1 106 SMS       
107 C2orf69 107 CCDC62 107 MPP6 107 KMT2E 107 VPS45 107 CD46       
108 PGAP1 108 MPL 108 DNAH10 108 CBR4 108 CEP162 108 ZSCAN16-AS1      
109 GIGYF2 109 ADAMTSL3 109 FAT2 109 ZSCAN23 109 TBC1D5 109 CCDC150       
110 INPP5D 110 PCDHA13 110 ABCB9 110 AKT3 110 ADGRA3 110 FAM83D       
111 AMBRA1 111 HECW2 111 DQX1 111 PAIP2B 111 STAG1 111 
MPHOSPH
9       
112 ZKSCAN4 112 PEX5L 112 DPP4 112 
FPGT-
TNNI3K 112 ELOVL1 112 DHX35       
113 LRRIQ3 113 ASTN1 113 PLCL2 113 PTPRF 113 ZDHHC5 113 ZSWIM6       
114 
TMEM110-
MUSTN1 114 PCDHA12 114 PPP1R16B 114 FAM53C 114 GATAD2A 114 SF3B1       
115 MYO1A 115 ANKRD44 115 CPEB1-AS1 115 SOX2 115 MDK 115 NFATC3       
116 OR2B2 116 NYAP2 116 AP3B2 116 IMMP2L 116 SMS 116 KMT5A       
117 PLXNA2 117 SLC4A10 117 FAM57B 117 PODXL 117 TMEM161A 117 ITGA9       
118 PCDHGA6 118 GPR52 118 PLCL1 118 OXNAD1 118 SNX7 118 RNF220       
119 PCDHGB3 119 SNAP91 119 ADSS 119 SLC25A42 119 DUS2 119 ZNF691       
120 PCDHGA4 120 LYPD6B 120 DPYD 120 AOX2P 120 ENO1 120 ZNF48       
121 PCDHGA5 121 DNAJC6 121 HTRA2 121 UGT1A6 121 TMEFF2 121 FANCL       
122 CBR4 122 SH3GL3 122 MOB4 122 MIR3160-1 122 GPM6A 122 HIRIP3       
123 ZSCAN23 123 R3HDM2 123 IBTK 123 UGT1A8 123 PCDHGA12 123 INO80E       
124 KMT2E 124 IL34 124 PDE6D 124 LRRIQ3 124 GRIN2A 124 ADSL       
125 RC3H1 125 SRPK2 125 SATB2 125 MYO1A 125 SLC2A5 125 EP300       
126 AKT3 126 ERI3 126 TSSK6 126 OR2B2 126 NT5C2 126 KDM4A       
127 PAIP2B 127 NEK4 127 LRRIQ3 127 EBNA1BP2 127 NEK1 127 SOX2-OT       
128 BOLA3 128 PEMT 128 BOLA2 128 DPH3 128 TOM1L2 128 MAD1L1       
129 MOB4 129 SRR 129 OGFOD2 129 IK 129 
CACNA1C-
AS4 129 RFTN2       
130 DCTN1 130 USP40 130 CTNND1 130 FAM114A2 130 
CACNA1C-
IT3 130 SLX1A       
131 DENR 131 ACTR8 131 TTYH3 131 GTF2H3 131 PDE4D 131 CNTN4       
132 VPS33A 132 MRPS14 132 C12orf65 132 SLC35G2 132 CACNA1C 132 AKT3       
133 EBNA1BP2 133 FRMD8 133 C7orf50 133 HSPA9 133 
ADAMTS9-
AS2 133 PTPRF       
134 DPH3 134 GALNT10 134 PSKH1 134 WDR55 134 PRUNE1 134 FPGT-TNNI3K      
135 IK 135 PCNX3 135 TBC1D5 135 C7orf31 135 CDHR3 135 ARL6IP4       
136 RTKN 136 AKAP13 136 VPS45 136 EFHD1 136 PCDHAC2 136 ANKHD1       
137 FAM114A2 137 SMG6 137 ITGA9 137 TMTC1 137 GABBR1 137 SMG1P2       
138 GTF2H3 138 AP1S3 138 RNF220 138 PTCHD1-AS 138 LINC00634 138 SATB2       
139 SFMBT1 139 NGEF 139 ATF7IP2 139 TSPAN9 139 SPATS2L 139 ATF7IP2       
140 ERI3 140 DGKZ 140 GIGYF2 140 PCDHA12 140 WDR81 140 
SAP30L-
AS1       
141 SLC6A9 141 EXOC6B 141 CCT7 141 PCDHA4 141 SNX8 141 MIR3188       
142 ACTR8 142 DPYD-AS1 142 ADSL 142 CCDC24 142 CTSS 142 PDE6D       
143 EXOC6B 143 PCDHGA3 143 INO80E 143 DAZL 143 DOCK10 143 TOX       
144 C11orf49 144 CREB3L1 144 ALMS1 144 CCDC39 144 LRP1 144 ADSS       
145 FER 145 DYSF 145 ZNF48 145 CFAP57 145 MIR22HG 145 DPYD       
146 SFXN5 146 MBTPS2 146 FANCL 146 NME5 146 PFKFB2 146 MOB4       
147 WBP1L 147 HCN1 147 HIRIP3 147 MIR137HG 147 PHEX 147 GIGYF2       
148 PCDHGB1 148 INPP4B 148 ZNF691 148 PCDHGA1 148 TLCD2 148 AOX2P       
149 PCDHGB2 149 ST3GAL3 149 EP300 149 NYAP2 149 SNORD32B 149 MYLPF       
150 DPYD-AS1 150 DDX60L 150 KDM4A 150 SLC4A10 150 ITIH3 150 MYO1A       
151 PCDHGA2 151 PSMB10 151 MAD1L1 151 ANKRD44 151 WBP1L 151 TSSK6       
152 PCDHGA7 152 RWDD2A 152 SOX2-OT 152 CACNA1D 152 PCDHGA10         
153 AOX2P 153 CHDH 153 SMS 153 LINC01122 153 ATPAF2         
154 ARL14 154 PCDHGB4 154 SF3B1 154 ZNF804A 154 PCDHGB6         
155 UGT1A7 155 PCDHGB7 155 KMT5A 155 PCDHA6 155 RWDD2A         
156 DGKZ 156 STAT6 156 NFATC3 156 PCDHA8 156 CHRNA3         
157 AOX1 157 GRIA1 157 MOB1A 157 PCDHA7 157 CCDC39         
158 ESAM 158 MAN2A1 158 WDFY1 158 PCDHA9 158 ZSCAN31         
159 GUSBP5 159 CA6 159 CCDC150 159 PCDHAC1 159 ITIH4         
160 PCDHGA3 160 C2orf78 160 FAM83D 160 PLD5 160 FAM124B         
161 GALNT10 161 SNORD63 161 DHX35 161 HECW2 161 CR1L         
162 VRK2 162 HSPA9 162 MPHOSPH9 162 PCDHA13 162 C1orf100         
 
 260 163 CA6 163 ALAS1 163 LOXL3 163 ZBED9 163 
PSMG3-
AS1         
164 KLHL20 164 HARS2 164 ZSWIM6 164 ZNF391 164 PPP2R3A         
165 HCN1 165 OXNAD1 165 C2orf69 165 PCDHA11 165 C3orf49         
166 INPP4B 166 PGM3 166 CUL3 166 CSMD1 166 PCDHA1         
167 MBTPS2 167 PCDHGC3 167 SBNO1 167 FTCDNL1 167 PCDHA2         
168 PDGFRL 168 PCDHGB6 168 MIR3188 168 NEK1 168 FSIP2         
169 ATP2A2 169 PITPNM2 169 RC3H1 169 NT5C2 169 PCDHA11         
170 USP38 170 ATG13 170 DAAM1 170 GRIN2A 170 SNORD63         
171 AP1S3 171 COQ10B 171 CD46 171 CCDC30 171 CSMD1         
172 SEMA4F 172 SNX8 172 
ZSCAN16-
AS1 172 IQCE 172 SDCCAG8         
173 NMUR2 173 SPATS2L 173 SAP30L-AS1 173 SPATA24 173 ADIG         
174 MYOT 174 MIR22HG 174 FOXP1 174 PER3 174 PCDHA10         
175 NPY6R 175 TLCD2 175 TOX 175 TFAMP1 175 PCDHA5         
176 GLRA1 176 PALLD 176 ARL6IP4 176 BRINP2 176 CYP26B1         
177 PLCL1 177 PCCB 177 ANKHD1 177 ASTN1 177 MIR339         
178 KCNH7 178 SPARC 178 SMG1P2 178 PEX5L 178 ZFP57         
179 MPP6 179 SLC12A4 179 AKT3 179 SRPK2 179 SMPX         
180 FAT2 180 CTNNA1 180 
FPGT-
TNNI3K 180 DNAJC18 180 NGEF         
181 STK31 181 RFTN1 181 PTPRF 181 PCDHAC2 181 SERPINE2         
182 C7orf31 182 PCDHGA6   182 BANK1 182 EFHD1         
183 EFHD1 183 PCDHGB3   183 ITIH3 183 PCDHA6         
184 PCDHA6 184 PCDHGA4   184 ITIH4 184 PCDHA8         
185 PCDHA8 185 PCDHGA5   185 ASB5 185 PCDHA7         
186 PCDHA7 186 SERPINF1   186 SEC16B 186 PCDHA9         
187 PCDHA9 187 PCDHGB1   187 TMEFF2 187 HECW2         
188 NTM 188 PCDHGB2   188 FAM13B 188 CA8         
189 OPCML 189 ACTG1P17   189 PHEX 189 FTCDNL1         
190 PCDHAC1 190 LINC01004   190 SLC2A5 190 SYNPR         
191 PLD5 191 
TMEM110-
MUSTN1   191 GALNT15 191 PLD5         
192 FTCDNL1 192 C1orf116   192 LRRC43 192 PCDHAC1         
193 ZNF391 193 MYO1A   193 CLU 193 ZBED9         
194 PCDHA11 194 OGFOD2   194 REEP2 194 MIR137HG         
195 CSMD1 195 BOLA2   195 CACNA1C 195 ARHGAP40         
196 SERPINC1 196 CTRL   196 PDE4D 196 LINC01122         
197 PCDHA1 197 LRRIQ3   197 DOCK10 197 LYPD6B         
198 PCDHA2 198 MIR33B   198 GPM6A 198 SH3GL3         
199 PARP8 199 LAPTM5   199 PCDHGA11 199 ZNF804A         
200 PPP2R3A 200 ARHGAP15   200 PCDHGA12 200 NYAP2         
201 PCDHA10 201 SLX1A   201 DGKD 201 SLC4A10         
202 PCDHA5 202 LINC00698   202 SCG2 202 SNAP91         
203 C4BPA 203 PCDHGA7   203 TRANK1 203 ANKRD44         
204 SMPX 204 GFRA3   204 COQ10B 204 DGKD         
205 PCDHGA1 205 SEMA3G   205 CYSTM1 205 SRPK2         
206 DCTN1-AS1 206 KMT2E   206 AP1S3 206 MRAP2         
207 CACNA2D3 207 SEMA6C   207 PITPNM2 207 C2orf82         
208 MIR137HG 208 NT5M   208 CLIP1 208 SH3PXD2A         
209 EPHB1 209 PLCL2   209 MFAP3 209 
PTCHD1-
AS         
210 NCAN 210 PLPPR5   210 SH3RF1 210 PCDHA12         
211 PCDHA3 211 RNF220   211 PCDHGB6 211 PCDHA4         
212 PSD3 212 RAI1   212 TVP23A 212 PCDHA13         
213 PPM1L 213 PLEKHO1   213 CLCN3 213 ADAMTSL3         
214 CNKSR2 214 RERE   214 TCTN2 214 PEX5L         
215 PLPPR5 215 DIS3L2   215 RILPL2 215 ASTN1         
216 CEP170 216 DCTN1   216 SNX8 216 BRINP2         
217 DPP4 217 EPC2   217 RFTN1 217 R3HDM2         
218 PLCL2 218 KCNJ13   218 CREB3L2 218 CCDC62         
219 RFTN2 219 MYO15A   219 PALLD 219 PPARGC1A         
220 CCNH 220 TNNI3K   220 GRIA1 220 MOG         
221 LINC00461 221 DPEP3   221 MAN2A1 221 MPL         
222 RASA1 222 MIR4677   222 PCCB 222 GPX5         
223 TNNI3K 223 CNNM2   223 GBF1 223 SLC2A7         
224 SLC25A42 224 
TMX2-
CTNND1   224 ST3GAL3 224 TLR9         
225 UGT1A10 225 RFTN2   225 CYP26B1 225 PCDHGA11         
226 UGT1A9 226 TTC14   226 PCDHGA2 226 PCDHGB7         
227 MIR3160-1 227 ABCB9   227 PCDHGA7 227 PCDHGB4         
228 UGT1A8 228 RTN4RL1   228 DGKZ 228 PCDHGA1         
229 PKD2L2 229 CPEB1-AS1   229 MBTPS2 229 GRM3         
230 SEMA3G 230 AP3B2   230 VRK2 230 BOLL         
231 UGT1A6 231 GLRA1   231 DDX60L 231 STAC3         
232 PEX5L 232 FAM57B   232 GSDME 232 NDUFA4L2         
233 BRINP2 233 PLCL1   233 AOX1 233 TMX2-CTNND1        
234 ASTN1 234 PCDHA3   234 ESAM 234 CNNM2         
235 TNR 235 CNKSR2   235 PCDHGB4 235 RFTN2         
236 ALMS1P1 236 PSD3   236 PCDHGB7 236 TTC14         
237 NAT8 237 NLGN4X   237 GALNT10 237 GFRA3         
238 PCDHA4 238 PRKD1   238 CA6 238 VTRNA1-1         
239 DAZL 239 EPHA7   239 HCN1 239 LINC00698         
240 CSGALNACT1 240 SFMBT1   240 FCHSD1 240 SEMA3G         
241 PCDHA12 241 G3BP1   241 RELL2 241 LAPTM5         
242 HECW2 242 CDC20   242 KCNJ13 242 MIR33B         
243 PCDHA13 243 CDC25C   243 PKD2L2 243 SNORD63         
244 BRINP3 244 CCDC150   244 PPARGC1A 244 SLX1A         
245 ZNF804A 245 MPHOSPH9   245 BNIPL 245 LRRIQ3         
246 LINC01122 246 POC1A   246 IQCF1 246 
TMEM110-
MUSTN1        
247 RABGAP1L 247 SSRP1   247 UGT1A10 247 MYO1A         
248 GPR52 248 CENPL   248 UGT1A9 248 C1orf116         
249 NYAP2 249 ANP32E   249 IL19 249 OGFOD2         
250 SLC4A10 250 NEMP1   250 UGT1A7 250 BOLA2         
251 ANKRD44 251 IPO11   251 PCDHGA8 251 CTRL         
252 CACNA1D 252 PCGF6   252 PCDHGA9 252 LINC01004         
253 KLHL29 253 CCT7   253 DPYD-AS1 253 DPEP3         
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254 MEF2C 254 SF3B1   254 PCDHGA3 254 MIR4677         
255 EMX1 255 NFATC3   255 PCDHA10 255 KCNJ13         
256 PCDHGA12 256 DESI2   256 PCDHA5 256 TNNI3K         
257 DOCK10 257 POLDIP3   257 C4BPA 257 PCDHA3         
258 MSRA 258 RPS6KA3   258 SMPX 258 CNKSR2         
259 GPM6A 259 HDAC2   259 BOLL 259 ZKSCAN3         
260 SEC16B 260 ACTR5   260 SLC17A7 260 ABCB9         
261 GRIN2A 261 TAF5   261 GPX5 261 RTN4RL1         
262 TNFSF4 262 BAZ2A   262 GPX6 262 KCNH7         
263 GALNT15 263 MSL2   263 RFTN2 263 GLRA1         
264 LRRC43 264 CD46   264 SDCCAG8 264 FAM57B         
265 CLU 265 KMT2E-AS1   265 TNNI3K 265 PLCL1         
266 REEP2 266 GNL3   266 PCDHA3 266 PCDHGB1         
267 AIG1 267 PPP2R2A   267 EPHB1 267 PCDHGB2         
268 CACNA1C 268 MAP3K11   268 NCAN 268 PCDHGA2         
269 PDE4B 269 SMS   269 CNKSR2 269 PCDHGA7         
270 PDE4D 270 MDK   270 PLPPR5 270 DPYD-AS1         
271 FAM13B 271 BNIP3L   271 NMUR2 271 PCDHGA3         
272 PHEX 272 MOGS   272 MYOT 272 CREB3L1         
273 SLC2A5 273 TMEM161A   273 NPY6R 273 DYSF         
274 TMEFF2 274 FXR1   274 FAT2 274 MBTPS2         
275 SCG2 275 GID4   275 STK31 275 VRK2         
276 TRANK1 276 TYW5   276 GLRA1 276 USP40         
277 DGKD 277 C2orf69   277 PLCL1 277 ERI3         
278 BOLA3-AS1 278 CUL3   278 KCNH7 278 NEK4         
279 SRPK2 279 BAHD1   279 MPP6 279 SRR         
280 INO80B 280 SBNO1   280 ATP2A2 280 PEMT         
281 RILPL2 281 STAG1   281 ERI3 281 AKAP13         
282 SPATA24 282 ADGRA3   282 SLC6A9 282 SMG6         
283 PER3 283 KDM4A   283 PPP2R3A 283 ZNF592         
284 TFAMP1 284 SUFU   284 TCF4 284 DDX60L         
285 CCDC39 285 PBRM1   285 PCDHA1 285 PSMB10         
286 CFAP57 286 ALMS1   286 PCDHA2 286 ST3GAL3         
287 NME5 287 FANCL   287 C11orf49 287 ATXN7         
288 NISCH 288 SOX2-OT   288 FER 288 PGM3         
289 PCDHGB6 289 MAD1L1   289 PCDHGA10 289 HSPA9         
290 GAB1 290 VPS37B   290 WBP1L 290 HARS2         
291 ANKRD45 291 DNAJC19     291 STAT6         
292 TCTN2 292 DARS2     292 GRIA1         
293 NEK1 293 SFXN2     293 MAN2A1         
294 NT5C2 294 THOC7     294 PALLD         
295 DNAJC18 295 PGAP1     295 SPARC         
296 PCDHAC2 296 RTN4RL2     296 PCCB         
297 CCDC24 297 RASAL2     297 SLC12A4         
298 HYDIN 298 DDHD2     298 CTNNA1         
299 IQCE 299 TOX     299 RFTN1         
300 CCDC30 300 PHF21A     300 ATG13         
301 SLC9C2 301 P2RX3     301 COQ10B         
302 MFAP3 302 PTBP2     302 PITPNM2         
303 CLCN3 303 AMBRA1     303 AP1S3         
304 SNX8 304 C7orf50     304 CA6         
305 IL17RB 305 HARS     305 HCN1         
306 TCF4 306 PRADC1     306 PCDHGA9         
307 CHDH 307 EIF4E2     307 PCDHGA8         
308 PCDHGA10 308 KAT5     308 SNORD63         
309 TMTC1 309 PDE6D     309 IL19         
310 PTCHD1-AS 310 PARK7     310 ITIH1         
311 TSPAN9 311 TWF2     311 DGKZ         
312 CLIP1 312 DPH3     312 PCDHGC3         
313 ITIH3 313 SLC25A33     313 GALNT10         
314 ITIH4 314 MARS     314 YY2         
315 TVP23A 315 ADSS               
316 ASB5 316 CACYBP               
317 BANK1 317 PSMG3               
318 FCHSD1 318 SNX7               
319 RELL2 319 DUS2               
320 KCNJ13 320 ENO1               
321 SLC17A7 321 ELOVL1               
322 SLC4A5 322 GATAD2A               
323 ZBTB37 323 GLT8D1               
324 BNIPL 324 CTNND1               
325 IQCF1 325 SREBF1               
326 PPARGC1A 326 CEP162               
327 TNN 327 TBC1D5               
328 IMMP2L 328 H6PD               
329 PCCB 329 PSKH1               
330 GBF1 330 ALKBH5               
331 ST3GAL3 331 MED8               
332 GRIA1 332 DUSP11               
333 MAN2A1 333 SLC35G2               
334 CREB3L2 334 ARL6IP4               
335 PALLD 335 GAS5               
336 PCDHGA8 336 LEPR               
337 PCDHGA9 337 SMG1P2               
338 CYP26B1 338 GIGYF2               
339 BOLL 339 INPP5D               
340 IL19 340 FAM53C               
341 DDX60L 341 SOX2               
342 SDCCAG8 342 FPGT-TNNI3K               
343 TNNC1 343 PTPRF               
344 PCDHGA11 344 AKT3               
345 PCDHGB4 345 RRP7BP               
346 PCDHGB7 346 SERHL2               
347 HSPA9 347 CBR4               
348 ALAS1 348 COX20               
349 WDR55 349 SAP30L-AS1               
350 RFTN1 350 SATB2               
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351 SH3RF1 351 FOXP1               
352 PITPNM2 352 PLXNA2               
353 COQ10B 353 DPYD               
354 CYSTM1 354 PLCB2               
 
 
Table 3.17 | List of genes shown in RNA correlation heatmaps. 
List of genes (by row) in the order they appear in each cell type’s full connectome 









































Table 19Table 3.18 |  Summary of results from RN A-seq sampling/permut ation anslyses 











P-value (full v. 
string) 
P-value (full v. string; string 
removed from random) 
NPC vs COS 308 290 0.2455 1000000, 1000 < 0.000001 < 0.001     
NEU vs COS 358 314 0.2329 1000000, 1000 < 0.000001 < 0.001     
GLIA vs COS 165 151 0.2066 1000000, 1000 0.00001 0.264     
string NPC 77 77 0.2963 1000000 < 0.000001  0.007 < 0.001 
string NEU 73 73 0.2877 1000000 < 0.000001  0.008  
string GLIA 31 31 0.2225 10000 0.02  0.595  
string NPC medium 139 138 0.2725747 1000000 < 0.000001  0.012  
string NEU medium 138 138 0.2654931 1000000 < 0.000001  0.003  
string GLIA medium 58 58 0.2183428 10000 0.001  0.434  
 
Table 3.18 | Summary of results from RNA-seq sampling/permutation 
anslyses. 
Summary of results from RNA-seq sampling/permutation analyses (see Materials 
and methods, "RNA transcriptomic correlation heatmaps"). List name, list being 
compared against a background (COS = Childhood Onset Schizophrenia cohort); 
length, number of genes in the input list; length after deletions, number of genes 
remaining after filtering out genes with CPM < 1 across 30% of individual RNA-
seq experiments; absolute correlation mean, the organization score for each 
heatmap; # of samplings/permutations, (random analysis, distance-constrained 
analysis); P-value (random), P-value from randomized sampling analysis without 
distance constraint; P-value (distance constraint), P-value calculated from 
distance-constrained randomized sampling (x1,000) analysis (featured in Fig 
3.10, D); P-value (full v. string), P-value from the comparison between STRING 
heatmaps against those from the full connectome background (featured in Fig 
3.13, B); P-value (full v. string; string removed from random), P-value from a 
version of the comparison that removed the subset STRING genes from the full 
connectome gene list before randomly sampling 1000 times    
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Table 20Table 3.19 |  Neuronal signaling and chromatin  regulatory genes clustered  in RN A heatmap  
NPC 1 NPC 2 NEURON 1 NEURON 2 GLIA 1 GLIA 2 
EIF2B1 UGT1A6 PCDHA1 SFMBT1 ANKRD44 OGFOD2 
CUL3 PEX5L FSIP2 G3BP1 SNAP91 CTNND1 
MARS2 BRINP2 PCDHA2 CDC20 BRINP3 TTYH3 
DNAJC19 ASTN1 CSMD1 CDC25C ZNF804A C12orf65 
ORC5 TNR PCDHA11 CCDC150 RABGAP1L C7orf50 
ZEB2 ALMS1P1 CHRNA3 MPHOSPH9 LINC01122 PSKH1 
PHF21A NAT8 ATPAF2 POC1A SLC4A10 TBC1D5 
ZBTB18 PCDHA4 PCDHGA10 SSRP1 MIR137HG VPS45 
ITGA9 DAZL IL17RB CENPL GRAMD1B ITGA9 
ALMS1 CSGALNACT1 PSMG3-AS1 ANP32E OPCML RNF220 
TET3 PCDHA12 C3orf49 NEMP1 CSMD1 ATF7IP2 
CCDC150 HECW2 PPP2R3A IPO11 HECW2 GIGYF2 
MPHOSPH9 PCDHA13 BRINP3 PCGF6 PLD5 CCT7 
KNTC1 BRINP3 FBXO41 CCT7 DOCK10 ADSL 
POC1A ZNF804A LINC01122 SF3B1 CHRM3 INO80E 
ANP32E LINC01122 GRM3 NFATC3 GPM6A ALMS1 
CDC25C RABGAP1L PCDHGA1 DESI2 TRANK1 ZNF48 
SGO2 GPR52 PCDHA6 POLDIP3 GALNT15 FANCL 
CENPL NYAP2 PCDHA8 RPS6KA3 PDE4B HIRIP3 
PPIH SLC4A10 PCDHA7 HDAC2 PTCHD1-AS ZNF691 
BRD8 ANKRD44 PCDHA9 ACTR5 UTS2 EP300 
SUGP1 CACNA1D PCDHAC1 TAF5 C1orf100 KDM4A 
CD46 KLHL29 PLD5 BAZ2A EMX1 MAD1L1 
EPB41 MEF2C KCNH7 MSL2 ALMS1P1 SOX2-OT 
RSRC2 EMX1 SYNPR CD46 NAT8 SMS 
GTF3C3 PCDHGA12 CA8 KMT2E-AS1 HYDIN SF3B1 
SBNO1 DOCK10 FTCDNL1 GNL3 SLC9C2 KMT5A 
PPP1CC MSRA NTM PPP2R2A NEK1 NFATC3 
SF3B1 GPM6A OPCML MAP3K11 GRIN2A MOB1A 
TAF5 SEC16B ARHGAP40 SMS PLXNA4 WDFY1 
ZSWIM6 GRIN2A MIR137HG MDK  CCDC150 
RAD54L2 TNFSF4 EFHD1 BNIP3L  FAM83D 
RPS6KA3 GALNT15 SERPINE2 MOGS  DHX35 
RANGAP1 LRRC43 PCDHGA2 TMEM161A  MPHOSPH9 
SUGP2 CLU PCDHGA8 FXR1  LOXL3 
ARNT REEP2 PCDHGA9 GID4  ZSWIM6 
FXR1 AIG1 NDUFA4L2 TYW5  C2orf69 
MDK CACNA1C STAC3 C2orf69  CUL3 
NCK1 PDE4B IL19 CUL3  SBNO1 
TKT PDE4D ITIH1 BAHD1  MIR3188 
NUBP1 FAM13B BOLL SBNO1  RC3H1 
HDAC3 PHEX EGR4 STAG1  DAAM1 
PIH1D1 SLC2A5 SDCCAG8 ADGRA3  CD46 
PSMD14 TMEFF2 PCDHA10 KDM4A  ZSCAN16-AS1 
EIF3B SCG2 PCDHA5 SUFU  SAP30L-AS1 
GATAD2A TRANK1 MIR339 PBRM1  FOXP1 
SNX7 DGKD SMPX ALMS1  TOX 
CETN3 BOLA3-AS1 CYP26B1 FANCL  ARL6IP4 
FGFR1 SRPK2 ADIG SOX2-OT  ANKHD1 
PPP2R2A INO80B MIR548AI MAD1L1  SMG1P2 
DESI2 RILPL2 NT5C2 VPS37B  AKT3 
NFATC3 SPATA24 ALMS1P1 DNAJC19  FPGT-TNNI3K 
SMS PER3 NAT8 DARS2  PTPRF 
NOSIP TFAMP1 PHEX SFXN2   
PCGF6 CCDC39 TOM1L2 THOC7   
FAM53C CFAP57 MSRA PGAP1   
DUS2 NME5 NEK1 RTN4RL2   
RFT1 NISCH CCDC39 RASAL2   
PRDX6 PCDHGB6 ANKRD45 DDHD2   
ADSS GAB1 DCDC1 TOX   
ETF1 ANKRD45 PTCHD1-AS PHF21A   
HSPD1 TCTN2 FAM124B P2RX3   
FANCL NEK1 ITIH4 PTBP2   
MAD1L1 NT5C2 C1orf100 AMBRA1   
KDM4A DNAJC18 CR1L C7orf50   
KDM3B PCDHAC2 CTSS HARS   
SOX2-OT CCDC24 DOCK10 PRADC1   
STAG1 HYDIN LRP1 EIF4E2   
HPF1 IQCE PFKFB2 KAT5   
ASH2L CCDC30 CPEB1 PDE6D   
DARS2 SLC9C2 JAK1 PARK7   
VPS45 MFAP3 AIG1 TWF2   
ABCD3 CLCN3 PDE4B DPH3   
TBC1D5 SNX8 PDE4D SLC25A33   
B4GALT2 IL17RB HIVEP2 MARS   
MAU2 TCF4 CACNA1C ADSS   
ADGRG6 CHDH CACNA1C-AS4 CACYBP   
SOX2 PCDHGA10 CACNA1C-IT3 PSMG3   
CMTR2 TMTC1 GALNT15 SNX7   
RANBP10 PTCHD1-AS PRUNE1 DUS2   
ATP6V0A2 TSPAN9 ADAMTS9-AS2 ENO1   
EP300 CLIP1 EPN2 ELOVL1   
FPGT-TNNI3K ITIH3 GPM6A GATAD2A   
PTPRF ITIH4 TMEFF2 GLT8D1   
OXNAD1 TVP23A EMX1 CTNND1   
PODXL ASB5 PCDHGA12 SREBF1   
AADAT BANK1 MEF2C CEP162   
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EPC2 FCHSD1 PCDHGA11 TBC1D5   
SLC39A8 RELL2 DGKD H6PD   
CHST12 KCNJ13 SLC2A5 PSKH1   
GFRA3 SLC17A7 ITIH3 ALKBH5   
LYPD6 SLC4A5 PRKCB MED8   
NLGN4X ZBTB37 CDHR3 DUSP11   
SATB1 BNIPL LINC00634 SLC35G2   
PLEKHO1 IQCF1 PCDHAC2 ARL6IP4   
RERE PPARGC1A BRINP2 GAS5   
RPRD2 TNN CACNA1D LEPR   
 IMMP2L KLHL29 SMG1P2   
 PCCB PCDHA4 GIGYF2   
 GBF1 SH3PXD2A INPP5D   
 ST3GAL3 GRIN2A FAM53C   
 GRIA1 MRAP2 SOX2   
 MAN2A1 INO80B FPGT-TNNI3K  
 CREB3L2 SLC2A7 PTPRF   
 PALLD TLR9 AKT3   
 PCDHGA8 PPARGC1A RRP7BP   
 PCDHGA9 CCDC62 SERHL2   
 CYP26B1 MPL CBR4   
 BOLL ADAMTSL3 COX20   
 IL19 PCDHA13 SAP30L-AS1   
 DDX60L HECW2 SATB2   
 SDCCAG8 PEX5L FOXP1   
 TNNC1 ASTN1 PLXNA2   
 PCDHGA11 PCDHA12 DPYD   
 PCDHGB4 ANKRD44 PLCB2   
 PCDHGB7 NYAP2    
 HSPA9 SLC4A10    
 ALAS1 GPR52    
 WDR55 SNAP91    
 RFTN1 LYPD6B    
 SH3RF1 DNAJC6    
 PITPNM2 SH3GL3    
 COQ10B R3HDM2    
 CYSTM1 IL34    
  SRPK2    
 
Table 3.19 | Neuronal signaling and chromatin regulatory genes clustered 
in RNA heatmap. 
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Table 21Table 3.20 |  GOs of gene clust ers with high  correlat ion scores from Table 3.19 
NPC CLUSTER 1     
GOID GOTerm 
Term PValue Corrected 
with Benjamini-Hochberg 
% Associated 
Genes Nr. Genes 
Total # 
Genes 
R-HSA:2555396 Mitotic Metaphase and Anaphase 6.64E-06 4.43 9.00 203.00 
R-HSA:68882 Mitotic Anaphase 9.56E-06 4.46 9.00 202.00 
GO:0007062 sister chromatid cohesion 1.20E-05 5.76 8.00 139.00 
R-HSA:2500257 Resolution of Sister Chromatid Cohesion 2.20E-05 5.51 7.00 127.00 
R-HSA:2467813 Separation of Sister Chromatids 2.62E-05 4.19 8.00 191.00 
R-HSA:68877 Mitotic Prometaphase 2.63E-05 4.00 8.00 200.00 
R-HSA:141424 Amplification of signal from the kinetochores 2.82E-05 6.25 6.00 96.00 
R-HSA:141444 Amplification  of signal from unattached  kinetochores via a MAD2  inhibitory signal 2.82E-05 6.25 6.00 96.00 
GO:0000775 chromosome, centromeric region 2.95E-05 4.02 8.00 199.00 
GO:0000922 spindle pole 4.13E-05 4.43 7.00 158.00 
R-HSA:69618 Mitotic Spindle Checkpoint 5.47E-05 5.36 6.00 112.00 
R-HSA:5663220 RHO GTPases Activate Formins 1.82E-04 4.26 6.00 141.00 
GO:0000777 condensed chromosome kinetochore 4.68E-04 4.63 5.00 108.00 
GO:0000779 condensed chromosome, centromeric region 7.32E-04 4.13 5.00 121.00 
KEGG:04110 Cell cycle 7.61E-04 4.03 5.00 124.00 
GO:0000118 histone deacetylase complex 8.51E-04 5.56 4.00 72.00 
GO:0000123 histone acetyltransferase complex 1.50E-03 4.71 4.00 85.00 
GO:0018023 peptidyl-lysine trimethylation 1.60E-03 7.69 3.00 39.00 
GO:0031248 protein acetyltransferase complex 2.10E-03 4.17 4.00 96.00 
GO:1902493 acetyltransferase complex 2.10E-03 4.17 4.00 96.00 
GO:0051568 histone H3-K4 methylation 3.13E-03 5.88 3.00 51.00 
GO:0008287 protein serine/threonine phosphatase complex 3.14E-03 5.77 3.00 52.00 
GO:1903293 phosphatase complex 3.14E-03 5.77 3.00 52.00 
GO:0021695 cerebellar cortex development 3.34E-03 5.56 3.00 54.00 
GO:0005876 spindle microtubule 3.36E-03 5.45 3.00 55.00 
GO:0061733 peptide-lysine-N-acetyltransferase activity 3.92E-03 5.08 3.00 59.00 
GO:0009066 aspartate family amino acid metabolic process 4.13E-03 4.92 3.00 61.00 
GO:0043967 histone H4 acetylation 4.96E-03 4.55 3.00 66.00 
KEGG:04720 Long-term potentiation 4.97E-03 4.48 3.00 67.00 
GO:0034212 peptide N-acetyltransferase activity 4.97E-03 4.48 3.00 67.00 
GO:0003725 double-stranded RNA binding 5.20E-03 4.35 3.00 69.00 
R-HSA:400253 Circadian Clock 5.22E-03 4.29 3.00 70.00 
KEGG:04520 Adherens junction 5.45E-03 4.17 3.00 72.00 
R-HSA:1234174 Regulation of Hypoxia-inducible Factor (HIF) by oxygen 5.91E-03 4.00 3.00 75.00 
R-HSA:2262749 Cellular response to hypoxia 5.91E-03 4.00 3.00 75.00 
            
NPC CLUSTER 2      
GOID GOTerm 
Term PValue Corrected 
with Benjamini-Hochberg 
% Associated 
Genes Nr. Genes 
Total # 
Genes 
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules 8.88E-09 7.55 12.00 159.00 
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules 6.32E-07 4.88 12.00 246.00 
GO:0032596 protein transport into membrane raft 6.25E-05 50.00 3.00 6.00 
GO:0032594 protein transport within lipid bilayer 1.34E-04 16.67 4.00 24.00 
GO:1903044 protein localization to membrane raft 1.55E-04 33.33 3.00 9.00 
KEGG:05031 Amphetamine addiction 4.09E-04 7.35 5.00 68.00 
GO:0097440 apical dendrite 4.71E-04 21.43 3.00 14.00 
GO:1903115 regulation of actin filament-based movement 7.56E-04 8.89 4.00 45.00 
GO:1903115 regulation of actin filament-based movement 7.56E-04 8.89 4.00 45.00 
GO:0005891 voltage-gated calcium channel complex 7.79E-04 9.09 4.00 44.00 
GO:0005891 voltage-gated calcium channel complex 7.79E-04 9.09 4.00 44.00 
GO:0071871 response to epinephrine 8.58E-04 15.79 3.00 19.00 
GO:0005234 extracellularly glutamate-gated ion channel activity 9.14E-04 15.00 3.00 20.00 
KEGG:04713 Circadian entrainment 9.70E-04 5.21 5.00 96.00 
GO:0051453 regulation of intracellular pH 1.00E-03 5.26 5.00 95.00 
GO:0030641 regulation of cellular pH 1.04E-03 5.05 5.00 99.00 
GO:0006885 regulation of pH 1.33E-03 4.72 5.00 106.00 
GO:0070252 actin-mediated cell contraction 1.70E-03 4.35 5.00 115.00 
GO:0070252 actin-mediated cell contraction 1.70E-03 4.35 5.00 115.00 
KEGG:04724 Glutamatergic synapse 1.74E-03 4.39 5.00 114.00 
GO:0030004 cellular monovalent inorganic cation homeostasis 1.74E-03 4.27 5.00 117.00 
GO:0086003 cardiac muscle cell contraction 1.76E-03 5.88 4.00 68.00 
GO:0034704 calcium channel complex 1.76E-03 5.88 4.00 68.00 
GO:0086003 cardiac muscle cell contraction 1.76E-03 5.88 4.00 68.00 
GO:0034704 calcium channel complex 1.76E-03 5.88 4.00 68.00 
GO:0099094 ligand-gated cation channel activity 1.76E-03 5.88 4.00 68.00 
GO:0071300 cellular response to retinoic acid 1.78E-03 5.71 4.00 70.00 
GO:0005262 calcium channel activity 1.82E-03 4.13 5.00 121.00 
GO:0032743 positive regulation of interleukin-2 production 1.89E-03 9.38 3.00 32.00 
GO:0051393 alpha-actinin binding 2.55E-03 8.33 3.00 36.00 
GO:0051393 alpha-actinin binding 2.55E-03 8.33 3.00 36.00 
GO:0086004 regulation of cardiac muscle cell contraction 2.97E-03 7.69 3.00 39.00 
GO:0086004 regulation of cardiac muscle cell contraction 2.97E-03 7.69 3.00 39.00 
GO:0015297 antiporter activity 2.98E-03 4.65 4.00 86.00 
GO:0071867 response to monoamine 3.07E-03 7.32 3.00 41.00 
GO:0071869 response to catecholamine 3.07E-03 7.32 3.00 41.00 
GO:0035249 synaptic transmission, glutamatergic 3.07E-03 4.76 4.00 84.00 
GO:0007215 glutamate receptor signaling pathway 3.07E-03 4.76 4.00 84.00 
KEGG:05033 Nicotine addiction 3.07E-03 7.50 3.00 40.00 
GO:0001659 temperature homeostasis 3.40E-03 6.98 3.00 43.00 
GO:0042805 actinin binding 3.51E-03 6.82 3.00 44.00 
GO:0042805 actinin binding 3.51E-03 6.82 3.00 44.00 
R-HSA:1592230 Mitochondrial biogenesis 3.62E-03 4.21 4.00 95.00 
GO:0014888 striated muscle adaptation 3.62E-03 6.67 3.00 45.00 
GO:0006195 purine nucleotide catabolic process 4.09E-03 6.25 3.00 48.00 
GO:0005231 excitatory extracellular ligand-gated ion channel activity 4.47E-03 6.00 3.00 50.00 
GO:0032663 regulation of interleukin-2 production 5.68E-03 5.45 3.00 55.00 
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GO:0072523 purine-containing compound catabolic process 5.81E-03 5.36 3.00 56.00 
R-HSA:2151201 Transcriptional activation of mitochondrial biogenesis 5.81E-03 5.36 3.00 56.00 
GO:0015296 anion:cation symporter activity 5.94E-03 5.26 3.00 57.00 
GO:0086065 cell communication involved in cardiac conduction 6.08E-03 5.17 3.00 58.00 
GO:0071398 cellular response to fatty acid 6.08E-03 5.17 3.00 58.00 
GO:0086065 cell communication involved in cardiac conduction 6.08E-03 5.17 3.00 58.00 
GO:0098739 import across plasma membrane 7.46E-03 4.76 3.00 63.00 
GO:0099516 ion antiporter activity 7.46E-03 4.76 3.00 63.00 
GO:0032623 interleukin-2 production 7.46E-03 4.76 3.00 63.00 
GO:0051966 regulation of synaptic transmission, glutamatergic 7.93E-03 4.62 3.00 65.00 
KEGG:04720 Long-term potentiation 8.41E-03 4.48 3.00 67.00 
GO:0003341 cilium movement 8.55E-03 4.41 3.00 68.00 
GO:0006901 vesicle coating 8.55E-03 4.41 3.00 68.00 
GO:0032729 positive regulation of interferon-gamma production 8.55E-03 4.41 3.00 68.00 
GO:0009166 nucleotide catabolic process 8.55E-03 4.41 3.00 68.00 
GO:1901863 positive regulation of muscle tissue development 8.70E-03 4.35 3.00 69.00 
GO:0048199 vesicle targeting, to, from or within Golgi 9.55E-03 4.17 3.00 72.00 
GO:0050795 regulation of behavior 9.70E-03 4.11 3.00 73.00 
GO:1901292 nucleoside phosphate catabolic process 9.85E-03 4.05 3.00 74.00 
            
NEURON CLUSTER 1      
GOID GOTerm 
Term PValue Corrected 
with Benjamini-Hochberg 
% Associated 
Genes Nr. Genes 
Total # 
Genes 
GO:0007156 homophilic cell adhesion via plasma membrane adhesion molecules 5.18E-23 13.84 22.00 159.00 
GO:0098742 cell-cell adhesion via plasma-membrane adhesion molecules 4.52E-19 8.94 22.00 246.00 
GO:0051001 negative regulation of nitric-oxide synthase activity 4.06E-04 25.00 3.00 12.00 
GO:0005891 voltage-gated calcium channel complex 7.33E-04 9.09 4.00 44.00 
GO:0032769 negative regulation of monooxygenase activity 7.63E-04 18.75 3.00 16.00 
GO:0071871 response to epinephrine 8.69E-04 15.79 3.00 19.00 
GO:0051966 regulation of synaptic transmission, glutamatergic 2.08E-03 6.15 4.00 65.00 
KEGG:05031 Amphetamine addiction 2.20E-03 5.88 4.00 68.00 
GO:0086003 cardiac muscle cell contraction 2.20E-03 5.88 4.00 68.00 
GO:0034704 calcium channel complex 2.20E-03 5.88 4.00 68.00 
KEGG:04724 Glutamatergic synapse 2.28E-03 4.39 5.00 114.00 
GO:0051354 negative regulation of oxidoreductase activity 2.77E-03 9.09 3.00 33.00 
GO:0008038 neuron recognition 3.25E-03 8.33 3.00 36.00 
GO:0086004 regulation of cardiac muscle cell contraction 3.48E-03 7.69 3.00 39.00 
GO:0007215 glutamate receptor signaling pathway 3.64E-03 4.76 4.00 84.00 
GO:0035249 synaptic transmission, glutamatergic 3.64E-03 4.76 4.00 84.00 
GO:0071867 response to monoamine 3.74E-03 7.32 3.00 41.00 
GO:0071869 response to catecholamine 3.74E-03 7.32 3.00 41.00 
KEGG:04713 Circadian entrainment 4.20E-03 4.17 4.00 96.00 
GO:0004867 serine-type endopeptidase inhibitor activity 4.27E-03 4.08 4.00 98.00 
GO:0030212 hyaluronan metabolic process 4.28E-03 6.82 3.00 44.00 
KEGG:04973 Carbohydrate digestion and absorption 4.28E-03 6.82 3.00 44.00 
GO:0099601 regulation of neurotransmitter receptor activity 4.28E-03 6.67 3.00 45.00 
GO:1903115 regulation of actin filament-based movement 4.28E-03 6.67 3.00 45.00 
GO:0006195 purine nucleotide catabolic process 4.34E-03 6.25 3.00 48.00 
GO:0050999 regulation of nitric-oxide synthase activity 5.47E-03 5.66 3.00 53.00 
GO:0098900 regulation of action potential 5.78E-03 5.45 3.00 55.00 
GO:0072523 purine-containing compound catabolic process 5.81E-03 5.36 3.00 56.00 
GO:0086065 cell communication involved in cardiac conduction 6.14E-03 5.17 3.00 58.00 
GO:0030374 ligand-dependent nuclear receptor transcription coactivator activity 6.17E-03 5.08 3.00 59.00 
GO:0030276 clathrin binding 7.43E-03 4.69 3.00 64.00 
GO:0032768 regulation of monooxygenase activity 7.79E-03 4.55 3.00 66.00 
KEGG:04720 Long-term potentiation 7.82E-03 4.48 3.00 67.00 
GO:0032729 positive regulation of interferon-gamma production 7.85E-03 4.41 3.00 68.00 
GO:0009166 nucleotide catabolic process 7.85E-03 4.41 3.00 68.00 
GO:1901863 positive regulation of muscle tissue development 7.89E-03 4.35 3.00 69.00 
GO:0071300 cellular response to retinoic acid 7.94E-03 4.29 3.00 70.00 
GO:1901292 nucleoside phosphate catabolic process 8.95E-03 4.05 3.00 74.00 
            
NEURON CLUSTER 2     
GOID GOTerm 
Term PValue Corrected 
with Benjamini-Hochberg 
% Associated 
Genes Nr. Genes 
Total # 
Genes 
GO:0070603 SWI/SNF superfamily-type complex 1.11E-04 7.79 6.00 77.00 
GO:1904949 ATPase complex 2.81E-04 5.88 6.00 102.00 
GO:0090568 nuclear transcriptional repressor complex 2.87E-04 11.11 4.00 36.00 
GO:0090568 nuclear transcriptional repressor complex 2.87E-04 11.11 4.00 36.00 
GO:0006338 chromatin remodeling 3.20E-04 4.24 7.00 165.00 
GO:0006338 chromatin remodeling 3.20E-04 4.24 7.00 165.00 
GO:0097346 INO80-type complex 1.17E-03 13.64 3.00 22.00 
GO:0000118 histone deacetylase complex 2.15E-03 5.56 4.00 72.00 
KEGG:04110 Cell cycle 2.29E-03 4.03 5.00 124.00 
R-HSA:6804758 Regulation of TP53 Activity through Acetylation 2.49E-03 10.00 3.00 30.00 
KEGG:04914 Progesterone-mediated oocyte maturation 4.00E-03 4.04 4.00 99.00 
GO:0004812 aminoacyl-tRNA ligase activity 4.28E-03 6.38 3.00 47.00 
GO:0016575 histone deacetylation 4.28E-03 4.35 4.00 92.00 
GO:0016706 
oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, 2-
oxoglutarate as one donor, and incorporation of one atom each of oxygen into both donors 4.36E-03 6.52 3.00 46.00 
GO:0050681 androgen receptor binding 4.36E-03 6.52 3.00 46.00 
GO:0000422 autophagy of mitochondrion 4.38E-03 4.21 4.00 95.00 
GO:0061726 mitochondrion disassembly 4.38E-03 4.21 4.00 95.00 
R-HSA:379724 tRNA Aminoacylation 4.47E-03 7.14 3.00 42.00 
GO:0006418 tRNA aminoacylation for protein translation 4.69E-03 5.88 3.00 51.00 
GO:0043038 amino acid activation 5.13E-03 5.45 3.00 55.00 
GO:0000049 tRNA binding 5.17E-03 5.56 3.00 54.00 
GO:0043039 tRNA aminoacylation 5.17E-03 5.56 3.00 54.00 
GO:0050661 NADP binding 5.36E-03 5.26 3.00 57.00 
GO:1903146 regulation of autophagy of mitochondrion 5.36E-03 5.26 3.00 57.00 
GO:0070491 repressing transcription factor binding 6.72E-03 4.76 3.00 63.00 
GO:1901983 regulation of protein acetylation 7.22E-03 4.48 3.00 67.00 
GO:0051881 regulation of mitochondrial membrane potential 7.22E-03 4.48 3.00 67.00 
KEGG:00970 Aminoacyl-tRNA biosynthesis 7.27E-03 4.55 3.00 66.00 
KEGG:04662 B cell receptor signaling pathway 8.09E-03 4.23 3.00 71.00 
GO:0030521 androgen receptor signaling pathway 8.31E-03 4.05 3.00 74.00 
GO:0043044 ATP-dependent chromatin remodeling 8.35E-03 4.11 3.00 73.00 
      
GLIA CLUSTER 2     
 
 268 GOID GOTerm 
Term PValue Corrected 
with Benjamini-Hochberg 
% Associated 
Genes Nr. Genes 
Total # 
Genes 
GO:0002292 T cell differentiation involved in immune response 1.05E-04 6.45 4.00 62.00 
GO:0002286 T cell activation involved in immune response 2.95E-04 4.17 4.00 96.00 
GO:0051310 metaphase plate congression 4.94E-04 5.26 3.00 57.00 
GO:0002287 alpha-beta T cell activation involved in immune response 5.86E-04 5.36 3.00 56.00 
GO:0002293 alpha-beta T cell differentiation involved in immune response 5.86E-04 5.36 3.00 56.00 
GO:0043367 CD4-positive, alpha-beta T cell differentiation 6.34E-04 4.55 3.00 66.00 
KEGG:04520 Adherens junction 7.01E-04 4.17 3.00 72.00 
GO:0002294 CD4-positive, alpha-beta T cell differentiation involved in immune response 7.40E-04 5.45 3.00 55.00 
 
Table 3.20 | GOs of gene clusters with high correlation scores from Table 
3.19.  
























Table 22Table 3.21 |  Protein  net works (string-db)  in SZ r isk connections 
NPC (PGC + CLOZUK) NEURON (PGC + CLOZUK) GLIA (PGC + CLOZUK) NPC (PGC) NEURON (PGC) GLIA (PGC) 
ACTR8 ACTR5 ADSL CA6 ENO1 UTS2 
ADSS ACTR8 ADSS SLC2A5 CA6 RNF220 
AKT3 ADSS ALMS1 EPB41 SLC2A5 ADSS 
ALMS1 AKT3 ANKHD1 PPIH H6PD GRIN2A 
ANKRD45 ALMS1 AOX1 EBNA1BP2 MPL MAPK3 
ANP32E AMBRA1 CCT7 ST3GAL3 CDC20 NFATC3 
AOX1 ANKRD45 CHRM3 B4GALT2 MED8 TCF4 
ARNT ANP32E CNKSR2 DPYD RNF220 JUND 
ASB5 AP1S3 CUL3 ANP32E ANP32E DPP4 
ASH2L ATG13 DPP4 RPRD2 SEMA6C HECW2 
B4GALT2 ATXN7 EP300 ARNT IL19 SF3B1 
BRD8 BAHD1 GPER SEC16B PFKFB2 MOB4 
CA6 BAZ2A GRIA1 SDCCAG8 PLXNA2 AOX1 
CACNA1C BOLL GRIN2A AKT3 SDCCAG8 CUL3 
CACNA1D CA6 HECW2 ADSS AKT3 UGT1A8 
CACNA2D3 CACNA1C JUND NT5C2 ADSS UGT1A10 
CCNH CACNA1D KLHL20 TAF5 SUFU UGT1A9 
CDC25C CCT7 MAPK3 PHF21A NT5C2 UGT1A7 
CENPL CDC20 MASK-BP3 CACNA1C TAF5 UGT1A6 
CHST12 CDC25C MEF2C PPP1CC PHF21A UGT1A5 
CIRH1A CENPL MOB4 CLIP1 CREB3L1 UGT1A4 
CLCN3 CHDH NFATC3 KNTC1 DGKZ ADSL 
CLIP1 CPEB1 NMUR2 GTF2H3 AMBRA1 EP300 
CLU CREB3L1 PDE4B TCTN2 ATG13 SH3RF1 
CREB3L2 CTNNA1 PLXNA4 GRIN2A CTNND1 MEF2C 
CSGALNACT1 CTNND1 RNF220 UTP4 CACNA1C ANKHD1 
CUL3 CUL3 SDCCAG8 SNTB2 BAZ2A NMUR2 
CYP26B1 DGKD SF3B1 NCAN MARS GRIA1 
DCTN1 DGKZ SH3RF1 SUGP1 PLCB2 GPER1 
DNAJC18 DNAJC19 SLC4A5 MAU2 BAHD1 PLXNA4 
DNAJC19 DNAJC6 TCF4 GATAD2A SH3GL3 CNKSR2 
DPYD DPYD UGT1A10 CYP26B1 GRIN2A  
EBNA1BP2 DYSF UGT1A5 EPC2 PSKH1  
EP300 EGR4 UGT1A8 PSMD14 PSMB10  
EPB41 ENO1 UTS2 HECW2 SLC12A4  
EPC2 EPC2  SF3B1 WDR81  
EPHB1 EPHA7  HSPD1 NT5M  
ETF1 EPN2  SGO2 SREBF1  
FGFR1 FBXO41  AOX1 GATAD2A  
GAB1 GABBR1  CUL3 DYSF  
GATAD2A GATAD2A  UGT1A8 HECW2  
GBF1 GRIA1  UGT1A10 SF3B1  
GFRA3 GRIN2A  UGT1A9 CUL3  
GPM6A GRM3  UGT1A7 PDE6D  
GRIA1 H6PD  UGT1A6 DGKD  
GRIN2A HARS  EP300 ACTR5  
GTF2H3 HARS2  RANGAP1 POLDIP3  
HDAC3 HDAC2  OXNAD1 SEMA3G  
HECW2 HECW2  PLCL2 ITIH3  
HSPA9 HSPA9  ITIH3 ITIH4  
HSPD1 IL19  ITIH4 THOC7  
INO80B INO80B  CACNA1D ATXN7  
INPP4B INPP4B  EPHB1 PPP2R3A  
INPP5D INPP5D  PPP2R3A STAG1  
ITGA9 ITIH3  PCCB DNAJC19  
ITIH3 ITIH4  STAG1 PPARGC1A  
ITIH4 JAK1  NCK1 PDE4D  
KLHL20 KAT5  DNAJC19 CDC25C  
KNTC1 KDM4A  PPARGC1A HSPA9  
MAD1L1 KIAA1009  SH3RF1 CTNNA1  
MAU2 LEPR  CLCN3 HARS  
MEF2C MAD1L1  GPM6A HARS2  
MLL5 MAP3K11  ASB5 ZMAT2  
NCAN MARS  PDE4D SPARC  
NCK1 MBTPS2  BRD8 GRIA1  
NFATC3 MED8  CDC25C GABBR1  
NISCH MEF2C  HSPA9 SNAP91  
NLGN4X MLL5  DNAJC18 CEP162  
NT5C2 MPL  HDAC3 PSMG3  
OXNAD1 NFATC3  GRIA1 MAD1L1  
PCCB NGEF  MAD1L1 GRM3  
PDE4B NT5C2  CHST12 CA8  
PDE4D NT5M  KMT2E MBTPS2  
PHF21A OXNAD1  CREB3L2   
PLCL2 PCGF6  CLU   
PLXNA2 PDE4B  NLGN4X   
PPARGC1A PDE4D  RPS6KA3   
PPIH PDE6D     
PPP1CC PEMT     
PPP2R2A PFKFB2     
PPP2R3A PHF21A     
PSMD14 PLCB2     
RANGAP1 PLXNA2     
RASA1 POLDIP3     
RASAL2 PPARGC1A     
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RPRD2 PPP2R2A     
RPS6KA3 PPP2R3A     
SDCCAG8 PRKCB     
SEC16B PRKD1     
SEMA3G PSKH1     
SF3B1 PSMB10     
SGOL2 PSMG3     
SH3RF1 RNF220     
SLC2A5 SDCCAG8     
SLC4A5 SEMA3G     
SNTB2 SEMA6C     
ST3GAL3 SH3GL3     
STAG1 SLC12A4     
SUGP1 SLC2A5     
TAF5 SMG6     
TCF4 SNAP91     
TCTN2 SPARC     
TNN SREBF1     
TNR STAG1     
UGT1A10 STAT6     
UGT1A5 SUFU     
UGT1A8 TAF5     
 THOC7     
 
Table 3.21 | Protein networks (string-db) in SZ risk connections. 
Proteins recognized by string-db as part of an association network from the list of 
genes in Table 3.15 for NPCs, neurons, and glia. Highlighted groups of rows (in 
PGC2 set) for indicated genes that are located in the same or adjacent TADs 
(i.e., chromatin colocalization). Different colors are merely for ease of 


























Table 23Table 3.22 |  Demographics of brain  cohort used  for proteomic analysis 
  Schizophrenia (n=23) Healthy/Control (n=20) 
Age   
Mean 82.2 83.3 
SD 8.6 10 
Sex, n (%)   
Male 8 (35) 7 (35) 
Female 15 (65) 13(65) 
PMI   
Mean 11.4 8 
SD 3.6 4.2 
 
Table 3.22 | Demographics of brain cohort used for proteomic analysis. 
Demographic information of postmortem adult brains that were assayed for 
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Materials and methods 
In situ Hi-C from hiPSC-derived cells 
 In situ Hi-C libraries were generated from 2 million to 5 million cultured 
hiPSC derived NPCs, glia, and neurons as described in (Rao et al., 2014) without 
modifications in the protocol. Briefly, in situ Hi-C consists of 7 steps: (i) 
crosslinking cells with formaldehyde, (ii) digesting the DNA using a 4-cutter 
restriction enzyme (e.g., MboI) within intact permeabilized nuclei, (iii) filling in and 
biotinylating the resulting 5′-overhangs, (iv) ligating the blunt ends, (v) shearing 
the DNA, (vi) pulling down the biotinylated ligation junctions with streptavidin 
beads, and (vii) analyzing these fragments using paired end sequencing. As 
quality control (QC) steps, we checked for efficient restriction with an agarose 
DNA gel and for appropriate size selection using the Agilent Bioanalyzer after 
steps (v) and (vi). For the final QC, we performed superficial sequencing on the 
Illumina MiSeq (~2-3Mreads/sample) to assess quality of the libraries using 
metrics such as percent of reads passing filter, percent of chimeric reads, and 
percent of forward-reverse pairs (Table 3.1). For the forebrain directed 
differentiation neuronal library from subject S1, the Arima Hi-C kit (Arima 
Genomics, San Diego) was used according to the manufacturer’s instructions. 
Hi-C read mapping and matrix generation  
 The Hi-C libraries were sequenced on the Illumina HiSeq1000 platform 
(125bp paired-end) (New York Genome Center). Technical replicates of subject 
 
 273 S2 NPCs, neurons, and glia were also sequenced to enhance resolution. Initial 
processing of the raw 2 ×125 bp read pair FASTQ files was performed using the 
HiC-Pro analysis pipeline (Servant et al., 2015). In brief, HiC-Pro performs four 
major tasks: aligning short reads, filtering for valid pairs, binning, and normalizing 
contact matrices. HiCPro implements the truncation-based alignment strategy 
using Bowtie v2.2.3 (Langmead et al., 2009), mapping full reads end-to-end or 
the 5′ portion of reads preceding a GATCGATC ligation site that results from 
restriction enzyme digestion with MboI followed by end ligation. Invalid 
interactions such as same-strand, dangling-end, self-cycle, and single-end pairs 
are not retained. Binning was performed in 10kb, 40 kb and 100 kb 
nonoverlapping, adjacent windows across the genome and resulting contact 
matrices were normalized using iterative correction and eigenvector 
decomposition (ICE) as previously described (Imakaev et al., 2012), using HiC-
Pro's default settings of 100 maximum iterations, filtering of the sparse bins 
(lowest 2%), and a relative result increment of 0.1 before declaring convergence 
(http://nservant.github.io/HiC-Pro/MANUAL.html). Data are reported in browser-
extensible-data-like (BED) format and visualized in the Washington University 
Epigenome Browser (http://epigenomegateway.wustl.edu). Hierarchical 
clustering was performed on the ICE-corrected intrachromosomal contact 
matrices after the bins with the 1% most extreme interaction values were 
excluded as largely artifactual. Clustering was performed using Ward's method 
on the 1, 5, 10, 25, 50, and 100% most variable remaining bins using (1-
 
 274 correlation) as a distance metric. The results using the 10% most variable 
interaction bins, shown here in a cluster dendrogram and a Pearson correlation 
matrix, are representative of these results. 
Hi-C loop calls using Juicer 
 Loop calling was performed using the software HiCCUPS (Rao et al., 
2014). To format data for HiCCUPS input, we remapped reads from Hi-C libraries 
using the Juicer pipeline (Durand, Shamim, et al., 2016). Similar to HiC-Pro, the 
Juicer pipeline performs read alignment, filtering, binning, and matrix 
normalization. Samples were pooled for each cell type (S1 and 2 technical 
replicates from S2) to generate the maximum amount of coverage required for 
accurate loop calling. The resulting .hic matrix files (MAPQ > 0) were then used 
as input to HiCCUPS. The following parameters were set for HiCCUPS following 
the analysis in (Rao et al., 2014): FDR threshold ( f ) = 0.10, 0.10; peak width (p) 
= 4, 2; window width (i ) = 7, 5; merge distance (d) = 20 kb, 20 kb. Values for 
parameters correspond to calls made at 5kb and 10kb, respectively. 
Representative neuronal and non-neuronal loops are presented in Figure 3.4. As 
the number of loops called is dependent upon the number of Hi-C contacts in the 
matrix (Forcato et al., 2017), we also generated matrices with equivalent total Hi-
C contacts via subsampling. hiPSC-derived Hi-C interaction matrices were 
randomly subsampled to 372,787,143 cis only contacts (the lowest number of cis 
contacts across all cell types) and HiCCUPS was rerun on the subsampled 
matrices. After loops were called for each cell type, we performed a reevaluation 
 
 275 on this union set of loop loci. HiCCUPS was rerun using the union set of loop loci 
as input to produce q-values for each loop in the union set for every cell type. By 
default, HiCCUPS does not output a q-value for every pixel. Hence, this 
reevaluation produced q-values for pixels in cells that did not pass the 
significance threshold. We then defined any pixel from the union set with a q-
value < 0.10 with respect to the donut neighborhood surrounding the pixel to be a 
loop and defined the loop to be shared with any cell types having a q-value < 
0.10 for the same pixel.  
 These loop calls were used for comparing loop calls between cell types. 
Loops were also called and subsampled as above for the GM12878 cell line 
using the processed data from (Rao et al., 2014) found here: 
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE63525. Loop calls were 
overlapped with compartment calls (Materials and methods), such that AA, BB, 
and AB refer to loops with both anchors in A, both anchors in B, and one anchor 
in A and other anchor in B, respectively. Loops in chromosomes 4, 18, 19, and X 
were removed from this compartment analysis since the first principle component 
most likely corresponded to p versus q arm distinctions and not A versus B 
compartments. 
Hi-C interactions at risk loci 
 To approach 3DG conformation in context of the disease-relevant 
sequences, we adapted the binomial statistics based mapping strategy 
previously described by Won et al (Won et al., 2016). The set of schizophrenia 
 
 276 risk loci used in this study included the original (PGC2, Psychiatric Genomics 
Consortium) (Ripke et al., 2014) risk sequences, or 108 physically distinct 
association loci defined by 128 index SNPs (corrected P 10−8) and an additional 
37 loci from the CLOZUK (a series of UK cases registered for clozapine 
treatment with a clinical diagnosis of schizophrenia) study for a total of 145 loci 
defined by 179 independent genome-wide significant SNPs (corrected P < 5 × 
10–8), determined by GWAS in 40,675 cases and 64,643 controls (Pardiñas et 
al., 2018). A risk locus is defined as a collection of (SNPs) existing in linkage 
disequilibrium, ranging from 1bp to 8.9Mb (average 256.2 kb) in length and in 
total equivalent to approximately 0.012% of human genomic sequence.  
 To identify significantly enriched interactions involving a bin of interest with 
another bin, our principal approach was to first estimate the expected interaction 
counts for each interaction distance by calculating the mean of all 
intrachromosomal bin-bin interactions of the same separation distance 
throughout the raw intrachromosomal contact matrix. We used the R package, 
HiTC (Servant et al., 2012), to facilitate manipulation of our HiC-Pro-produced 
raw contact matrices and estimation of the expected counts at various interaction 
distances. The probability of observing an interaction between a bin-of-interest 
and another bin was then defined as the expected interaction between those two 
bins divided by the sum of all expected interactions between the bin-of-interest 
and all other intrachromosomal bins. A P value was then calculated as binomial 
probability of observing the number of interaction counts or more between the 
 
 277 bin-of interest and some other bin where the number of successes was defined 
as the observed interaction count, the number of tries as the total number of 
observed interactions between the bin-of-interest and all other intrachromosomal 
bins, and the success probability as the probability of observing the bin-bin 
interaction estimated from the expected mean interaction counts. The Benjamini-
Hochberg method was used to control false discovery rate (FDR) for P values 
determined for all interactions with a bin-of interest (includes all bins 1Mb up and 
downstream in our tests). 
Generation of stable selected dCas9-VP64/VPR and Cas9 NPCs 
 All CRISPR-based epigenomic editing assays were performed on 
antibiotic selected dCas9-VP64 (VP64 as the tetrameric VP16 activator domain) 
and dCas9-VPR (VPR as the tripartite activator, VP64-p65-Rta) NPCs derived as 
described in (Ho et al., 2017). For generation of Cas9 stable, selected NPCs, we 
used a plasmid of lentiCRISPR v2 gifted by Feng Zhang (Addgene plasmid # 
52961). DNA sequencing with a U6 primer confirmed the identity. Lentiviral 
production and titration were performed as described previously (Ho et al., 2016). 
Control S1 and S2 NPCs were spinfected with lentiCRISPR v2 virus as described 
(Ho et al., 2017). 48 hours post-transduction, cells were selected by exposure to 
puromycin at 0.3 µg/mL. Without transduction, all control cells died within around 
5 days after the antibiotic addition. The puromycin-selected NPCs were subject 
to Western blot analysis of Cas9 expression. 30 µg of proteins were 
electrophoresed in NuPAGE 4-12% Bis-Tris Protein Gels (NP0323PK2, Life 
 
 278 Technologies) in 1× MES running buffer, 200 V constant, 35 min. Proteins were 
transferred onto nitrocellulose membrane (IB23002, Life Technologies) on the 
iBlot® 2 Dry Blotting System (program P3, 7:00 min). The membranes were 
incubated with primary antibodies against Cas9 (1:250, monoclonal, clone 7A9, 
Millipore) and b-Actin (1:10,000, mouse, 1406030, Ambion) overnight at 4°C. 
Then, membranes were incubated with the IRDye-labeled secondary antibodies 
for 45 min at RT in the dark on the rocker. Fluorescence was visualized using a 
Li-CorOdyssey Imaging System. 
In vitro transcription and transfection of gRNAs  
 Guide RNAs (gRNAs) were designed on Benchling (www.benchling.com) 
using the CRISPR tool. gRNAs were generated via in vitro transcription (IVT) 
with the GeneArt Precision gRNA Synthesis Kit (Thermo Fisher Scientific, 
A29377) as per manufacturer instructions. Five gRNAs were designed per 
condition (i.e., “loop SNP”, negative control, and positive control) and pooled for 
transfection. The genomic ranges within which loop-SNP gRNAs were designed 
(i.e., region spanning the SNP of interest and all gRNAs in the condition) were 
roughly 600 bp for ASCL1, 550 bp for MATR3, 460 bp for EFNB1 (with 2/5 
gRNAs directly overlapping the SNP), 300 bp for SOX2. Puromycin-selected 
(1µg/mL in NPC media; Sigma, #P7255) dCas9-VP64 and dCas9- VPR NPCs 
(Ho et al., 2017) were seeded at a density of ~400,000 per well on Matrigel-
coated (BD Biosciences) 24-well plates. Pooled IVT gRNAs (500 ng total 
RNA/well) and 2 µL EditPro Stem lipofectamine (MTI-GlobalStem, #GST-2174; 
 
 279 now, ThermoFisher, STEM00003) were diluted in 50 µL Opti-MEM (Thermo 
Fisher Scientific, #31985062) and added dropwise to each well. Cells were 
harvested with TRIzol for total RNA extraction 48 hours later. All experiments 
were conducted with 3 to 6 biological replicates from 1 donor (subject S1), 
generated in parallel, with the donor contributing isogenic dCas9-VP64 and 
dCas9-VPR effector cells. Each data point in Figure 3.8, D to F, represents one 
biological replicate within each condition. For each target gene promoter and 
candidate loop, control gRNAs were strategically placed into the middle third of 
the (linear) genome portion bypassed by the candidate loop. CRISPRa results 
were analyzed on PRISM with a one-way ANOVA across 3 conditions with a 
Dunnett’s test for multiple comparisons. Cas9 mutagenesis was also performed 
as described above with the exception of the negative control, which in these 
experiments consisted of an empty transfection (i.e., lipofectamine + Opti-MEM 
without any gRNA). Cas9 results were analyzed with an unpaired t test 
comparing the loop-SNP and negative control conditions. 
RNA transcriptomic correlation heatmaps 
 Pearson correlation coefficient matrices were calculated for gene 
expression in the childhood onset schizophrenia data set (Hoffman et al., 2017) 
using R from lists of genes that are located in cell-type-specific loops anchored at 
schizophrenia risk loci and, as a subset of this list, sets of genes whose proteins 
participate in an association network for each of the three cell types (see below). 
Significance was computed calculating the absolute mean correlation coefficient 
 
 280 of each correlation matrix (“organization score”) as a test statistic against a null 
distribution generated by random gene sampling. Randomized gene lists were 
drawn only from the pool of genes with over 1 count per million (CPM) in at least 
30% of the experiments described in (Hoffman et al., 2017). To generate a null 
distribution of organization scores for a given cell type that accounted for 
genomic distance and neighborhood effects, we began by randomly selecting a 
significant PGC interaction for that cell type. Using the bp genomic distance of 
this interaction we randomly selected two 10kb bins from the genome separated 
by the same distance. All genes overlapping these bins were then added to the 
list of genes with which to calculate the organization score. This process was 
iterated until enough genes were added to the list to match the number of genes 
used in the original cell-type-specific organization score. Finally, this protocol was 
repeated 1000 times to generate the null distribution of random organization 
scores. This distribution was then used to calculate significance of co-regulation 
(i.e., P = number of times |r |avg of the null exceeded that of the test heatmap / 
1000). Note that STRING gene network transcriptomic analyses (Figure 3.13, B) 
were performed with 1000 random permutations of genes sampled from the full 
schizophrenia risk connectome (i.e., risk locus + risk locus connect genes) for 
each cell type. 
Generation of hiPSC-derived cell types 
 NPCs were derived from human iPSCs, as described (Brennand et al., 
2011). Briefly, hiPSCs reprogrammed from two independent controls (Subjects 
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suspension in N2 medium (Invitrogen) for 7 days. They were then plated onto 
polyornithine/laminin-coated plates and visible rosettes were manually dissected 
after 1 week and cultured in NPC medium (Brennand et al., 2011). NPCs were 
maintained at high density on Matrigel (BD Biosciences) and split approximately 
1:4 once a week with Accutase (Millipore). In our hands, doubling time of hiPSC-
derived forebrain NPCs is 3.69±0.05 days, with the percentage of cells in G1 cell 
cycle phase is 62.3 ± 0.2%, in S phase is 24.6±0.1% and G2 phase is 6.5 ± 
0.03% (Brennand et al., 2015).  
 NPCs were further differentiated along the glial lineage as previously 
described (TCW et al., 2017). Briefly, NPCs described above were seeded at a 
density of 15,000 cells/cm2 on Matrigel-coated plates in astrocyte medium 
(ScienCell). Cells were split at 95% confluency, approximately every 6-7 days, to 
the initial seeding density with Accutase (Millipore). After 30 days of 
differentiation, glia were used in assays or were maintained in astrocyte medium 
(with 2% FBS), splitting 1:3 every week with Accutase. 
 To arrive at hiPSC-neurons via Neurogenin2 induction as previously 
described (Ho et al., 2016), NPCs were seeded at low density on Matrigel-coated 
plates and transduced with lentiviral constructs to overexpress NGN2, driven by 
a TetO promoter, in NPC-medium. Doxycycline (Sigma, #D9891) was added in 
NPC medium to activate the system and puromycin (Sigma, #P7255) was 
introduced for selection. 2 days after doxycycline addition, puromycin is 
 
 282 withdrawn and NPC medium was switched to neuron medium (Ho et al., 2016). 
Cells were maintained with regular half-medium changes until day 20 after first 
doxycycline addition. At this point, neurons were ready to be used for assays. In 
our hands, as described, combining puromycin induction and Ara-C treatment to 
block proliferation of dividing cells results in pure or near-pure (approaching 99-
100% homogeneity by cell type) populations of postmitotic excitatory 
(glutamatergic) neurons, with other cell types undetectable in the culture (Ho et 
al., 2016). 
 For forebrain neuronal differentiation, as previously described (Brennand 
et al., 2011), for S1, NPCs were seeded at low density and cultured in neural 
differentiation medium (DMEM/F12, 1xN2, 1xB27-RA, 20 ng ml−1 BDNF 
(Peprotech), 20 ng ml−1 GDNF (Peprotech), 1mM dibutyryl-cyclic AMP (Sigma), 
200nM ascorbic acid (Sigma) and 1 μgml−1 laminin (ThermoFisher Scientific) 1–
2 days later. Cells were maintained in differentiation medium for 7.5 weeks 
before harvesting. Note that forebrain differentiated cultures reflect the dual 
lineage potential of the NPC, and therefore contain a neural population of βIII-
TUBULIN-positive neurons, which comprise 70-80% of all cells in the culture. 
Another 20-30% of cells in culture are glial fibrillary acidic protein (GFAP)-
positive astrocytes. In addition, while the majority of forebrain hiPSC neurons 
express the glutamatergic marker VGLUT1, another (approximately 30%) subset 
of neurons expresses the GAD67 GABAergic marker gene (Topol, Tran and 
Brennand, 2015). 
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 NPCs: NPCs on coverslips (24-well plate) were fixed in ice cold 4% PFA 
(Electron Microscopy Sciences, #15714) for 10 minutes and rinsed with PBS 
(containing Ca2+ and Mg2+; Thermo Fisher Scientific 21300-058). Blocking was 
performed with a buffer consisting 0.5% BSA/0.1% Triton-X (Sigma, 
#T8787)/PBS for 30 minutes at 4°C. Cells were incubated overnight at 4 degrees 
with primary antibody that was diluted in the blocking buffer. Primary antibodies 
used were Nestin (Alexa 647-conjugated, BD. #560341; 1:100) and SOX2 (Goat, 
Santa Cruz, #sc-17320; 1:500). Cells were then washed twice with PBS for 5 
minutes. Then, secondary Alexa 488 donkey anti-goat (Jackson Immuno, #705-
545-147; 1:400) was added in 300 μL PBS for 1-2 hours at room temperature. 
Cells were then washed again twice with PBS. Nuclei were counterstained with 
DAPI (Sigma, #D9542) for 10-15 minutes in 300 μL PBS. Coverslips containing 
the fluorescent stained NPCs were mounted onto slides with AquaPolymount 
mounting solution (Polysciences Inc., #18606-20) that was equilibrated to room 
temperature. Mounted coverslips were then left to air-dry overnight in the dark. 
 Neurons: Followed the staining protocol as per (Ho et al., 2016). Primary 
antibodies used were TUJ1 (Rabbit, Covance, #PRB-435P; 1:1000) and MAP2 
(Chicken, ABcam, #ab5392; 1:500). Secondary antibodies used were Alexa 488 
donkey anti-chicken (Jackson Immuno, #703-545-155) and Cy3 donkeyanti-
rabbit (Jackson Immuno, #711-165-152), both at 1:400. 
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antibodies used were S100β (Mouse, Sigma-Aldrich, #S2532; 1:1000) and 
Vimentin (Rabbit, Cell Signaling, #3932; 1:500). Secondary antibodies used were 
Alexa 488 donkey anti-mouse (Jackson Immuno, #715-545-151) and Alexa 647 
donkey-a-rabbit (Jackson Immuno, 711-605-152), both at 1:400. 
 All imaging was performed with a Zeiss LSM 780 confocal microscope. 
Hi-C A/B compartment calling 
 To identify boundaries of low-resolution A/B compartments associated 
with open and closed chromatin, respectively, the first eigenvector from PCA on 
the Pearson’s correlation matrix of Knight-Ruiz balanced observed/expected 
interaction frequencies (Knight and Ruiz, 2013) was calculated using `pearson` 
and `eigenvector` functions within the pre module of the Juicer tools suite 
(https://github.com/theaidenlab/juicer/wiki/Pre) at 500kb and 1Mb resolution 
(Durand, Shamim, et al., 2016). Positively and negatively signed PC1 regions 
were used to establish compartments. For each library, the PC1 region that had 
higher gene density was defined as open-chromatin-associated compartment A 
while the other region was defined as closed-chromatin-associated compartment 
B as per previously described methods (Lieberman-Aiden et al., 2009). 
Hi-C topologically associating domain calling 
 Topologically associated domains (TADs) were called using the 
`arrowhead` algorithm in the Juicer tools suite with a 10kb resolution and 2kb 
sliding windows, `-r 10000 –m 2000 –ignore -sparsity`, on the ICE-corrected 
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contact matrices sampled to have similar cis interactions (see below). Statistically 
significant differences in distributions were determined using the Wilcoxon-Mann-
Whitney test. 
Cumulative distribution of loop size 
 Cumulative plots were generated using loop calls from subsampled Hi-C 
data. Two-sample two-tail Kolmogorov-Smirnov test was used to determine the 
p-value, testing the hypothesis that two samples come from the same 
distribution. Refer to the script “loop_distance.R” at the following link: 
https://github.com/tborrman/Schahram-project. 
Gene expression v. loop analyses 
 To test whether looping architecture was associated with increased gene 
expression, we overlapped genes with our non-subsampled HiCCUPS loop calls. 
We defined Gene Body Loop genes to be genes that overlap with loop anchor 
loci and defined TSS Loop genes to be genes whose TSS lies within a loop 
anchor loci. We then calculated the mean log10(FPKM + 1) for Gene Body loop 
genes and TSS Loop genes, and performed one-tail Z-tests to determine if 
expressions in gene sets were significantly high. Refer to the scripts 
“get_overlapping_genes.py” and “FPKM_cell_type_specific_boxplots.R” at the 
following link: https://github.com/tborrman/Schahram-project.  
 
 286 Gene ontology 
 To examine the functional role of significant interactions, genes present in 
bins participating in interactions of interest (e.g., brain-specific loops, celltype-
specific schizophrenia risk interactions, etc) were tested for enrichment of gene 
ontology categories using ClueGO (adjusted p-value threshold of < 0.05 with 
Bonferroni step-down or Benjamini-Hochberg correction, at “Medium” or 
“Medium-high” network specificity, and with “GO Term Fusion” enabled to avoid 
redundant terms (Bindea et al., 2009). For the brain-specific loops GO, we took 
the 818 loops shared by all NPCs, glia, and astrocytes from the non-subsampled 
datasets. For the GO of loops lost in the neurons or glia upon transitioning from 
NPCs, the union set of all loops called with HiCCUPS was filtered to extract only 
those that were q-value < 0.1 (“present”) in NPCs and q-value > 0.1 (“lost”) in 
neurons or glia. Genes were annotated from anchors of the top 1000 most 
significant loops lost in neurons or glia. 
ATAC-seq and accessibility processing 
 To assess chromatin accessibility, ATAC-seq was performed as described 
in (Buenrostro et al., 2015). Briefly, 50,000 cells from each sample were snap 
frozen, resuspended in cold lysis buffer (10 mM Tris-HCl pH 7, 10 mM NaCl, 3 
mM MgCl2, 0.01% Igepal CA-630) and spun down at 500 x g for 10 min at 4°C. 
Cells were incubated with 25 μL TD buffer, 2.5 μL Tn5 transposase (Illumina; Cat 
No: #FC-121-1030) and 22.5 μL nuclease-free H20 at 37°C for 30 min. After 
purification (Qiagen; Cat No: #28004), transposed DNA fragments were amplified 
 
 287 with custom Nextera PCR primers (Buenrostro et al., 2013) for a total of 9 cycles. 
To minimize GC and size bias, the final PCR cycle number needed to minimally 
amplify libraries was determined by a separate qPCR reaction as described in 
Buenrostro et al., 2015. Purified libraries were sequenced on an Illumina HiSeq 
2500. 
 To evaluate accessibility, ATAC-seq raw FASTQs were quality (minimum 
Q20) and adapter trimmed using Trim Galore! v0.4.1 
(https://www.bioinformatics.babraham.ac.uk/projects/trim_galore/). Trimmed 
reads were aligned to hg19 using `bwa mem` v0.7.17. Aligned reads were then 
Insertion-Deletion realigned and Base Quality Score Realigned using the 
Genome Analysis Tool Kit v3.1.1 (McKenna et al., 2010). Duplicates were 
marked using Picard MarkDuplicates v1.137 
(https://broadinstitute.github.io/picard/). Genome-wide accessibility signal was 
computed from R1 alignments with 5’ ends shifted 4 bases and 3’ ends shifted 5 
bases towards the center of the purported transposition event. Shifted R1 
alignments were then aggregated at each base pair. NGN2-neuron Rep1 and 
NPC libraries were subsampled to approximately 227 million reads, comparable 
to the lowest coverage library, NGN2-neuron Rep2. Aggregated coverage in the 
subsampled libraries was log2-converted. To evaluate genome-wide 
accessibility, the mean accessibility signal across 1kb-tiled windows was 
calculated. The mean ATAC-seq signal within HiCCUPS loop anchor bin 
coordinates was used to assess the accessibility of loop calls. 
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 In order to assess whether the observed rate of overlap of our brain-
specific (i.e., loops shared by NPCs, neurons, and glia) Hi-C loops with the 
Common Minds Consortium brain cis-eQTLs (with FDR < 10-5) was significant, 
we first constructed a set of background loops. To do so, we annotated the 
anchors of the observed loops with functional classes using ChIPseeker (Yu, 
Wang and He, 2015). We used separate annotations to represent the 0-1kb, 1-
2kb, 2-3kb, 3-4kb, and 4-5kb upstream promoter. To retain any hidden nuance in 
exon/intron annotations, we also preserved intron and exon numbers 1 through 5 
and a separate merged class of intron and exon numbers 6 or greater. 
Downstream intergenic and unassociated intergenic served as additional sets of 
annotations. We similarly annotated the set of all 10kb genomic bins used in 
creating the Hi-C contact matrix. To create the null sets, we randomly selected a 
genomic bin that matched the annotation of the first anchor of our observed 
loops, then scanned up and downstream for a second bin a similar distance 
away (within ±25% of the observed loop distance), with a matching functional 
annotation to the second loop anchor. For each loop, we tried up to 100 random 
bin selection iterations to find a suitable bin pair match (with a failure rate of 
approximately 0.1%). Thus, each null set was similar or identical in size to the 
observed loop set. All bins associated with our observed loops and the bins 
±20kb flanking its anchors were excluded from the null sets. We overlapped the 
background loops with the Common Minds cis-eQTLs with FDR<10-5 to estimate 
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sampled 1000 null sets as described and calculated the fraction of each that fully 
overlapped an eQTL—requiring both SNP and gene-body to overlap each loop 
anchor. The one-sided empirical p-value was defined as the fraction of null-
loop/eQTL overlap rates that were greater than or equal to our observed brain-
specific-loop/eQTL overlap rate. 
Comparing interaction intensity within interactions with PCDH locus 
 Observed/Expected (O/E) interaction scores were extracted from the 
subsampled Glia, NPC, and Neuron *.hic files using juicer-tools 
(https://github.com/aidenlab/juicer/wiki/Data-Extraction) (Durand, Shamim, et al., 
2016). Interactions falling within the regions of interest were selected:  
1. chr5:140120000:140222664 || chr5:140110382:140960850  
2. chr5:139730111-139952633 || chr5:140023665-140119999  
Violin plots for all bin-bin interactions falling within the regions of interest were 
plotted and significant differences in O/E scores were tested for using a 
Wilcoxon-Rank Sum test. 
Single SNP-level eQTL analysis 
 For the 61 genes within the PCDH locus with above-threshold expression, 
gene-level gene expression quantitative trait loci (eQTL) were obtained for the 
rs111896713 genotype across the N = 579 genetically inferred samples within 
the published CommonMind Consortium dataset (Fromer et al., 2016) A linear 
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Bonferroni correction for multiple testing. 
Real-time qPCR 
 Quantitative expression analysis was performed with a QuantStudio 7 Flex 
Real-Time qPCR System using the Power SYBR Green RNA-to-Ct Real Time 
qPCR kit for primers (Thermo Fisher Scientific). 50 ng of RNA template was 
added to PCR master mix containing primers. qPCR conditions were 48°C for 15 
minutes, 95°C for 10 minutes, and 40 cycles of 95°C for 15 seconds followed by 
60°C for 60 seconds. 
Determining cell-type-specific interactions 
 The distribution of all -log10 q-values from Hi-C interaction mapping of 
PGC risk loci indicated the 95th percentile log q-value = 1.47. For an interaction to 
be cell type-specific, it has to exceed this threshold in one cell type while that 
same interaction must have log q-value below the 50th percentile (log10 q = 0.33) 
in the other two cell types. Similar thresholds were applied for contacts anchored 
in the newer CLOZUK risk loci (95th percentile -log10 q = 1.42, 50th percentile -
log10 q = 0.30). 
RNA-seq and transcriptome processing 
 A reference transcriptome, built from recently published RNA-seq datasets 
filtered through a stringent set of quality controls, included 47 NPC and 47 
neuronal cultures from 22 independent donors including 11 subjects diagnosed 
with childhood onset schizophrenia (5 females, 6 males) (using unmodified DSM 
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females 6 males) (Hoffman et al., 2017). The donors range in age at biopsy was 
8-30 years, as described (see Table 1 and Supplemental Data 1, 2 from 
reference (Hoffman et al., 2017)). Using a cut-off of > 1 counts per million (CPM) 
in at least 30% of the experiments, the reference set included altogether 56,632 
expressed sequences, including annotated genes, non-coding RNA, etc. 
Random distance-matched samplings (1,000x) were run to assess the 
significance of pair-wise gene correlation strength for each of the risk-associated 
chromosomal connectomes of the 3 cell types separately. 
 In addition, we generated RNA-seq libraries of glia from donor #2 and 
NPCs and excitatory neurons from both donors #1 and #2 that were used for the 
Hi-C studies (who are independent from the donors for the reference 
transcriptome described above). Libraries were prepared with the Kapa Total 
RNA library prep kit with ribo-depletion and strand-specific cDNA library 
construction (Kapa Biosystems). The libraries were then sequenced (125bp 
paired-end) on the Illumina HiSeq2000 platform (New York Genome Center). 
RNA-seq reads were aligned with STAR v2.4.0g1 (Dobin et al., 2013) to 
GRCh37, after which uniquely mapped reads overlapping genes were counted 
with featureCounts v1.4.4 (Liao, Smyth and Shi, 2014) (with ENSEMBL v70 
annotations). FPKM values were generated using Cufflinks (Trapnell et al., 2012) 
and then compared by hierarchical clustering, multi-dimensional scaling and 
principal component analyses to 2082 RNA-seq data sets from stem cells and 
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described in (Hoffman et al., 2017). Genes with > 1 count per million in 10% of 
the samples in each data set were retained. This left 12,670 genes in common 
across all data sets. All expression values were converted to log2 RPKM, 
resulting in 12,670 genes common to all 2082 datasets. Of note, RNA-seq of 
subject S1 and S2 hiPSC-derived NPC clustered together with these previous 
NPC RNAseq and prenatal BRAINSPAN datasets from different individuals. 
However, S1 and S2 neuronal cultures (differentiated by NGN2 into 
glutamatergic neurons and also by neural differentiation medium and BDNF and 
GDNF growth factors into a more mixed population primarily comprised of 
forebrain-like neurons) clustered together with the previously generated RNA-seq 
from neuronal cultures (from a different set of individual) and in close proximity to 
pre- and postnatal BRAINSPAN brain tissue samples. Finally, our RNA-seq from 
the astrocyte-like glial cells (differentiated from NPC of Subject S1) did not co-
cluster with either NPC or neurons, as expected. Thus, transcriptome mapping 
further confirms the specificity of our various cell culture systems.  
Protein-protein interaction network analysis 
 To assess whether the proteins of the genes associated with 
schizophrenia risk loops are linked by physical functions or interactions, we input 
lists of genes from cell type-specific schizophrenia risk chromatin contacts for 
each cell type into the STRING v10.5 database (http://string-db.org) (Szklarczyk 
et al., 2015, 2017). Default settings were used except for 1) “confidence” as the 
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required interaction score. We noticed that in the NPC and glia high-confidence 
networks the significance could have been driven by numerous connections 
(“edges”) among the UGT gene cluster, all located within one 10kb bin on the 
genome. While continuing our analyses with the remaining highest confidence 
protein-protein associations, we re-ran the same gene lists, with all but one UGT 
gene (UGTA10) removed, at medium confidence to confirm significant networks 
(PNPC = 0.0438; PNeuron = 0.0876 ; PGlia = 0.0134). 
Human postmortem prefrontal cortex tissue 
 Postmortem brain tissues were derived from the University of 
Pennsylvania Brain bank, for which subjects with schizophrenia were 
prospectively accrued. Subjects with psychiatric illnesses were evaluated for 
Diagnostic and Statistical Manual of Mental Disorders Fourth Edition (DSM-IV) 
diagnostic criteria for SCZ. Diagnosis was determined by consensus of at least 
two board-certified research psychiatrists after comprehensive review of medical 
records, direct clinical assessments and interviews with caregivers. Autopsy 
consent was obtained from the next of kin or a legal guardian in all cases, based 
on a protocol approved by the Institutional Review Board at the University of 
Pennsylvania. Control and psychiatric subjects were matched for sex, age, 
smoking history and postmortem interval Table 3.22. All subjects with 
schizophrenia were treated with antipsychotics except 6 (24%) at the time of 
death. 
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 Whole tissue homogenates were prepared from gray matter of the 
dorsolateral prefrontal cortex (DLPFC), BA 9 or 46, of SCZ and matched control 
subjects (Table 3.22) using a variation of the protocol we have developed and 
validated in human postmortem brain tissue. 50 mg grey matter was 
homogenized in .5 ml solution A (0.32 M sucrose, 1mM MgCl2 and 0.1mM CaCl2) 
with a Teflon pestle. ~45 μl of the homogenate (H) was saved, solubilized with 
1% SDS and clarified by centrifugation. 
Sample preparation and LC-SRM/MS 
 20 μg whole tissue homogenate preparations were mixed with the [13C6] 
brain ISTD at a ratio of 1:1 (μg/μg) and processed for LC-SRM/MS (liquid 
chromatography selected reaction monitoring mass spectrometry) analysis by 
on-gel trypsin digestion as described (MacDonald et al., 2012). LC-SRM/MS 
analyses were conducted on a TSQ Vantage triple stage quadrupole mass 
spectrometer (ThermoFisher Scientific) with an Eksigent 2Dnano LC (Eksigent) 
and a CaptiveSpray source (Michrom). 5 μl (~2.5μg protein) sample was loaded 
on to a Magic C18 column (Michrom) at 1 μl/min for 12 min, and eluted at 
750nl/min over a 25 min gradient from 3-35% mobile phase B (ACN containing 
.1% formic acid). SRM transitions were timed using 1 – 1.5 min retention 
windows, depending on the number of SRMs to be assayed. Transitions were 
monitored, allowing for a cycle time of 1 sec, resulting in a dynamic dwell time, 
never falling below 10 msec. The MS instrument parameters were as follows: 
 
 295 capillary temperature 275 οC, spray voltage 1100 V, and a collision gas of 1.4 
mTorr (argon). The resolving power of the instrument was set to 0.7 Da (FWHM) 
for Q1 and Q3. Data were acquired using a chrom filter peak width of 4.0 sec. 
Mass spectrometry data processing, informatics and statistics 
 Peak areas and area ratios were calculated within Pinpoint (Thermo 
Scientific). Raw files generated by LC-SRM/MS analysis were loaded into 
Pinpoint files containing target proteins/peptides/transitions. All individual SRM 
transitions and integration areas were manually inspected. Transitions for which 
the signal-to-noise ratio was below 3 were excluded from analysis. The ratios of 
the integrated areas for “light” endogenous peptides and “heavy” [13C6]brain ISTD 
peptides were calculated to obtain peptide measures using multiple transitions 
per peptide. Peptide measures from the same protein were averaged to obtain 
the measure for that protein. Prior to comparison of SCZ and control groups, 
protein measures were normalized in each fraction. Outlier subjects were 
identified by manual inspection for the number of individual protein or enrichment 
value outliers and principle component analysis of the entire dataset, run as a 
plug-in in Excel. Permutation analysis to determine significant coexpression of 
synaptic proteins of interest was performed by randomly sampling 4 proteins 
from the pool of 182 synaptic proteins and calculating the organization score for 




 296 CHAPTER IV: ATLAS: A DATABASE LINKING BINDING 
AFFINITIES WITH STRUCTURES FOR WILD‐TYPE AND MUTANT 
TCR‐PMHC COMPLEXES 
Preface 
 This chapter comprises work published in PROTEINS: Structure, 
Function, and Bioinformatics by myself, Jennifer Cimons, Michael Cosiano, 
Michael Purcaro, Brian G. Pierce, Brian M. Baker, and Zhiping Weng. The 
publication reference is “ATLAS: A database linking binding affinities with 
structures for wild‐type and mutant TCR‐pMHC complexes” PROTEINS: 
Structure, Function, and Bioinformatics. Vol. 85 Issue 5 May 2017 (Borrman et 
al., 2017)  
 Data curation was performed by myself, Jennifer Cimons and Michael 
Cosiano. Frontend and backend of the ATLAS website was developed by myself 
and Michael Purcaro. All data analysis and regression modeling was performed 
by myself. Research was supervised by Zhiping Weng, Brian G. Pierce and Brian 
M. Baker. The paper was written and figures were produced by myself, Brian G. 
Pierce, Brian M. Baker, and Zhiping Weng with contributions from all coauthors. 
Abstract 
 The ATLAS (Altered TCR Ligand Affinities and Structures) database 
(https://zlab.umassmed.edu/atlas/web/) is a manually curated repository 
containing the binding affinities for wild-type and mutant T cell receptors (TCRs) 
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(pMHC). The database links experimentally measured binding affinities with the 
corresponding three dimensional (3D) structures for TCR-pMHC complexes. The 
user can browse and search affinities, structures, and experimental details for 
TCRs, peptides, and MHCs of interest. We expect this database to facilitate the 
development of next-generation protein design algorithms targeting TCR-pMHC 
interactions. ATLAS can be easily parsed using modeling software that builds 
protein structures for training and testing. As an example, we provide structural 
models for all mutant TCRs in ATLAS, built using the Rosetta program. Utilizing 
these structures, we report a correlation of 0.63 between experimentally 
measured changes in binding energies and our predicted changes. 
Introduction  
 The binding of a T cell receptor (TCR) to an antigenic peptide presented 
by a major histocompatibility complex (pMHC) is a fundamental step in cell-
mediated immunity. To eliminate pathogens and diseased cells, TCRs recognize 
foreign antigens displayed by MHC molecules on the surface of antigen 
presenting cells (Zinkernagel and Doherty, 1974; Babbitt et al., 1985) (Figure 4.1, 
a). This recognition triggers T cell activation and an ensuing signaling cascade 









Figure 4.1 | ATLAS data statistics. 
(a) A6/Tax/HLA-A*02:01 TCR-pMHC complex (PDB: 1AO7). TCR  and  chains 
(green, orange), MHC molecule (cyan), peptide (magenta), and 2 microglobulin 
(yellow) are shown in cartoon style. (b) Histogram of the binding affinities of 
TCR-pMHC complexes in ATLAS. (c) Pie charts for percentage of entries with 
modeled mutations made to the TCR, the MHC or the peptide (left), percentage 
of MHC subclasses (right). 
 
 The ability to manipulate TCR-pMHC recognition has broad applications in 
a variety of biomedical arenas. One example is adoptive T cell transfer, which 
 
 299 uses tumor recognizing T cells to eradicate cancer cells (Restifo, Dudley and 
Rosenberg, 2012). The TCRs of these T cells can be genetically engineered to 
enhance their affinities toward specific tumor antigens (Varela-Rohena et al., 
2008; Linette et al., 2013; Morgan et al., 2013). In a related approach, high 
affinity TCRs can be used as soluble biologic therapeutics to target tumor-
associated antigens (Oates and Jakobsen, 2013). Another example is peptide-
based vaccination, which uses peptides to selectively stimulate T cells capable of 
battling infections or cancers (Purcell, McCluskey and Rossjohn, 2007). Many 
tumor associated peptides are derived from self proteins and are only weakly 
immunogenic because TCRs that strongly recognize self-antigens have been 
eliminated during negative selection in the thymus. Thus attempts have been 
made to develop modified peptides that can selectively enhance T cell activation 
(Chen et al., 2005; Cole et al., 2010). 
 TCR-pMHC binding strength is an important parameter in determining the 
quality of the ensuing immune response. TCR affinity has been shown to 
correlate positively with T cell activation (Holler and Kranz, 2003; Aleksic et al., 
2010); however, robust immune responses appear to result from TCR affinities in 
an optimal range, which is not necessarily high (Stone and Kranz, 2013). Past an 
apparent affinity threshold, the strength of the T cell response may plateau or 
attenuate. 
 Another consideration while striving for a desirable immune response is to 
avoid the cross-recognition of TCRs between foreign and self peptides, which 
 
 300 can lead to autoimmune diseases, such as multiple sclerosis, type 1 diabetes, 
and paraneoplastic syndromes (Wooldridge et al., 2012; Sethi et al., 2013). 
Before any potential therapeutic use of T cells, it is vital to identify off-target 
binding (Obenaus et al., 2015); this consideration is particularly important for 
engineered TCRs, as demonstrated by adverse events in clinical trials (Linette et 
al., 2013; Morgan et al., 2013).  
 Precise prediction and manipulation of both TCR affinity and specificity is 
therefore essential for designing effective T-cell-based therapeutics. A number of 
methods have been developed for altering TCR-pMHC interactions, including in 
vitro molecular evolution and structure-guided protein design (Holler et al., 2000; 
Li et al., 2005; Varela-Rohena et al., 2008; Borbulevych et al., 2009; Zoete et al., 
2013; Malecek et al., 2014; Pierce et al., 2014). Structure guided design 
algorithms can alter affinity and specificity directly and efficiently, but are limited 
by the accuracy of their scoring functions.  
 Prediction of protein-protein binding affinity from protein-complex structure 
is a challenging problem. When nine unique scoring functions developed for 
docking programs or web servers were tested on a benchmark of 81 protein 
complexes, correlations between scores and binding affinities were low or 
nonexistent (r ranging from -0.18 to 0.32) (Kastritis and Bonvin, 2010). More 
recent studies utilizing supervised learning methods have increased correlations 
between predicted and experimental affinities, and there is still room for 
improvement (Vreven et al., 2012; Xue et al., 2016). Prediction of changes in 
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between predicted and experimental G in a study analyzing >1,500 point 
mutations ranged from 0.28 to 0.61 depending on the prediction method used 
(Geng, Vangone and Bonvin, 2016). Progress in G prediction is critical to the 
field of TCR design where point mutants may be made to increase a TCR’s 
affinity toward an antigen to trigger a robust immune response. 
 The improvement of TCR design algorithms requires access to both 
structural and binding data. We have built the ATLAS (Altered TCR Ligand 
Affinities and Structures) database (https://zlab.umassmed.edu/atlas/web/) to 
meet this demand. ATLAS links measurements of TCR affinity with structural 
information, and allows a user to query for a TCR, MHC, or peptide of interest. 
Results from such queries include details on affinity, mutation information, and 
structures of associated TCR-pMHC complexes that exist in the Protein Data 
Bank (Berman et al., 2000). ATLAS includes structural and binding data for point-
mutant TCRs that have been studied. If PDB structures for the relevant mutant 
complexes are not available, the database provides computationally modeled 
TCR-pMHC structures.  
 The immune epitope database (IEDB) (Vita et al., 2015) and the Anti-Jen 
database (Toseland et al., 2005) both provide binding affinities for TCR-pMHC 
complexes; however, these databases are peptide-epitope-centric and do not 
allow the user to query specific TCRs. Furthermore, there is no direct link 
between affinity and structural data in these databases. The IEDB does allow the 
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surface plasmon resonance (SPR) experiments; however, in many cases a query 
using one peptide epitope will return multiple TCR-pMHC complexes that contain 
the peptide. Hence, to correctly match a TCR-pMHC complex with its reported 
binding affinity, the user needs to manually inspect the literature.  
 In comparison with IEDB and AntiJen, ATLAS allows the user to search 
specific TCRs, MHCs, and peptides. Full datasets in ATLAS can also be 
downloaded as flat files. With the goal of providing a repository to train and test 
next generation TCR design strategies and scoring functions, ATLAS also 
provides experimental details such as the resolutions of the structures and 
references for each of its entries. As low resolution structural data may skew 
scoring results, this information will be critical for the selection of a subset of the 
data to optimize prediction algorithms. As of this writing, the database includes 
data only for  TCRs, but can be readily extended as more experimental data 
for the  TCR family becomes available. 
Results  
 The ATLAS database currently contains affinity and structural data on 
human and mouse TCR-pMHC complexes, with a total of 694 measured affinities 
ranging from high nanomolar affinities to low affinities with KD > 200 M (Figure 
4.1, b, c). As more affinity data exist than structural data, ATLAS also contains a 
set of models for all TCR-pMHC affinity entries lacking crystal structures (see 
Materials and methods). Below, we first illustrate a usage case for the data in 
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interface.  
 
Using the data in ATLAS to develop energy functions  
 As a proof of concept, we performed multiple linear regressions using 
ATLAS data to develop scoring functions capable of affinity prediction. We 
examined two cases of energy prediction: prediction of TCR-pMHC binding 
energy, G, and prediction of change in binding energy upon mutation, G 
(see Materials and methods). Prior to regression analysis, no correlation was 
found between experimental and predicted Gs (or Gs) using the Rosetta 
modeling software’s standard scoring function (Leaver-Fay et al., 2011). Eight 
energy terms from Rosetta—solvation, hydrogen bonding expressed in four 
terms, attractive and repulsive van der Waals, and a statistical pair potential—
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Figure 4.2 | Results of predicting binding free energies in ATLAS.  
(a) Table of coefficients and p-values for all energy features of the regression 
analysis. One insignificant feature (repulsive van der Waals) is highlighted in red. 
(b) Scatterplot of predicted G versus G determined by SPR for all ATLAS 
entries. Linear regression analysis was performed to predict G using the 
following best set of features: attractive van der Waals energy, Lazaridis–Karplus 
solvation energy and all four hydrogen bond energy terms. r = 0.48 and RMSE = 
1.48 kcal mol-1. (c) Scatterplot of predicted G versus G determined by SPR 
for 575 mutant ATLAS entries determined by regression analysis using the 
following best set of features: attractive van der Waals energy, Lazaridis–Karplus 
solvation energy and side-chain-side-chain hydrogen bond energy. r = 0.63 and 
RMSE = 1.58 kcal mol-1. Red line represents perfect prediction. 
 
 Performing leave-one-out cross-validation (LOO-CV) on all 694 ATLAS 
entries, we report a correlation of 0.65 between predicted G and experimentally 
measured G with a root mean square error (RMSE) of ~1.09 kcal mol-1. 
However, many of the ATLAS entries differed by only a few residues and used 
the same PDB structure as the template for structure modeling. To accurately 
assess scoring function performance, we ran a cross-validation scheme where 
the training set for each prediction excluded any entries that used the same PDB 
structure as the template to model the structures. For example, many ATLAS 
entries were mutants of the A6-Tax/HLA-A2 TCR-pMHC complex and used the 
1AO7 PDB structure as the template for modeling the mutant structures. For 
prediction of any of these mutants, we exclude from the training set all other 
mutants that were also modeled using 1AO7 as the template. Following this 
leave-one-complex-out cross-validation (LOCO-CV) scheme, we report a 
correlation r of 0.45 between experimental and predicted Gs and an RMSE of 
1.52 kcal mol-1.  
 
 306  The attractive van der Waals energy along with the solvation energy were 
the most important features for prediction, judged by the P values for these 
features (10-41 and 10-23). We asked whether steric clashes in the modeled 
structures might have caused the poor performance of the repulsive van der 
Waals term. However, even after removing outlier entries with unfavorable 
repulsive van der Waals terms from the regression model, the coefficient for the 
repulsive van der Waals term remained insignificant. To extract the best 
predicting combination of features, we implemented LOCO-CV on all 255 
combinations of the eight energy features. A slight increase in performance was 
seen when the van der Waals repulsive and pair potential terms were removed 
from the regression model, r = 0.48 and RMSE = 1.48 kcal mol-1 (Figure 4.2, b). 
 We then proceeded to build multiple linear regression models for 
prediction of Gs. We included all multiple residue mutation cases in this study; 
however, 73% of the G mutations were single residue mutations. Following the 
LOCO-CV scheme and analyzing all feature combinations, we report the 
maximal correlation of 0.63 between experimental and predicted G with an 
RMSE of 1.58 kcal mol-1 (Figure 4.2, c). This best performing model used only 
the attractive van der Waals energy, solvation energy, and side-chain–side-chain 
hydrogen bond energy to predict G.  
 Given that the majority of structural data used for training in the regression 
model was designed via Rosetta, we assessed the accuracy of these modeled 
structures. Twenty-one out of the 694 ATLAS entries had both wildtype and 
 
 307 mutant crystal structures available (Table 4.1). Seven of these 21 entries were 
point mutations to residues with at least one side-chain dihedral angle (). The 
other 14 entries were either point mutations to Ala or were complexes designed 
with multiple mutations. We used these seven entries to evaluate the accuracy of 
the modeled mutant structures in ATLAS. The Dunbrack rotamer library was 
used to assess whether Rosetta designed mutant side chains had the same 
rotamers as those of the mutant crystal structures (Shapovalov and Dunbrack, 
2011). Here, a side-chain conformation is defined as one of the combinations of 
multiple  angle conformations for a side-chain. We found that four of the seven 
mutant side chains were of identical conformation to the side chain in the crystal 
structure. For two of the three side chains with incorrect conformations, only the 
terminal  angle was inaccurate (2 in Asp and 3 in Glu). Hence, only one side-
chain, a mutation from Val to Arg, was completely mismodeled (Table 4.2). 
Although this is only a small sample of the entire dataset, it provides some 
evidence that the majority of the designed ATLAS mutations have correctly 
modeled side-chain conformations.  
 The modeled TCR-pMHC complexes from the regression analysis were 
generated using a fixed backbone approach. However, the complementarity 
determining region (CDR) loops of TCRs can change conformations upon 
binding with pMHC (Gagnon et al., 2006; J. B. Reiser et al., 2003; J. B. Reiser et 
al., 2002). To assess whether modeling flexibility of CDR loops could improve 
affinity prediction performance, we also generated another set of modeled 
 
 308 complexes via the Rosetta backrub application which accounted for flexibility of 
the CDR loops. These structures were then employed in our LOCO-CV scheme. 
Analyzing all features combinations, we saw a modest reduction in G prediction 
performance, r = 0.45 and RMSE = 1.50 kcal mol-1 for the set of best performing 
features. A larger reduction in performance was found in prediction of G, r = 
0.47 and RMSE = 1.80 kcal mol-1 (compared with r = 0.63 and RMSE = 1.58 kcal 
mol-1 for the fixed backbone approach) (Figure 4.3). This result was not entirely 
surprising as previous studies have reported poorer correlations when modeling 
backbone flexibility compared with using fixed backbone calculations (Mandell 
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Figure 4.3 | Results of predicting binding free energies in ATLAS after 
modeling flexibility of CDR loops. 
(a) Scatterplot of predicted G versus G determined by SPR for all ATLAS 
entries. Linear regression analysis was performed to predict G using the 
following best set of features: attractive van der Waals energy, Lazaridis–Karplus 
solvation energy and backbone-backbone hydrogen bond energy close in 
primary sequence. r = 0.45 and RMSE = 1.50 kcal mol-1. (b) Scatterplot of 
predicted G versus G determined by SPR for 575 mutant ATLAS entries 
determined by regression analysis using the following best set of features: 
attractive van der Waals energy, Lazaridis–Karplus solvation energy, statistics-
 
 310 based pairwise energy, and repulsive van der Waals energy. r = 0.47 and RMSE 
= 1.80 kcal mol-1. Red line represents perfect prediction. 
 
 Although there is room for improvement, TCR-pMHC binding affinity 
prediction is feasible through the use of the structural information in ATLAS. As a 
starting point for engineering TCRs, peptides, or MHCs to enhance binding 
affinity, the ATLAS database is a useful resource to guide the design process.  
The web-based user interface of ATLAS  
 As many users may be only interested in a specific TCR or peptide, 
ATLAS provides a searchable interface so that the user can extract the relevant 
data of interest. To browse the entire ATLAS dataset, the user may simply submit 
a search leaving all fields with their default parameters.  
 As a demo, we queried for all entries that contain the human A6 TCR, the 
MHC allele HLA-A*02:01, and a peptide whose amino sequence contained 
LFGYPVY, with binding free energies lower than -6 kcal mol-1 (Figure 4.4, a). 
Note that the user may also search ATLAS by specifying TRAV or TRBV genes, 
as well as MHC allele or class. Submission of the search form brings the user to 
the results page (Figure 4.4, b). Each ATLAS entry (row) of the search results 
corresponds to a unique TCR-pMHC complex with an experimentally determined 
binding affinity and a 3D structure which can be used as a template for design. 
The binding affinity is reported in both KD (M) and G (kcal mol-1). The PDB 
column provides the PDB ID for a structure matching the TCR-pMHC complex 
with the reported experimental binding affinity. For many entries an exact 
 
 311 structure corresponding to the recorded binding affinity does not exist. To make 
use of such binding data, the Template PDB column refers to the PDB ID for a 
template structure for which a TCR-pMHC complex matching the reported 
binding affinity may be generated by modeling the mutations described in the 
TCR mutation, MHC mutation, and Peptide mutation columns of the entry. For 
further information on each entry, the results page provides a link to the abstract 
of the publication in which the binding affinity was determined in the PMID 
column. Lastly, the query results can be downloaded as individual files directly 












 313 Figure 4.4 | ATLAS web interface and data accession.  
(a) The search page for querying the ATLAS database. ATLAS is searchable by 
TCR (1) and MHC (2) features, binding energies G below a user specified 
kcal/mol (3) and by case-insensitive peptide sequence motifs (4). (b) The search 
results page linking binding energies to complex structures. The PDB structure 
specified in (1) refers to a structure identical to the TCR-pMHC used in the 
binding assay. The template PDB structure in (2) can be designed to replicate 
the TCR-pMHC used in the binding assay by modeling the mutations listed in the 
TCR mutation, MHC mutation, and Peptide mutation columns. (c) Protein Viewer 
and individual PDB downloads. An example shows the selection of PDB ID 1AO7 
from the Template PDB column for the D26W TCR mutant. Template structures 
and Rosetta designed structures are both available for download. 
 
 Selecting a PDB ID from the results page brings the user to the PV 
Javascript Protein Viewer (Marco Biasini, 2015) and downloadable PDB content. 
Continuing the demo, we selected the template PDB 1AO7 for the D26W TCR 
mutant from our previous results page (Figure 4.4, c). The Rosetta modeled 
mutant structure is displayed in the PV viewer. The modeled mutant tryptophan 
side-chain of the TCR is highlighted in ball-and-stick style in the protein complex. 
From this page the user can download the individual template PDB complex 
along with the Rosetta-designed mutant PDB complex, both structures adjusted 
for consistency as described in the Materials and methods section. 
Downloading data tables of ATLAS  
 The Downloads page provides the four tables used to build ATLAS in 
Microsoft Excel format. The TCR gene table contains the TRAV and TRBV genes 
for all TCRs in ATLAS. The MHC class table contains the classes for all MHC 
alleles. The ATLAS table provides all of the structural and affinity data for each 
ATLAS entry and is the extended version of tables found by browsing or 
 
 314 searching the web interface. Lastly, we also provide the set of consistency 
adjusted TCR-pMHC structures described earlier, TCR-pMHC structures, which 
contain the template PDB structures and the mutant structures. We provide two 
sets of mutant structures: (1) structures predicted using the fixed backbone 
approach and (2) structures predicted allowing flexibility in CDR loops via the 
Rosetta backrub application. All mutant structures are generated using the 
mutation information recorded in ATLAS.  
Discussion 
 The multiple search parameters of ATLAS make it particularly useful for 
studying specific subsets of TCR or MHC. One recent application involved 
identifying TCRs that recognized the human Class I MHC allele HLA-A* 02:01 
and TCRs that recognized human Class I MHC alleles that were not HLA-
A*02:01. The links to PDB structures were used to make structural comparisons 
between the two groups of TCRs (Blevins et al., 2016). Additionally, the option to 
search entries by TRAV/TRBV genes, MHC allele, and peptide sequence allow 
for comparisons to be made involving these parameters. For example, searching 
by a variable chain segment can allow the user to compare the effects that 
mutations within the shared chain have on binding affinity. The accumulation of 
affinity values for all published binding studies also allows for the identification of 
potentially important residues for pMHC recognition. Similarly, searching by 
peptide sequence can identify all TCRs known to recognize a particular peptide 
 
 315 (or a substring of residues in a peptide), as well as how mutations on the peptide 
impact TCR binding.  
 As a further example to demonstrate the utility of a large TCR database, 
ATLAS was recently used in a separate study to identify single point mutations 
when training a generalized approach for engineering TCRs (Riley et al., 2016). 
In this study, nearly 200 point mutations in multiple HLA-A2 restricted TCRs (A6, 
B7, DMF5, and DMF4) and one HLA-B8 restricted TCR (LC13) were modeled 
using Rosetta and utilized in a multiple linear regression model. Using Rosetta 
energy terms and molecular dynamics derived flexibility terms as predictor 
variables and the experimental binding energies as the response variable, a 
score function was parameterized which emphasized van der Waals forces, 
solvation effects, and flexibility. This score function was rigorously cross-
validated and found to estimate the effects of any given mutation relative to wild 
type with an average error of <1.5 kcal mol-1 and was used to identify additional 
affinity enhancing mutations in the B7, DMF5, and DMF4 TCRs. 
 We have developed the ATLAS database as a centralized resource to link 
structural and binding data for TCR-pMHC complexes, with an emphasis on the 
impacts of mutations within TCR-pMHC interfaces. The database can be queried 
multiple ways, and when structures do not exist, ATLAS provides modeled 
structures, as well as the means to visualize experimental or modeled structures. 
We anticipate that ATLAS will be useful in the design and optimization of TCRs, 
including the development of next-generation design algorithms for TCR-pMHC 
 
 316 interactions. It can also be used in combination with other large datasets of 
structural and affinity data, such as the AB-Bind database of antibody affinities 
(Sirin et al., 2015), which would be useful in structure-based immune receptor 
design. Beyond this, the database may serve as a resource for studies aiming to 




















 317 Tables 


















































MHC mutation  MHC mutation 
chain  
Peptide mutation  
2VLJ  2VLR  S99A  B  WT  nan  WT  
3MV7  3MV9  Q55A  B  WT  nan  WT  
3MV7  3MV8  Q55H  B  WT  nan  WT  
1AO7  1QSE  WT  nan  WT  nan  V7R  
1AO7  1QRN  WT  nan  WT  nan  P6A  
1AO7  1QSF  WT  nan  WT  nan  Y8A  
2AK4  3KXF  WT  nan  Q65A | T69A | 
Q155A  
A | A | A  WT  
1AO7  3QFJ  WT  nan  WT  nan  Y5F  
3HG1  4JFF  D27F | R28L | 
I50T | S52R | 
N53E | Y71H | 
V93D | A94G 
| K96R | S97L 
| L44P | 
S50W | V51G 
| G52P | I53F 




A | A | A | A | 
A | A | A | A | 
A | A | B | B | 
B | B | B | B | 
B | B | B  
WT  nan  WT  
4JFF  4JFD  WT  nan  WT  nan  G4A  
4JFF  4JFE  WT  nan  WT  nan  I7A  




B |B | B | B  WT  nan  WT  
3VXR  3VXS  WT  nan  WT  nan  F6L  
4PRI  4PRH  WT  nan  WT  nan  E5D  
4G8G  4G9F  WT  nan  WT  nan  L6M  
2F54  2F53  Q50P | S51F | 
S52W | G49S 
| A50V | I52M  
A | A | A | B | 
B | B  
WT  nan  WT  
2BNR  2P5E  Q51T | S52P | 
S53W | T95L | 
S96L | G97D | 
S99T | G50A | 
A51I | G52Q | 
I53T | V95L  
A | A | A | A | 
A | A | A | B | 
B | B | B | B  
WT  nan  WT  
2BNR  2P5W  Q51T | S52P | 
S53W | G50S 
| A51V | I53M 
| T95L | S96L 
| G97D | S99T 
| V95L  
A | A | A | B | 
B | B | A | A | 
A | A | B  
WT  nan  WT  
3QDG  4L3E  D26Y | L98W  A | B  WT  nan  WT  
3QIU  3QIW  WT  nan  WT  nan  K9E  
4P23  4P46  Y31A  A  WT  nan  WT  
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3MV7_WT_nan_Q55H_B_WT.pdb  3MV8.pdb  2,6  2,6  175.53, -150.03  167.17, -143.99  
1AO7_WT_nan_WT_nan_V7R.pdb  1QSE.pdb  2,2,2,3  3,1,2,2  -163.59, -173.07, 
-170.48, -86.61  
-110.06, 46.25, 
-175.26, 162.23  
1AO7_WT_nan_WT_nan_Y5F.pdb  3QFJ.pdb  3,1  3,1  -61.62, 97.64  -47.74, -77.15  
3VXR_WT_nan_WT_nan_F6L.pdb  3VXS.pdb  3,2  3,2  -65.24, 166.16  -69.84, 160.56  
4PRI_WT_nan_WT_nan_E5D.pdb  4PRH.pdb  3,1  3,5  -72.25, -15.16  -95.35, 115.36  
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Materials and methods 
Data collection 
To collect data suitable for training and testing TCR-pMHC scoring 
functions, we required all ATLAS entries to meet the following two criteria: (1) 
The affinity of the TCR-pMHC must be measured experimentally with purified 
proteins (most frequently) using SPR or isothermal titration calorimetry (ITC); and 
(2) The 3D structure of the complex has been determined experimentally, or for 
mutants, a template wild-type structure exists in the PDB. To provide the most 
comprehensive list of TCR-pMHC complexes, we did not make any quality 
restrictions pertaining to the affinity or structure data; instead, we recorded the 
resolution of crystallographic structures in the full dataset flat files available in the 
Downloads page.  
To identify TCR-pMHC complexes for inclusion in ATLAS, we first found 
all crystallographic structures of TCR-pMHC complexes in the IMGT database 
(Ehrenmann, Kaas and Lefranc, 2010) verified by a careful inspection of the 
corresponding PDB entries. We next manually searched the literature for 
experiments measuring the affinity of each TCR-pMHC complex, including 
measurements with TCR or MHC mutants and/or peptide variants. If we could 
identify quantitative data on binding affinity, we then proceeded to include the 
TCR-pMHC complex in ATLAS, along with experimental details as metadata for 
the entry. We describe these metadata fields in the following sections.  
 
 320 Metadata fields  
As many of the binding experiments recorded in ATLAS tested the effects of 
mutations on TCR-pMHC affinity, it follows that the majority of ATLAS entries pair 
mutant affinity data with wild-type template structures as opposed to the actual 
mutant TCR-pMHC complexes to which the binding affinities refer. Thus we 
recorded detailed information on the mutations such that one could build a 3D 
structure model of the mutant complex that corresponded to the affinity data, 
given the template structure. With this application in mind, the data tables of 
ATLAS are designed not only for information, but also for easy parsing by protein 
design software. The following five fields represent the information required for 
modeling a mutant TCR-pMHC complex structure from a template structure.  
 TCR mutation: <wild-type residue><residue number><mutant residue> 
 TCR mutation chain: <chain>; A for  or B for  chain 
 MHC mutation: <wild-type residue><residue number><mutant residue> 
 MHC mutation chain: <chain>; A for  chain B for  chain 
 Peptide mutation: <wild-type residue><residue number><mutant residue> 
Some fields may be left empty if one or more molecules in the template 
structure are the same as the molecules used to measure affinity. In the case of 
a complete match between the complex structure and the complex tested for 
binding, all mutation fields may be left empty. As mentioned previously, all entries 
are required to have at least a template structure and in some case both 
experimental and template structures for mutants exist. These cases could be 
 
 321 particularly helpful in assessing the accuracy of the structural modeling.  
Inconsistent chain naming, structure boundaries, and prevalence of water 
molecules complicate the design and scoring process. To overcome these 
challenges, we also supply a set of files for all experimentally determined TCR 
pMHC structures in ATLAS with the following consistency adjustments: renaming 
of chains, truncation of chains to the binding domains, and removal of water 
molecules. When there were multiple complexes in the asymmetric unit of a 
crystal structure, the first complex was selected. 
Protein modeling 
As a proof of principle, we wrote a script to parse ATLAS and build models 
using Rosetta for all listed mutations upon the adjusted template structures. 
These models were built using the fixed backbone design option of Rosetta, 
fixbb, and are available for download. The example parser script, 
“build_models.py,” is also available at the Github site of ATLAS 
(https://github.com/weng-lab/ATLAS). Although this example is specific for 
design via the Rosetta protein modeling software, the ATLAS database can be 
easily integrated with any other design software. 
Regression analysis 
Many ATLAS entries have low affinities with unreliableGs or undetectable 
binding. Hence, we assigned all entries with a G > -5.05 kcal mol-1 (KD > 200 
M) and all non-binding entries to have G = -5.05 for the regression analysis. 
The following equation was used to calculate G for each independent 
 
 322 variable in the regression model: 
G = GCOMPLEX – (GTCR + GpMHC), (1) 
where GCOMPLEX is the energy of a feature in the regression model for the TCR-
pMHC complex and GTCR and GpMHC are the energies of a feature for the 
isolated TCR structure and isolated pMHC structure, respectively. 
Similarly, we use the following equation to define G for changes in energy 
upon mutation: 
G = GMUT – GWT, (2) 
where GWT is the G for a wild type TCR-pMHC entry and GMUT is the G for a 
mutated version of the wild type (mutations may involve multiple residues).  
Coefficients for the regression models were estimated by the ordinary 
least squares method. P-values were calculated from the t statistics of the 
coefficients using a two tailed t test. All regression calculations were made using 
the python statistics module statsmodels. 
Architecture 
The backend of ATLAS was built using the archetypal web service 
solution stack, LAMP, consisting of Linux (Ubuntu version 14.04), Apache 
(version 2.4.7), MySQL (version 5.5.41) and PHP (version 5.5.9). The front end 
was designed using the Bootstrap framework (version 3.3.5). All programs 




 323 CHAPTER V: HIGH-THROUGHPUT MODELING AND SCORING 
OF TCR-PMHC COMPLEXES TO PREDICT CROSS-REACTIVE 
PEPTIDES 
Preface 
 This chapter is adapted from a manuscript currently under review at 
Bioinformatics authored by myself, Brian G. Pierce, Thom Vreven, Brian Baker, 
and Zhiping Weng titled: High-throughput modeling and scoring of TCR-pMHC 
complexes to predict cross-reactive peptides. 
 Peptide sequence extraction and filtering, modeling of TCR-pMHC 
complexes, computational scoring, and prediction performance analysis was 
performed by myself. Original project hypothesis was conceived by Brian G. 
Pierce. Research was supervised by Thom Vreven, Zhiping Weng and Brian M. 
Baker. The paper was written and figures were produced by myself, Brian G. 
Pierce, Thom Vreven, Brian M. Baker, and Zhiping Weng. 
Abstract 
 The binding of T cell receptors (TCRs) to their target peptide MHC 
(pMHC) ligands initializes the cell-mediated immune response. In autoimmune 
diseases such as multiple sclerosis, the TCR erroneously recognizes self-
peptides as foreign and activates an immune response against healthy cells. 
Such responses can be triggered by cross-recognition of the autoreactive TCR 
with foreign peptides. Hence, it would be desirable to identify such foreign-
 
 324 antigen triggers to provide a mechanistic understanding of autoimmune diseases. 
However, the large sequence space of foreign antigens presents an obstacle in 
the identification of cross-reactive peptides. 
 Here, we present an in silico modeling and scoring method which exploits 
the structural properties of TCR-pMHC complexes to predict the binding of cross-
reactive peptides. We analyzed three mouse TCRs and one human TCR isolated 
from a patient with multiple sclerosis. Cross-reactive peptides for these TCRs 
were previously identified via yeast display coupled with deep sequencing, 
providing a robust dataset for evaluating our method. Our method accurately 
selected the top binding peptides from sets containing more than a hundred 
thousand unique peptides. 
Introduction 
As a surveillance mechanism against pathogens and cancer, T cells of the 
host immune system use their αβ T cell receptors (TCRs) to inspect other cells. 
Targets recognized by TCRs are peptides bound and presented by the host 
major histocompatibility complex (MHC) proteins on the outer surface of the 
cellular membrane, and the peptide epitope may derive, for instance, from a viral 
protein. TCR recognition triggers complex signaling pathways that lead to a 
variety of outcomes, such as the destruction of infected or diseased cells, T cell 
proliferation, and release of pro-immune cytokines. 
 
 325 Determining peptide epitopes that can be recognized by TCRs is of 
considerable interest, impacting fields ranging from virology to cancer 
immunotherapy. Peptide immunogenicity involves three steps, each of which 
have been addressed via various predictive algorithms: peptide processing 
(Bhasin and Raghava, 2004; Nielsen et al., 2005), peptide binding to an MHC 
(Andreatta and Nielsen, 2015; Jurtz et al., 2017; O’Donnell et al., 2018), and 
TCR recognition of the peptide-MHC (pMHC) complex (Tung et al., 2011; Pierce 
and Weng, 2013; Schneidman-Duhovny et al., 2018; Lanzarotti, Marcatili and 
Nielsen, 2019; Ogishi and Yotsuyanagi, 2019; Riley et al., 2019). While progress 
has been made in predicting the outcome of each step, the fixed size of the TCR 
repertoire relative to the much larger number of possible peptide epitopes that T 
cells may encounter presents a particularly significant challenge.  
Even with a TCR repertoire estimated to lie in the tens of millions, 
estimates are that any particular TCR would need to recognize at least one 
million different pMHC complexes in order to provide sufficient immune coverage 
(Mason, 1998; Sewell, 2012). This high level of cross-reactivity has been verified 
using combinatorial peptide libraries (Maynard et al., 2005; Wooldridge et al., 
2012). Thus, although specificity is considered a hallmark of immunity, TCRs 
display significant cross-reactivity. Even if such cross-reactivity can be 
rationalized at a high level from structural and biophysical principles (Singh et al., 
2017), determining the range of peptides recognized by a specific TCR remains a 
major goal in immunology. Demonstrating the biological significance of the 
 
 326 problem, TCR cross-recognition of self-peptides is believed to underlie various 
autoimmune disorders (Gravano and Hoyer, 2013), and patient deaths have 
occurred due to unanticipated “off-target” recognition of TCRs used in clinical 
trials for cancer immunotherapy (Linette et al., 2013; Morgan et al., 2013). 
Given the availability of TCR-pMHC structural information, together with 
advances in protein design and prediction methodologies, in principle, the 
peptide specificity profile of a TCR should be predictable using in silico methods. 
One challenge, however, is the availability of detailed experimental datasets 
against which such prediction methods could be benchmarked. In addition to 
combinatorial peptide libraries, Garcia and colleagues have used yeast display of 
pMHC libraries coupled with TCR staining and deep sequencing to assess the 
specificity profiles of TCRs (Birnbaum et al., 2014; Adams et al., 2016; Gee et al., 
2018). With each yeast cell expressing a unique random peptide, these libraries 
allow for affinity-based interrogation of over one hundred million peptides against 
a query TCR. Affinity based selection proceeds through multiple rounds where 
yeast libraries are enriched for yeast that bound bead-multimerized TCR. 
Subsequent deep sequencing of yeast DNA from final selection rounds produces 
enrichment counts for peptides selected by the query TCR. Such experiments 
provide rich datasets for developing and benchmarking in silico approaches to 
evaluating TCR specificity. 
Here, we used structure-based in silico methods to predict the specificity 
profiles for four TCRs assessed using yeast display and deep sequencing: 2B4, 
 
 327 226, 5cc7, and Ob.1A12 (Birnbaum et al., 2014). Three of these TCRs recognize 
a peptide derived from moth cytochrome C presented by the murine class II MHC 
protein I-Ek (Newell et al., 2011). The fourth (Ob.1A12) was isolated from a 
patient with relapsing-remitting multiple sclerosis and recognizes a peptide 
derived from the myelin basic protein presented by the human class II MHC 
protein HLA-DR2) (Wucherpfennig et al., 1994). The deep sequencing data 
provided more than 100,000 peptides for each TCR, including both binders and 
non-binders, ideal for benchmarking structure-based in silico methods.  
Using the crystal structures for the four TCR-pMHC complexes (Hahn et 
al., 2005; Newell et al., 2011; Birnbaum et al., 2014), we modeled all of the query 
peptides within the TCR-pMHC complexes and scored the structural models to 
predict cross-reactive peptides for each of the four TCRs. Our modeling and 
scoring approach was capable of recovering cross-reactive peptides from large 
pools of primarily non-binding peptides for each TCR tested. We further show 
that our method outperforms the strategy of selecting peptides closest in 
sequence to each TCR’s cognate peptide epitope (i.e., the target peptide found 
in crystallographic structure), underscoring the value of including structural 
information in epitope prediction.  
 
 328 Results 
High-throughput modeling reproduces experimentally observed 
enrichment of binder peptides 
Previously described experimental yeast display and deep sequencing 
generated libraries that were enriched for peptides specifically recognized by four 
TCRs (Birnbaum et al., 2014). Beginning with the crystallographic structures of 
the 2B4, 226, 5cc7, and Ob.1A12 TCRs in complex with their cognate pMHC 
complexes, we computationally modeled and scored the peptides with 
sequences in the preselection libraries and four sequential selection rounds—
347,210 peptides for 2B4, 811,481 peptides for 226, 809,156 peptides for 5cc7, 
and 514,906 peptides for Ob.1A12, and 2,482,753 peptides in total (Birnbaum et 
al., 2014).  
To increase the computational throughput in modeling the structures of 
these approximately 2.5 million peptides, we performed a restricted structural 
modeling procedure using Rosetta’s fixed backbone design application, fixbb, 
which optimizes side-chain conformations on a fixed backbone using the Rosetta 
energy function (Leaver-Fay, Snoeyink and Kuhlman, 2008). We retained TCR 
and MHC side chains in the conformations adopted in the crystallographic 
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Figure 5.1 | Prediction of TCR-pMHC binding free energies.                            
(A) Crystal structure of TCR-pMHC interface for the 2B4 TCR (red) interacting 
with the MCC peptide (magenta) displayed by the I-Ek MHC (cyan). Bottom box: 
profile of the MCC peptide. (B) Fixed backbone model structure of TCR-pMHC 
interface for the 2B4 TCR (red) interacting with the 2A peptide (yellow) displayed 
by the I-Ek MHC (cyan). 2A peptide was modeled onto the backbone of the MCC 
peptide in (A), TCR and MHC protein structures remain identical to (A). Bottom 
box: profile of the 2A peptide. (C) Table of peptide names and amino acid 
sequences. Amino acids in red differ from the MCC peptide at the corresponding 
 
 330 position. (D) Scatter plot of ΔGBIND from computational modeling and scoring 
versus ΔG from experimental binding energies determined by SPR from 
Birnbaum et al. for peptides in Table (C). Pearson correlations are 0.73, 0.98 and 
0.70 for TCRs 2B4, 226, and 5cc7, respectively. Correlation for the entire set of 
peptides = 0.70. Peptides with unreliable KDs due to weak or non-binding 
interactions were assigned a KD of 200 μM (ΔG = -5.05 kcal/mol, gray dotted 
line). Individual TCR correlations were similar if we assigned a ΔG of 0 kcal/mol 
for these weak/non-binding peptides and the correlation for the entire set 
remained the same (r = 0.70).  
Once each TCR-pMHC model was generated, we scored the full complex 
(GCOMPLEX) and isolated components (GTCR/MHC, GPEPTIDE) using Rosetta’s score 
application (see Materials and methods). These scores were combined to 
produce a binding score, ΔGBIND, which accounted for the peptide’s interaction 
energy with both the MHC and the TCR.  
To quantitatively assess our peptide modeling and scoring approach, we 
examined sets of peptides for which experimental binding free energies were 
available for the 2B4, 226, and 5cc7 TCRs (Figure 5.1, C) (Birnbaum et al., 
2014). Correlations between ΔGBIND and experimentally measured binding free 
energies were greater than 0.69 for all TCRs, and 0.70 for the entire set together 
(Figure 5.1, D).  
We next examined the distributions of ΔGBIND across the four experimental 
selection rounds of the yeast display library where each successive round was 
further enriched in cross-reactive peptides via TCR selection. Indeed, ΔGBIND 
scoring of modeled complexes revealed an increasing enrichment of favorable 
energy scores for peptides in each subsequent selection round, in congruence 
with the subsequent enrichment of cross-reactive peptides for each round (Figure 
 
 331 5.2). Thus, relying on a relatively simple structural modeling method to enable 
computational throughput permits the recovery of experimentally determined 
peptides bound by TCR.  
 
Figure 0.2F igure 5.2 |  Distributions of  ΔGBIND  for peptides recov ered from different selection rounds  
 
Figure 5.2 | Distributions of ΔGBIND for peptides recovered from different 
selection rounds.                                                                                                
We generated structural models of TCR-pMHC complexes using peptide 
sequences from all experimental selection libraries. For each unique peptide 
recovered in each selection round, we modeled its structure bound to MHC and 
TCR and computed ΔGBIND for the TCR-pMHC complex. The probability densities 
for ΔGBIND are plotted for each round of selection for the four TCRs analyzed in 
this study, 2B4, 226, 5cc7 and Ob.1A12. The probability density is defined such 
that the histogram has a total area of one. (n = total number of unique peptides in 
 
 332 the given round; < 200: percent of peptides in the round with ΔGBIND less than 
200). 
Footnote: The deep sequencing results present only a sample of the total unique 
peptides in each selection round. It is thus important to note, the Round 4 
peptides while a subset of the full experimental pre-selection library with >108 
peptides, is not a strict subset of the >105 unique peptides recovered from 
sequencing the pre-selection library. 
 
Correlation between top computationally selected peptides and top 
experimentally selected peptides 
To examine the extent to which our modeling and scoring approach 
selected the peptides recognized by the TCRs with the strongest affinities, we 
compared the 50 peptides with the most favorable ΔGBIND to the 50 peptides with 
the most reads recovered by deep sequencing after the fourth round of selection 
for the 2B4, 226, 5cc7, and Ob.1A12 TCRs (Birnbaum et al., 2014). Rather than 
simply selecting from the round-four peptides, which are highly enriched in 
binders, we asked the computational method to identify top-scoring peptides from 
the pool of unique peptides in the union of the preselection and the round four 
libraries, providing for a more unbiased test. We note, while the full preselection 
pool contains all the round four peptides, the deep sequencing data present only 
a sample of the preselection pool peptides. Hence, we use the union of both the 
preselection and round four sequencing to ensure the true binders are accounted 
for. For a successful computational method, we would expect peptides with the 
most favorable ΔGBIND to be members of the smaller, round-four peptide sets and 
to share amino acid preferences with the peptides that have the most abundant 
 
 333 reads in the fourth round. The amino acid preference generated using the 50 top 
experimentally selected peptides (50 peptides with the most abundant reads 
counts in round four) illustrated binding motifs distinct for each TCR (Figure 5.3, 
A). Among the 50 peptides that had the most favorable ΔGBIND according to our 
modeling and scoring method, 41, 45, 24, and 38 were among the peptides in the 
round-four library for the 2B4, 226, 5cc7, and Ob.1A12 TCRs, respectively. 
Therefore, our scoring method was capable of identifying true binders within a 








 335 Figure 5.3 | Amino acid frequencies for top peptides selected by yeast 
display or by computation for mouse and human TCRs.                                
(A) Heatmaps represent the amino acid frequencies at peptide positions for the 
50 peptides with the most abundant reads in the fourth round of selection for four 
TCRs (2B4, 226, 5cc7, and Ob.1A12). (B) Amino acid frequencies at peptide 
positions for the 50 peptides with the most favorable ΔGBIND. Peptide pool for 
ΔGBIND computation was the union of the preselection library and round 4 library 
(>105 peptides). The peptide residues from the template TCR-pMHC structures 
used for modeling, (2B4, 226) MCC, (5cc7) 5c1, and (Ob.1A12) MBP are 
outlined in black. Peptide positions restricted in the yeast display libraries to 
maintain MHC binding are marked in red beneath heatmap. Correlations of 
frequencies between the experimental and computational heatmap for 2B4, 226, 
5cc7, and Ob.1A12 TCRs are 0.91, 0.85, 0.83, and 0.85 respectively (excluding 
restricted positions). (C) Pearson correlations between the experimental and 
computational ΔGBIND heatmaps as a function of the number of top selected 
peptides used to generate the heatmaps for each TCR (red, blue, green, purple). 
Pearson correlations between the experimental heatmap and heatmap generated 
from peptides with lowest hamming distance to wildtype peptide for each TCR 
(2B4-MCC, 226-MCC, 5cc7-MCC, Ob.1A12-MBP) as a function of the number of 
top selected peptides used to generate the heatmaps (gray). 
 
To further examine how the best scoring peptides compared to those 
identified experimentally after TCR selection, we compared heatmaps of amino 
acid preferences for the 50 top experimentally selected peptides and the top 50 
computationally selected peptides (50 peptides with the most favorable ΔGBIND 
from the union of preselection and round 4) for each TCR (Figure 5.3, A and B). 
Many sequence features were shared between the top-scoring peptides and the 
peptides with the most abundant read counts. To quantify similarity between 
heatmaps, we flattened the heatmap matrices into vectors and calculated the 
Pearson correlation between them. Excluding those anchor positions restricted in 
the libraries for MHC binding, correlations between the heatmaps representing 
 
 336 strongly selected and top-scoring peptides were 0.91, 0.85, 0.83, and 0.85 
for TCRs 2B4, 226, 5cc7, and Ob.1A12, respectively.  
We also assessed a different binding score that only incorporated 
interaction energies between TCR and pMHC. A comparison of the different 
binding scores revealed the inclusion of interaction energies between peptide 
and MHC as in ΔGBIND was critical to the success of cross-reactivity predictions 
(Figure 5.4). A possible reason is that some of the peptides in the preselection 
library may not bind stably to the MHC. Because a stable peptide-MHC 
interaction is a prerequisite for TCR binding, the incorporation of interaction 
energies between peptide and MHC improved the correlation between prediction 
and experiment. We also tested the GCOMPLEX score by itself. While ΔGBIND 
represents interactions between the peptide and TCR and also the peptide and 
MHC, GCOMPLEX additionally accounts for deformations of the peptide itself. 
However, predictive performance of GCOMPLEX was worse than that of ΔGBIND with 
correlations between the heatmaps representing strongly selected and top-
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Figure 5.4 | Prediction comparison of scoring approaches.                  
Pearson correlations between the experimental and computational ΔGBIND 
heatmaps of cross-reactivity profiles (See Figure 5.3) as a function of the number 
of top selected peptides used to generate the heatmaps for each TCR (A, B, C, 
D). Correlations for scoring approach such that  
ΔGBIND = GCOMPLEX - (GTCR/MHC + GPEPTIDE) 
is shown in red, blue, green and purple lines. Correlations for scoring approach 
such that  
ΔGBIND = GCOMPLEX - (GTCR + GpMHC)  
is shown in gray. 
 
 
 338 We note that in the case of Ob.1A12, our scoring method was successful 
in assigning favorable scores to peptides carrying the ‘HF’ motif as was found 
experimentally (Birnbaum et al., 2014). It is evident from the experimental 
heatmap that Ob.1A12 is tolerant of amino acid substitutions outside the anchor 
residues and the central HF motif. This feature of Ob.1A12 is also captured by 
our modeling and scoring method, with the exception of a strong preference for 
Lys at position -1 in the experimental heatmap and a few other less frequent 
substitutions our method could not reproduce.  
The 2B4, 226 and 5cc7 TCRs all recognize the MCC peptide 
(ADLIAYLKQATKG), which is presented in the TCR-pMHC crystal structures of 
2B4 and 226, but the crystal structure for 5cc7 had a different peptide (5c1, 
ANGVAFFLTPFKA). Both the experimentally selected peptides and the top-
scoring peptides by our modeling method revealed peptide motifs similar to these 
cognate peptides (their residues are in black boxes in Figure 5.3).  
Because our modeling method started with the ternary complex structure 
containing cognate peptides, our method may simply favor peptides with similar 
sequences. Nevertheless, our scoring method does reproduce many amino acid 
substitutions seen in the top experimentally selected peptides (marked with 
amino acid frequency in Figure 5.3). We defined a substitution to be shared 
between the experimental and computed peptide sets if the frequency of the 
mutant amino acid at its peptide position was 2 fold higher than what would be 
expected by chance in both heatmaps (based on the NNK codon library used to 
 
 339 design the yeast-display libraries). The following substitutions are shared 
between the two heatmaps for 2B4: L-1H, L-1Q, L-1W, Y3F, Q6E, and T8S. For 
226, the shared substitutions are L-1W, A2G, Y3F, and Q6A. For 5cc7, the 
shared substitutions are A2G, 5LK, T6A, P7A, and F8Y. For Ob.1A12, the shared 
substitutions are E-4A, N-3H, N-3E, P-2Q, P-2R, H2F, K5R, N6A, I7Q, V8I, T9G, 
T9C, P10R. Hence, although our modeling method may be biased toward the 
cognate peptide, our modeling and scoring method is still capable of identifying 
target peptides with beneficial or permissible mutations.  
To provide a quantitative assessment of whether our method 
outperformed a baseline method simply based on sequence similarity to the 
cognate peptide, we computed the Hamming distance between the cognate 
peptide sequence and the sequence of each peptide in the union of the 
preselection and the round-four library for each TCR. The top peptides with the 
highest sequence similarity to the cognate peptide (lowest Hamming distance) 
were used to generate heatmaps of amino acid preference. The correlation 
between these heatmaps and heatmaps of the top experimentally selected 
peptides was compared to the equivalent correlation derived from the top ΔGBIND 
peptides as described above (Figure 5.3, C). For one TCR (2B4) similar 
correlations were found when peptides were selected based on the ΔGBIND score 
or Hamming distance. However, a notable improvement in correlation was 
detected for the other three TCRs (226, 5cc7, and Ob.1A12) when peptides were 
selected based on ΔGBIND as opposed to mere sequence similarity with cognate 
 
 340 peptide. The strong improvements in correlation for three of the four TCRs 
highlight the value of incorporating structural information in next-generation 
peptide prediction algorithms.  
Discussion  
 Numerous methods exist for the prediction of peptide binding to either 
class I or class II MHC molecules and have achieved high accuracy dependent 
upon the training and testing data utilized (Zhao and Sher, 2018). However, far 
fewer tools are available for prediction of TCR binding to pMHC and the accuracy 
of existing tools show room for improvement (Tung et al., 2011; Pierce and 
Weng, 2013; Lanzarotti, Marcatili and Nielsen, 2018; Schneidman-Duhovny et 
al., 2018; Ogishi and Yotsuyanagi, 2019). Utilizing structural information from 
four TCR-pMHC complexes, we present a high throughput modeling and scoring 
approach capable of successfully selecting cross-reactive peptides from large 
pools of primarily non-binding peptides. Our method outperforms the approach 
based on sequence similarity to the cognate peptides.  
Several other groups incorporated structural information of the TCR-
pMHC interface to aid in binding prediction. In a recent study, optimized FoldX 
and Rosetta energy terms were used to predict peptide binding given the 
sequences of MHC, TCR and a query peptide (Lanzarotti, Marcatili and Nielsen, 
2018). The authors noted that the availability of a high sequence identity 
structural TCR template and successful prediction of peptide binding to MHC 
were vital to the success of their TCR-pMHC binding prediction. Similarly, the 
 
 341 method ITCell utilizes atomic statistical potentials to predict a TCR’s peptide 
epitope from all possible peptides in the full-length parent protein when given 
sequences of class II MHC, the TCR variable region, and the parent protein 
antigen as input (Schneidman-Duhovny et al., 2018). In the majority of test 
cases, ITCell ranked the correct peptide epitope among the top 20 peptides 
among all peptides that could result from the parent antigen.  
Benchmarking sets for the aforementioned methods were generated by 
using overlapping peptides from the parent protein sequence of the cognate 
peptide as negatives (excluding the cognate), based on the assumption that 
parent protein sequence would harbor only peptide epitopes for a single TCR, 
which resulted in ~102-103 query peptides per TCR-pMHC test case (Lanzarotti, 
Marcatili and Nielsen, 2018; Schneidman-Duhovny et al., 2018). A more exact 
set of non-binding peptides would require experimental evidence for failed 
binding. Here, we present deep-sequencing results from yeast display as a 
robust and larger benchmarking tool for TCR epitope prediction. In particular, 
each preselection library provided >105 peptides, which were not selected by the 
TCR of interest and are likely negative non-binding peptides. Although 105 
peptides is still a small subset of the theoretical diversity for the 13-mer (~8.1 x 
1016) and 14-mer (~1.6 x 1018) peptides, they represent a larger challenge than 
previous benchmarks for predicting TCR epitopes.   
Like our study, the success of both of the aforementioned methods relied 
on accurate template-based modeling of the TCR-pMHC complex (Lanzarotti, 
 
 342 Marcatili and Nielsen, 2018; Schneidman-Duhovny et al., 2018). In our work, 
modeling of the TCR-pMHC was simplified because crystal structures of TCR-
pMHC complexes existed for all four TCRs investigated and only structural 
changes resulting from the different peptide sequences needed to be accounted 
for. Previous studies showed the TCR’s complementarity determining region 
(CDR) loops can be flexible and change their conformations upon ligand binding 
(Reiser et al., 2002, 2003; Gagnon et al., 2006; Scott et al., 2011; Pierce and 
Weng, 2013). Furthermore, it has been shown CDR flexibility can contribute to 
cross-reactivity (Reiser et al., 2003; Hawse et al., 2014). It may be surprising how 
well our modeling and scoring method performed without making any structural 
adjustments to the TCR molecules. It is unlikely our modeling method could 
predict antigens that require large backbone movements, or altered binding 
orientation, of the TCR for recognition. However, while our modeling method is 
conservative in terms of modeling any structural changes of the TCRs CDR3 
loops, it appears to perform well in providing poor scores for unfavorable 
peptides.  
Large conformational changes of the peptide can also occur upon TCR 
binding. For example, the DMF5 TCR that recognizes the MART-1 melanoma 
antigen presented by the class I MHC protein HLA-A2 was shown to cross-react 
with the DRG class of peptides that are chemically distinct from MART-1 (Gee et 
al., 2018). DMF5 TCR binding to an HLA-A2-presented DRG-class peptide led to 
a ‘register shift’ in the peptide, causing a C-terminal peptide extension from the 
 
 343 MHC binding groove (Riley et al., 2018). Identification of cross-reactive peptides 
with such large structural adjustments relative to cognate peptide would be 
missed by our fixed-backbone peptide-modeling approach, as would instances in 
which MHC deformations are required (Borbulevych et al., 2009; Borbulevych, 
Piepenbrink and Baker, 2011). However, peptides of class II pMHC complexes 
(i.e., those studied here) typically do not bulge from the groove and class II 
pMHC complexes are thus less prone to backbone rearrangements (Tynan et al., 
2005; Ayres, Corcelli and Baker, 2017). Hence, the success seen here with class 
II complexes may not fully translate when predicting cross-reactivity in class I 
systems, although we should anticipate success with conformationally simpler 
modes of cross-reactivity that involve more commonly observed molecular 
mimicry mechanisms (Macdonald et al., 2009; Borbulevych, Piepenbrink and 
Baker, 2011).  
Even when accounting for simple molecular mimicry mechanisms in cross-
reactivity, peptide side-chain must also be precise because a single erroneous 
side-chain conformation could lead to false positive or false negative predictions. 
While we do not have an estimate for the accuracy of side-chain modeling for our 
modeled peptides here, our previous work showed Rosetta’s side-chain 
optimization methods performed well, albeit on a limited set of TCR-pMHC point 
mutations (Borrman et al., 2017). As advancements in technology allow for faster 
and more accurate modeling of larger conformational changes, future studies 
may focus on allowing for flexibility in CDR loops, MHC, and peptide backbone to 
 
 344 potentially identify cross-reactive peptides with distinct structural and chemical 
signatures. 
To score the modeled TCR-pMHC structures, we accounted for the 
interactions made by the peptide with the TCR and the MHC using Rosetta’s 
scoring application with default weights for energy terms. Future work could 
potentially improve upon our results by optimizing energy term weights using 
machine learning approaches and taking advantage of structural and chemical 
trends in known TCR-pMHC complexes. For example, there is evidence that 
immunogenic peptides are enriched in hydrophobic amino acids at peptide 
centers (Calis et al., 2013), and structural modeling combined with neural-
network optimized scoring has been used to predict neoantigen immunogenicity 
(Riley et al., 2019). Here, we employed timesaving modeling and scoring 
methods to efficiently interrogate large pools of peptides for binding. Future 
studies optimizing score functions and weights for predicting TCR cross-reactivity 
might take into account the consequences of the weak affinities TCRs have for 
their ligands, which can stem from ‘imperfect’ interfaces that are traditionally 
difficult to discriminate between with default functions. 
One potential application of our method is in cancer immunotherapy. 
Accurate identification and targeting of neoantigens (peptides derived from 
mutated tumor proteins) could lead to successful development of immuno-
therapeutics. Recent work highlighted the importance of incorporating MHC 
binding strength, self-similarity to reference antigen, and peptide-centric features 
 
 345 to accurately predict neoantigen immunogenicity (Bjerregaard et al., 2017; Smith 
et al., 2019). Building on this and other work, structural modeling and scoring of 
peptide neoantigens in the context of the full TCR-pMHC complex rather than the 
MHC alone may provide additional insights beneficial to immunogenic prediction 
(Riley et al., 2019). 
Many efforts have been made to enhance TCR affinity for tumor and viral 
antigens (Holler et al., 2000; Li et al., 2005; Chervin et al., 2008). However, 
enhanced affinity may lead to increased cross-reactivity (Linette et al., 2013; 
Riley and Baker, 2018; Hellman et al., 2019). To check for unwanted cross-
reactivity of engineered TCRs, one may perform alanine scanning of the antigen 
to identify motifs essential for binding and then searching for possible self-
antigens in a protein sequence database (Obenaus et al., 2015). The alanine 
scanning can be expedited using DNA barcode-labeled MHC multimers (Bentzen 
et al., 2016, 2018). A more direct approach is to interrogate all human peptides 
for cross-reactivity, like the recent T-Scan method which utilized the lentiviral 
delivery of an antigen library spanning the entire human proteome into antigen-
presenting cells. Selected peptides confirmed the cognate MAGE-A3 epitope 
along with several novel cross-reactive endogenous self-peptides (Kula et al., 
2019). Our modeling and scoring method could represent an in silico approach 
with a similarly broad coverage. We could scan all peptides of the entire human 
proteome computationally for possible binding to an engineered TCR granted a 
template TCR-pMHC crystal structure is available. The thus identified cross-
 
 346 reactive antigens could be further tested experimentally using binding assays or 
assays measuring immunogenic response.  
Materials and methods  
Sequence extraction 
Sequencing data were downloaded from the Sequence Read Archive 
(SRA) under project code SRP040021 and converted to FASTQ files using the 
SRA Toolkit. Sequencing reads were split by barcode into their individual 
selection rounds. Nucleotide sequences were translated into amino acid 
sequences and peptide sequences containing stop codons or unknown amino 
acids were discarded. The resulting counts for each unique peptide were 
recorded for each round of selection for each TCR. 
Peptide structure modeling 
 Template TCR-pMHC complex structures were downloaded from the 
protein data bank (PDB) with the following PDB IDs: 3QIB (2B4-MCC-I-Ek), 3QIU 
(226-MCC-I-Ek), 4P2R (5cc7-5c1-I-Ek), and 1YMM (Ob.1A12-MBP-HLA-DR2). 
To reduce computation time the structures were truncated to contain only the 
binding interface (up to residue 83 for the class II MHC α chain and residue 93 
for the β chain). Each TCR was truncated to just contain the variable domains, 
excluding the constant domains that are distal from the binding interface. Water 
molecules were also removed to simplify scoring and for consistency across 
TCR-pMHC structures with different resolutions. To model peptides onto the 
template TCR-pMHC structures, we utilized the fixed backbone application, fixbb, 
 
 347 of the Rosetta suite of programs (Version 3.5) (Leaver-Fay, Snoeyink and 
Kuhlman, 2008; Leaver-Fay et al., 2011), with parameters “extrachi_cutoff 1 –ex1 
–ex2 –ex3” to increase χ angle rotamer sampling for side-chain placement of 
peptide residues. All side chains of the TCR-pMHC aside from those modeled on 
the peptide were left in their original poses. The following is an example Rosetta 
command used for peptide structural modeling: 
rosetta_source/bin/fixbb.linuxgccrelease –database rosetta_database/ -s 
pdb -resfile my_resfile -suffix my_label -extrachi_cutoff 1 -ex1 -ex2 -
ex3  
Prediction of peptide–MHC/TCR binding free energy 
Each modeled TCR-pMHC complex was scored using the following 
formula: 
ΔGBIND = GCOMPLEX - (GTCR/MHC + GPEPTIDE)                              (1) 
such that GCOMPLEX is the Rosetta score for the entire TCR-pMHC complex, 
GTCR/MHC is the Rosetta score for the TCR and MHC chains bound without the 
peptide, and GPEPTIDE is the score for the isolated peptide in its bound 
conformation. To score each component we used Rosetta’s scoring application, 
score (Leaver-Fay et al., 2011). This scoring function is a linear combination of 
19 energy terms, including van der Waals, solvation, electrostatics, and hydrogen 
bonding interactions along with other statistical potentials. The weights for the 
energy terms were left in their default settings (those specified in the 
standard.wts file along with the score12.wts_patch file found in Rosetta’s weights 
 
 348 directory). The following is an example Rosetta command used for scoring 
modeled TCR-pMHC structures (i.e. scoring commands for GCOMPLEX, GTCR/MHC, 
and GPEPTIDE):  
rosetta_source/bin/score.linuxgccrelease –database rosetta_database/ -s 
















 349 CHAPTER VI: DISCUSSION 
Defining compartment principles by liquid chromatin Hi-C 
 Knowledge pertaining to mechanisms driving compartmentalization of 
chromatin states in the nucleus is lacking. In Chapter II, I sought to answer 
fundamental questions regarding compartment formation and maintenance. This 
goal was accomplished by applying a new experimental technique, liquid 
chromatin Hi-C, to quantitatively assess chromatin interaction stability and 
dissolution kinetics of 3D chromatin conformations.  
 Through liquid chromatin Hi-C, we fragmented the human genome to 
varying sizes and assessed whether compartment formation was perturbed. We 
estimate that compartmentalization requires chromatin fragments to be at least 
11±4 kb in length. Digesting the genome into fragments less than 6 kb disrupts 
the canonical compartment checkerboard pattern and increases mixing of A and 
B loci.  
 Furthermore, digesting chromatin into less than 6 kb fragments leads to a 
loss of short range intra-chromosomal interactions and an increase in long range 
intra-chromosomal interactions as well as inter-chromosomal interactions. The 
loss of short range interactions is not uniform across the genome, but instead 
dependent on chromatin state. Specifically, we find loci in A compartments lose 
more short range interactions in comparison with loci in B compartments.  
 Tracking these changes in interactions throughout time we assign a half-
life of interaction stability, t1/2, to every 40 kb locus, representing the time it takes 
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sub-nuclear structures, we find interactions with lamin associated domains to be 
the most stable, and interactions near nuclear speckles to be the least stable.  
 Our results are in accordance with polymer models describing strong 
heterochromatic B-B interactions driving compartmentalization in nuclei (Falk et 
al., 2019). We find homotypic A-A interactions to be only slightly stronger than A-
B interactions after a 4-hour digest of chromatin into fragments smaller than 6 kb. 
Furthermore, after 16 hours of digestion, where the majority of fragments are 
smaller than 3.5 kb, the A-A interaction preference is completely abolished. In 
contrast, the B-B interaction preference remains distinct in some loci even after 
16 hours of digestion.  
 The unstable A-A interactions reported here, contradict models where 
stable interactions between active regions drive compartmental segregation. 
Nevertheless, transcription can successfully predict compartment patterning in 
various genomes and blocking of transcription leads to a reduction in 
compartment strength (Rowley et al., 2017). When analyzing the effect of gene 
expression on chromatin stability we discovered expressed regions in B 
compartments had shorter half-lives than unexpressed B regions. Such a result 
is in line with active regions being more or less dispensable in maintaining 
chromosome conformations. However, when analyzing expressed versus non-
expressed regions in the highly active A1 subcompartment, we find a small but 
significant increase in stability (longer t1/2) for expressed regions. This longer t1/2 
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mechanism of chromatin interaction stabilization. However, it is unclear whether 
such small increases in t1/2 are a consequence of transcription, Pol II occupancy, 
epigenetic modifications, or other factors. In reference to this conundrum, super 
enhancer regions, rich in the active histone mark H3K27ac, are known to cluster 
together upon cohesin depletion, providing evidence that some active regions 
can form stable contacts, but are ordinarily obstructed by other 3D chromatin 
structures (Rao et al., 2017).  
 In the context of transcription’s role in compartmentalization, our results 
indicate transcription and active regions, in general, have a minor effect on 
compartment maintenance and the formation of stable homotypic chromatin 
interactions. This position is supported by both polymer simulations (Falk et al., 
2019) and by the presence of compartments seen in mouse sperm which is 
transcriptionally inert (Jung et al., 2017). However, we cannot definitively rule out 
a role for transcription in compartmentalization. Liquid chromatin Hi-C 
investigates the architecture of purified nuclei, with a potentially altered 
transcriptional state compared to intact cells. Modifications to liquid chromatin Hi-
C, for instance, performing the cross-linking step on cells as opposed to 
extracted nuclei (extracted nuclei were used for easier digestion by restriction 
enzymes), could help to establish the role of transcription in 
compartmentalization. 
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chromatin positioned within active or inactive compartments. Chromatin diffusion 
and mobility results largely from incessant Brownian motion which can be 
modeled as a random walk due to random bombardment of molecules (Marshall 
et al., 1997; Carmo-Fonseca, Platani and Swedlow, 2002). We note the most 
extensive mixing between A and B loci only occurs after chromatin is segmented 
into fragments smaller than 6 kb. This upper limit in length may be informative in 
terms of chromatin diffusion. Assuming the diffusion of chromatin fragments 
through the nucleoplasm conforms to a random walk, the conformation of these 
fragments may affect their own mobility. The persistence length of chromatin 
(length below which chromatin behaves as a rigid rod) is estimated to be 2.4 kb 
(Dekker et al., 2002; Dekker, 2008). Hence, the persistence length is on the 
same order of magnitude as the upper limit fragmentation length (6 kb) required 
for extensive mixing and compartment disruption. It is possible longer fragments, 
greater than 6 kb, can form higher order 3D conformations which obstruct and 
limit fragment mobility. 
 Our estimations of t1/2 suggest heterochromatic loci exhibit slower 
dissociation kinetics relative to euchromatic loci, with the slowest dissociation 
kinetics found near lamin associated domains at the nuclear periphery. Modeling 
chromatin mobility as a random walk, its diffusional motion may be modulated or 
restricted by sub-nuclear structures such as the nucleolus or nuclear envelope 
(Carmo-Fonseca, Platani and Swedlow, 2002). We find proximity and 
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in mobility have been documented in yeast with telomeres displaying low 
mobility, due in part to their tethering with the nuclear periphery (Heun et al., 
2001). Furthermore, such telomere tethering restricts mobility of genes linearly 
proximal to telomeres, which is in agreement with predictions from random walk 
polymer models (Avşaroǧlu et al., 2014). Most relevant to our study, an excised 
repressed locus in yeast also shows constrained mobility localizing to the nuclear 
periphery. When the locus is derepressed, the excised locus shows enhanced 
mobility capable of sampling space throughout the entire nucleoplasm 
(Gartenberg et al., 2004). Of important note in Gartenberg et al.’s results, 
excision of loci from the polymeric constraint of full chromosomes led to 
enhanced mobility in both repressed and derepressed loci. Our work builds on 
this study, by interrogating the spatial positioning of excised fragments with one 
another across the entire genome and throughout time.  
 One of the most difficult challenges faced in analysis of liquid chromatin 
Hi-C results was decoupling effects from both fragmentation and homotypic 
compartment attraction on chromatin interaction stability. In an ideal experiment 
to accurately compare interaction stabilities, one would cut the genome into 
equal segments at exactly the same time and then measure the dissolution 
kinetics. However, restriction enzymes have biases for where and when they 
begin cutting their restriction sites which themselves are not equally distributed 
across the genome. Such biases convolute comparisons of interaction stability 
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accounted for such biases via measuring a timecourse of digestion efficiency. 
However, while we measured residuals of t1/2 derived from deviations of expected 
t1/2 based on digestion efficiency, small perturbations in t1/2 may be undetected 
due to over or under correction. 
 Correlating t1/2 with chromatin marks, we show polycomb bound chromatin 
have short half-lives compared to other condensed heterochromatic regions. In 
many cases, polycomb bound regions are located in larger A compartment 
regions. The neighboring chromatin environment of a loci potentially has an 
effect on its dissolution kinetics. For instance, the shorter t1/2 of polycomb bound 
regions may be attributed, in part, to excision of a condensed piece of chromatin 
within an open chromatin environment. In such situations, more complex models 
accounting for neighboring sites may need to be investigated to accurately 
assign interaction stabilities to distinct loci.  
 The development of liquid chromatin Hi-C sets a foundation for 
investigating chromatin stability under a variety of experimental conditions. To 
test effects of nuclear positioning, liquid chromatin Hi-C could be applied to the 
inverted nuclei (euchromatin localized to nuclear periphery and heterochromatin 
localized to nuclear interior) of rod photoreceptors in nocturnal mammals. The 
static Hi-C maps between inverted and conventional nuclei look similar in terms 
of compartment formation (Falk et al., 2019). However, dynamic differences 
related to compartment stability may exist. For example, it would be interesting to 
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nuclear periphery, display the same levels of instability seen in conventional 
nuclei.  
 In terms of revealing principles of compartment formation, adaptations of 
liquid chromatin Hi-C could be applied to nuclei or cells inhibited for transcription, 
or depleted for factors contributing to compartment formation such as HP1α, 
lamins, or polycomb-group proteins.  
 Furthermore, while we assume our results presented here in human 
lymphoblastoid cells are representative of general chromatin characteristics, it 
would also be insightful to test whether our results are conserved across varying 
cell types, tissues, and species. Such experiments could provide insights to 
developmental processes. For instance, a switch from strong A-A interactions to 
strong B-B interactions occurs upon differentiation of embryonic stem cells to 
cortical neurons (Bonev et al., 2017). Comparing t1/2 values for A and B loci 
between embryonic stem cells and cortical neurons could help unravel the 
mechanisms driving these conformation changes.  
 Liquid chromatin Hi-C would also be applicable in cell cycle studies. For 
example, chromatin mobility is shown to be high in G1 cells but markedly slower 
in S phase (Heun et al., 2001). Also, compartments are shown to disappear upon 
transitioning from G2 phase to prometaphase (Gibcus et al., 2018). Examining 
changes in t1/2 between these cell cycle stages could expand these results and 
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the cell cycle.  
Chromatin loops and liquid chromatin Hi-C 
 We show fragmentation of the genome to segments smaller than 6 kb 
results in a loss of loop structures. Following the loop extrusion model, we 
propose this may be due to cohesin rings sliding off fragmented chromatin ends 
near loop anchors destabilizing loop contacts (Sanborn et al., 2015; Fudenberg 
et al., 2016). We support this hypothesis by showing that after one hour of 
digestion, loop contacts disappear in Hi-C maps and cohesin is released from 
DNA in chromatin fractionation assays.  
 At 10 kb resolution, the mean size of identified K562 loops is 670 kb. 
Hence, it may be surprising that when the genome is cut by HindIII into 10-25 kb 
sized fragments, loop contacts are still present. With average loop size being 
greater than half a megabase, HindIII fragmentation would lead to a 
fragmentation of internal loop structure in the majority of loops. This implies the 
anchors of loop loci do not require a continuous chromatin loop body to sustain 
contacts. Such a conjecture is still in accordance with loop extrusion models, 
whereby cohesin could be in contact with CTCF loop anchors prior to 
fragmentation and thus aid in the preservation of anchor contacts.  
 When fragments are smaller than 6 kb, we propose cohesin may slip off 
nearby fragmented ends destabilizing loop anchor contacts leading to a loss in 
cohesin chromatin binding and a disappearance of 3D looping interactions. 6 kb 
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Considering the relative size of the cohesin complex, with an estimated ring 
diameter of ~ 40 nm, traversing the necessary fragment length for release is not 
definitively reconciled (Haering et al., 2002). However, as cohesin is shown to 
form loops at a rate up to 2.1 kb per second in vitro, and the conformation and 
DNA packing density of fragments at loop anchors is unknown, dissociation of 
cohesin from fragment ends may be a reasonable hypothesis (Davidson et al., 
2019). It should be noted, cohesin mediated loop formation is dependent on 
cohesin’s ATPase activity (Davidson et al., 2019; Kim et al., 2019). As there may 
be insufficient ATP levels to support active loop extrusion in isolated nuclei, 
future modifications to liquid chromatin Hi-C, examining the effects of varying 
ATP concentrations, may support or contradict current models of looping 
mechanisms. 
 Visually and computationally, we identify loops in Hi-C maps as dots of 
significantly high interactions standing out above background (Rao et al., 2014). 
Considering the increase in A-B interactions in our DpnII digested Hi-C maps, 
random mixing of fragments less than 6 kb in size may inadvertently wash out 
looping signal. Of particular relevance, in our aggregation plots of loop loci, 
looping signal was highly reduced, but not completely abolished after 4 hours of 
DpnII digestion. As Hi-C maps represent a population average, it is unclear 
whether remaining loop contacts are driven by a subset of nuclei in a particular 
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digestion has on loop structure per cell.  
 Further obfuscating conclusions, the manner in which cohesin pseudo-
topologically or non-topologically interacts with chromatin to form loops is still 
under investigation, along with the number of cohesin complexes required for 
loop formation (Davidson et al., 2019; Kim et al., 2019). Future studies defining 
how cohesin, CTCF, and other factors interact with chromatin to form loops will 
be critical to understanding how loops are maintained and how these 
conformations regulate nuclear processes. We propose liquid chromatin Hi-C 
experiments will be impactful in such studies by providing information pertaining 
to the dynamics and stability of loop contacts.  
3D genome architecture and schizophrenia 
In Chapter III, we sought to expand potential schizophrenia risk genes by 
investigating the 3D interactions occurring at coding and nocoding risk loci. As 
schizophrenia risk variants are shown to be elevated in neuronally expressed 
genes (Genovese et al., 2016; Skene et al., 2018), we applied hiPSC technology 
to generate near pure populations of NPCs, glial cells, and excitatory neurons 
(Takahashi and Yamanaka, 2006; Brennand et al., 2011; Ho et al., 2016; TCW et 
al., 2017).  To map the 3D architecture of the different brain cell types, we 
performed Hi-C experiments and investigated resultant 3D contacts in the 
context of schizophrenia risk (Lieberman-Aiden et al., 2009; Rao et al., 2014). 
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chromatin loop structures in our brain cell types, presuming some of these loops 
could link risk variants to candidate risk genes. Loop calling was accomplished 
through two separate approaches based on either global or local enrichments of 
interactions (Ay, Bailey and Noble, 2014; Rao et al., 2014; Mifsud et al., 2017). A 
large percentage of loops were conserved across our cell types and genes 
overlapping brain-specific loops were enriched for brain specific gene ontology 
terms. Notably, neurons displayed decreased loop numbers and harbored larger 
sized loops relative to NPCs and glial cells, suggesting differentiation rewires the 
3D genome in a cell type specific manner.  
Upon analyzing loops in schizophrenia risk loci, we found an increase in 
neuron specific and NPC specific loops overlapping risk loci in comparison to 
glial specific loops. We then tested whether NPC loops, linking risk loci to 
candidate genes, had regulatory effects via CRISR/Cas9 based editing assays. 
Both CRISPR activation and deletion assays in NPCs confirmed regulatory roles 
for some risk loci. In several cases, editing of a risk locus changed the 
expression of a loop linked gene located hundreds of kilobases away.  
We annotated genes overlapping our cell type specific loops as either 
within a risk locus or connected to a risk locus via a cell type specific looping 
interaction. This resulted in a set of risk locus and risk locus connect-genes 
(potentially containing novel risk genes) for each cell type. Integrating these gene 
sets with independent gene expression and protein expression datasets revealed 
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coregulation patterns exemplify regulatory pathways involving risk loci and 3D 
architectures underlying the genetic etiology of schizophrenia.  
Our work in Chapter III was largely inspired by a similar study linking 3D 
genome architecture to schizophrenia in the human brain (Won et al., 2016). 
Won and colleagues performed Hi-C on human brain tissue from the germinal 
zone (composed primarily of NPCs) and the cortical plate (composed primarily of 
post-mitotic neurons). Significant Hi-C interactions between schizophrenia risk 
loci and candidate risk genes were identified and validated for regulatory 
potential via CRISPR/Cas9 editing assays. We employed a similar methodology, 
but took advantage of hiPSC technology to uncover cell-type specific 3D genome 
architecture changes as opposed to changes seen in bulk tissue.  
Recent work of the PsychENCODE Consortium has revealed the 
importance of cell type in characterization of variance among transcriptional 
datasets (Wang et al., 2018). As an example, the gene for dopamine receptor, 
DRD3, displayed expression levels that varied greater in cell type than in bulk 
tissue measurements across individuals in a population. Such examples highlight 
that cell-type proportions in individuals largely account for cross-population 
variation in bulk tissue expression. Further illustrating the importance of cell type, 
schizophrenia risk genes identified by Hi-C and eQTL data were shown to be 
highly expressed in single cell profiles of excitatory neurons (Wang et al., 2018). 
Beyond cell type specific changes in transcription, we show cell type specific 
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evidence supporting functional roles for these changes.  
Before our work, cell type specific 3D genome architecture changes were 
also presented in mouse NPCs and cortical neurons either derived from in vitro 
differentiation or from primary tissue (Bonev et al., 2017). In mouse, cell type 
specific loop formations were associated with increased gene expression. We 
present similar findings here, whereby genes overlapping loop anchors have 
significantly higher expression compared to random gene sets. We also show 
changes in loop formations may be accompanied with changes in gene 
expression. For example, expression of the loop anchored CUX2 gene is high in 
neurons possessing the loop, but lower in NPCs where the loop interaction is 
reduced, and not expressed in glia where the loop interaction is abolished. Our 
results indicate a large portion of genome architecture is conserved between 
brain cell types. However, cell type specific changes exist with regulatory and 
potentially clinical relevance.  
Provided sufficient sequencing depth, loops can be visualized on Hi-C 
maps at 10 kb resolution. To identify loops in our cell types we thus pooled 
replicate samples to obtain sufficient coverage. Hence, we do not have 
statistically significant evidence that neurons contain less loop formations than 
NPCs or glia. However, processing of independent datasets in mouse and 
human reveal a similar loss of loops upon differentiation from NPCs to neurons 
(Won et al., 2016; Bonev et al., 2017). In our processing of mouse ES cells, 
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cells to NPCs (Bonev et al., 2017). This increase in loops is also supported by an 
independent study where loss of pluripotency is accompanied by a widespread 
gain of chromatin loops (Pękowska et al., 2018). Such a gain occurs upon 
transitioning from mouse ES cells to neural stem cells and is proposed to effect 
the regulation of developmental genes (Pękowska et al., 2018). However, this 
model of developmental reorganization could be challenged by considering the 
technical variance in Hi-C quality metrics for these different cell types. Our work 
supports a hypothesis that loops are gained upon differentiation from ES to 
NPCs and then lost upon further differentiation from NPCs to neurons.  
Along with a loss in neuronal loops we report an increase in neuron loop 
size relative to NPC and glia. Once again, we find this increase in neuron loop 
size is also consistent with an increase in loop size upon the NPC to neuron 
transition when processing independent Hi-C datasets of mouse and human 
tissue (Won et al., 2016; Bonev et al., 2017). Previous studies have reported 
knockout of the cohesin release factor WAPL leads to an increase in larger loop 
structures as WAPL acts to restrict loop extension (Haarhuis et al., 2017). 
Intriguingly, gene expression of Wapl in mouse is decreased in neurons relative 
to NPCs, potentially contributing to the larger loop structures in neurons (Bonev 
et al., 2017). While the larger neuronal loops agree with the larger loop structures 
seen in WAPL knockout cells, the decreased number of loops in neurons 
contradicts the expected larger number of loops found in WAPL knockout cells 
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whether multi-dot clusters in Hi-C maps are representative of multiple loops in a 
single cell or variable sized loops across different cells, further studies refining 
annotation of loop size and number will be critical toward understanding 
developmental changes in 3D chromatin organization.  
We note in CRISPR/Cas9 editing assays, deletion of loop-connected risk 
loci leads to an increase in expression in both ASCL1 and EFNB1 genes. Such 
an increase is suggestive that risk loci carry a repressive as opposed to 
enhancer function (Traxler et al., 2016). Furthermore, CRISPR/Cas9 activation 
assays show a reduction in gene expression as opposed to enrichment when 
activators are targeted to risk loci. It has been reported that there is an inverse 
correlation between basal level expression and CRISPR-based activated 
expression across genes (Konermann et al., 2015), and in some cases weak 
activators can cause repression rather than activation in highly expressed genes 
(Li et al., 2017). Our RNA-seq analysis estimated EFNB1 expression to be above 
the 95th percentile in NPC samples. Additionally, targeting of an activator to the 
promoter of EFNB1 as opposed to risk loci led to a minimal increase in 
expression level or no increase dependent on activation system. Conversely, 
targeting of the ASCL1 promoter caused up to 4-fold changes in expression of 
ASCL1. Hence, while we can speculate on the mechanisms driving such 
regulation patterns, further tests would be required to unravel precisely how 
these risk loci regulate their target genes. It would be particularly insightful to 
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editing, as such changes may also have regulatory effects.  
We show significant coregulation occurs between genes annotated as risk 
locus and risk locus-connect when compared to gene sets with similar genomic 
distance distributions. However, it remains unclear whether coregulation of gene 
sets is driven by participation in significant 3D interactions, or whether 
coregulation is a result of genes residing in and near schizophrenia risk loci.  
Deeper analyses could examine coregulation patterns of genes in schizophrenia 
risk loci which are not involved in looping contacts, and conversely examine 
coregulation of genes that make looping contacts in other regions of the genome. 
Such analyses could help further delineate the role of 3D genome architecture in 
the context of schizophrenia.  
 Our results support a hypothesis where schizophrenia pathology can be 
explained, in part, by variant loci at enhancer elements misregulating their 
spatially proximal target genes. We show CRISPR/Cas9 based editing of risk loci 
can lead to target gene expression changes. However, these genome edits did 
not identically mimic the schizophrenia mutations. Furthermore, these tests were 
conducted on genomes derived originally from non-schizophrenic human 
samples. Future studies performing Hi-C experiments on samples derived from 
patients with schizophrenia could examine directly whether disease specific 3D 
architectures exist. For instance, it would be interesting to discover the 
percentage of our risk locus and risk-locus connect loops that are actually 
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technology to such studies could also further parse out the role of cell type in 
schizophrenia etiology. 
There is currently a limited number of chromosome conformation datasets 
for cell types of the human nervous system. Our work represents a primary 
resource to the scientific community highlighting functional differences in 3D 
architectures between brain cell types. Similarly, a recent study described cell-
type-specific 3D contacts associated with cell-type-specific expression within 
three different iPSC derived human neuronal cell types: excitatory neurons, 
hippocampal dentate gyrus-like neurons and lower motor neurons (Song et al., 
2019). As expression and 3D architecture changes occur even within neuronal 
subtypes, mapping out cell type specific architectures and regulatory pathways 
may prove essential for characterizing the pathology of schizophrenia and other 
psychiatric diseases. 
Our study expanded the set of candidate genes conferring schizophrenia 
risk by integrating 3D interactions with previously annotated risk loci. Beyond 
GWAS and Hi-C assays, different groups have worked to further expand and 
refine the map of genetic schizophrenia risk by incorporating data from ChIP-seq, 
RNA-seq, NOMe-seq, and QTLs (Rhie et al., 2018; Wang et al., 2018). Such 
studies aid in the construction of enhancer profiles, and highlight their variability 
across cell types, individuals, and in disease. Future studies incorporating single 
cell protocols may help to further elucidate the mechanistics behind cell type 
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interpret the role of the cell cycle in brain specific 3D architecture relevant to 
schizophrenia risk (Nagano et al., 2017).   
Prediction of TCR-pMHC binding energies and cross-reactive peptides 
 Chapters IV and V focus on prediction of TCR-pMHC binding energies 
and prediction of cross-reactive peptides, respectively. In both cases, prediction 
is based on structural modeling and scoring of TCR-pMHC complex interactions. 
 In Chapter IV, we developed a publicly accessible and queryable 
database, ATLAS, to link 3D structures of TCR-pMHC complexes to associated 
binding energies. Utilizing ATLAS data, we performed multilinear regression 
analyses to assess performance in prediction of TCR-pMHC binding energy by 
combinations of energy features calculated from crystal structures. We report a 
correlation of 0.48 between experimental and predicted binding energies, along 
with a correlation of 0.63 between experimental changes in binding energies 
upon mutation and our predicted changes.  
 In Chapter V, we repurposed deep sequencing data from yeast display of 
pMHC libraries (Birnbaum et al., 2014) to create a functional benchmark for in 
silico prediction of cross-reactive peptides for specific TCRs. Structural modeling 
and scoring of peptides in TCR-pMHC complexes resulted in a high concordance 
between experimental and predicted TCR cross-reactivity profiles. In addition, we 
show incorporation of structural information to predict cross-reactive peptides 
improves upon prediction of cross-reactivity based solely on sequence 
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information in cross-reactive antigen prediction.  
ATLAS expands on other immunological databases, such as IEDB and 
Antijen, by directly linking TCR-pMHC affinity measurements to complex 
structure (Toseland et al., 2005; Vita et al., 2015). Incorporating all affinity and 
structural information currently available, our work sets a baseline for TCR-pMHC 
binding energy prediction within a machine learning framework. We hypothesize 
predictions will improve as more affinity and structural data becomes available, 
along with advances and optimizations to machine learning methods.  
Our study in Chapter V expands upon structure based peptide prediction 
methods such as ITCell, and Lanzarotti and colleague’s TCR:p:MHC pipeline 
(Lanzarotti, Marcatili and Nielsen, 2018; Schneidman-Duhovny et al., 2018). In 
particular, we integrated deep sequencing data with structural modeling of TCR-
pMHC complexes. Compared to previous methods, our integrative approach 
increased the peptide test space by several orders of magnitude. As T cells are 
required to interrogate a vast space of peptide antigens for efficient 
immunological protection, our work pushes toward the development of larger 
scale clinically applicable prediction methods.  
A caveat to the work presented in both Chapters IV and V is the unknown 
level of accuracy in our modeled mutations and peptides, respectively. We were 
able to determine that the majority of modeled side chain conformations were 
correct in a small subset of ATLAS entries containing structures of both wildtype 
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peptides are mismodeled among our entire datasets. It also remains to be 
understood the effect mismodeled side chain conformations have on binding 
energy or cross-reactive antigen prediction. Mismodeled residues involved in 
contacts between TCR and pMHC may disrupt essential interactions; however, 
the degree to which a single mismodeled χ angle affects prediction is unclear. 
Deeper analyses investigating patterns in side chain conformations at specific 
regions in the TCR-pMHC interface may aid in the validation of modeled 
structures and predictive performance.  
In regard to cross-reactive peptide prediction, we show structural modeling 
and scoring is successful in prediction of binding peptides from large sets of non-
binding peptides. This method was successful for the four TCR structures 
investigated in Chapter V; yet, it remains to be seen how such methods would 
perform on any given TCR.  The large majority of TCRs engage pMHC in a 
canonical diagonal docking orientation (Rossjohn et al., 2015). However, 
conformational changes in CDR loops and the antigen recognition surface have 
been reported across a wide selection of TCR-pMHC complexes (Baker et al., 
2012). The studies of Birnbaum et al. suggest some TCRs may also be more 
cross-reactive than others, capable of tolerating a higher number of amino acid 
substitutions at specific peptide positions (Birnbaum et al., 2014). Applying our 
scoring and modeling methods to a variety of TCRs would help to answer how 
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performance. 
We focused our studies on prediction of TCR-pMHC binding. While 
binding is a prerequisite to TCR signaling, the relationship between affinity and 
signaling is not clearly defined. TCR-pMHC affinity and subsequent signaling are 
correlated, but high affinity does not necessarily ensure a strong signaling 
response (Holler and Kranz, 2003; Stone and Kranz, 2013). Our work, 
concentrating on the first step in a T cell mediated immune response, inspires 
further development of models relating TCR-pMHC affinity with downstream 
signaling. For instance, the kinetic proofreading model hypothesizes TCRs must 
engage with pMHC with a sufficient dwell time to produce an activation signal, 
while also disengaging quickly enough to allow the pMHC molecule to interact 
with other TCRs in the contact zone (Mckeithan, 1995; Bridgeman et al., 2012). 
Another important note, we only consider the 1:1 interaction between a TCR 
molecule and pMHC molecule; however, T cell activation results from the 
clustering of multiple TCRs at the cell surface into supramolecular activation 
clusters (Monks et al., 1998). It follows that more complex models taking into 
account energies and kinetics on the macromolecular and supramolecular scale 
will be essential to accurate prediction of T cell mediated immune responses.  
As more TCR-pMHC complexes are solved with matched affinity data, it 
will be interesting to see how incorporation of new data optimizes weight 
estimates in scoring functions and affects overall prediction performance. When 
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prediction, results were poorer than using default scoring weights from Rosetta. 
We assume this is largely due to the fact that ATLAS is trained on structures with 
peptide bound to MHC. Hence, weights are not trained to account for peptides 
which are incapable of MHC binding. It follows, future optimization of scoring 
functions may need to incorporate MHC binding for successful cross-reactive 
prediction from peptide sequence alone. 
In terms of clinical use we propose our methods could be used to advance 
the fields of TCR design in T cell based therapeutics and TCR testing for cross-
reactivity. While our prediction performance lacks the accuracy required for 
cross-reactivity testing in a clinical setting, we provide evidence that 
computational approaches can be used to discriminate binding peptides from 
large pools of non-binders. We hypothesize further integration of deep 
sequencing and structural data will lead to improvements in antigen prediction 
and pave the way for interrogation of large peptide sets derived from the human 
proteome and foreign pathogens.   
Conclusion 
 Much is yet to be discovered in terms of how the 3D architecture of the 
genome regulates cell function. This thesis presented principles governing 
genome compartmentalization and the formation of chromatin loops. These two 
structural phenomenons represent essential genomic features across a wide 
variety of organisms. As such, a deep understanding of the mechanisms driving 
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processes. The results of this thesis contribute to characterizing these structural 
phenomenons and may provide further insights into disease pathology where 
such phenomenons are perturbed.  
By identifying chromatin loop formations in hiPSC derived NPCs, neurons, 
and glial cells, this thesis expanded the set of schizophrenia risk genes by linking 
risk loci with loop linked genes. Our results define cell type specific schizophrenia 
related “chromosomal connectomes”, consisting of schizophrenia risk loci and 
their 3D proximal genes. Such connectomes harbor genes associated with 3D 
architecture changes during development and genes critical to neuronal and 
chromatin remodeling processes. We propose our reported chromosomal 
connectomes provide a foundation for further studies aimed at characterizing the 
etiology of schizophrenia.  
Lastly, this thesis presents methods for prediction of TCR-pMHC binding 
energies and cross reactive peptides. We developed a public database, ATLAS, 
to facilitate modeling and scoring of TCR-pMHC interactions by the scientific 
community. We used ATLAS to train scoring functions for successful prediction 
of TCR-pMHC binding energies and changes in binding energy upon mutation. 
By integrating deep sequencing data with structural methods, we also present 
successful predictions of TCR cross-reactivity upon interrogation of large peptide 
sets. We hope our database, methods, and results support future in silico 
approaches to TCR design and cross-reactivity prediction. 
 









You want to know how I did it? This is how I did it, Anton.  I never saved 
anything for the swim back. 
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